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Abstract of Thesis
The corpus luteum is formed from the preovulatory follicle after ovulation and its main
function is the secretion of progesterone which is essential for the establishment of
pregnancy. Growth of the corpus luteum is associated with extensive vascular
remodelling, so that by the mid-luteal phase every steroidogenic cell is adjacent to a
capillary for optimal synthesis and secretion of progesterone. In the non-fertile cycle
luteal vascular regression takes place and progesterone production falls. If conception
occurs the corpus luteum is rescued and continues to produce progesterone. The
corpus luteum provides a unique example of tightly controlled physiological
angiogenesis. Little is known about the effect of inhibition of physiological
angiogenesis that occurs in female reproductive tissues. Elucidation of the process of
luteal angiogenesis may provide new insights into tumour therapy and treatment of
infertility, and offer a novel approach to contraception research. Previous research
focused on angiogenesis in the non-primate ovary but the mechanisms that regulate
luteal function in primates are markedly different, therefore the marmoset monkey,
supplemented with archived human corpora lutea, was used for the research described
in this thesis.
Angiogenesis is a dynamic process of endothelial cell proliferation and capillary
tubule formation, controlled primarily by vascular endothelial cell growth factor
(VEGF); and capillary stabilisation by the association of pericytes. In vivo luteal
angiogenesis was assessed by measuring these parameters in luteal sections by
quantitative immunocytochemistry. It was established that 1) quantification of cell
proliferation by bromodeoxyuridine administration to label DNA during the S phase of
the cell cycle was a robust and reproducible technique; 2) over 80% of proliferating
cells in marmoset corpora lutea were endothelial cells; and 3) quantification of these
parameters in one luteal section reflected the angiogenic activity of the whole corpus
luteum. In the primate, early luteal development was associated with intense
angiogenesis, expression of VEGF and the growth of a stable microvascular network.
In the mid-luteal mature gland angiogenesis was ongoing but at a reduced level, VEGF
expression remained high and a full microvascular network had been established
containing both stable microvessels and small immature capillaries, optimal for maximal
progesterone production and secretion. In the late corpus luteum, endothelial cell
proliferation and VEGF expression declined, there were signs of immature vessel
regression and progesterone levels decreased markedly. Human chorionic
gonadotropin administered to women from the mid-luteal phase to rescue the corpus
luteum, was associated with increased angiogenesis and VEGF production, and
stabilisation of newly formed vessels.
xxi
In the marmoset luteal angiogenesis was manipulated by the administration of
various putative angiogenesis inhibitors specifically targeting the intense angiogenesis
in the early luteal phase and mid-luteal ongoing angiogenesis. Luteal function was
assessed by measuring plasma progesterone. Firstly, in two studies marmosets were
treated with a GnRH antagonist to analyse the control of luteal angiogenesis by the
major luteotropic factor, LH in the early and mid-luteal phases. Withdrawal of LH had
a marked inhibitory effect on the high level of endothelial cell proliferation in the early
luteal phase but did not disturb the ongoing mid-luteal phase angiogenesis. Lutein cell
morphology was severely disrupted after treatment at both stages, preventing the
production and secretion of progesterone. Secondly, the effects of the angiogenesis
inhibitor, TNP-470, shown to inhibit pregnancy in the mouse, was examined. This
failed to affect endothelial cell proliferation or development of the microvasculature,
which was confirmed by normal plasma progesterone concentrations, emphasising the
need for caution in extrapolating results from the rodent. Finally, VEGF was
immunoneutralised in three separate regimes of treatment, in the early, from early to
mid-, and specifically in the mid-luteal phase. Treatment suppressed proliferation in the
early luteal phase and subsequently prevented formation of the mid-luteal microvascular
network. The ongoing angiogenesis of the mid-corpus luteum was shown to be VEGF
dependent, and VEGF withdrawal affected pericyte recruitment at all stages.
To explore the molecular control of luteal angiogenesis, expression of the
angiopoietins and their receptor, Tie 2 were analysed in association with expression of
VEGF and its receptors in the human, using quantitative RT-PCR. The early luteal
phase was associated with peak expression of all factors with slight increases in
mRNAs for Ang-2 in the late corpus luteum and VEGF in the rescued.
This study highlights the importance of researching reproductive angiogenesis
in vivo in the primate. It demonstrates that luteal angiogenesis is dependent upon LH
stimulation of the lutein cells during the early luteal phase. The specific angiogenic
factor having a major role in stimulating luteal angiogenesis has been demonstrated to
be VEGF. Suppression of VEGF and luteal angiogenesis results in profound inhibitory
effects on luteal function in vivo. Since physiological angiogenesis occurs exclusively
in reproductive tissues in the healthy adult, manipulation of angiogenesis may have
important clinical implications in the treatment of infertility, in which angiogenesis is
lacking, or for the development of a new approach to post-ovulatory fertility control
based upon suppression of angiogenesis.
Chapter 1 Introduction 1
Chapter 1
Introduction
Chapter 1 Introduction 2
1.1 Overview
Angiogenesis is a process of new blood vessel growth that depends on the sprouting and
proliferation of capillaries from pre-existing vessels. In the adult, capillary growth
occurs rarely and is largely associated with repair of damaged tissues and pathological
conditions such as tumour growth, diabetic retinopathy, psoriasis and rheumatoid
arthritis. Physiological angiogenesis is almost unique to the female reproductive system,
the ovary, uterus and placenta. In the ovary, cyclic angiogenesis occurs in relation to
follicular development and corpus luteum formation. It is the regulation of angiogenesis
in the primate corpus luteum that is the subject of this thesis.
The corpus luteum is formed from the dominant follicle after ovulation of the
oocyte. Its predominant role is in the production of progesterone which alters the
morphology and function of the uterine endometrium, preparing it for implantation of
the developing blastocyst. The luteal phase of the cycle is the time at which the corpus
luteum is functionally active. The corpus luteum has a functional lifespan or luteal phase
of approximately 14 days (human), or 20 days (marmoset monkey), and the synthetic
capacity of the corpus luteum changes during this period. Progesterone secretion rises in
the early luteal phase to reach a maximum in the mid-luteal phase, and in the late luteal
phase the functional integrity of the corpus luteum is lost and progesterone production
falls. Withdrawal of progesterone results in endometrial destabilisation and menstruation
in the human.
During corpus luteum formation, the avascular granulosa cell layer of the follicle
becomes vascularised and the corpus luteum is transformed into a highly vascularised
endocrine gland. Extensive angiogenesis occurs throughout development culminating in
the formation of the large, solid, orange-red gland, typical of the mid-corpus luteum,
with its high blood supply and lipid content. In the late luteal phase, in a process known
as luteolysis, the newly formed vasculature regresses and progesterone production
decreases resulting in the formation of a small relatively avascular, fibrous mass which
may be apparent in subsequent cycles. In the presence of an implanting blastocyst,
luteolysis is prevented by exposure to chorionic gonadotropin synthesised by the
trophoblast of the developing pregnancy. The continued presence of progesterone
maintains the uterine environment and prevents menstruation, allowing implantation and
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early embryonic development. In a conceptual cycle, the corpus luteum is 'rescued'
from luteolysis which is paramount for the establishment of pregnancy.
The factors potentially involved in the regulation of the intense vascularisation
seen in the corpus luteum have been predicted largely from the effects of gene knock-out
studies on embryonic vascular development in transgenic mice, from tumour
angiogenesis analysis, and in vitro culture studies. However, direct research relating to
in vivo luteal angiogenesis in the primate is lacking. It was proposed that since the
corpus luteum is so dynamic, it has the potential to provide a unique model for studying
the regulation of angiogenesis during the processes of growth, differentiation and
regression of luteal tissue and vasculature. Such angiogenesis must be tightly regulated,
being switched on and off over a brief time schedule measured in days. The
understanding of the regulation of physiological angiogenesis in the corpus luteum is
clinically relevant. Inadequate luteal function may be associated with decreased luteal
vascularisation. Tumour growth and metastasis is highly dependent on angiogenic
activity. Also, the ability to manipulate luteal angiogenesis and consequently luteal
function could lead to novel approaches in post-ovulatory fertility control.
This chapter reviews the current understanding of 1) the control of the functional
and structural lifespan of the corpus luteum and 2) the angiogenic process. It begins by
discussing the ovarian cycle: the gonadotropin control of follicular growth, the
mechanisms of ovulation, formation of the corpus luteum, luteolysis and the maternal
recognition of pregnancy, emphasising the functional relevance of ovarian
vascularisation. The control of angiogenesis is then discussed. This outlines the
molecular mechanisms involved in the regulation of angiogenesis and highlights areas
for further study. Finally, the clinical relevance of the study of in vivo angiogenesis in
the primate corpus luteum will be discussed. This chapter serves as an introduction to
the following experimental chapters which report studies of the quantification of luteal
in vivo angiogenesis, its manipulation and molecular control in the primate.
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1.2 Folliculogenesis
The corpus luteum is formed from ovulation of the preovulatory follicle, and
developmental events that transpire during the follicular phase of the cycle are essential
for the appropriate functioning of the corpus luteum, so any discussion concerning the
corpus luteum must first consider follicular development. Similarly, the control of
follicular development and corpus luteum function are dependent on gonadotropins from
the anterior pituitary gland. The control of the secretion of these gonadotropins will be
discussed at this stage. It is also worth noting that the majority of research into
folliculogenesis and luteal function has been carried out in rodent and domestic livestock
species. This review emphasises findings in women and primates and extrapolates from
other species where necessary, however, the control of ovarian function between these
species is likely to differ and caution is needed when extrapolating such research.
Folliculogenesis is the growth of ovarian follicles from primordial to preovulatory stages
of development, in preparation for ovulation of the maturing oocyte. Primordial growth
is not dependent upon pituitary gonadotropins. Further development becomes
increasingly dependent on gonadotropin support and preovulatory follicular
development occurs solely under the influence of cyclical levels of these hormones
(reviewed by Zeleznik and Hillier, 1996). Morphologically, the primordial follicle has a
single layer of epithelial cells surrounding a single oocyte (Block, 1951; Koering, 1969).
At the preovulatory stage these cells have differentiated into cuboidal granulosa cells
and divided numerous times forming multiple layers around the oocyte; a fluid-filled
antrum has formed from granulosa cell secretions; and elongated theca cells,
differentiated from stromal progenitor cells, become fully vascularised surrounding the
avascular granulosa cell layer, separated by a basement membrane (Block, 1951;
Koering, 1969). This is a highly sophisticated structure, the theca and granulosa cells of
which co-ordinate to synthesise oestrogen, and, at the expense of other less mature
follicles the preovulatory follicle directs its own survival. The process of





GranulosacellFSH-R=============== Gonadotropin- independent GCproliferation TCformation Primordial RecruitmentS lec ioDominanceGonadotropin- responsive GCproliferation Antrumformation ThecalvascularisationOestrogensynth sis Thecalvascularisation

















Chapter 1 Introduction 6
1.2.1 Pituitary gonadotropin secretion
Pituitary gonadotropin synthesis and release is controlled by binding of gonadotropin
releasing hormone (GnRH) to its receptor on anterior pituitary gonadotrope cells and the
activation of protein kinase C. The gonadotropins luteinising hormone (LH) and follicle
stimulating hormone (FSH) are heterodimeric polypeptides comprising a common a-
subunit and a unique, structurally related (3-subunit that confers biological specificity.
GnRH is released in a pulsatile manner, from the synaptic terminals of the GnRH
neurones in the hypothalamus into the hypophysial portal vessels, which connect a
primary capillary bed in the median eminence to a secondary capillary bed in the
anterior pituitary gland (reviewed by Clarke, 1996). The GnRH receptor is the crucial
regulatory molecule that transduces the action of GnRH to stimulate gonadotropin
synthesis and release. Occupation of the receptor by GnRH triggers a rapid increase in
intracellular calcium levels and activation of protein kinase C, both of which may lead to
the exocytosis of secretory granules and enhanced biosynthesis of gonadotropin
subunits. The maintenance of both a- and (3-subunit mRNA (messenger ribonucleic
acid) levels is reliant upon GnRH input. They are regulated by changes in the frequency
and amplitude of the GnRH pulses (Marshall et al., 1991), as is the exocytosis of LH and
FSH hormones. Binding of a GnRH antagonist to the receptor does not induce
activation, and leads to a rapid decline in gonadotropin subunit mRNA synthesis and
prevents gonadotropin release. GnRH action is also subject to control by gonadal
hormones such as oestrogen, progesterone and inhibin (reviewed by Clarke, 1996).
1.2.2 Pre-antral and early antral development
Folliculogenesis begins with the transition of primordial follicles which were generated
during fetal life. The transition is characterised by the expansion of the epithelial-like
granulosa cells to a cuboidal appearance, the initiation of cellular replication of
granulosa cells, and the initiation of growth of the oocyte. When the follicle has acquired
3-6 layers of granulosa cells, some stromal cells align in a parallel fashion around the
primary follicle. These cells eventually differentiate into theca cell layers capable of
steroidogenesis (reviewed by Zeleznik and Benyo, 1994). Following formation of 6-7
layers of granulosa cells the antral cavity begins to form, and a specific group of
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granulosa cells surrounding the oocyte form the cumulus (reviewed by Gougeon, 1996).
This process takes approximately 85 days (Gougeon, 1986). Pre-antral and early antral
follicles are found in hypophysectomised and pre-pubertal monkeys, indicating that the
early stages of follicular development, up to and including the formation of early antral
follicles are independent of the secretion of the pituitary gonadotropins LH and FSH
(Goldenberg et al., 1976; Knobil et al., 1959; Peters et al., 1975; van Wagenen and
Simpson, 1973). Granulosa cells are responsive to FSH as demonstrated by the
production of oestrogen following prolonged incubation of granulosa cells from early
antral follicles with FSH and androgen substrate. They are however, not responsive to
LH. This follows because only cell surface receptors for FSH, and not LH are present on
granulosa cells at this time (Zeleznik et al., 1981). Early antral follicles are present
throughout the cycle as a result of the continuous entry of primordial follicles into the
pool of developing follicles, and so it is generally accepted that the process of pre-antral
follicular development serves to provide a constantly suitable source of maturing
follicles for further development when provided with appropriate gonadotropin support
(Zeleznik and Benyo, 1994).
1.2.3 Antral follicular development
The maturation of follicles beyond the early antral stage is under obligatory
gonadotropic control. Since early antral follicles possess only FSH receptors it is this
gonadotropin which is responsible for further development and the associated
biochemical changes within the follicle that accompany this process. Binding of FSH to
its granulosa cell surface receptor activates adenylyl cyclase and cAMP (cyclic
adenosine monophosphate)-dependent protein kinases, leading to altered expression of
multiple genes crucial to cytoproliferation and differentiation (Richards, 1994).
Granulosa cell genes that are responsive to FSH include: aromatase (P450arom) the
steroidogenic cytochrome P450 crucial to oestrogen synthesis; cholesterol side-chain
cleavage (P450scc), rate limiting in progesterone synthesis; the LH receptor; and
polypeptide growth factors and binding proteins such as insulin-like growth factors
(IGFs) and their binding proteins (reviewed by Zeleznik and Hillier, 1996). The
mitogenic action of FSH is facilitated by locally produced growth factors, production
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and/or action of which may be modified by FSH (Skinner and Parrott, 1994). Tonic
stimulation by FSH is sufficient to sustain the development of small antral follicles,
however cyclic levels of FSH are required for further development, and so before
puberty all follicles that survive to this stage become atretic. When sufficiently high
levels of FSH are present during the reproductive life of a female, follicles at such an
intermediate stage are rescued from atresia and preovulatory development begins.
1.2.4 Preovulatory follicular recruitment
At the beginning of the follicular phase of the cycle pituitary secretion of FSH increases
due to withdrawal of the negative feedback of action of oestradiol, progesterone and
inhibin produced by the corpus luteum of the previous cycle (Baird et al., 1984;
Goodman and Hodgen, 1983; Le Nestour et al., 1993). The rise in plasma FSH level
causes multiple antral follicles to enter the stages of preovulatory development.
Evidence from ovulation induction using exogenous FSH suggests that each follicle has
a 'threshold' requirement for FSH beyond which it must be stimulated by FSH if it is to
be protected from atresia and continue to develop (Brown, 1978; Goodman et al., 1977).
Small (10-30%) differences exist between individual follicles at this stage of
development with respect to the threshold amount of FSH required to initiate
preovulatory development, which explains why not all follicles recruited to begin
preovulatory development mature fully and ovulate.
1.2.5 Preovulatory follicular selection
In mono-ovulatory species (e.g. human) only one of the follicles initially recruited to
begin preovulatory development actually survives to secrete oestrogen in the late
follicular phase. In other species such as rodents approximately 10 preovulatory follicles
are ovulated, and in the marmoset monkey, the species used for the current research, 2-3
ovulations occur, reflecting the fact that marmosets give birth to 2-3 offspring at any one
time. The number of follicles that develop to the preovulatory stage is dependent on the
duration that FSH concentrations are maintained above the threshold (Zeleznik and
Kubik, 1986). For simplicity this section discusses singular follicular selection and
dominance. The ability of the follicle most rapidly to begin oestrogen synthesis is crucial
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to its survival as the dominant follicle (Goodman et al., 1977; Zeleznik, 1981). The
hypothesis is that the maturing follicle inhibits the development of less mature follicles
by suppressing FSH secretion by way of its production of oestrogen which has a
negative feedback effect at the hypothalamic-pituitary axis, down regulating FSH
secretion. In the follicular phase of the cycle the plasma FSH level rises, and P450arom,
responsible for oestrogen synthesis, is increasingly expressed in the granulosa cell layer
of the dominant follicle. This activation of the aromatase system has been likened to a
switch, which is turned on as the FSH threshold level is surpassed (Hillier, 1981). The
first follicle to secrete oestradiol is the one with the greatest sensitivity to FSH (i.e. the
lowest FSH threshold) (Zeleznik and Kubik, 1986). In addition FSH stimulates
granulosa cell inhibin synthesis (Findlay, 1993), which also has a negative effect on
pituitary FSH secretion (Groome et al., 1995). Passive immunisation of rhesus monkeys
with anti-oestradiol antibodies in the mid-late follicular phase of the cycle prevented the
fall in FSH concentrations and caused the maturation of more than one preovulatory
follicle (Zeleznik et al., 1985). It is presumed that this effect of passive immunisation
occurred in the presence of elevated inhibin secretion from the increased number of
maturing follicles (McLachlan et al., 1986), suggesting that in the absence of oestrogen-
mediated suppression of FSH secretion, inhibin alone was not able to govern the
development of a single preovulatory follicle (Zeleznik and Benyo, 1994). Thus, under
the control of oestrogens, blood levels of FSH fall to insufficient concentrations to
sustain the further development of other follicles within the cohort, and they undergo
atresia.
Given that FSH is required for preovulatory growth and that the maturing follicle
inhibits the development of other follicles by suppressing FSH secretion, how is it that
the preovulatory follicle continues to develop in the presence of FSH concentrations that
are unable to sustain the development of less mature follicles? It appears that, as a direct
consequence of FSH stimulation, the preovulatory follicle undergoes maturation-
dependent changes which further increase its sensitivity to gonadotropins (i.e. lowers its
FSH threshold level) (Zeleznik and Hillier, 1996).
Chapter 1 Introduction 10
1.2.6 Responsiveness of dominant follicles to declining FSH concentrations
FSH and LH receptor levels
Increases in receptor numbers for FSH and LH should directly increase the sensitivity of
the follicle to falling gonadotropin levels. In rats, the density of FSH receptors on
granulosa cells increases during preovulatory follicular development (LaPolt et al.,
1992). In the primate, analysis of the dose-dependent relationship between FSH
concentrations and oestrogen production by marmoset granulosa cells revealed that cells
collected from preovulatory follicles were nearly four times more sensitive to FSH when
compared with granulosa cells harvested from less mature follicles (Harlow et al., 1988).
In addition to changes in density of FSH receptors on granulosa cells, a hallmark of the
action of FSH is the induction of receptors for LH (Zeleznik et al., 1974). As both FSH
and LH exert their actions via the stimulation of adenylyl cyclase and increase in
intracellular cAMP concentrations, the presence of LH receptors on granulosa cells of
the dominant follicle would protect it from the fall in FSH (Yong et al., 1992a). Less
mature follicles possess only FSH receptors and thus would be more susceptible to a fall
in FSH secretion, while the selected follicle, as a result of the FSH-mediated increase in
LH receptors, may survive the fall in FSH concentrations by developing the ability to
respond to LH (Zeleznik and Hillier, 1996).
Vascularisation
In addition to increases in hormone responsiveness, preferential delivery of
gonadotropins to the maturing follicle could protect it from the fall in FSH
concentrations. Early investigators observed the heterogeneity in follicular
vascularisation and suggested its importance in determining whether follicles remain
healthy or become atretic (Clark, 1900; Anderson, 1926; Bassett, 1943; Burr and Davies,
1951). Subsequent work has supported the contention that maintenance of the follicular
vasculature is important for maintaining follicular health. Early atretic ovine follicles
will regenerate when placed in vitro, suggesting that decreased vascularity may limit
access of atretic follicles to nutrients, substrates and tropic hormones in vivo (Moor and
Seamark, 1986). In rhesus monkeys, the density of the capillary network that supplies
the preovulatory follicle is at least three times greater than that supplying other less
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mature follicles, and this increased density of capillaries results in a greater delivery of
radiolabeled gonadotropin to the selected follicle (Zeleznik et al., 1981). The findings
that extracts of follicle cells or conditioned tissue culture medium from granulosa cells
were able to stimulate the proliferation of endothelial cells in vitro suggested that the
maturing follicle produces diffusible angiogenic factors that cause selective
vascularisation of the theca (Koos, 1986).
Autocrine andparacrine agents
The actions of FSH and LH on the maturing follicle can be modified in a positive or
negative manner by locally produced agents as demonstrated by in vitro studies (Hillier,
1991). Putative paracrine modulators of FSH action of granulosa cells are androgenic
steroids and polypetides such as transforming growth factors produced by LH-stimulated
theca cells (Magoffin and Erickson, 1994). This is based largely from studies in rodents
and in vitro culture systems. FSH-stimulated granulosa cells can produce steroidal (e.g.
oestradiol and progesterone) and non-steroidal (e.g. inhibin/activin and IGFs) substances
that may influence theca responsiveness to LH (reviewed by Zeleznik and Hillier, 1996).
In rats, IGF-1 contributes to this process by synergising the effects of FSH in the
induction of aromatase activity (Hillier, 1991), however in humans the variable
concentrations of IGFBPs (insulin like growth factor binding proteins) during follicular
development are thought to have a greater role than de novo IGF production (San
Roman and Magoffin, 1992). These and other factors may also exert autocrine
regulation within the cells that produce them.
1.2.7 Follicular oestrogen synthesis
The onset of follicular oestrogen synthesis reflects a functional interplay between the
two major steroidogenic cell types in the follicle, the granulosa and theca cells, regulated
by FSH and LH (Zeleznik and Hillier, 1996), typical of the "two-cell, two-
gonadotropin" model of oestrogen synthesis. Thus, both cell types and both
gonadotropins are crucial to oestrogen synthesis (Armstrong et al., 1979; Hillier et al.,
1994). Theca cells under LH stimulation produce Ci9 androgens (testosterone and
principally androstenedione) because they abundantly express 17a-hydroxylase/C17_2o
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lyase (P450cn), needed for androgen synthesis, however, theca cells lack significant
quantities of the aromatase enzyme and so cannot aromatise Q9 androgens to oestrogens
(Hillier, 1981). In contrast, granulosa cells lack the P450ci7 activities that are required to
metabolise C2i steroids to C|9 androgens but, under FSH stimulation, acquire the
aromatase enzyme that converts Q9 androgens to oestrogens, principally oestradiol
(Hillier et al., 1981). The theca interna is highly vascularised and so has direct access to
blood-borne precursor cholesterol and theca cells contain the steroidogenic enzymes
necessary to synthesise androgens from acetate and cholesterol (e.g. cholesterol side-
chain cleavage, P450scc). Within the preovulatory follicle the avascular granulosa cell
layer is exposed to high concentrations of aromatisable androgen that reach it by
diffusion from the theca interna. Cells on the outer (mural) granulosa cell layer are
presumed to be particularly active sites of aromatisation, since they express more
P450arom mRNA and LH receptors than do cells distal to the basement membrane
(Amsterdam et al., 1975; Whitelaw et al., 1992). The theca vasculature is so well
developed in the preovulatory follicle that murally located granulosa cells are effectively
in contact with adjacent blood vessels. They are therefore well-placed to respond to
changes in the circulating LH level which is important in the maintenance of follicular
dominance, and the oestrogen they produce can be directly discharged into the venous
effluent of the preovulatory follicle (Ravindranath et al., 1992b).
1.2.8 Maintenance of follicular dominance
By the mid-follicular phase the dominant follicle is recognisably the largest follicle in
the human ovary (Gougeon and Lefevre, 1983). At this time maintenance of its status
becomes increasingly dependent on LH. Since LH receptors are constitutively expressed
on theca cells and are induced on granulosa cells by FSH, the dominant follicle secretes
increased amounts of androstenedione as well as oestradiol in response to stimulation by
LH (McNatty et al., 1976). Paracrine signalling (granulosa on theca) is thought to
contribute to the selective enhancement of LH-responsive androgen synthesis that occurs
in this follicle. In vitro, LH co-ordinately stimulates aromatse and inhibin synthesis in
human granulosa cells from the dominant follicle (Hillier et al., 1991), and inhibin
potently stimulates LH-stimulated androgen synthesis (Hillier, 1991).
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1.3 Ovulation
Ovulation is the central event in the ovarian cycle when the oocyte is released from the
ovary and passes into the oviduct where it may be fertilised. Ovulation is stimulated by a
surge in LH, it is the terminal step in the growth and differentiation of the follicle and
marks the onset of the formation of the corpus luteum (reviewed by Zeleznik and Hillier,
1996).
1.3.1 The LH surge
As the oestrogenic production of the preovulatory follicle increases, its effect becomes
increasingly stimulatory on pituitary LH production and secretion, in turn the frequency
of pulsatile release of LH increases, culminating in what is termed the LH surge, which
stimulates ovulation. Maturation of the oocyte is reactivated in response to the LH surge,
as oocytes themselves do not express LH receptors this is presumably as a consequence
of a decrease in exposure to inhibitory cAMP (Tsafriri and Dekel, 1994) from the
breakdown in oocyte-granulosa cell connections (Albertini and Anderson, 1974). At the
granulosa cell level, immediate responses to the LH surge are inhibition of mitosis, the
cessation of follicular growth, and increased expression of P450scc (Yong et al., 1992a;
Yong et al., 1994) and 3|3-hydroxysteroid dehydrogenase (3|3-HSD), the steroidogenic
enzymes necessary for progesterone synthesis (Miller, 1988). This is known as
granulosa cell luteinisation. Oestrogen synthesis declines due to inhibition of P450ci7
activity and the attendant lack of aromatase substrate (Hillier and Wickings, 1985). Thus
as ovulation approaches the ovary increasingly secretes progesterone while oestrogen
secretion temporarily declines.
1.3.2 Follicular rupture
The LH surge stimulates a proteolytic cascade within the preovulatory follicle, resulting
in its rupture approximately 36 hours later. The biochemical nature of ovulation has
been likened to an inflammatory response (Espey, 1980), which leads to ovarian
hyperaemia and local increases in proteolytic enzyme activities that reduce the tensile
strength of the apical wall. The follicular response to LH includes increased production
of prostaglandins, platelet activating factor, plasminogen activators and matrix
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metalloproteinases such as collagenases, gelatinases and stromelysins, which serve to
digest the follicle wall (reviewed by Zeleznik and Hillier, 1996). Locally synthesised
prostaglandins appear to be primarily responsible for the increase in vascular
permeability which sustains positive intrafollicular pressure during the period when
follicular fluid begins to leak through the partially digested wall (Zeleznik and Hillier,
1996). The gradual reduction in the tensile strength of the follicular wall eventually
results in complete rupture and the release of the cumulus-enclosed oocyte in follicular
fluid over many minutes.
A role for progesterone in follicular rupture has been proposed. Progesterone
levels in follicular fluid rise markedly following the LH surge. Incubation of pieces of
human follicular wall with progesterone in vitro decreases the formation of collagen
(Tjugum et al., 1984), and follicular steroids have been implicated in the regulation of
plasminogen activator synthesis and the activation of collagenase, thereby facilitating
breakdown of the follicular wall (Ohno and Mori, 1985). After follicular rupture the
collapsing follicle becomes the corpus luteum.
1.4 The corpus luteum
The luteal phase of the ovulatory cycle is dominated by the corpus luteum which
secretes large amounts of progesterone priming the endometrium for blastocyst
implantation. In the non-fertile cycle, the corpus luteum grows, matures and regresses in
14 days in the human (Lenton and Woodward, 1988) and approximately 20 days in the
marmoset (Hearn, 1983). If conception occurs the corpus luteum is rescued from
regression which is essential for the establishment of pregnancy (Hartman and Corner,
1947; Csapo et al., 1973).
1.4.1 Formation of the corpus luteum
The corpus luteum forms from the preovulatory follicle after ovulation. The basement
membrane which separated the granulosa and theca cell layers, disintegrates (Corner,
1956). The blood-filled theca forms invaginations into the luteinising granulosa cell
layer (Corner, 1956, Niswender and Nett, 1994) and both cell types invade the follicular
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antrum. Blood vessels undergo extensive angiogenesis to form a microvascular network
which serves each and every lutein cell in the structure (Redmer and Reynolds, 1996;
Reynolds et al., 1992). Luteinisation is the first stage in functional and structural luteal
development. The hallmarks of luteinisation are evident directly after the LH surge, in
the expression of enzymes critical for progesterone production (Yong et al., 1992a;
Yong et al., 1994), and progesterone contributes to rupture of the follicle at ovulation
(Ohno and Mori, 1985; Tjugum et al., 1984). However, luteinisation is a gradual process
which is completed 5-6 days into the luteal phase, when the characteristic morphological
effects of lutein cells are fully evident (Adams and Hertig, 1969). This section discusses
luteal formation in association with the acquired capacity for lutein cells to secrete
progesterone and the structural changes which take place as the gland becomes fully
functional.
1.4.1.1 Luteinisation and luteal steroidogenesis
The LH surge is the stimulus for luteinisation. Marmoset antral follicles spontaneously
luteinise in vitro (Wehenberg and Rune, 2000), and so it appears in vivo that the LH
surge removes the inhibitory effect of the preovulatory environment. Luteinisation
involves the transformation of the granulosa and theca cells of the preovultory follicle to
lutein cells of the corpus luteum. They terminally differentiate, and so granulosa cell
proliferation ceases (Gougeon, 1981) and theca and granulosa lutein cells acquire the
steroidogenic enzymes necessary to produce progesterone (Yong et al., 1992a; Yong et
al., 1994). Progesterone becomes the major product of the corpus luteum. Although
oestrogens are still produced by the primate corpus luteum, their synthesis is secondary
to that of progesterone (reviewed by Zeleznik and Hillier, 1996).
Progesterone synthesis
Progesterone production by the corpus luteum relies on cholesterol as a substrate.
Although luteal cells can manufacture cholesterol de novo from acetate, the corpus
luteum relies extensively on serum low density (LDL) and high density lipoprotein
(HDL)-cholesterol for use as a precursor for the synthesis of progesterone (Tureck and
Strauss, 1982; Soto et al., 1984). Uptake of LDL-cholesterol is via receptor-mediated
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endocytosis (Brown and Goldstein, 1986), and HDL-cholesterol entrance to the cell is
by receptor binding, but cholesterol is transported into the cell by an unknown
mechanism which does not appear to be receptor-mediated endocytosis (reviewed by
Niswender et al., 2000). A rate limiting step in the steroidogenic pathway appears to be
the transport of cholesterol from the outer to the inner mitochondrial membrane (Stevens
et al., 1993) which is dependent on the phosphorylation of the steroidogenic acute
regulatory protein (StAR) (Lin et al., 1995). Once transported to the mitochondrial
matrix, P450scc cleaves the side chain from cholesterol to form pregnenolone, which is
then transported to the closely associated smooth endoplasmic reticulum, where 3|3-HSD
converts pregnenolone to progesterone (reviewed by Niswender et al., 2000).
Cellular levels of 3(3-HSD and P450scc mRNA are highest shortly after ovulation,
declining progressively throughout the luteal phase (Bassett et al., 1991), whereas
progesterone secretion is maximal during the mid-luteal phase. Dissociation of luteal
steroidogenic secretion rate and biosynthetic potential may occur because the new
corpus luteum is incompletely vascularised such that its access to precursor cholesterol
in form of LDL is restricted (Carr et al., 1982). When luteal vasculature becomes fully
developed in the mid-luteal phase, precursor cholesterol no longer rate limits
steroidogenesis. Thus the luteal progesterone secretion rate progressively increases
during the early luteal phase in spite of the age related decline in steroidogenic potential
at the cellular level (Zeleznik and Hillier, 1996).
Progesterone actions on the uterus
In the uterus, progesterone acts on the endometrium as a differentiation factor
(Cummings and Yochim, 1984). During the follicular phase, oestrogens induce
proliferation of cells of the endometrium, and elevated concentrations of progesterone
during the luteal phase inhibit mitosis in the endometrium and down regulate receptors
for oestradiol (reviewed by Niswender et al., 2000), thereby blocking the mitogenic
actions of oestrogens. Progesterone also induces stromal differentiation, stimulates
glandular secretions and changes the pattern of proteins secreted by endometrial cells
(Strinden and Shapiro, 1983; Maslar et al., 1986). These uterine proteins provide an
environment that supports early embryonic growth.
Chapter 1 Introduction 17
Oestradiol production
The luteal phase plasma oestradiol pattern mirrors progesterone in reaching a maximum
at the mid-luteal phase when total aromatase activity is declining (Fisch et al., 1989).
Similar to granulosa cells in the preovulatory follicle, granulosa lutein cells in the corpus
luteum cannot undertake oestradiol synthesis unless supplied with an aromatase
substrate (reviewed by Zeleznik and Hillier, 1996). Theca lutein cells are presumed to
provide precursor androgen for aromatisation by granulosa lutein cells in an extension of
the "two-cell, two-gonadotropin" type mechanism of oestrogen synthesis that occurs in
the preovulatory follicle. A high rate of Ci9 steroid synthesis in the theca depends on
access to extracellular precursor cholesterol (Carr et al., 1982). Presumably therefore
androgen synthesis in the theca lutein cells, like progesterone synthesis in the granulosa
lutein cells, benefits from the increased vascularisation of the corpus luteum that occurs
during the first week after ovulation (Zeleznik and Hillier, 1996).
1.4.1.2 Structural formation of the corpus luteum
When the corpus luteum is fully formed it comprises a heterogeneous population of
steroidogenic and non-steroidogenic cells (reviewed by Grazul-Bilska et al., 1997). In
the human, the two steroidogenic cell types, theca and granulosa derived cells, differ in
their cellular origin and morphology, rate of progesterone production, response to LH,
production of peptide hormones and angiogenic factors. Whereas in the marmoset, the
origin of steroidogenic cells is unclear and both theca and granulosa cells are
incorporated into the body of the corpus luteum (Webley et al., 1990). The corpus
luteum also contains other cell types including endothelial cells, pericytes, fibroblasts
and immune cells. It is a dynamic gland in which the cellular morphology and relative
contributions of each cell type change during its lifespan. The structure of a human mid-
luteal phase corpus luteum is shown in Figure 1.2. Two morphologically distinct cell
types are visible; large luteal cells of granulosa cell origin occupy much of the corpus
luteum, and smaller luteal cells derived from follicular theca cells form a separate layer
around the periphery with small indentations into the centre. In the mature marmoset
corpus luteum (Figure 1.3b) the population of steroidogenic cells is more uniform and
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heterogeneity arises from other luteal cell types such as endothelial cells, pericytes and
fibroblasts.
During luteal formation, the increased steroidogenic capacity to secrete
progesterone occurs in parallel with changes in the morphology of the granulosa lutein
cells in the human and most primates, and both granulosa and theca derived cells in the
marmoset. In the rhesus monkey, granulosa cells collected from the preovulatory
follicles during the late follicular phase have a diameter of approximately 10|a,m, contain
sparse amounts of endoplasmic reticulum, and possess mitochondria with lamelliform
cristae. In contrast, lutein cells of newly formed corpora lutea have undergone
hypertrophy, so measure approximately 25p,m in diameter, and possess abundant smooth
and rough endoplasmic reticulum and mitochondria with tubular cristae (Crisp and
Channing, 1972), assuming the full morphological characteristics of steroid secretory
endocrine cells. The structural remodelling of granulosa cells during luteinisation is
dependent on LH secretion because granulosa cells collected from rhesus monkeys prior
to the LH surge fail to produce substantial amounts of progesterone in vitro and failed to
exhibit morphological signs of luteinisation (Channing, 1970).
The morphological events associated with luteinisation are not completed until 5-
6 days post ovulation and so a marked difference in morphology and size of lutein cells
are evident between the early and mid-luteal phases (Adams and Hertig, 1969). Figure
1.3 demonstrates the increase in lutein cell cytoplasmic volume associated with
formation of the mature marmoset corpus luteum and the lutein cell shrinkage which
begins in the mid-late luteal phase (Adams and Hertig, 1969), and is evident in the early
regressing late luteal corpus luteum. Whilst lutein cells show degenerative changes
during this time, this figure demonstrates that other cell types with little cytoplasm and
densely staining nuclei, for example fibroblasts, become the major cell type in the
regressed corpus luteum and there is little evidence of steroidogenic cell presence.
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Figure 1.2 Morphology of the human corpus lutcum
Hacmatoxylin and cosin staining of a mid luteal phase human corpus luteum. The theca
and granulosa-derived lutein cells arc present in two distinct compartments within the
corpus luteum. The theca lutein cells are located on the outside of the structure and
processes penetrate the granulosa lutein cells which make up the major part of the mature
gland. The antrum of the preovulatory follicle forms the corpus luteum cavity which
consists of blood, residual follicular fluid and connective tissue. Blood vessels are present
in both the theca and granulosa-derivcd compartments after the extensive vascular
remodelling which takes place during formation of the gland. Scale bar = 200pm.
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Figure 1.3 Morphology of the marmoset corpus lutcum
Haemtoxylin and cosin staining of the marmoset corpus luteum at different stages of
development, (a) An early luteal phase corpus luteum. Note that the lutein cells have
similar morphology, the origins of which arc not clear. Streaming of the lutein cells to
fill the preovulatory antrum is taking place, and the residual follicular antrum (A) is still
present at this stage. The morphology of the lutein cells reflects the early stage of
development, and lutein cell hypertrophy is underway, (b) A mid-luteal phase corpus
luteum. Lutcinisation is complete and the lutein cells are fully mature, the appearance of
which is consistent with active steroidogenic cells. They are large and spherical with
central round nuclei and abundant cytoplasm. Note that the remodelling of the micro-
vasculature is complete with the presence of many luminal blood vessels (BV). (c) A late
luteal phase corpus luteum. Luteal degeneration is taking place, lutein cell death and
vacuolation (V) are apparent, giving rise to a lower proportion of steroidogenic cells per
unit area. Proliferation and infiltration of small cells with little cytoplasm has occurred as
indicated by the arrows. These cells arc probable fibroblasts and immune cells, (d) A
regressed corpus luteum. This corpus luteum is mainly composed of connective tissue
from the mass influx of fibroblasts which are indicated by the arrow heads. Few if any
steroidogenic cells remain. Scale bars = lOOpm.
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In addition to alterations in cellular morphology, luteinisation is associated with
terminal cellular differentiation. Studies in rats have convincingly demonstrated that
corpora lutea do not incorporate tritiated thymidine in lutein cell nuclei, a measure of
DNA synthesis, whereas such incorporation is readily apparent in follicular granulosa
cells (Hirshfield, 1984). Analysis of human ovaries has indicated that the mitotic index
of granulosa cells decreases dramatically after the LH surge (Gougeon, 1981), and
mitotic figures in human corpora lutea are rare (Corner, 1956). The luteinising stimulus
generated by the LH surge thus results in a co-ordinated series of responses of granulosa
cells that include intracellular remodelling, enhanced gene expression, as well as
modulation of the cell cycle (Zeleznik and Benyo, 1994), which have shown to be driven
via the LH-induced massive increase in intracellular cAMP. Exposure of granulosa cells
to maximal stimulatory concentration of LH in vitro resulted in increases in intracellular
cAMP levels that were 15-fold greater than those induced by FSH (Yong et ai, 1992b).
This suggests that during follicular development, FSH generated relatively low levels of
cAMP within granulosa cells which favours DNA synthesis and the acquisition of
steroidogenic capacity, whereas the LH surge, through generation of high intracellular
concentrations of cAMP, arrests cell division and maximally stimulates the
steroidogenic capacity of the luteinising granulosa cells (Zeleznik and Benyo, 1994).
Neovascularisation
In the preovulatory follicle, the granulosa cell layer is not vascularised; the capillary
network that supplies the preovulatory follicles abruptly terminates at the basement
membrane that separates the granulosa cell layer from the theca cell layer. Following
ovulation, as the basement membrane loses integrity and the luteinising granulosa cell
layer grows thicker, blood vessels infiltrate from the theca layer and form a network of
capillaries that supplies every one of the lutein cells (Corner, 1943). The changes in
vascularisation of the marmoset follicle and corpus luteum is shown in Figure 1.4.
Within a few days after ovulation, endothelial cell proliferation is such that the corpus
luteum becomes highly vascularised and on a tissue-weight basis, blood flow to the
gland is among the greatest of any tissue in the body (Abdul-Karim and Bruce, 1973).
The capillary network of the corpus luteum is so extensive that the majority of
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steroidogenic cells are adjacent to one or more capillaries. This increased vascularity in
addition to providing a conduit for the delivery of luteal steroids to the general
circulation, is also necessary for the provision of cholesterol substrate in the form of
LDL for progesterone biosynthesis (Carr et al., 1982).
1.4.2 Trophic regulation of the corpus luteum
LH
Historically, the requirement for LH in the control of progesterone secretion and the
functional lifespan of the corpus luteum has been the subject of numerous debates.
Gemzell (1965) noted that induction of ovulation by hCG (human chorionic
gonadotropin) in hypophysectomised women who had been treated with FSH to induce
follicular growth was followed by luteal phases of normal duration, suggesting that,
once formed, the human corpus luteum functioned independently of additional pituitary
gonadotropin support. Subsequent studies by Vande Wiele et al., (1970) demonstrated
that the long half-life of hCG used to induce ovulation provided extended gonadotropin
support to the corpus luteum; when LH was used to induce ovulation, the corpus luteum
regressed after 5-6 days unless additional LH was given throughout the luteal phase. An
obligatory requirement for LH in the maintenance of the corpus luteum was indicated
when Moudgal et al., (1971) passively immunised rhesus monkeys with antibodies
against LH and found that treated animals exhibited premature luteal regression. Studies
in rhesus monkeys in which pituitary gonadotropin secretion was controlled directly by
pulsatile infusion of synthetic GnRH provided compelling evidence that pituitary
secretion of gonadotropin was absolutely required for luteal function (Hutchison and
Zeleznik, 1984), and others have shown that in both human and macaques that GnRH
antagonist treatment rapidly suppresses luteal progesterone secretion and concomitantly
evokes premature menses (Fraser et al., 1986; Mais et al., 1986).
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Figure i.4 Cell proliferation and vascularisation ofmarmoset follicles and corpus
luteum
Immunostaining for the endothelial cell marker, CD31, and the cell proliferation marker,
bromodeoxyuridine. (a) An early antral follicle. The antrum (A) of this follicle is just
beginning to develop and many granulosa cells (G) are proliferating (black nuclear
staining). Blood vessels (red cell membrane staining) are restricted to the thcca layer
(T) and ovarian stroma, many endothelial cells of which arc proliferating (dual stained
cells), (b) A preovulatory follicle, the large antral cavity of which is clearly visible.
Fewer granulosa cells (G) in this follicle are proliferating. The high power inset
demonstrates that most thecal (T) cell proliferation is restricted to the vascular endo¬
thelium. (c) A corpus luteum approximately 12 hours after ovulation. Granulosa and theca
cells are invading the antrum (A) of the preovulatory follicle, and granulosa and theca cell
proliferation has almost ceased. The vessels from the theca layer now penetrate the gran¬
ulosa lutein cells, the endothelial cells of which arc actively dividing, as the basement
membrane which separated the two is disintegrating, (d) An early luteal phase corpus
luteum. The former follicular antrum has almost been fdlcd and blood vessels have
proliferated so that an extensive vascular network has been formed. Note also that most
proliferating cells in the corpus luteum are endothelial cells. Scale bars = 100pm.
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A close temporal association exists between secretory bursts of LH and episodes
of progesterone production by the corpus luteum (Ellinwood et al., 1984; Filicori et al.,
1984; Mais et al., 1986). The speed of progesterone response to each pulse of LH
implies an acute effect of LH on precursor cholesterol metabolism, such as StAR
phosphorylation (reviewed by Niswender et al., 2000), rather than increased production
of steroidogenic enzymes per se, after the initial induction of expression by the LH surge
(Zeleznik and Hillier, 1996). However, suppression of LH during the luteal phase with
GnRH antagonist resulted in a decline in mRNA concentrations of P450arom and 3|3-HSD
to undetectable levels over a 3 day period (Ravindranath et al., 1992b), thus LH is also
required for the long term maintenance of steroidogenic capacity of the primate corpus
luteum.
FSH
FSH receptors have been identified in the human corpus luteum (McNeilly et al., 1980),
but FSH does not stimulate progesterone secretion in either human or macaque corpora
lutea in vitro (Stouffer et al., 1977; Fisch et al., 1989), and the sensitivity of human
luteinised granulosa cells to LH with respect to both progesterone and oestrogen
secretion is more than 10-fold greater than that of FSH (Zeleznik and Benyo, 1994).
Furthermore, the observations that exogenous hCG and LH are able to maintain luteal
function in hypophysectomised women indicate that FSH does not play an obligatory
role in the regulation of the primate corpus luteum in vivo (Gemzell, 1965; Vande Wiele
et al., 1970).
Autocrine andparacrine regulation
Progesterone itself may represent a broader regulator of the lifespan and function of the
corpus luteum in primates (Stouffer, 1996). Progesterone promotes the synthesis of both
the LH receptor and luteotrophic prostaglandins (e.g. PGI2 and PGE2), which enhance
luteal function in the bovine (reviewed by Stouffer, 1996). In the rhesus monkey, the
progesterone receptor is driven by the LH peak. In luteinising granulosa cells from
patients undergoing in vitro fertilisation, progestins induce cell differentiation and
increased progesterone production (Stouffer, 1996). Moreover, the secretion of
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progesterone itself during the early luteal phase is maintained by progesterone, as
reported for the rat corpus luteum (Rothchild, 1981).
Insulin-like growth factor-1 mRNA is highly expressed in the ovary (Adashi et
al., 1991; Hernandez et al., 1992), and it has been demonstrated that IGF-1 is produced
in the ovaries of several non-primate species, and influences the steroidogenic activity of
follicles in a paracrine and autocrine manner (Adashi et al., 1991). This growth factor
also stimulates oestradiol synthesis by human granulosa cells (Mason et al., 1993). In
the human, several observations indicate that IGF-1 regulates luteal steroidogenic
function, eliciting a positive action on progesterone and oestradiol synthesis (reviewed
by Vega and Devoto, 1997). For example IGF-1 and IGF-1 receptor mRNAs are
expressed by the human corpus luteum and binding studies demonstrate functional
receptors for IGF-1 in human luteal tissue (Johnson et al., 1996).
Prostaglandins may also have a luteotrophic role in the corpus luteum.
Prostacyclin (PGI2) is a major product of endothelial cells and it plays an important role
in vasodilation. Moreover, PGI2 levels were demonstrated to be highest in the early
luteal phase and that injection of a PGI2 inhibitor during luteal development decreased
progesterone production and luteal lifespan in the bovine (Milvae and Hansel, 1985;
Milvae et al., 1986), probably via restriction of blood flow and decreased availability of
LDL-cholesterol. PGE2 has also been demonstrated to stimulate progesterone secretion
by lutein cells of many species (Hamberger et al., 1987; Myamoto et al., 1993).
Direct cell-cell contact
Interactions between certain luteal cell types based on the demonstration of gap
junction-mediated intercellular communication between the different types of luteal
cells, has been demonstrated in mature bovine and ovine corpora lutea, suggesting that
gap junction communication may be an important mechanism for co-ordinating the
growth, development, and differentiated function of the corpus luteum (Grazul-Bilska et
al., 1997). Connexins (Cxs) are a family of specific gap junctional proteins (reviewed by
Grazul-Bilska et al., 1997). The expression of Cx43 is localised exclusively between
luteal cells in the bovine (Grazul-Bilska et al., 1997), and the expression of Cx43 in
luteal tissue is greatest during the early and mid-luteal phases and decreases during
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luteal regression in the human and the baboon (Khan-Dawood et al., 1996). LH appears
to increase the rate of gap junctional intercellular communication between ovine or
bovine luteal cell types (reviewed by Grazul-Bilska et al., 1997) suggesting that the
luteotropic effects of LH are also in controlling the luteal cell interactions. The
phenomenon of direct intercellular communication by cell types in the corpus luteum
has generated considerable interest but as yet the extent of such communication to the
control of luteal function has still to be fully elucidated.
1.4.3 Luteolysis
The regression of the corpus luteum in the absence of conception is obligatory for the
initiation of a new ovulatory cycle because its secretion of progesterone, oestradiol and
inhibin (Burger, 1993) exert negative feedback at the hypothalamic-pituitary axis to
prevent the rise of FSH and LH secretion that are essential for the development of a new
preovulatory follicle (Baird et al., 1975; Zeleznik and Resko, 1980). In many infra-
primate species luteolysis is brought about by the luteolytic action of uterine PGF2a on
the corpus luteum. In primates however, hysterectomy does not result in prolonged
luteal phases (Neil et al., 1969; Beling et al., 1970; Castracane et al., 1979), and it is not
completely clear if one such luteolysin is responsible. Normal luteolysis is associated
with a loss of capacity to synthesise progesterone (McGuire et al., 1994) followed by
loss of lutein cells (Knickerbocker et al., 1988).
Functional luteolysis
The increased progesterone production from the corpus luteum throughout the luteal
phase exerts a negative feedback effect on the frequency of pulsatile LH secretion by the
pituitary gland, which falls from approximately 1 pulse per hour during the early luteal
phase to 1 pulse every 4-8 hours during the mid-luteal phase (Ellinwood et al., 1984;
Filicori et al., 1984). However, this decline in pulse frequency cannot be the direct cause
of luteal regression because setting the pulse frequency at 1 pulse per hour throughout
the luteal phase does not prolong the lifespan of the corpus luteum (Knobil et al., 1980;
Leyendecker et al., 1980). Similarly, premature reduction of the LH pulse frequency to 1
pulse every 8 hours during the early luteal phase does not cause premature luteal
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regression (Hutchison et al., 1986; Zelinski-Wooten et al., 1992). The best explanation
for luteal regression is that the corpus luteum undergoes an age-related reduction in
sensitivity to LH, so that progressively more intense stimulation by LH is required to
sustain luteal function. In other words the corpus luteum may regress not because of
reduced exposure to LH, but due to its ever-decreasing ability to respond to the low
plasma levels of LH that prevail throughout the luteal phase (Zeleznik and Hillier,
1996).
At the cellular level, factors thought to be involved in this decrease in LH
responsiveness and the initiation of luteolysis include oestrogen, prostaglandins,
oxytocin, reactive oxygen species, and various polypeptide growth factors and
cytokines. In humans, direct injection of oestrogen into the ovary containing corpus
luteum resulted in premature menstruation (Gore et al., 1973; Karsch et al., 1973) which
led to a suggestion that internally produced oestrogen leads to the regression of the
corpus luteum. This was supported by the findings that concentrations of oestradiol and
oestrone in the macaque corpus luteum increase during the late luteal phase as
progesterone declines. However, administration of oestrogen inhibitors to spontaneously
cycling animals does not prolong the luteal phase (reviewed by Zeleznik and Benyo,
1994).
Although uterine prostaglandins are not responsible for luteal regression in the
primate, numerous studies have shown that prostaglandins can affect luteal function. In
vivo, infusions of PGF2a directly into the corpus luteum have been shown to cause luteal
regression (Auletta et al., 1973; Auletta et al., 1984; Auletta and Flint, 1988). Similarly,
intramuscular injections of PGF2a or analogue in the marmoset causes luteolysis
(Summers et al., 1985; Webley et al., 1989). Considered with the fact that luteal cells
themselves produce prostaglandins in vitro (reviewed by Zeleznik and Benyo, 1994) it is
supposed that locally produced prostaglandin may exert luteolytic effects on the primate
corpus luteum. Luteolytic actions of PGF2a include the down regulation of adenylyl
cyclase and LH receptor signal transduction (Agudo et al., 1984; Garverick et al., 1985),
decreased transport of cholesterol across the mitochondrial membranes (Juengel et al.,
1995; Pescador et al., 1996) and decreases in 3(3-HSD mRNA (Hawkins et al., 1993;
Tian et al., 1994). It has been suggested that many of the effects of PGF2a on reducing
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mRNA encoding StAR, and 3(3-HSD in the bovine are mediated via the effect of PGF2a
on reducing luteal blood flow which would deprive the gland of nutrients, substrates and
luteotrophic support (Pharriss et al., 1970). Endothelial cells express PGF2a receptors
and PGF2a has been shown to cause degeneration of luteal endothelial cells resulting in
marked reduction in capillary density, thereby reducing blood flow to lutein cells
(reviewed by Niswender et al., 2000). Endothelin-1 has been implicated as a possible
mediator of the effects of PGF2a on luteal blood flow (Girsh et al., 1996a; Girsh et al.,
1996b). Endothelin-1 is stimulated by PGF2a in vitro (Girsh et al., 1996b) and in vivo
(Ohtani et al., 1998), and can cause arteriole constriction (Ohtani et al., 1998). In
addition to its potent vasoconstrictive activity (reviewed by Huggins et al., 1993),
endothelin-1 also inhibits the steroidogenic activity of enriched populations of
steroidogenic lutein cells (Girsh et al., 1996b). This potential modulator of PGF2a in the
bovine corpus luteum may have such luteolytic effects in the primate.
Other factors produced locally in the corpus luteum such as oxytocin could also
have a role in luteolysis. Oxytocin has an inhibitory effect on hCG-stimulated
progesterone synthesis in bovine luteal cells (Tan et al., 1982a; Tan et al., 1982b), alters
blood flow in many organs (Auletta and Flint, 1988), and is synthesised in the primate
corpus luteum (Dawood and Khan-Dawood, 1986; Einspanier et al., 1994) where
receptors are present (Khan-Dawood et al., 1993), so a role in primate luteal regression
cannot be overlooked. In addition, prolactin receptors have been described in the human
ovary and corpus luteum (McNeilly et al., 1980; Bramley et al., 1987), however, a role
for prolactin in the demise of the corpus luteum has not been proven.
The immune system also appears to play a role in luteolysis. Leukocytes
infiltrate the corpus luteum during luteolysis (reviewed by Murdoch et al., 1988) and
eosinophils and macrophages, accumulate in the regressing corpus luteum in response to
chemotactic factors before the decline in serum levels of progesterone (Murdoch, 1987).
Immune cells and cytokines are believed to perform three functions during luteolysis: 1)
cytokine mediated inhibition of steroidogenesis, 2) stimulation of PGF2a secretion by the
corpus luteum. and 3) phagocytosis of degenerative luteal cells (reviewed by Niswender
et al., 2000).
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Reactive oxygen compounds are integrally involved in luteolysis and apoptosis
(Riley and Behrman, 1991; Carlson et al., 1993). Superoxide anion radicals, hydroxyl
radicals, and hydrogen peroxide are the primary reactive oxygen species generated by
steroidogenic cells (Hornsby and Crivello, 1983a; Hornsby and Crivello, 1983b), and an
appreciable amount of oxidative stress experienced during luteolysis is possibly
produced by macrophages within the regressing corpus luteum (reviewed by Niswender
et al., 2000). Consistent with the concept of decreased cellular protection against
oxidative stress in the regressing corpus luteum, levels of mRNA encoding protective
enzymes such as superoxide dismutase and catalase are decreased in bovine corpora
lutea during luteolysis (Rueda et al., 1995).
Structural luteolysis
Morphological changes associated with structural luteal regression are visible in the late
luteal phase. The corpus luteum begins to show signs of degeneration that include
shrinkage of lutein cells and vacuolation of the cytoplasm. As regression continues cell
shrinkage becomes more pronounced, and nuclear chromatin condensation and pyknosis
are apparent (reviewed by Zeleznik and Benyo, 1994). This morphology is typical of cell
death by apoptosis. Apoptosis is an active, energy-dependent process by which non¬
essential populations of cells delete themselves from a tissue (Kerr et al., 1972).
Granulosa cells deprived of FSH undergo apoptosis during follicular atresia (Hurwitz
and Adashi, 1992; Tilly, 1997), and PGF2a promotes apoptosis in cells comprising the
ovine corpus luteum (Sawyer et al., 1990). Apoptosis has been implicated as part of
human corpus luteum degeneration (Shikone et al., 1996; Yuan and Giudice, 1997),
however, ultrastructural studies in the marmoset suggest cell death during luteolysis is
predominately via a process other than apoptosis (Fraser et al., 1999b).
Luteolysis is also associated with regression of luteal vasculature as
demonstrated in many species (Niswender et al., 1976; Lei et al., 1991; Zheng et al.,
1993; Modlich et al., 1996; Gaytan et al., 1998). There is evidence from some species
that luteal blood vessel degeneration is via endothelial cell apoptosis and that endothelial
cell injury is an early marker of regression (O'Shea et al., 1977; Azmi and O'Shea, 1984;
Behrman et al., 1991). Vascular apoptotic cells have been found in the sheep (Sawyer et
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al., 1990) and human (Gaytan et al., 1998) corpora lutea during luteolysis. However, if
demonstration of this phenomenon is restricted to in situ visualisation of DNA
fragmentation, this can be limited because endothelial cells have been shown to detach
from the vessel wall into the lumen before becoming positive for nucleosomal
fragmentation products, and are thus cleared from the corpus luteum in the circulation
(Modlich et al., 1996). Depletion of endothelial cells could be a consequence of previous
regressive changes in the corpus luteum. Conversely, regression of blood vessels may
also trigger degenerative changes leading to functional and/or structural luteolysis. The
latter appeals as progesterone synthesis is dependent on uptake of LDL-cholesterol
which in turn is dependent on an extensive vascular network supplying every
steroidogenic cell with cholesterol precursor, nutrients and 02 for active steroidogenesis.
1.4.4 Maternal recognition of pregnancy in the primate
The lifespan of the corpus luteum during the normal reproductive cycle is not adequate
to provide progesterone for maintenance of pregnancy until the shift to placental
progesterone can occur. Maternal recognition of pregnancy involves biochemical
communication between the conceptus and its mother to provide uninterrupted synthesis
and release of progesterone. There are many species differences concerning the
mechanism of maternal recognition of pregnancy. The mechanisms in the primate are
unique and involve production of a signal from the conceptus. Trophoblastic cells of the
implanting blastocyst secrete chorionic gonadotropin (CG) 8-12 days after fetilisation
and the plasma CG level increases exponentially over the first trimester of pregnancy.
This rescues the corpus luteum from regression by providing a luteotropic signal. CG is
structurally and biologically similar to LH and both interact with the same cell surface
receptor (Cameron and Stouffer, 1982; Lapthorn et al., 1994) and directly stimulate the
primate corpus luteum to secrete progesterone. The question therefore arises how CG,
unlike LH, is able to prevent the corpus luteum from involuting. The half-life of CG in
blood is considerably longer than that of LH because of an increased sialic acid content
of the P subunit of CG, which results in enhanced biological activity (reviewed by
Niswender et al., 2000). Therefore CG provides a more intense and sustained
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gonadotropic stimulus to the ageing corpus luteum, overriding its diminished
responsiveness to the intermittent LH pulses secreted by the pituitary gland.
1.5 Ovarian vascularisation
Neovascularisation of the ovary is fundamental to its function. The developing follicle
appears to be dependent on an extensively vascularised theca layer, and Clark (1900)
concluded that "the vital impulse to growth of the theca interna depends not on a
maintenance of its primitive blood supply but upon a decided increase of that supply."
Today it is known that the establishment and maintenance of preovulatory follicular
dominance is dependent on an increased supply of androgen precursors and nutrients
and 02 for active steroidogenesis culminating in the synthesis of oestrogens, and on
preferential delivery of gonadotropins to the dominant follicle, which are obtained from
the increased blood supply of the follicle. Conversely, reduced thecal vascularisation
appears to be a primary component of follicular atresia. Similarly, the vascular
remodelling which occurs upon formation of the corpus luteum appears to be critical for
normal luteal functioning, although this has not been demonstrated experimentally. To
support the phenomenal rate of tissue growth in the corpus luteum, microvascular
growth and development also have to be extremely rapid. For example, most luteal cell
proliferation occurs in the microvascular compartment (reviewed by Reynolds et al.,
2000). As a result, in the mature corpus luteum microvascular endothelial cells and
pericytes comprise 50-70% of the total cell population (Farin et al., 1986; Lei et al.,
1991). The corpus luteum becomes so vascular that the majority of the steroidogenic
cells are in contact with one or more capillaries (Dharmarajan et al., 1985; Reynolds et
al., 1992; Redmer and Reynolds, 1996; Reynolds and Redmer, 1998). In addition the
mature corpus luteum receives most of the ovarian blood supply, and ovarian blood flow
is highly correlated with the rate of progesterone production (Reynolds, 1986;
Niswender and Nett, 1994; Reynolds et al., 1994).
It was demonstrated by Gospodarowicz and Thakral (1978) that the newly
ovulated follicle produces diffusible angiogenic substances that direct capillary
proliferation into the luteinising tissue. More recently, an array of potential angiogenic
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growth factors and their receptors have been shown to be present in corpus luteum
(Reynolds et al., 1994; Redmer and Reynolds, 1996; Maisonpierre et al., 1997; Goede et
al., 1998; Hazzard et al., 1999a). The next section of this review considers the actual
process of angiogenesis and reviews the current understanding of the primary factors
which are involved in the control of luteal angiogenesis.
1.6 Angiogenesis
The term angiogenesis was first used in anatomical studies of the developing blood
vessels of the placenta (Hertig, 1935). Angiogenesis is the process of new blood vessel
growth that depends on the sprouting of capillaries from pre-existing vessels, and is
essential for normal tissue growth and development (Folkman and Klagsbrun, 1987;
Klagsbrun and D'Amore, 1991). It differs from vasculogenesis in which new
microvessels arise in situ and endothelial cells are born from progenitor cell types,
usually during embryonic development (Poole and Coffin, 1989; Risau, 1991). In the
adult, angiogenesis is the predominant mechanism of microvascular growth. In most
adult tissues, capillary growth occurs only rarely and the vascular endothelium
represents a stable population of cells with a low mitotic rate (Denekamp, 1984).
Physiological angiogenesis
Physiological angiogenesis is tightly regulated. It is switched on and off over a brief
time scale measured in days. The angiogenesis that occurs in repair of wounds, fractures,
peptic ulcers and myocardial infarctions is of slightly longer duration than physiological
angiogenesis and its termination is not tightly regulated (Folkman, 1992). Physiological
angiogenesis is almost unique to the female reproductive organs: the ovary, uterus and
placenta. Intense local angiogenesis is associated with follicular growth, corpus luteum
formation, endometrial development, implantation of the fertilised ovum, and
development of the placenta. The angiogenesis associated with follicular development
and corpus luteum formation has been addressed. Here endometrial and placental
angiogenesis is briefly discussed.
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In the uterus, the innermost endometrial layer exhibits cyclical growth and
vascularisation. In primates, growth of the endometrial vasculature begins during the
proliferative (follicular) phase and continues at a lower level throughout the secretory
(luteal) phase of the cycle (Meschia, 1983). Associated with endometrial capillary
proliferation is increased DNA (deoxyribonucleic acid) synthesis of vascular endothelial
cells (Ferenczy et al., 1979). In the cow, endometrial vascularity is greatest in the early
secretory phase (Ferenczy et al., 1979). The rate of blood flow to uterine tissues also
varies regularly throughout the non-pregnant cycle, being greatest at or just before
ovulation when systemic levels of oestrogens are maximal, and least during the luteal
phase of the cycle when systemic levels of progesterone are high (Meschia, 1983;
Reynolds, 1986).
Placental vascular growth begins early in pregnancy and continues throughout
gestation in association with a continued and dramatic increase in rates of uterine and
umbilical blood flows (reviewed by Reynolds et al., 1992). The importance of placental
vascular development in supporting foetal growth and development has long been
recognised (Ferrell, 1989; Meschia, 1983; Teasdale, 1976). In addition, inadequate
vascular development may be a major contributor to embryonic loss and reduced birth
weights (Ferrell, 1989; Meegdes et al., 1988).
Pathological angiogenesis
In contrast to physiological angiogenesis, pathological angiogenesis is prolonged and
often unabated (Folkman, 1992). Rampant and persistent capillary growth is associated
with numerous pathological conditions, including tumour growth, retinopathies,
haemangiomas, fibroses, and rheumatoid arthritis. Folkman and co-workers were the
first to demonstrate that recruitment of a blood supply is required for sustained growth
of tumours (reviewed by Folkman and Klagsbrun, 1987; Klagsbrun and D'Amore,
1991). Neovascularisation permits rapid tumour growth mainly because it solves the
problem of exchange of nutrients, oxygen and waste catabolites by a crowded three-
dimensional cell population. Simple diffusion of these molecules across the outer
surface of a tumour spheroid would be inadequate (Folkman, 1992). Similarly, to
support the growth of physiological structures such as the ovarian follicle and corpus
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luteum angiogenesis must occur. In addition, vascular endothelial cells of growing
tumours exhibit an extremely high mitotic rate compared with endothelial cells of most
normal tissues (Denekamp, 1984). It has also been demonstrated that the extent of
vascularisation of a tumour may have a correlation with survival rate. In patients with
advanced ovarian carcinoma, Hollingsworth et al., (1995) demonstrated a trend between
higher average vessel counts in the tumour and worse overall patient survival. Similarly,
in patients with the same disease, tumour endothelial cell area was compared between
patients who survived for more than 6 years and those who died of the disease. The
mean endothelial cell area of the survivors was significantly less than that of non-
survivors (Schoell et al., 1997).
Conversely, insufficient capillary growth occurs in several disease states,
including delayed wound healing, non-healing fractures, chronic varicose ulcers, limb
and myocardial ischaemia (Redmer and Reynolds, 1996). There is also a suggestion that
inadequate luteal function is associated with decreased vascularisation (Redmer and
Reynolds, 1996).
1.6.1 The angiogenic process
The field of angiogenesis research began as an enquiry into the mechanisms of tumour
angiogenesis, and much of what is currently known about the angiogenic process at the
morphological, biochemical and molecular levels has been gained from the study of how
tumours induce angiogenesis (Folkman and Shing, 1992). Before the process of
angiogenesis can be explained it is relevant to briefly outline the characteristics and
cellular content of the blood vessels which constitute the vascular makeup of organs.
Arteries and arterioles
The arterial vessels are thick walled with variable quantities of elastic fibres. There are
three layers within their walls: the inner endothelial lining, which is surrounded by
layers of smooth muscle and an outer layer of connective tissue. Medium sized arteries
have distinct strips of elastic material between the endothelial cells and smooth muscle
layer, and between the smooth muscle layer and the connective tissue. These arteries
have between 10 and 40 layers of smooth muscle arranged spirally and the connective
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tissue layer is relatively thick. Arterioles have only 1 or 2 layers of smooth muscle cells,
elastic fibres may be absent and the connective tissue is thin. The smaller arterioles are
surrounded by discontinuous smooth muscle cells and together with larger arterioles
contribute significantly to vascular resistance according to the state of relaxation or
contraction of their smooth muscle. Endothelial cells contribute to vessel dilation and
constriction. In response to changes in blood flow, exposure to histamine or
acetylcholine for example, endothelial cells may release nitric oxide which results in
vessel dilation, and can release endothelin which causes vasocontriction. Endothelial
cells also produce anticoagulant and coagulant factors; the former predominate under
normal physiological conditions. In addition, endothelial cells contain glycoproteins
such as fibronectin and von Willebrand factor which are prothrombotic, acting to induce
platelet plugs if the vessel is injured. The terminal arterioles with a diameter of
approximately 30pm, reduce in size to give rise to capillaries, which usually have a
diameter of 4-8pm.
Capillaries
Capillaries are endothelial tubes encircled by a basement membrane. Because of the
slow blood flow, large surface area and very thin walls, capillaries are well adapted for
the exchange of diffusible substances between blood and the surrounding environment.
Capillaries are often associated with pericytes, which are contractile type cells located at
intervals along the outer circumference of the capillary wall. Pericytes are found
adjacent to capillaries in a variety of tissues in many species, continuous with vascular
smooth muscle cells of arteries and veins, and distinctively shaped with many
cytoplasmic processes that encircle capillaries (reviewed by Hirschi and D'Amore,
1996). Each pericyte possesses a cell body with a prominent nucleus and a small amount
of surrounding cytoplasm (reviewed by Hirschi and D'Amore, 1996). Protruding from
the cell body are long projections which parallel the long axis of the capillary and taper
to smaller processes which encircle the capillary wall. Pericytes are embedded within the
basement membrane which surrounds the capillary tubes. In vitro evidence suggests that
both endothelial cells and pericytes contribute to the formation of the basement
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membrane (Mandarino et al., 1993). Their processes penetrate the basement membrane
to directly contact the underlying endothelium (Tilton et al., 1979).
Pericytes have a variety of proposed functions including regulation of capillary
blood flow and regulation of new capillary growth (Hirschi and D'Amore, 1996).
Pericytes exhibit a number of characteristics consistent with muscle cell activity and
their location in capillaries would enable then to regulate the contraction of the
underlying endothelium. The presence of actin in pericytes has been demonstrated in the
cytoplasmic processes adjacent to the vessel lumen (Le Beux and Willemot, 1978;
Wallow and Burnside, 1980). There is a suggestion of pericyte heterogeneity based on
their expression of a-smooth muscle actin (a-SMA). Nehls and Drenckhahn (1991)
found that only the pericytes of pre- and post-capillary microvessels of bovine retina
expressed a-SMA, whereas mid-capillaries had no detectable levels. However, Hirschi
and D'Amore (1996) suggest that lower levels of a-SMA may be present in pericytes of
mid-capillaries that were not detectable by the methods used, and report of many
findings of a-SMA in pericytes both in vivo and in vitro. Alpha-smooth muscle actin
was not detectable in endothelial cells in culture or in vivo (Boado and Pardridge, 1994;
Hirschi and D'Amore, 1996).
A study of mesenteric capillary growth in rats (Rhodin and Fujita, 1989) suggests
that fibroblasts transform into capillary pericytes, which in turn, become vascular
smooth muscle cells. This has been confirmed more recently (reviewed in Folkman and
D'Amore, 1996). Hence, as capillaries are remodelled into larger vessels to meet an
increased functional demand, pericytes are further differentiated to become true smooth
muscle cells, as needed.
Venules and veins
Once blood leaves a capillary network it enters the first and smallest sized vessels of the
venous vascular system, the post-capillary venules, which are 10-30p,m in diameter.
They also contain pericytes but have no smooth muscle layer as such. Larger venules of
more than 50p,m, begin to show some smooth muscle fibres and enlarge to form veins.
Generally veins have a larger diameter than any accompanying artery, with a thinner
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wall that has more connective tissue and less muscle fibres. Most medium sized veins
have valves which prevent backflow of blood which is travelling at low pressure.
New capillary growth
New capillaries originate from pre-existing microvasculature, mainly from capillaries
and venules, rather than large vessels with layers of smooth muscle. The development of
a new capillary network is a complex process involving tissue disruption and
reorganisation, cellular growth and changes in the composition of the fluid environment
and the extracellular matrix (Folkman, 1985; Schor and Schor, 1983). The angiogenic
process begins with capillary proliferation and culminates in the formation of a new
microcirculatory bed composed of arterioles, capillaries and venules. The initial
component of angiogenesis, capillary proliferation, consists of at least three processes:
1) Fragmentation of the basement membrane of the existing vessel and degradation of
the extracellular matrix, on the side closest to the angiogenic stimulus. This is thought to
result from the activity of collagenase and other matrix metalloproteinases (MMPs) and
plasminogen activator secreted by the endothelial cells in response to the angiogenic
stimulus. 2) Migration of elongated endothelial cells as cords of cells from the existing
vessel towards the angiogenic stimulus. 3) Proliferation of endothelial cells occurring
behind the tip of the growing capillary. The cells at the tip do not usually divide
(Findlay, 1986; Folkman and Klagsbrun, 1987; Klagsbrun and D'Amore, 1991).
Neovascularisation is completed by formation of capillary lumina, by cessation of
endothelial cell proliferation, curvature of the endothelial cell and adherence to each
other to form the capillary lumen. Canalisation follows as individual sprouts join or
anastomose with each other. The newly formed vessels differentiate into arterioles and
venules, as pericytes emerge along the length of the sprout. Blood flow begins slowly as
the new vessels are highly permeable until the basement membrane is laid down and
pericyte stabilisation is complete (Findlay, 1986).
Capillary proliferation
The major component of capillary growth is endothelial cell proliferation. Endothelial
cells of normal, resting vasculature are quiescent due to their confluent nature,
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unresponsiveness to growth factors, and the association of pericytes. Signals such as
angiopoietin-2 (Section 1.6.3) cause dissociation of pericytes and endothelial cells
allowing access of growth factors and activation of proteases etc. for basement
membrane degradation, and endothelial cells begin to migrate toward the angiogenic
stimulus. The change in shape of endothelial cells to a more elongated configuration
confers responsiveness to mitogens (Ingber and Folkman, 1989). Under mitogenic
stimulation, endothelial cells leave the G0 resting phase of growth and re-enter the cell
cycle. Proliferation of endothelial cells can be measured by quantifying the expression of
specific proteins associated with the cell cycle, or by the incorporation of nucleotide
analogues during the DNA synthesis phase of growth. Studies using these approaches
have quantified luteal endothelial cell proliferation in the human (Rodger et al., 1997;
Gaytan et al., 1998) rhesus macaque (Christenson and Stouffer, 1996b), ovine
(Jablonka-Shariff et al., 1993) and bovine (Zheng et al., 1994) and all demonstrate peak
endothelial cell proliferation in the early luteal phase in association with corpus luteum
formation, whereas luteal regression was associated with a decreased proliferative rate.
It has been suggested that endothelial cell proliferation is not a major factor contributing
to the initial increase in vessel density in tumours (Gasparini et al., 1996; Orre et al.,
1998). They suggest that incorporation of endothelial cells from surrounding
vasculature, remodelling of the existing vasculature and decreased endothelial cell
apoptosis contribute to increased vessel densities in certain kinds of tumour. Therefore
when measuring capillary growth both endothelial cell proliferation and endothelial cell
content in the population being studied should be considered.
Capillary stabilisation
Pericytes from pre-existing microvessels, or newly derived pericytes from fibroblast
differentiation, come into contact with endothelial cells that are forming new vessels and
exert an inhibitory effect on endothelial cell proliferation (Crocker et al., 1970). The
inhibitory effect is induced by cell-cell contact between pericytes and endothelial cells.
Early in angiogenesis, during endothelial cell migration and proliferation, pericytes
appear to play a different role in capillary sprouting. Nehls et al., (1992) demonstrated
that pericytes were regularly found lying at and in front of the advancing tips of
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endothelial sprouts. At many sites pericytes were seen to bridge the gap between the
edges of opposing endothelial sprouts, which were apparently preparing to merge,
suggesting that pericytic processes may serve as guiding structures aiding outgrowth of
endothelial cells. However, pericyte association (contact) with growing vessels marks
the cessation of vessel growth and the deposition of a basement membrane (Crocker et
al., 1970).
In co-culture of pericytes and endothelial cells, cell-cell contact leads to the
activation of latent transforming growth factor-(3 (TGF-p) that is produced by both cell
types (Antonelli-Orlidge et al., 1989). Transforming growth factor-P inhibits endothelial
cell proliferation. Endothelial cells can also influence pericyte growth, depending on
their morphology and stage of growth. Endothelial cells in vitro are refractory to growth
factors when they are confluent, that is foreshortened (Ingber and Folkman, 1989), and
media conditioned by post-confluent endothelial cells are strongly inhibitory for pericyte
growth (Dodge et al., 1993). Endothelial cell spreading increases sensitivity to specific
growth factors (Ingber, 1990) and media collected from such endothelial cells are mildly
stimulatory for pericyte growth (Dodge et al., 1993).
Endothelial cells themselves are thought to be responsible for the recruitment and
differentiation of mural cells, such as pericytes and smooth muscle cells, by the secretion
of diffusible factors (Hirschi and D'Amore, 1996). Among the diffusible soluble factors
synthesised and secreted by endothelial cells, are a variety of polypeptide growth
factors, including platelet derived growth factor (PDGF) (Westermark et al., 1990) and
basic fibroblastic growth factor (bFGF) (Montesano et al., 1986), which appear to
function in a paracrine fashion to promote mural cell proliferation and or migration.
Microcapillary endothelial cells express PDGF-B, and PDGF-B-receptor mRNA is
readily detectable in fibroblast-like cells and smooth muscle cells (Holmgren et al.,
1991). Hirschi et al., (1998) using an in vitro co-culture system of endothelial cells and
smooth muscle cell precursors, demonstrated that endothelial cells induced migration of
smooth muscle cell precursors, via PDGF-B, and these mural precursors differentiated
into smooth muscle cells in the presence of endothelial cells but not when cultured
alone, which was shown to be driven by TGF-(3. In addition, PDGF-B ligand null mice
die perinatally from haemorrhage and are reported to lack pericytes throughout the entire
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microvascular bed (reviewed by Folkman and D'Amore, 1996). Basic FGF is angiogenic
as well as mitogenic (D'Amore and Smith, 1993) and chemotactic (Sato et al., 1991) for
smooth muscle cells. Gap junctional formation and cellular adhesion molecules are also
thought to mediate endothelial cell-pericyte interactions (Hirschi and D'Amore, 1996).
Neovascular regression
Two types of vascular regression have been demonstrated. Firstly, when an angiogenic
stimulus is removed, microthrombosis of the capillary tips occurs before the subsequent
disappearance of new blood vessels (Ausprunk et al., 1978). Platelet thrombi accumulate
at the tips of new capillaries, followed by stasis of the circulation in the more proximal
capillary network. Macrophages infiltrate the new capillary bed, enter the lumen, and
begin to phagocytose injured or dying endothelial cells. After a few days the tubular
remnant of blood vessel contains mainly basement membrane without endothelial cells.
The tubular structure gradually retracts and disappears (Folkman, 1992). A second type
of involution is illustrated by endothelial cell rounding and detachment. Instead of
microthrombosis, there is a gradual foreshortening and rounding of capillary endothelial
cells over a period of about 24-48 hours which occurs after dissociation of pericytes
from the vessel. These cells begin to detach, presumably dying by apoptosis, float in the
lumen and are cleared by the circulation in vivo. The new capillary then retracts back
into the parent venule from which it arose (Folkman, 1992).
1.6.2 Angiogenesis assays
Angiogenesis in normal tissues must remain in a constant state of readiness yet be held
in check for long periods of time (Folkman and Klagsbrun, 1987). Angiogenesis is
therefore thought to be regulated by both angiogenic and anti-angiogenic factors
(Folkman and Klagsbrun, 1987; Klagsbrun and D'Amore, 1991) which remain to be
identified in order for the process to be understood. The development of in vivo and in
vitro assays over the last two decades has made possible the isolation and
characterisation of some of these angiogenic and anti-angiogenic factors from numerous
tissues (Folkman and Klagsbrun, 1987; Klagsbrun and D'Amore, 1991).
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In vivo assays
In vivo methods have been used to evaluate the ability of a factor to influence
neovascularisation, that is to influence the entire process of angiogenesis (Folkman and
Klagsbrun, 1987; Klagsbrun and D'Amore, 1991). The most commonly used techniques
are the corneal pocket assay, which permits linear measurement of capillary growth
induced by a substance implanted into the cornea of a rabbit, mouse or rat, and the
chorio-allantoic membrane (CAM) assay, which evaluates the ability of a substance to
stimulate or inhibit neovascularisation when placed into the CAM of a chicken embryo
(Folkman and Klagsbrun, 1987; Klagsbrun and D'Amore, 1991). A significant
observation was that tissues from tumours, corpora lutea, uteri and placentae induce a
neovascular response in the CAM assay, whereas most other foetal or adult tissues do
not (Redmer et al., 1988; Klagsbrun and D'Amore, 1991; Reynolds et al., 1992).
In vitro assays
In contrast to in vivo techniques, in vitro assays evaluate the ability of a factor to
influence one of the individual components of the angiogenic process. The assay tests
the ability of a substance to influence 1) production of proteases by endothelial cells; 2)
migration of endothelial cells, by the separation of endothelial cells and a test solution
by a porous membrane, so that migration across the barrier is indicative of a
chemoattractant present in the test solution; or 3) proliferation of endothelial cells, which
measures either increased cell number or the incorporation of radiolabeled or modified
nucleotides to detect cells in the S phase of the cell cycle (Folkman and Klagsbrun,
1987). Factors identified by these in vitro assays are likely to have similar effects in
vivo, since close agreement has been shown among in vitro and in vivo assays for
angiogenic factors (Folkman and Klagsbrun, 1987; Redmer et al., 1988; Reynolds et al.,
1992). Nevertheless the angiogenic factors identified by using the in vitro assays need to
be confirmed with one of the in vivo bioassays described above (Klagsbrun and
D'Amore, 1991; Reynolds et al., 1992). Bovine corpus luteum obtained from three
stages of the oestrous cycle (early, developing corpus luteum; mid-cycle, mature corpus
luteum; late cycle, regressing corpus luteum) produced angiogenic activity, as confirmed
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by in vivo (CAM) and in vitro (endothelial cell migration and proliferation) assays
(Redmer etal., 1988).
1.6.3 Angiogenic growth factors
Much of the work on angiogenesis and its regulation has focused on pathological
processes. However, during the last 10-15 years, many growth factors and cytokines
have been found in luteal extracts, luteal cells, or luteinised granulosa cells in culture
(reviewed by Reynolds et al., 1994). A major finding from these studies was that the
angiogenic activity present in media conditioned by bovine follicles and bovine and
ovine corpus luteum binds relatively strongly to heparin affinity columns (Reynolds et
al., 1992; Grazul-Bilska et al., 1992; Grazul-Bilska etal., 1993; Reynolds et al., 1994;
Grazul-Bilska et al., 1995). This observation led Reynolds et al., (1992; 1994) to
hypothesise that these ovarian angiogenic factors belong to one of the families of
heparin-binding angiogenic factors, namely the fibroblastic growth factors (FGF) or the
vascular endothelial growth factors (VEGF).
More recently a third family, the angiopoietins, quite distinct from the heparin-
binding growth factors have been localised in the rat ovary (Maisonpierre et al., 1997).
Histological techniques have proved essential to the elucidation of the potential roles of
some of these factors. Immunocytochemical staining for various growth factors and their
receptors demonstrates the location of expression, i.e. the cell type, and receptor
localisation indicates a site of action. By quantifying such expression throughout the
reproductive cycle and using previous knowledge concerning the angiogenic activity of
the tissue, perhaps from cell proliferation studies, potential roles of such growth factors
in the process of angiogenesis can be established.
Fibroblastic growth factors
Using the aforementioned assays the first inducer of angiogenesis discovered, in 1982,
was basic fibroblastic growth factor (bFGF), followed shortly by its relative acidic FGF
(aFGF) (reviewed by Hanahan and Folkman, 1996). Each protein is unusual in its lack
of a traditional sequence for secretion. Both however, can be released from cells under
certain circumstances (reviewed by Hanahan and Folkman, 1996). A correlation
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between expression of FGFs and angiogenic activity of a tissue has not been
demonstrated. Similar amounts of bFGF protein and mRNA were present across all
stages of the ovine and bovine oestrous cycles (reviewed by Reynolds et al., 2000), and
receptors for FGFs increased during the late luteal phase, the least angiogenic stage,
therefore, it is not clear what function these factors play as angiogenesis occurs
primarily early in the luteal phase (reviewed by Reynolds et al., 2000). It is known that
FGFs and other angiogenic factors can be sequestered in the ECM (extracellular matrix)
of many cell types, including endothelial cells, presumably to be released by proteolytic
degradation of the matrix (Baird and Ling, 1987; Folkman et al., 1988), so it may be the
activation of sequestered growth factors which confers their angiogenic nature.
Vascular endothelial growth factors
In 1983, a secreted protein was identified by its ability to elicit vascular permeability
(Senger et al., 1983); subsequently this factor, VEGF was shown to be a potent inducer
of angiogenesis (reviewed by Brown et al., 1996; Ferrara and Davis-Smyth, 1997).
VEGF is a dimeric glycoprotein which elicits a strong angiogenic response in in vivo
models including the CAM (Leung et al., 1989; Plouet et al., 1989), and the rabbit
cornea (Phillips et al., 1994). VEGF, which has three tyrosine kinase receptors that are
located on endothelial cells (Fit-1, KDR/Flk-1 and Flt-4), is a potent mitogen,
morphogen and chemoattractant for endothelial cells and is stimulated by hypoxia,
cytokines and various hormones (reviewed by Klagsbrun and D'Amore, 1996).
Development of blood vessels in the embryo is dependent on VEGF as the formation of
vessels in mouse embryos lacking a single VEGF allele, was aberrant and resulted in
embryonic lethality (Ferrara et al., 1996). VEGF also increases expression of
plasminogen activators (Pepper et al., 1991) and collagenase (Unemori et al., 1992),
consistent with the predegradative environment that facilitates migration and sprouting
of endothelial cells. VEGF can induce nitric oxide and so may mediate the vasodilation
and increased blood flow that precedes angiogenesis (Ku et al., 1993).
A number of isoforms of VEGF, resulting from mRNA splice variations of the
transcribed VEGF gene, have been discovered. The 121 and 165-amino acid variants
predominate. VEGFi2i is freely soluble and does not bind to heparin. VEGF|65 binds to
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heparin and can be secreted or may bind to the cell surface and ECM. The larger
isoforms, VEGF189 and VEGF206 are sequestered in the ECM and can be cleaved to
release a diffusible proteolytic fragment, VEGF1I0 (reviewed by Ferrara and Davis-
Smyth, 1997).
VEGF binds with high affinity to two tyrosine kinase receptors, Fit-1 (fms-like
tyrosine kinase-1) and KDR (Vaisman et al., 1990). Binding of VEGF causes receptor
dimerisation followed by autophosphorylation and signal transduction. There are
significant differences in VEGF function depending on the receptor utilised. Disruption
of the gene encoding Flt-1 does not prevent the early differentiation of endothelial cells
but impairs development of functional vessels. Activation of Flt-1 results in
autophosphorylation of receptor but does not activate the MAP kinase cascade and does
not mediate mitogenic action of VEGF, it mainly promotes cell migration (Fong et al.,
1995). Disruption of the KDR gene prevents the differentiation of haemangioblasts into
endothelial cells and prevents endothelial cell proliferation. VEGF stimulation of the
receptor results in receptor autophosphorylation and activation of the MAP (mitogen
activated protein) kinase cascade, resulting in increased expression of early response
genes and stimulation of endothelial cell proliferation (Fong et al., 1995). The
distribution and role of Flt-4 seems to be restricted to venous and lymphatic vessels
(Joukov et al., 1996).
VEGF expression in the ovary has been documented in rats (Phillips et al.,
1990), the cynomolgus monkey (Ravindranath et al., 1992a) and humans (Gordon et al.,
1996; Otani et al., 1999). Yan et al., (1993; 1998) have demonstrated VEGF expression
in luteinising granulosa cells aspirated during IVF oocyte retrieval, and suggest that this
factor serves as a paracrine signal in corpus luteum formation. In the corpus luteum
granulosa lutein cells are strongly positive for VEGF in the early luteal phase,
suggesting that luteinising granulosa cells are influenced by the LH surge and ovulation
and are associated with an increased level of VEGF expression (Ravindranath et al.,
1992a; Kamat et al., 1995; Neulen et al., 1998). VEGF mRNA and protein expression is
stimulated by increased LH or hCG levels, in cultured bovine and human granulosa cells
(Gospodarowicz et al., 1985; Neulen et al., 1995; Christenson and Stouffer, 1997;
Neulen et al., 1998). In patients with polycystic ovarian syndrome characterised by
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hypersecretion of LH, intense staining for VEGF occurs in both granulosa and theca
cells, suggesting that VEGF expression is regulated by gonadotropins, especially LH and
hCG (Kamat et al., 1995), and functions in the corpus luteum.
VEGF is required to inhibit apoptosis of endothelial cells not associated to
pericytes. These immature cells are susceptible to falling levels of VEGF causing
disassembly of young vessels, leaving intact those mature vessels with associated
pericytes. This has been shown in some prostate cancers where androgen ablation,
caused VEGF withdrawal which in turn led to the selective demise of immature vessels
not coated with pericytes (Benjamin et al., 1999). Also in the late luteal phase, studies
have shown a correlation with a decrease in VEGF and relative increase in the
proportion of mature, pericyte coated vessels, which are said to function independently
of VEGF (Goede et al., 1998).
The family of VEGF-related molecules has recently grown and contains five
mammalian family members: VEGF (referred to as either VEGF or VEGF-A), placental
growth factor (P1GF), VEGF-B, VEGF-C and VEGF-D. P1GF expression is not
restricted to the placenta, 3 forms have been described, which bind with high affinity to
Fit-1 only (Park et al., 1994). P1GF can potentiate the activity of suboptimal
concentration of VEGF-A (Park et al., 1994). However, because it can form
heterodimers with VEGF-A, which are less potent than VEGF-A homodimers, P1GF
may reduce the bioavailability of active VEGF-A molecules (Cao et al., 1996). P1GF can
stimulate angiogenesis in the rabbit cornea assay, and the mitogenic effect of P1GF is
dependent on endothelial cell type, therefore it has been suggested that the preferential
target of P1GF is the endothelium of postcapillary venules (Ziche et al., 1997).
VEGF-B is particularly abundant in heart and skeletal muscle. Two isoforms
have been detected: VEGF-B]67, which remains associated with the cell or extracellular
matrix, and VEGF-B186, homodimers of which are readily secreted (Olofsson et al.,
1996). In a similar way to P1GF, VEGF-B can heterodimerise with VEGF-A and
influence the bioavailability of this molecule (Olofsson et al., 1996). Mice lacking
VEGF-B are healthy and fertile although hearts are reduced in size which signifies a role
for VEGF-B in the development or function of coronary vasculature (Bellomo et al.,
2000).
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VEGF-C binds to KDR and with greater affinity to the Flt-4 receptor. It increases
vascular permeability and stimulates migration and proliferation of endothelial cells.
VEGF-C is expressed during embryonic development in regions where lymphatics
sprout from venous vessels (Kukk et al., 1996). It is expressed in adult tissues and is
postulated to play a role in the maintenance of lymphatic endothelial differentiation
(Kukk et al., 1996). VEGF-D is the newest member of the VEGF family, and is 48%
identical to VEGF-C. It is strongly expressed in the foetal lung during development, and
in the adult, it is primarily found in skeletal muscle, heart, lung and intestine (Yamada et
al., 1997).
The functions of these other VEGF family members in angiogenesis in the adult
are unclear. P1GF and VEGF-B may play a role in the modulation of VEGF-A actions.
Expression of these factors has not been clearly demonstrated in the primate ovary and
so a role in ovarian angiogenesis remains to be elucidated. There is compelling evidence
to suggest that VEGF-A plays a major role in physiological angiogenesis, it is expressed
in the ovary and has multiple functions promoting the angiogenic process.
Angiopoietins
Over the last 3-4 years another family of angiogenic growth factors, the angiopoietins,
have been discovered. Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) are specific
for the endothelial cell receptor tyrosine kinase, Tie-2 (Tyrosine dinase with
immunoglobulin and epidermal growth factor homology domains, also known as TEK).
Ang-1 is an agonist for the receptor inducing autophosphorylation, whereas, Ang-2 is a
naturally occurring antagonist, which has the same affinity for the receptor but does not
induce phosphorylation. There is another related receptor, Tie-1, the ligand(s) for which
have not been identified. The general functions of the Tie-2 receptor have been deduced
from studies in mice where the gene has been removed or over expressed. (Puri et al.,
1995; Sato et al., 1995; Suri et al., 1996; Vikkula et al., 1996; Maisonpierre et al.,
1997). The absence of Tie-2 or its agonist Ang-1 prevents normal angiogenesis (Sato et
al., 1995; Suri et al., 1996), demonstrated by the severe retardation of remodelling and
stabilisation of primitive vasculature, it also has a direct action on endothelial cell
survival (Papapetropoulos et al., 1999). In vitro, Ang-1 has no control over endothelial
Chapter 1 Introduction 47
cell proliferation but stimulates vessel sprouting (Koblizek et al., 1998), Ang-2 inhibits
this effect (Maisonpierre et al., 1997). Similarly, mouse embryos with over expressed
Ang-2 have defects similar to those lacking Tie-2 or Ang-1 (Maisonpierre et al., 1997).
In the adult, Ang-1 appears to be constitutively expressed serving to maintain the
integrity of the already established vasculature (Maisonpierre et al., 1997; Witzenbilcher
et al., 1998). The effect of Ang-1, has been attributed to a role in pericyte-endothelial
cell interactions and stabilisation of the neovasculature.
In the presence of Ang-2 the role of Ang-1 is decreased by competitive inhibition
at the receptor level. Ang-2 when implanted with VEGF to the cornea promoted
angiogenic activity culminating in the formation of long, wide and immature vessels
(Asahara et al., 1998). Detailed localisation of Ang-2 mRNA in the rat ovary revealed
that Ang-2 was either expressed at regions of active angiogenesis together with VEGF at
sites of vessel sprouting and ingrowth, in the early corpus luteum, or at sites of vascular
regression in the absence of VEGF, in atretic follicles (Maisonpierre et al., 1997). This
led to the hypothesis that Ang-2 causes destabilisation of the vessels by preventing Ang-
1-induced pericyte-endothelial cell associations, facilitating vessel sprouting in response
to VEGF; and that in the absence of VEGF Ang-2 destabilisation results in regression of
the vasculature. Temporal changes in the expression of angiopoietins and VEGF in the
rat ovary have been described and support this hypothesis of angiopoietin/VEGF
regulation of angiogenesis (Maisonpierre et al., 1997). Control of luteal function differs
markedly between species and it is not known whether similar relationships between
positive and negative mechanisms exist in the primate corpus luteum.
1.6.4 Anti-angiogenic factors
Endogenous
It appears that most endogenous angiogenesis inhibitors are stored as cryptic parts of
larger molecules that are not themselves inhibitors of angiogenesis, with the exception of
non-specific inhibitors such as platelet factor-4 and certain interferons. This prototype
came from the discovery that a 29kDa (kilodalton) fragment of fibronectin inhibited
endothelial cell proliferation in vitro (Homandberg et al., 1985). Subsequently, a
fragment of prolactin, the 16kDa fragment, was shown to be an inhibitor of endothelial
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cell proliferation, whereas the intact fragment was not (Ferrara et al., 1991; Clapp et al.,
1993). Also a potent inhibitor of angiogenesis, angiostatin, has been identified as a
fragment of plasminogen (O'Reilly et al., 1994). In tumour cases, circulating angiostatin
is able to maintain the dormancy of metastases and primary tumours by blocking blood
vessel growth, resulting in small nests of tumour cells that cycle through proliferation
and apoptosis, restrained by their inability to induce angiogenesis to support their growth
(O'Reilly et al., 1994; Holmgren et al., 1995). More recently, endostatin, a proteolytic
cleavage product of collagen XVIII, itself a normal component of the basement
membranes that envelope the vascular tubes formed by endothelial cells, inhibited
subcutaneous growth of four tumour types reducing tumour volume by more than 90%
(O'Reilly etal., 1997).
The capability to release inhibitor fragments from storage as cryptic segments of
abundant proteins may contribute to maintaining the normal quiescence of the
vasculature and to turning off transitory angiogenic processes such as wound healing.
Hanahan and Folkman (Hanahan and Folkman, 1996) suggest for tumour angiogenesis
at least, that the switch to the angiogenic phenotype depends on the balance between
expression of active angiogenic factors and inhibitors. They suggest that when the levels
of inhibitors are sufficiently high, the signals of the positive activator(s) are overruled,
keeping (or turning) the angiogenic switch off. And when the expression of angiogenic
growth factors increases, most likely in the face of declining inhibition, the balance
shifts and angiogenesis ensues. Activation of intense angiogenesis during the formation
of the corpus luteum could be triggered from such a shift in balance. Angiogenesis
inhibitors are blood or blood vessel borne and could be present in the extensive follicular
vasculature, maintaining the low level of angiogenic activity necessary for the
maintenance of follicular dominance. The balance may then shift, under stimulation
from the LH surge, to increased production of angiogenic inducers, such as VEGF,
which initiate a prolific angiogenic response.
Exogenous
In addition to endogenous inhibitors, synthetic compounds with anti-angiogenic activity
have been identified using cell culture assays. In 1990, Ingber et al., (1990) discovered a
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fungal contamination that induced a local gradient of endothelial cell rounding, but was
not toxic. Further work led to the isolation and identification of the fungus Aspergillus
fumigatus. The active fraction was identified as a naturally secreted antibiotic
fumagillin. TNP-470 (also known as AGM-1470) is a synthetic analogue that retains the
potent anti-angiogenic activity of fumagillin without its toxic side effects. In vitro, both
fumagillin and TNP-470 inhibit endothelial cell proliferation, migration and capillary
tube-like formation with a minimal effect on growth of non endothelial cells. Systemic
administration of TNP-470 inhibits bFGF-induced neovascularisation in subcutaneous
sponge implants (Kusaka et al., 1991) and has marked anti-tumour activity (Brem and
Folkman, 1993). Klauber et al., (1997) demonstrated that when non-pregnant cycling
female mice were treated with TNP-470 an inhibition of both corpus luteum and
endometrial maturation occurred. Exposure of pregnant mice resulted in complete failure
of embryonic growth as a result of interference with decidualisation reflecting impaired
endothelial maturation.
Other exogenous inhibitors of angiogenesis have been found. Suramin is a
polyunsulphonated naphthylurea that blocks angiogenesis at several points. Initially it
binds to heparin-binding growth factors, suppressing cell proliferation and interferes
with the expression of cell adhesion molecules and produces significant cell shape
changes, thus reducing the capacity of endothelial cells to respond to growth factors
(Fan et al., 1995). Platelet factor-4 has anti-coagulent activity which could create
problems in its use as an angiogenic inhibitor. A recombinant synthesised version (rPF-
4-241) has been developed in which the heparin binding site has been mutated and so the
molecule has no anti-coagulent activity (Maione et al., 1991). Suppressers of protease
activity such as tissue inhibitors of matrix metalloproteinases (TIMPs) occur naturally
and keep MMP activity in check in normal non-angiogenic tissues. A synthetic non-
peptide MMP inhibitor, batimastat, has been shown to strongly inhibit tumour growth in
murine models (Davies et al., 1993).
With the increased knowledge of the factors which control angiogenesis
monoclonal antibodies and soluble receptors have been developed to specifically inhibit
growth factor biological activity, and have potential therapeutic use. Because VEGF is
specific for endothelial cell receptors, VEGF is a promising target for the development
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of specific anti-angiogenic drugs. Soluble VEGF receptor has been shown to inhibit
angiogenesis in vitro (Kendall and Thomas, 1993), and antibodies to VEGF have been
demonstrated to block tumour growth in three mouse models (Kim et al., 1993). In
addition, research has been carried out on the development of treatments to selectively
inhibit protein tyrosine kinases and specifically kill endothelial cells. The selective
tyrosine kinase inhibitors, lavendustin A and genistein, were shown to suppress the
angiogenic action of VEGF in rats (Hu and Fan, 1995), and inhibit the growth of
cultures of proliferating endothelial cells (Fotsis et al., 1993), respectively. The selective
toxicity of endothelial cells has been reported by the administration of a chemically
linked recombinant VEGF conjugated to a truncated from of diphtheria toxin to mice
with established subcutaneous tumours. The VEGF-toxin was shown to be selectively
toxic to endothelial cell lines, inhibited experimental neovascularisation of the CAM
(chorio-allantoic membrane), and the conjugate-treated animals displayed a significant
inhibition of tumour growth with the absence of injury to highly vascularised normal
tissues (Olson et al., 1997).
1.7 Clinical relevance of luteal angiogenesis research
The physiological angiogenesis that occurs in the corpus luteum and other female
reproductive organs occurs in a cyclical manner and therefore must be tightly regulated.
Growth and development of the ovarian preovulatory follicle and subsequent formation
of the corpus luteum is believed to be dependent on associated intense angiogenic
activity for the supply of oxygen, nutrients, steroid precursors and gonadotropic stimulus
for normal functioning. The corpus luteum is critical for successful maintenance of
pregnancy in mammals because it is the primary source of the progestational hormone
progesterone. In the corpus luteum in the absence of conception, this intense
angiogenesis is followed by programmed cell death culminating in luteal vascular
regression and luteolysis so that the next cycle can commence. This tight physiological
control contrasts to that of tumours in which prolonged and often unabated angiogenesis
takes places. This raises the possibility that endogenous inhibitors of angiogenesis play
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an integral role in the reproductive tract. Therefore these tissues represent an
outstanding, readily available system in which to study physiological angiogenesis.
The clinical relevance of such studies becomes apparent. The inhibition of luteal
angiogenesis could lead to defects in progesterone production and provide a novel
approach to post-ovulatory fertility control. Administration of the angiogenic inhibitor
TNP-470, to cyclical mice resulted in inhibition of corpus luteum formation and
endometrial maturation (Klauber et al., 1997). Such luteal angiogenesis is believed to be
necessary for progesterone production, which in turn is essential for the establishment of
pregnancy. Therefore, inhibition of luteal angiogenesis could lead to decreased luteal
function and failure to establish pregnancy. Conversely, promotion of ovarian
angiogenesis, particularly in the follicle, could help treat some infertile conditions such
as luteal phase deficiency, which is characterised by low plasma progesterone
concentrations, and is primarily caused by an under developed follicle.
The association of angiogenesis and tumour growth and metastasis has been well
documented. The growth of any tissue mass, demonstrated by Folkman in tumours, is
dependent on an ever increasing vascular supply for provision of oxygen, nutrients and
growth factors (Folkman et al., 1985). Increased microvessel densities are characteristic
of advanced tumours and are demonstrated to have a bearing on potential metastasis and
patient survival. The corpus luteum offers a unique opportunity to study the factors
involved in regulation of angiogenesis in vivo and may have direct clinical relevance on
research into tumour biology.
1.8 Aims of the thesis
At the beginning of this project little was known about the effect of inhibition of the
highly active physiological angiogenesis that occurs in the reproductive tissues,
especially in the primate corpus luteum. The aims of this thesis were to increase our
understanding of the control of primate luteal angiogenesis, and assess its role in luteal
function, by specifically inhibiting this process in the marmoset monkey, and at the same
time to develop a working primate model to test putative angiogenic inhibitors.
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Before the effects of such putative angiogenesis inhibitors could be examined in
the marmoset, increased knowledge of the control of angiogenesis in the corpus luteum
of this species was needed. Firstly, the primary objectives of the thesis were to examine
the angiogenic activity associated with the luteal phase, using semi-quantitative
immunocytochemical methods to measure parameters of angiogenesis, such as
endothelial cell proliferation, luteal endothelial cell content, and expression of the
angiogenic growth factor, VEGF. Secondly, the periods of most prolific angiogenesis
were targeted for inhibition by in vivo administration of potential luteal angiogenesis
inhibitors. To assess the endocrine control of luteal angiogenesis, a GnRH antagonist
was used. Subsequent studies targeted the angiogenic process directly with the use of
TNP-470 and VEGF immunoneutralisation. The efficacy of such treatments were
addressed by examining parameters of the angiogenic process, and their effects on luteal
function determined by measurement of plasma progesterone concentrations. Lastly, the
availability of hCG rescued human corpus luteum provided an opportunity to assess the
contribution of angiogenic activity to the mechanisms of luteal rescue in early
pregnancy; and to investigate the endogenous molecular control of luteal angiogenesis
by analysing the relationship in expression of the angiopoietins, their Tie-2 receptor, and
VEGF-A and its Flt-1 and KDR receptors.
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2.1 Sources of reagents, enzymes and antibodies
All reagents and Rnase (ribonuclease)-free H20 were obtained from Sigma Chemical
(Poole, Dorset, UK), all enzymes were from Promega (Promega UK, Southampton,
UK), and all antibodies were from Dako Ltd., (High Wycombe, Bucks, UK), unless
otherwise stated.
2.2 Experimental models
The marmoset monkey (Callithrix jacchus) was the animal model used for this in vivo
exploration of luteal angiogenesis. Rodents were not suitable because the mechanisms
which regulate luteal function in rodents and primates are markedly different, and in the
non-fertile cycle of the rodent, the corpus luteum is active for less than a day, while that
of many primates is functional for at least 2 weeks prior to its regression (Behrman et
al., 1993). The common marmoset is becoming more popular for biomedical science
research. Some salient features of this versatile animal are: ease of handling, fecundity,
absence of post-partum acyclicity related to lactation, and quick sexual maturation (Torii
et al., 1996).
2.2.1 The marmoset ovulatory cycle
The marmoset ovulatory cycle lasts approximately 28 days and there are usually two or
three ovulations (Harding et al., 1982; Hearn, 1983). The follicular phase lasts about 8
or 9 days (Harding et al., 1982). In most cycles the 2 or 3 follicles grow at similar rates
and ovulation occurs at approximately 12 hour intervals (Torii et al., 1996). Follicular
growth in primates was believed to be suppressed until the end of the luteal phase (Baird
et al., 1975; diZerega and Hodgen, 1981). However, Summers et al., (1985) have
demonstrated that an average interval of 10.7 days is required for growth of follicles to
the ovulatory stage after the sudden termination of the corpus luteum with PGF2a
analogue, indicating that follicular growth begins during the last two days of the natural
luteal phase, concomitant with a gradual decline in circulating progesterone and
estradiol as luteal function is ending.
Chapter 2 General Materials and Methods 55
The luteal phase lasts approximately 20 days (Harding et al., 1982). The primate
corpus luteum is dependent on trophic support of LH from the pituitary gland. LH binds
specifically to the LH receptor, a seven transmembrane G-protein-coupled receptor
(Segaloff and Ascoli, 1993) on the surface of luteal cells, to stimulate steroidogenic
enzymes to produce progesterone via an increase in intracellular cAMP. Luteal function
in the marmoset is dependent on continuing LH secretion (Fraser et al., 1986).
Luteal regression is characterised by decreasing steroid hormone production and
a reduction in luteal mass; however, the exact mechanisms controlling structural and
functional regression in primates are poorly understood. The decrease in steroid
production associated with physiological luteal regression is not associated with any
apparent changes on either serum LH concentrations or pulse frequency (Hutchison et
al., 1986). Neither is a uterine luteolytic signal responsible, as in ruminants and rodents.
It is therefore likely that an intraovarian mechanism is important in controlling luteal
regression in primates. In marmosets, luteal regression can be induced by treatment with
either PGF2ot or a GnRH antagonist.
2.2.1.1 PGF2a-induced luteolysis
In the marmoset, induction of luteolysis by administration of PGF2a is a commonly used
tool in the investigation of marmoset luteal regression (Summers et al., 1985; Webley et
al., 1989; Michael and Webley, 1993; Fraser et al., 1995; Young et al., 1997; Duncan et
al., 1998b; Fraser et al., 1999b). It is known that a single intramuscular injection of
PGF2a analogue, such as cloprostenol, causes luteolysis when given after day 8 of the
luteal phase (Summers et al., 1985), and that only the mature corpus luteum is
susceptible (Summers et al., 1985), perhaps because of an age-related increase in PG
receptors. However, the mechanism of action of PGF2ot in the marmoset corpus luteum is
not fully understood. Webley et al., (Webley et al., 1991) demonstrated that within one
hour of administration, clostoprenol induced a significant fall in peripheral progesterone
concentrations and administration was not associated with any drop in circulating LH
concentrations. Human CG failed to sustain progesterone when given with clostoprenol,
thus providing indirect evidence that cloprostenol acts directly at the corpus luteum to
prevent the luteotropic actions of LH.
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Duncan et al., (Duncan et al., 1998b) demonstrate that PGF2a-induced luteolysis
results in a rapid loss of LH receptor mRNA and protein inhibiting the luteotropic action
of LH. In vitro, PGF2a inhibited LH-stimulated progesterone production, which was
thought to be a post-cAMP mediated effect (Abayasekara et al., 1993; Auletta and Flint,
1988; Michael et al., 1994). PGF2a is known to activate protein kinase C (Niswender et
al., 1994), which has several effects on the steroidogenic pathway, one being the
inhibition of cholesterol transport to the cytochrome P450scc enzyme (Wiltbank et al.,
1993). Duncan et al., (1998b) have demonstrated that 3P-HSD mRNA and protein
expression are also inhibited during PGF2ot-induced luteolysis in the marmoset. These
data and Michael and Webley (Michael and Webley, 1993) confirm that PGF2a-induced
luteolysis involves the inhibition of LH action at sites both prior and subsequent to
cAMP accumulation.
2.2.1.2 Comparison with GnRH antagonist-induced luteolysis
It is agreed that the GnRH antagonist acts at the pituitary to prevent the release of LH
(Fraser et al., 1986; Hodges et al., 1988; Webley et al., 1991). Webley et al., (Webley et
al., 1991) demonstrated that progesterone concentrations declined after an initial
decrease in LH, and that the corpus luteum could be rescued from luteolysis by
administration of hCG, suggesting that the action of the GnRH antagonist in reducing
progesterone was the result of LH suppression.
Ultrastructural studies of PGF2c(- and GnRH antagonist-induced luteal regression
demonstrate marked morphological changes (Fraser et al., 1999b). Degenerative
changes in the smooth ER were more advanced than any observed in the mitochondria,
suggesting that the early failure to secrete progesterone was a result of the acute
sensitivity of the smooth ER. After PGF2a administration the smooth ER became
markedly swollen and formed a number of vesicles, such that in the advanced state these
vesicle coalesced into large vacuoles. After GnRH antagonist treatment, the membranes
of the smooth ER and possibly segments of the redundant plasma membrane, became
condensed into islands of concentric membranes that resulted in the formation of myelin
bodies. This phenomenon was rarely observed following PGF2a administration. While
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the suppressive effects of GnRH antagonist treatment can be overcome by concomitant
administration of hCG (Fraser et al., 1987; Webley et al., 1991), the marmoset corpus
luteum cannot be rescued when PG analogue and hCG are given together (Webley et al.,
1991). Since both treatments result in failure of LH stimulation of steroidogenesis, the
ultrastructural differences indicate an additional effect of PG on the lutein cell as a result
of its direct action.
2.2.2 The primate luteal phase
There are three distinct phases during the normal structural and functional lifespan of the
primate corpus luteum. The early luteal phase when the corpus luteum is forming and
increasing its production of progesterone, the mid-luteal phase when the corpus luteum
is fully formed and its progesterone production is maximal, and the late luteal phase
when progesterone production falls and the gland begins to regress. Marmoset luteal
tissue from these three stages of development was used to investigate the control of
luteal angiogenesis in this species. In the human, the fall in progesterone production
during the late luteal phase was prevented by exposure to logarithmically increasing
concentrations of exogenous chorionic gonadotropin, simulating early pregnancy. This
'rescued' corpus luteum can be considered a fourth stage of the luteal lifespan. Human
tissue from these four stages was available to investigate the control of angiogenesis
throughout the normal lifespan of the human corpus luteum and during luteal rescue. In
addition, subsequent studies involved the manipulation of marmoset luteal angiogenesis
and function by specific targeting of factors involved in the angiogenic process.
Home Office regulations restrict the use of other mono-ovulatory species of
primate with a luteal phase length more analogous to that of a human, for such
experimentation. However, where appropriate it was possible to compliment this work
with previously collected human luteal tissue. Together, using the marmoset and human
corpora lutea, these models were powerful tools for the exploration of luteal
angiogenesis throughout the normal functioning luteal phase and after manipulation with
specific anti-angiogenic agents.
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2.3 Marmoset tissue
2.3.1 Marmoset husbandry
All marmosets were housed in a 'state of the art' primate centre located on the outskirts
of Edinburgh. Primate centre staff were responsible for upkeep and maintenance of the
animals and unit. Common marmoset monkeys were housed in cages in rooms
maintained at temperatures between 20°C and 25°C and artificially lit between 0.700 h
and 19.00 h. The animals were fed daily with a selection of fruit, SDS Mazuri (E)
primate diet pellets, and high protein porridge with multivitamin supplements three
times per week and water was continuously available. Adult females having a body
weight of approximately 350g, with regular ovulatory cycles, were housed together with
a younger sister or prepubertal female in cages measuring 1.15m in height, 1.1m in
depth and 0.6m wide. Each contained larch branches and a nest box with the floor of the
cage filled with wood chippings to allow foraging. Blood samples were collected three
times per week by femoral venepuncture without anaesthesia while the animals were
held in a restraining device (Hearn et al., 1978). Syringes were sealed and centrifuged
for 20 minutes at 1000 x g, plasma was subsequently removed and stored at -20°C until
assayed for progesterone to determine the date of ovulation and luteal stage.
2.3.2 Treatment regimes
Administration of treatments was undertaken by staff at the primate centre. All
experiments were carried out in accordance with the Animals (Scientific Procedures)
Act, 1986. To synchronise the timing of ovulation and administration of treatments, all
control and experimental animals received lpg PGF2a analogue (chloprostenol, Planate,
Coopers Animal Health Ltd., Crewe, UK) intramuscularly (i.m.) during the mid- to late
luteal phase of the pre-treatment cycle to induce luteolysis. Ovulation normally followed
10 days later (Summers et al., 1985). Specific details of the dose, timing and duration of
treatment can be found in the relevant experimental chapters. The basic principle used
was to either prevent the onset of angiogenesis by administration for 3 days in the early
luteal phase (treatment regime 1) or continued treatment for 10 days from the early to
the mid-luteal phase (treatment regime 2), or to intervene in the process by
administration for 3 days specifically in the mid-luteal phase (treatment regime 3). A
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diagrammatic representation of the regimes used is shown in Figure 2.1. Blood was
taken daily for progesterone assay during experimentation.
Cell proliferation in luteal sections was measured as one parameter of
angiogenesis. In order to visualise proliferation, bromodeoxyuridine (BrdU; Boehringer
Mannheim, Sussex, UK) was administered. BrdU is a thymidine derivative which is
incorporated into the DNA of proliferating cells during the S-phase (DNA synthesis
phase) of the cell cycle. Twenty milligrams, dissolved in 500pl physiological saline, was
administered intravenously (i.v.) to all animals lh prior to tissue collection.
2.3.3 Collection of tissue
For most experiments tissue was collected throughout the luteal phase of the cycle or the
day after final treatment. Additionally, follicular phase tissue was used where necessary
to examine regressed corpora lutea, this had been obtained for previous experiments
which took place in our laboratory. Animals were sedated using 100p,l ketamine
hydrochloride (Parke-Davis Veterinary, Pontypool, UK), i.m., and killed with an i.v.
injection of 400ml Euthetal (sodium pentobarbitone, Rhone Merieux, Harlow, Essex,
UK). Ovaries and uteri were removed immediately, weighed, fixed in 4%
paraformaldehyde (PFA) in 0.01M phosphate-buffered saline (PBS; pH 7.4, containing
2.7mM KC1, 0.137M NaCl) for paraffin wax-embedding. For selected marmosets, a
small piece of corpus luteum was fixed in 3% glutaraldehyde in 0.1M cacodylate buffer,
pH 7.3, for araldite resin-embedding.
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D
Day relative to ovulation
Figure 2.1 Schematic of treatment regimes
Prostaglandin is given in the mid-late luteal phase of the pretreatment cycle to
induce luteolysis (progesterone levels decrease) and synchronise the timing of
ovulation, which occurs 10 days later as seen by the rise in progesterone
concentration. Treatment regime 1 is for 3 days starting from the day of ovulation,
treatment regime 2 is for 10 days starting at the time of ovulation, and treatment
regime 3 is for 3 days specifically in the mid-luteal phase, starting on luteal day 7.
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2.3.4 Progesterone radioimmunoassay (RIA)
Marmoset ovulatory cycles were monitored by three times weekly measurements of
plasma progesterone concentration for a number of cycles prior to use of the animal.
After treatment had commenced progesterone concentrations were monitored daily.
Progesterone RIA was carried out by the in-house assay according to Smith et al.,
(1990). Marmoset plasma samples were thawed, vortexed and 2.5jd of the plasma added
to 147.5|xl of progesterone assay buffer (1M phosphate citrate and 1% gelatin, pH 6). A
standard curve was prepared, from a progesterone standard, which was diluted in a
volume of lOOjul to 2.5, 5, 10, 25, 50, 100, 250, 500 and lOOOng/ml. In addition, human
post-menopausal serum (PMS), which does not contain progesterone, was diluted in
47.5jul of assay buffer and added to each of the standard curve samples so that the
volume in each was 147.5^1. All samples and the standard curve were prepared in
duplicate. To each of the samples and standard curve, lOOgl of primary antibody, sheep
anti-progesterone, diluted 1:1000 in assay buffer, was added. To assess non-specific
binding, a sample was prepared which contained IOOjj.1 of progesterone assay buffer,
primary antibody was omitted. Iodinated tracer, thymidine progesterone (125I-PGT,
Amersham, Bucks, UK) was diluted 1:5000 in tracer buffer (1M phosphate citrate, pH6)
and counts per minute (cpm) in lOOjxl determined. Thereafter, the tracer concentration
was adjusted to 15000cpm per 100|xl, 0.1% (w/v) ANSA (8-anilino-l-naptha-
lenesulfonic-acid) was added and 100|d was aliquotted to each sample. In addition, 2 x
IOOjj.1 samples of the diluted tracer containing 0.1% (w/v) ANSA was used in the assay
to assess 125I-PGT total counts. Assay samples were vortexed and incubated at room
temperature for 3 hours. Subsequently, the secondary antibody, donkey anti-goat diluted
1:64 in assay buffer, was added to all samples except those measuring the 125I-PGT total
counts. Normal sheep serum (SAPU, Carluke, Lanarkshire, UK) was diluted 1:32000 in
assay buffer and lOOgl was added to all samples. Samples were vortexed and incubated
overnight at 4°C. One millilitre of 0.9% saline/tritonX/polyethylene glycol was added to
each sample and samples centrifuged at 4°C for 30 min. The supernatant was
subsequently removed, the pellets air dried and the amount of the radioactivity
incorporated into each pellet measured using a gamma counter. The sensitivity of the
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assay was 0.07pmol per tube (0.022 ng/ml) and the inter- and intra-assay coefficients of
variation were 15% and 4% at the centre of the standard curve, respectively. The inter-
and intra-assay coefficients of variation were more varied at the extremes.
2.3.5 Classification of the stage of the ovulatory cycle
Classification of the stage of the marmoset ovulatory cycle was determined by
progesterone plasma concentrations based on sampling three times per week (Monday,
Wednesday and Friday). The follicular phase was defined as the period when plasma
progesterone concentration was < 12nmol/L. The luteal phase was determined as the
stage when plasma progesterone concentration rose above 30nmol/L and was followed
by a sustained increase. The specific day of the luteal phase was classified according to
the following guidelines: 1) If the first measurement of plasma progesterone
concentration above 30nmol/L was between 30 and 50nmol/L this was classified as day
0 (the day of ovulation). 2) If the first plasma progesterone measurement above 30
mnol/L was between 50 and lOOnmol/L this was classed as day 1 (assuming ovulation
on the previous day). 3) On the rare occasions when the first measurement above
30nmol/L was >100nmol/L (e.g. on a Monday) this was classed as day 2 (assuming
ovulation had occurred on the Saturday). Animals were classified as early luteal, days 2-
4 after a sustained rise in progesterone concentration above 30nmol/L; mid-luteal, days
8-10; and late luteal, days 14-20.
2.4 Human tissue
Patients were recruited and human tissue was collected by Dr Colin Duncan and Dr Faye
Rodger for previous studies. Paraffin wax blocks and frozen tissue from the early, mid-,
late and rescued stages of the luteal phase were available for use in subsequent studies.
In brief, the following methods were used for patient recruitment and tissue collection.
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2.4.1 Recruitment of patients
Healthy women, with regular menstrual cycles, who had not received any form of
hormonal therapy in the last three months, who did not have a history of infertility, and
who were having open abdominal hysterectomy for benign conditions, were identified
from the case records of all women on the waiting list for hysterectomy at the Royal
Infirmary of Edinburgh. A detailed menstrual history from women interested in
participating in the study was taken, and the women categorised as to whether their
operation would fall in the luteal phase of the cycle, would be suitable for luteal rescue
i.e. the operation falling 2 days before or after expected menses, or unsuitable for the
study. All women whose operation would fall in the luteal phase of the cycle collected
an early morning urine specimen for LH assay 7 days after their last menstrual period
(LMP) until hospital admission. Plasma was collected on the day of surgery and assayed
for progesterone concentration. Those women who agreed to take part in the luteal
rescue study took urine samples from day 7 of their menstrual cycle for LH assay. The
date of ovulation was defined as 24 hours after the start of any clear single day of
urinary LH peak (LH+1). Daily i.m. injections of hCG (Profasi; Serono, Welwyn
Garden City, Herts, UK) were given from LH+7 until operation. Dosage commenced at
125 IU and doubled daily for 5-8 days. This regime has previously been shown to mimic
the hormonal changes of early pregnancy (Illingworth et al., 1990).
2.4.2 Collection and dating of tissue
Whole corpora lutea were enucleated from the ovary at the time of hysterectomy. The
tissue was immediately divided into 4 radial segments to ensure that the whole thickness
of the gland was represented by any one piece. Two blocks were snap frozen in liquid
nitrogen and stored at -70°C for RNA extraction. One piece was frozen in embedding
medium (Tissue-Tek OCT compound; Miles Inc., Elkhart, IN, USA) and stored at -70°C
for sectioning. The final piece was fixed in 4% PFA for paraffin wax-embedding, as
described previously for marmoset tissue, for subsequent immunocytochemical
examination. In addition, an endometrial biopsy was obtained, fixed in 4% PFA and
embedded in paraffin wax.
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LH concentrations were measured in each of the serial urine samples. Corpora
lutea were classified as early luteal if collected 1-5 days after the urinary LH peak. They
were classified as mid-luteal 6-10 days after the LH peak, and late luteal from 11-14
days after. Those corpora lutea collected after hCG administration were classified as
'rescued'. In all cases, morphological examination of the luteal phase endometrium (Li
et al., 1988) was used to confirm the luteal phase classification. Only patients whose
urinary LH dating, LMP and endometrial dating were in agreement were used in
subsequent definitive studies.
2.5 Tissue fixation, processing and sectioning for paraffin blocks
Tissue fixation was needed to prevent autolysis and bacterial attack, and also to ensure
that the tissue remained as close to its in vivo state as possible without loss or
rearrangement. The fixative used in these studies was 4% paraformaldehyde (PFA).
Aldehyde fixatives form cross-links between protein and aldehydes developing a stable,
static structure. Morphology is retained to a satisfactory level and in their native states
DNA and RNA do not react to any extent with formaldehyde so for the purposes of
immunocytochemistry and in situ hybridisation this fixative was chosen. Ovaries and
uteri obtained were fixed in 4% PFA for 24 hours and transferred to 70% EtOH until
processed into paraffin wax. Ovaries were bisected through the maximal part of the
largest corpus luteum to ensure that cross sections through the widest part of the gland
could be obtained. Uteri were bisected longitudinally through the luminal cavity so that
sections would contain endometrium. Processing and paraffin wax-embedding was
carried out by the MRC HRSU Histology department. Tissue was dehydrated through a
series of graded alcohols before being saturated by paraffin wax. This process was
performed using a 17.5h automated cycle on a Leica TP-1050 processor (Leica UK
Limited, Milton Keynes, UK). The tissue was then embedded with the cut surfaces
facing up so that the maximal part of the corpus luteum and uterus containing
endometrium could be sectioned. Glass microscope slides to be used for
immunocytochemistry were dipped twice in a 4% (v/v) solution of 3-aminopropyl
triethoxysilane (TESPA) in acetone (BDH, Merck Ltd., Poole, Dorset, UK), washed in
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acetone, rinsed in double distilled water and dried overnight. The TESPA coating
increased the adherence of the tissue to the slide. Slides used for in situ hybridisation
were RNase free and electrostatically charged for improved binding (BDH). Paraffin
wax sections were cut (5gm) using a hand-operated microtome (Jung RM2035; Leica)
with disposable blades. Sections were floated onto a heated water bath (containing
distilled water for immunocytochemistry sections or RNase free water for sections to be
used for in situ hybridisation) at approximately 50°C. Sections were transferred onto
slides and dried overnight before use.
2.6 Haematoxytin and eosin staining
These stains were routinely prepared in the Histology department. Harris's haematoxylin
was prepared by dissolving 2.5g of haematoxylin (BDH) in absolute alcohol which was
added to alum which had previously been dissolved in 500ml warm dH20 (Stevens and
Wilson, 1996). This mixture was boiled and either mercuric oxide (1.25g) or sodium
iodate (0.5g) was carefully added. The stain was then rapidly cooled by plunging the
flask into a sink containing cold water and crushed ice. Once cold 20ml of glacial acetic
acid was added. Eosin Y is prepared by preparing a 1% solution with distilled water and
0.5ml of acetic acid added to 1L (Stevens and Wilson, 1996). The exact haematoxylin
and eosin (H and E) staining protocol is detailed in Chapter 3.
2.7 Immunocytochemistry
Immunocytochemistry is a method used to localise a specific antigen (usually protein)
within a cell using a specific antibody raised to an epitope of the protein in question.
This is a useful technique as it allows an antigen to be localised to a specific cell type,
often a specific cellular location. Quantification of immunocytochemical staining is
possible and is generally based on parameters, such as the number of positive cells in a
population, the area and intensity of staining, or any combination of the three. Advances
in image analysis systems have increased the efficiency and accuracy of quantification
of such immunostaining. The immunocytochemical procedure involves building up a
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sandwich of antibodies to increase the available binding sites for the tracer and detection
systems used, in this case either the alkaline phosphatase anti-alkaline phosphatase
(APAAP) or avidin/biotin complex - horse-radish peroxidase (ABC-HRP) based tracer
systems, as depicted in Figure 2.2.
2.7.1 Antigen retrieval
Fixation and paraffin wax-embedding can mask some antigenic epitopes. It was
necessary in most cases to expose these using either proteolytic digestion (Huang et al.,
1976) or heat treatment (Shi et al., 1991). These methods of antigen retrieval have to be
optimised because over digestion or heating can result in tissue damage and substantial
loss of morphology. Where proteolytic digestion was required, slides were incubated in
0.1% (w/v) trypsin with 0.1% (w/v) calcium chloride, buffered to pH 7.6 with 0.1M
sodium hydroxide, for 20 min at 37°C. Proteolytic digestion was stopped by submerging
slides in cold tap water. Where heat treatment was required slides were subjected to
microwaving or pressure cooking. Slides were microwaved for 4 rounds of 5 min on full
power (750W) in 0.01M citrate buffer, pH 6, after each round the volume of buffer was
topped up with warm dH20. Slides were left to stand in hot buffer for a further 20 min
before transferring to TBS. This was superseded by less time consuming pressure
cooking which was more consistent for antigen retrieval than the microwave which
contains 'hot' and 'cold spots'. Two litres of 0.01M citrate buffer or 3M glycine, 0.1%
EDTA (ethylenediaminetetra acetic acid) buffer, pH 3, were heated to boiling point in
the pressure cooker and the slides in a metal rack lowered in. The lid was sealed and
pressure applied, timing (5 min) began well full pressure was reached. After release of
pressure slides remained in hot buffer for a further 20 min before cooling in TBS.







eg. biotinylated goat anti-rabbit
Primary antibody
eg. rabbit anti-VEGF
Ag t.Ag • Am!?pr-R6 eg. VEGF
■ Tissue section
Figure 2.2 APAAP and ABC-HRP methods of immunocytochemistry
(a) The APAAP (alkaline phosphatase anti-alkaline phosphatase) method of
immunocytochemistry. Primary antibody binds to its specific antigen. A
bridging or secondary antibody permits binding of the APAAP label. A
coloured substrate is then used for visualisation, (b) The ABC-HRP (avidin-
biotin- horse radish peroxidase complex) method of immunocytochemistry.
The secondary antibody is biotinylated which permits binding of the
preconjugated AB-HRP complex. A coloured substrate is used for
visualisation.
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2.7.2 Blocking non-specific binding
The main cause of non-specific background was assumed to arise from non-
immunological binding of specific immune sera by hydrophobic and electrostatic forces
(Kraehenbuhl and Jamieson, 1974). As it was generally the first immune serum that gave
rise to highest levels of non-specific background, these sites were blocked prior to the
application of the primary antibody with immunoglobulins which would not react or
interfere with primary specific antiserum. In both the APAAP and HRP methods
sections were incubated in normal whole serum from species in which the bridging
(secondary) antibody was raised.
The APAAP method was favoured for marmoset ovary due to the high
endogenous peroxidase activity and biotin present in this tissue which gave false
positive staining when the ABC-HRP was used. When it was necessary to use ABC-
HRP detection in marmoset ovary, for example when haematoxylin counterstain for
visualising tissue morphology and a brown reaction product to contrast was desired,
endogenous peroxidase and biotin were blocked. Endogenous peroxidase activity was
blocked by incubation of sections in 0.9% (v/v) methanol/0.1% (v/v) hydrogen peroxide
(both BDH) for 30 min at room temperature.
Endogenous biotin was blocked by addition of exogenous avidin and biotin.
Biotin has one binding site for avidin, and avidin has 4 for biotin. In this blocking
regime exogenous avidin bound endogenous biotin, and all biotin binding sites on the
avidin molecule were saturated with addition of excess biotin. Avidin (Vector
Laboratories Inc., Burglingame, CA, USA) was added at a concentration of 8 drops per
ml of normal blocking serum and allowed to bind endogenous biotin for 30 min at room
temperature. Any unbound avidin was washed off with TBS (Tris-buffered saline).
Sections were incubated in Biotin (Vector; 8 drops per ml of TBS) for 20 min at room
temperature, and unbound biotin washed off with TBS.
When using APAAP detection endogenous alkaline phosphatase activity was
blocked by the addition of levamisole to the substrate solution. The alkaline phosphatase
tracer was of intestinal origin (calf) and so was resistant to blocking with levamisole.
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2.7.3 Immunocytochemical procedure
Immunocytochemical procedures were performed using an automated incubation
method, the Sequenza system (Shandon Scientific, Runcorn, Cheshire, UK), which
works by capillary action and is believed to increase the ratio of specific to non-specific
staining. Unbound antibody was washed from the section before incubation with the
next layer using TBS. This prevents antibody-antigen complexes from precipitating into
sections and giving rise to problems with interpretation and background staining.
Sections were dewaxed in Histoclear (National Diagnostics, Hull, UK) and
rehydrated in descending concentrations of industrial methylated spirits and finally tap
water. If necessary antigen retrieval was performed and the slides transferred to TBS. If
the ABC-HRP system was to be used endogenous peroxidase activity was blocked and
the sections washed in running tap water then TBS. Slides were set up in the Sequenza
system ensuring that no air bubbles were present. Endogenous biotin was blocked (in
normal serum block) if the ABC method was to be used in marmoset ovarian tissue. If a
biotin block had not been performed sections were incubated in normal whole serum
(SAPU) from the species in which the bridging antibody was raised, with the addition of
bovine serum albumin (BSA, Sigma). Primary antibody was applied at the working
concentration diluted in TBS and sections incubated overnight. For NBT (nitro blue
tetrazolium) detection, slides were incubated in non-biotinylated secondary antibodies
followed by a tertiary APAAP antibody. For ABC-HRP detection, the EnVision kit
(Dako Ltd.) was used, which supplied the secondary antibody pre-conjugated to ABC-
HRP.
2.7.4 Detection and mounting
The APAAP method can be used with a number of substrates to yield a variety of
colours. The two most commonly used were nitroblue tetrazolium (NBT; Sigma)
(McGadey, 1970) which forms a deep blue/black immunostain, and Fast red TR (Sigma)
used with naphthol AS-MX phosphate sodium (Sigma) which gives a bright red reaction
end product. The favoured substrate for HRP was 3,3V diaminobenzadine
tetrahydrochloride (DAB) provided in the EnVision kit (Dako Ltd.), which yields a
crisp, insoluble, stable, dark brown reaction product (Graham and Karnovsky, 1966). If
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desired sections were counterstained with haematoxylin as described for H and E
staining. Sections were then dehydrated in increasing concentrations of alcohol, cleared
in xylene before being mounted using Pertex mounting medium (Cell Path, Hemel
Hempstead, UK) and coverslipped, unless the alcohol soluble Fast red substrate was
used. These sections were mounted from tap water using Permaflour aqueous mounting
medium (Beckman Coulter, Luton, Beds, UK).
2.7.5 Negative controls
For immunocytochemical detection using a specific antibody for the first time on a
particular tissue, negative controls were used. The primary antibody was either replaced
with immunoglobulin G from the same species and at the same concentration as the
primary antibody, or where possible, with the primary antibody preabsorbed with the
peptide it was raised against.
2.8 Image analysis
2.8.1 Digital photomicroscopy
Tissue sections were examined using an Olympus Provis microscope (Olympus Optical,
London, UK) and images were captured using a digital camera, either the Kodak
DCS420 or Kodak DCS330 (Eastman Kodak, Rochester, NY, USA). Captured images
were stored on a G4 Macintosh (Apple Macintosh, Apple Computer, Cupertino, CA) and
montages were compiled using Photoshop 5.0 (Adobe Systems Inc., Mountain View,
CA) and the Extensis Intellihance Pro 4.0 programme before being printed using the
Epson Stylus Photo 750 printer.
2.8.2 Quantification of immunostaining
Quantification of BrdU incorporation into cells of the corpus luteum was done manually
by counting the number of positive cells and total cells in 6 graticule fields, arranged in a
cross formation, per corpus luteum, at a magnification of x400. A proliferation index for
each animal was obtained from meaning the percentage of proliferating cells per corpus
luteum.
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Where it was not possible to count cell numbers as a result of the poor visibility
of cell margins, for example when quantifying endothelial cell staining, area of
immunostaining was measured using Image Pro Plus 3.0 software (Media Cybernetics,
Silver Spring, Maryland, USA). An image was captured, converted to grey scale and the
area of dark objects on a white background was counted using a pre-recorded macro.
The threshold for recognition of staining intensity was set so that the captured image
portrayed the live image as closely as possible. As many fields of view as possible were
quantified, the number being dictated by the lens magnification and size of the corpus
luteum in question.
2.9 In situ detection of apoptotic cell death
Apoptosis is a complex regulatory process that controls cell death by intrinsic
programmed mechanisms (Erickson, 1997). Apoptotic and necrotic forms of cell death
are quite distinct in their histology (Wyllie et al., 1980; Walker et al., 1988). A
characteristic feature of necrosis is that cell death occurs in groups. In this form of death,
increases in cell permeability lead to cell swelling and cell and organelle rupture,
resulting in the release of cytoplasmic and nuclear contents into the interstitial space
(Wyllie et al., 1980; Walker et al., 1988; Schwartzman and Cidlowski, 1993).
Degradation of nuclear material and random DNA fragmentation occur at the later
stages of necrotic death (Shikone et al., 1996). Apoptosis occurs in single cells rather
than groups, and it involves cell shrinkage with no swelling (Erickson, 1997).
Morphological features are cell shrinkage, nuclear condensation, DNA fragmentation
and formation of intensely stained regions of fragmented nuclear material, known as
apoptotic bodies. DNA degradation during apoptosis is not random, endonucleases
cleave DNA at 185bp (base pair) intervals or at multiples of 185bp (Wyllie et al., 1980),
and if extracted DNA is run on a gel, the DNA is visualised as a ladder, the bands being
multiples of 185bp. The in situ 3' end labelling exploits the extensive DNA degradation
process of apoptotic cell death. This technique enables visualisation of fragmented DNA
in tissue sections by employing an enzyme, terminal transferase, to attach a digoxygenin
label onto the 3' ends of fragments. This label is detected by immunocytochemical
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methods. The in situ technique relies on the fact that a high number of DNA fragments
are generated during apoptotic cell death (Negoescu et ai, 1998), but ideally this method
should be used in conjunction with DNA separation by gel electrophoresis, as necrotic
cell death also involves DNA fragmentation. However, for these studies DNA extraction
was not possible. Therefore, the in situ 3' end labelling technique was used in
conjunction with morphological analysis, which determines whether cell death is
occurring in cellular groups or singly, permits the identification of apoptotic bodies and
allows the type of cell to be confirmed. This method is used in more than one study and
so will be described in full in this section, and referred to in the relevant experimental
chapters.
Sections were dewaxed and rehydrated as normal for immunocytochemistry.
Proteinase K digestion was needed for terminal transferase and digoxygenin access to
the intracellular 3V end DNA fragments. Proteinase K was employed at a concentration
of 20pg/ml in 0.1M Tris, 0.1M EDTA buffer, pH8, for 6 min at room temperature. This
step was crucial and was optimised carefully depending on the fixative and tissue used.
Slides were washed in TBS and endogenous peroxidase activity and endogenous biotin
blocked as previously described for immunocytochemistry. 3v-OH ends of DNA
fragments were labelled with 0.5nM digoxygenin-11-UTP (Uridine 5Vtriphosphate,
Boehringer Mannheim) by 25U/ml terminal deoxynucleotidyl transferase (TdT,
Boehringer Mannheim) in buffer containing 30mM Tris/HCl pH7.2, 140mM sodium
cacodylate (Agar Scientific Ltd., Essex, UK) and 1.5mM CoCl2 (Boehringer Mannheim)
for 30 min at 37°C. Slides were washed in TBS and non-specific immunostaining
blocked with normal rabbit serum (NRS, SAPU) diluted 1:5 in TBS + 0.25g bovine
serum albumin (Sigma) for 30 min at room temperature. Sheep anti-digoxygenin
antibody (Boehringer Mannheim) diluted 1:100 in blocking serum, was applied for 90
min at room temperature. Slides were washed in TBS and incubated in biotinylated
rabbit anti-sheep IgG (immunoglobulin G, Vector Laboratories), diluted 1:500 in
blocking serum, for 30 min at room temperature. Again slides were washed in TBS and
incubated in pre-made ABC-HRP (Dako Ltd.; 1 drop each of avidin and biotin per ml of
0.05M Tris pH8) for 30 min at room temperature. Visualisation was with DAB (Dako
Ltd.; 1 drop of chromagen substrate per ml of 0.05M Tris pH8).
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Negative control sections were treated with reaction mixture not containing TdT
enzyme. Staining was not only assessed in the corpora lutea but in atretic follicles which
were positively stained in those sections treated with TdT enzyme and negative in those
not treated with the enzyme, and healthy follicles which were negative in those sections
treated with TdT enzyme.
2.10 In situ hybridisation
In situ hybridisation was used for the detection of specific mRNA in tissue sections via
hybridisation with a complementary radioactive riboprobe and detection using
photographic emulsion. Quantification of mRNA has also benefited from the recent
advances in images analysis technology. All preparation of plasmids, riboprobes and in
situ hybridisation was carried out by Helen Wilson and Dr. Christine Wulff, resident
experts in the field (Wulff et al., 2000). Quantification was performed by myself. The
preparation of plasmids, synthesis of riboprobes and in situ hybridisation procedure were
performed for localisation of VEGF-A mRNA. These methods are used in a number of
studies and so will be described in detail in this section.
2.10.1 Preparation of plasmids
Riboprobes were synthesised from plasmids containing the cDNA sequence of interest
and RNA polymerase initiation sites. These plasmids were not generated in-house but
obtained already transfected into Epicurian coli (XL-1 Blue; Stratagene, La Jolla, CA,
USA) as glycerol stocks from Dr Charnock-Jones (University of Cambridge,
Department of Obstetrics and Gynaecology). Plasmids were amplified by growth of lOpl
glycerol stock of the Ampicillin resistant bacterium in 10ml LB Broth (Anachem, Luton
Beds, UK; 25 capsules per litre dH20) containing 0.5mg Ampicillin (Gibco BRL, Life
Technologies Ltd., Paisley, UK), overnight at 37°C on a shaking platform. Plasmids
were only extracted if the negative control solution, containing broth and ampicillin, was
clear.
Plasmids were purified from their host bacterium using the QIAprep Spin
Miniprep kit (QIAGEN Ltd., Crawley, West Sussex, UK), according to the
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manufacturers instructions, which used alkaline lysis of bacterial cells followed by
adsorption of DNA into silica in the presence of high salt. The concentration and purity
of plasmids was determined by spectrophotometry using GeneQuant Pro (Amersham
Pharmacia Biotech, Cambridge Science Park, Cambridge, UK). In addition, the quality
was checked using agarose gel electrophoresis. A 0.5% agarose gel was prepared by
heating 0.25g agarose per 50ml 1 x TBE buffer (containing 1M Tris, 1M boric acid and
0.02M EDTA in dH20). Ethidium bromide was added to the dissolved agarose at 2pl per
50ml of gel, for visualisation of the DNA under ultra violet (UV) light. The gel was cast
and wells formed using a comb. One microlitre of the purified plasmid was loaded with
2pl DNA/RNA loading buffer (containing 5% v/v SDS, 0.25M EDTA, 250% w/v Ficoll,
1.5% w/v bromophenol blue) and 7pl H20. The gel was run at 100V for 1 hour, viewed
under UV light and photographed.
Plasmids were linearised by restriction enzyme digestion using Xhol and Notl
restriction enzymes for antisense and sense VEGF-A riboprobe synthesis, respectively.
Briefly, 500ng-lpg plasmid was linearised with 50U restriction enzyme, 1 x
corresponding buffer, and O.lmg/ml bovine serum albumin in a lOOpl reaction, at 37°C
overnight. Agarose gel/ethidium bromide electrophoresis was performed on both cut and
uncut plasmids to check linearisation.
Linearised plasmid was purified through a filter using the High Pure PCR (polymerase
chain reaction) Product Purification kit (Boehringer Mannheim), according to the
manufacturers instructions.
2.10.2 Synthesis of riboprobe
Antisense and sense riboprobes for VEGF-A were generated using T7 and T3 RNA
35
polymerases, respectively. Riboprobes incorporating S UTP (9.25mbq; Nen Life
Science Products, Zaventem, Belgium) were synthesised using a MAXIscript in vitro
transcription kit (Ambion Inc., Austin, Texas, USA). A reaction mixture of 1 x buffer,
0.5 mM each rNTP (ribonucleotide triphosphate; rATP, riboadenosine triphposphate;;
rCTP, ribocytosine triphosphate; rGTP, riboguanine triphosphate), 2.3MBq 35S UTP,
10U RNA polymerase and RNase-free H20 to 20pl was added to lpg linearised
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plasmid. The riboprobe was synthesised at 37°C for 2 x 30-45 min and another 10U
RNA polymerase was added between incubations. Plasmid DNA was degraded by
addition of 1U Dnase (deoxyribonulease), and incubation at 37°C for 15 min.
Incorporation of 35S UTP was measured by counting the total radioactivity
(counts per minute, cpm) in lpl of the final reaction mix after riboprobe synthesis,
spinning through a ChromaSpin column (Clonetech Laboratories Inc., Palo Alto, CA,
USA), according to manufacturers instructions, which retained any free radioactivity,
and lpl of the eluate counted again. The incorporated count was expressed as a
percentage of total counts per minute. Thirty to fifty percent incorporation was
acceptable.
2.10.3 In situ hybridisation procedure
In situ hybridisation was performed on 4% PFA-fixed 5pm sections. All solutions used
in the in situ hybridisation procedure were made up using diethyl pyrocarbonate
(DEPC)-treated and autoclaved H20. Washes were performed at room temperature
unless otherwise stated. Sections were dewaxed for 10 min in xylene and rehydrated in
100%, 90% and 70% ethanol, 2 min in each. Sections were washed or incubated in the
following: 0.1M HC1 for 20 min, H20 for 2 x 5 min, Proteinase K (5pg/ml; in buffer
containing 1M Tris, 0.5 M EDTA, pH8) for 30 min at 37°C (optimised for VEGF-A
probe), 0.2% glycine for 10 min at 4°C, 0.1M TEA buffer (triethanolamine, pH8 with
NaOH) for 5 min, TEA buffer/0.25% (v/v) acetic anhydride for 10 min, and 4 x SSC
(salt sodium chloride, containing 0.6M NaCl, 0.06M Na citrate) for 5 min. Sections were
dried round, laid in humid boxes and incubated for 2 h at 50°C in lOOpl each of
prehybridisation buffer (containing 50% (v/v) deionised formamide, 4 x SSC, 1 x
Denhardt's solution, 125pg/ml salmon testis DNA, 125pg/ml yeast tRNA, and lOmM
DTT, dithiothreitol). Prehybridisation buffer was drained off and hybridisation buffer
(containing the same as prehybridisation buffer plus 10% (v/v) dextran sulphate and 0.5
x 106 cpm of probe optimised for VEGF-A probe) added, sections were coverslipped
(Gel Bond) and incubated overnight at 50°C (optimised for VEGF-A probe). From this
point conditions did not need to be RNase-free. Coverslips were peeled off and sections
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washed in the following: 4 x SSC for 10 min, RNase A (20pg/ml in buffer containing
0.2M Tris, 0.1M EDTA and 2.5M NaCl2) for 30 min at 37°C, 2 x SSC for 30 min, 1 x
SSC for 10 min at 60°C (optimised for VEGF-A probe), 0.1 x SSC for 30 min, 50%
(v/v) ethanol / 0.3M ammonium acetate, 85% (v/v) ethanol / 0.3M ammonium acetate,
and 94% (v/v) ethanol / 0.3M ammonium acetate, for 2 min each. Sections were air-
dried for 3-4 h, and dipped in emulsion in a dark room. G5 Emulsion (Illford, H+A
West, Edinburgh, UK) was diluted 1:1 with dH20, and heated until liquified at 45°C.
The slides were dipped in emulsion and dried in a light proof humid box overnight at
4°C. Desiccant was added and the emulsion exposed at 4°C for 2 weeks (optimised for
VEGF-A probe). Slides were developed in filtered Kodak D19 Developer (Edinburgh
Cameras, Edinburgh, UK) for 4 min at 14°C, rinsed in dH20, fixed in Kodak GBS Fixer
(Sigma) diluted 1:5 in dH20, for 10 min at room temperature, and rinsed in dH20.
Sections were counterstained with haematoxylin and mounted in Pertex as previously
described for immunocytochemistry.
2.11 Quantification of specific mRNA from total RNA
2.11.1 Total RNA extraction and quantification
Total RNA was extracted from tissues using Tri-Reagent, a guanidine thiocyanate based
reagent (Chomczynski and Sacchi, 1987), according to the manufacturers instructions.
This reagent allows simultaneous extraction of total RNA, DNA and protein. RNA
extraction is a routinely used technique in molecular biology and therefore the
methodology is assigned to this section. Extracted RNA can be used for Northern
analysis, RNase protection assay or reverse transcription-polymerase chain reaction
(RT-PCR). Extraction of DNA and protein was not carried out in these studies, so the
methodology for RNA extraction only will be described here. Briefly, tissue stored at -
70°C was placed in Tri-Reagent (10ml per gram of tissue) and homogenised using a
Polytron PT1200 homogeniser (Philip Harris Scientific, Coatbridge, Lanarkshire, UK)
followed by centrifugation at 4°C for 10 min at 12000 x g. The supernatant obtained was
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transferred to a fresh tube and 0.2 volume of chloroform added. The mixture was shaken
for 15 sec, allowed to stand at room temperature for 12 min and centrifuged at 4°C for
20 min at 12000 x g. The RNA, present in the upper aqueous layer, was transferred to a
new tube and precipitated by the addition of 0.5 volume of isopropanol and incubation
for 5 min at room temperature. The RNA was pelleted by centrifugation at 4°C for 20
min at 12000 x g. Thereafter, the supernatant was removed, the RNA pellet washed with
1 volume of 75% ethanol and centrifuged at 4°C for 20 min at 12000 x g. Following
centrifugation, the supernatant was removed and the RNA pellet dissolved in RNase free
H20 (Sigma). RNA was stored at -70°C until required.
The concentration and purity of the RNA was determined by spectrophotometry
using GeneQuant Pro (Amersham Pharmacia Biotech). This machine automatically
calculates the concentration (A26o) and quality (A26o/28o) of RNA. In addition, the quality
of the RNA was assessed by 1.5% agarose gel/ethidium bromide electrophoresis. Two
micrograms of RNA were loaded with 2(0.1 DNA/RNA loading buffer. The gel was run at
100V for 1 hour, viewed under UV light and photographed.
2.11.2 Real time quantitative reverse transcription polymerase chain reaction
Reverse transcription-PCR is a two-stage process. Complementary DNA (cDNA) is
initially produced from RNA; the cDNA is subsequently amplified in a cyclic process of
DNA denaturation, specific primer annealing and primer extension to exponentially
increase the primer specified cDNA fragment. Perkin Elmer have developed a new
technique which allows quantification of specific mRNA species in total RNA. Before
this method can be performed primers and probe, specific for the mRNA of interest must
be designed (Section 2.11.2.1). Real time quantification of this process allows
visualisation of the cDNA synthesised after each PCR cycle, through cleavage of a
fluorescent probe from its quencher during strand synthesis. Quantification is based on
calculations which consider an 18S control and the relationship between sample cDNA
content and a nominated standard. The principles used in this technique are further
clarified in Figure 2.3.










Figure 2.3 Basics of the TaqMan Real Time PCR method
(a) The PCR reaction exploits the 5' nuclease activity of AmpliTaq Gold DNA
polymerase to cleave the TaqMan probe during PCR. The TaqMan probe
contains a reporter dye at the 5' end of the probe and a quencher dye at the 3' end
of the probe. When the probe is intact, the proximity of the reporter dye to the
quencher dye results in suppression of the reporter fluorescence primarily by
Forster-type energy transfer (Lakowicz, 1983). During PCR, if the target of
interest is present, the probe specifically anneals between the forward and reverse
primer sites.
(b) and (c) During the reaction, cleavage of the probe separates the reporter dye
and the quencher dye, which results in increased fluorescence of the reporter.
Accumulation of PCR products is detected directly by monitoring the increase in
fluorescence of the reporter dye. The 5'-3' nucleolytic activity of the AmpliTaq
Gold DNA Polymerase cleaves the probe between the reporter and the quencher
dye only if the probe hybridises to the target.
(d) The probe fragments are then displaced from the target and polymerisation of
the strand continues. The 3' end of the probe is blocked to prevent extension of
the probe during PCR. This process occurs in every cycle and does not interfere
with the exponential accumulation of the product. The increase of fluorescence
signal is detected only if the target sequence is complementary to the probe and is
amplified during PCR. Because of these requirements, any non-specific
amplification is not detected.
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2.11.2.1 Design of probe and primers
Complementary DNA sequences for target genes were acquired from the National
Library of Medicine PubMed nucleotide enquiries, on the internet. Probe and primers
were designed against segments of the sequence which displayed low homology with
other genes of the same family and where possible to span two introns so that genomic,
exon containing, sequences would not be amplified. Both probe and primers were
designed using the Primer Express software which generated candidate probes and
primers against a specific sequence, a choice of probe and primers was made from the
list following certain guidelines. The probe was chosen first, the GC content was kept in
the 30-80% range, runs of identical nucleotides were avoided especially four or more
Gs, Gs were not put on the 5s end, the strand selected gave the probe more Cs than Gs
and the Tm was 68-70°C. Primers were designed either side of the probe, as close as
possible without overlapping the probe, to amplify short segments of DNA within the
target sequence, between 50 and 150bp was recommended for consistent results. The
same guidelines for designing the probe were used for primer design except that the Tm
of the primers was optimally 58-60°C, and that the five nucleotides at the 3" end should
have no more than two G and/or C bases.
The probe and primers for 18S were designed by Perkin Elmer Applied
Biosystems (Foster City, CA, USA) the sequences of which were not made public. They
were purchased in kit form from Perkin Elmer.
2.11.2.2 DNase treatment of RNA
RNA was extracted using Tri-Reagent which allows simultaneous extraction of DNA
and protein and so it was possible that extracted RNA could be contaminated with
genomic DNA, although steps to minimise this were taken. Before RT-PCR, RNA was
subjected to DNase I (Gibco BRL) treatment to degrade any contaminating DNA. The
methodologies for DNase treatment of RNA, reverse transcription and Real Time
quantitative PCR can be found in Chapter 7.
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2.12 Statistical analysis of data
Results of quantifications in three stages of the marmoset luteal phase, and four stages of
the human luteal phase, where more than two variables were present, were analysed
using an analysis of variance (ANOVA) with Fisher's protected least significant
difference (PLSD) post-hoc test. For assessing the significance of results using potential
inhibitors of angiogenesis, comparing treated against control measurements, two-tailed,
unpaired t-tests were used. The level of significance for both tests was P<0.05. All tests
were performed using StatView Version 4.0 for the Macintosh.
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3.1 Introduction
Angiogenesis refers to the formation of new blood vessels from pre-existing ones,
and is essential for normal growth and development (Folkman and Klagsbrun, 1987;
Klagsbrun and D'Amore, 1991). The angiogenic process consists of capillary
proliferation and stabilisation of newly formed vessels leading to the formation of a
new vasculature tree. Capillary proliferation consists of at least three processes: (1)
fragmentation of the basement membrane of the existing vessel, (2) migration of
endothelial cells from the existing vessel toward the angiogenic stimulus and (3)
proliferation of endothelial cells (Folkman and Klagsbrun, 1987; Klagsbrun and
D'Amore, 1991). Neovascularisation is completed by formation of capillary lumina
and differentiation of newly formed capillaries into arterioles and venules.
The female reproductive system (ovary, uterus and placenta) is unique in the
fact that spontaneous angiogenesis occurs in a cyclic manner. In no other normal
tissue in the adult does this happen. In a normal adult vessel, only one in every ten
thousand endothelial cells is in the cell division cycle at any given time (Engerman et
al., 1967; Hobson and Denekamp, 1984). Growth and regression of the female
reproductive organs however, is extremely rapid and is accompanied by equally
rapid changes in their vasculature (Reynolds and Redmer, 1995). For example the
rate of cellular proliferation in the early corpus luteum is comparable with or greater
than that of rapidly growing tumours or regenerating tissues ( Reynolds et al., 1994;
Zheng et al., 1994; Nicosia et al., 1995; Christenson and Stouffer, 1996b). In
contrast to the angiogenesis observed during pathological tissue growth, vascular
development of the female reproductive system is limited and, thus, must be tightly
regulated (reviewed by Redmer and Reynolds, 1996).
Due to the fact that luteal angiogenesis is a naturally regulated process,
occurring in a spontaneous cycle of active proliferation, vessel stabilisation and
regression, for quantification of such a dynamic process in vivo, it is necessary to
examine particular time points in the lifespan of the corpus luteum. Characteristically
the non-pregnant luteal cycle is divided into three stages: the early, developing
corpus luteum in which production of progesterone in increasing; the mid-luteal
stage, when maturity of the gland is reached and progesterone production is
maximal; the late luteal phase, which is associated with functional and structural
regression. A fourth luteal stage is available for analysis in the human corpus luteum
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which, by exposure to increasing concentrations of hCG, simulates the luteal rescue
associated with early pregnancy (Illingworth et al., 1990). It is therefore reasonable
to investigate the angiogenesis associated with these luteal stages as changes in gland
structure and function are directly related to the angiogenic activity of the system. In
quantifying luteal angiogenesis in vivo it is imperative that the dynamic vascular
changes are examined in context, in situ, so relationships with other luteal cells and
the associated changes in luteal morphology can also be analysed. It is for this reason
that quantification of luteal angiogenesis was performed on fixed luteal sections by
immunocytochemical methods.
Quantification of endothelial cell proliferation in the corpus luteum and the
resultant changes in luteal endothelial cell content are two effective methods of
measuring in vivo angiogenesis in luteal sections. Analysis of proliferation depends
on the assessment of the number of cells which are undergoing mitosis in any given
population, however the mitotic process is completed in approximately 5 min, so the
likelihood of observing mitotic figures in histological sections is very low (O'Shea et
al., 1986), therefore antigens expressed during other parts of the dividing cell cycle
are exploited as proliferation markers for detection by immunocytochemical
methods. The cell cycle has a period of intense DNA synthesis, the S phase, which
can take 7 to 12 hours to complete. This is followed by a post synthesis gap (G2)
which lasts 1 to 6 hours when the cell undergoes growth and prepares for mitosis.
After mitosis cells grow to an optimal size, known as the Gi phase of growth. This
stage can be of variable length and it is also at this stage when cells can enter G0,
during which they are not actively proliferating. Specific proliferative stimuli can
cause some cells to re-enter the cell cycle, whereas some cells lose their proliferative
competency and never re-enter the cell cycle, these are permanently in the G0 phase
and are often terminally differentiated (Boulton and Hodgson, 1995).
Cell proliferation antigens expressed during the cell cycle include: the nuclear
non-histone protein, Ki67, and proliferating cell nuclear antigen, PCNA. Other
markers, incorporated into DNA in vivo, include tritiated thymidine or a halogenated
thymidine derivative, 5-bromo-2'-deoxyuridine (BrdU). Ki67 is expressed during all
phases of the cell cycle except the early part of G) and G0 (Gerdes et al., 1984).
PCNA is an auxiliary protein for DNA polymerase 5, it has a long half life of up to
20 hours (Diebold et al., 1994) and is expressed over G,, S phase and G2 stages of
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the cell cycle. It is immunolocalised to the nuclei of proliferating cells although non¬
specific cytoplasmic staining is also common (Wolf and Dittrich, 1992; Sabattini et
al., 1993). BrdU and tritiated thymidine label proliferating cells in vivo by
incorporation into DNA during the S phase of the cell cycle. The labelling rate
depends on the amount of time the substance is available for incorporation which, in
turn, is dependent on its initial concentration and clearance rate. Best results are
obtained when the labelling period is shorter than the duration of the S phase for the
cell population concerned, so that only cells in the synthesis stage of the cycle are
labelled (Boulton and Hodgson, 1995). Detection of tritiated thymidine involves
autoradiography whereas monoclonal antibodies to BrdU are available to specifically
detect proliferating cells by immunocytochemistry. Proliferation studies in the
marmoset corpus luteum were performed using BrdU incorporation administered 1
hour before tissue collection to selectively label cells in the S phase of the cell cycle,
and incorporation detected by immunocytochemistry. Proliferation studies in the
human corpus luteum were performed using immunocytochemistry for Ki67.
Approximately 50% of the cells in the corpus luteum are endothelial cells
(Lei et al., 1991; Christenson and Stouffer, 1996b;), and an extensive capillary
network penetrates the corpus luteum, so much so that every steroidogenic cell is in
contact with at least one capillary (Redmer and Reynolds, 1996). The primary
function of the corpus luteum is the production of steroid hormones, and
steroidogenesis is entirely dependent on the delivery of cholesterol substrates and
regulatory gonadotropins through the luteal vasculature. Maximal plasma
progesterone concentrations do not occur until the luteal vasculature is fully
developed. Development of the vasculature can be assessed by the quantification of
luteal endothelial cells throughout the lifespan of the corpus luteum. Antibodies to
specific endothelial cell antigens are commercially available and quantification of
immunostaining using these antibodies is simplified with the advent of computer
based image analysis systems.
There exists extensive endothelial cell heterogeneity (Bicknell, 1996), and
expression of particular endothelial cell antigens for immunocytochemical detection
may vary according to the species and tissue in question, or age of the endothelial
cells. It is for this reason that immunocytochemistry was performed with antibodies
raised against three specific endothelial cell antigens: von Willebrand factor (or
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factor VHI-related antigen); CD31, (or PECAM-1, platelet endothelial cell adhesion
molecule-1); and CD34. von Willebrand factor is a multimeric plasma glycoprotein,
stored in endothelial cell cytoplasmic Weibel-Palade bodies. It mediates platelet
adhesion to injured vessel walls and serves as a carrier and stabiliser for coagulation
factor VIII (Zimmerman, 1987). It is often used to visualise the pattern of vascular
elements within a tissue. CD31 or platelet endothelial cell adhesion molecule-1, is a
single chain, endothelial cell membrane glycoprotein. It has an extracellular domain
which mediates endothelial cell-cell adhesion, plays a role in endothelial cell contact
and may serve to stabilise the endothelial cell monolayer, suggesting an involvement
in interactive events during angiogenesis. Staining of vessels with antibody to CD31
has shown to be suitable in the judgement of angiogenesis in several types of tumour
(Horak et al., 1992; Charpin et al., 1995; Giatromanolaki et al., 1996; Takebayashi et
al., 1996; Fox et al., 1997). CD34 is another single chain, endothelial cell
transmembrane glycoprotein (Simmons et al., 1992). Monoclonal anti-human CD31
and CD34, and rabbit polyclonal anti-von Willebrand factor antibodies were used for
endothelial cell immunostaining.
Endothelial cell immunostaining was either located to the cell cytoplasm or
plasma membrane making visualisation of individual cells difficult. It was therefore
not possible to measure absolute endothelial cell numbers in the corpus luteum, so
quantification based on area of immunostaining per unit area of the corpus luteum
proved optimal. When changes in a particular cell content are quantified per unit area
of luteal tissue, factors such as the change in luteal volume (translated to area in
tissue sections) over the lifespan of the corpus luteum have to be addressed, or
results will reflect the effects of expanding or contracting tissue as opposed to
increases or decreases in content of the particular cell in question. Many factors
affect the volume of the corpus luteum throughout the luteal phase. These include the
proliferation and demise of endothelial cells themselves, or periendothelial support
cells, the infiltration of immune cells, or proliferation of fibroblasts in the regressing
corpus luteum. However, the contribution of changes in numbers of these small cells
is believed to be negligible to overall luteal volume when compared to the effects of
hypertrophy of the larger steroidogenic cells in the developing corpus luteum and
atrophy in the regressing corpus luteum. The change in lutein cell cytoplasmic
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volume thus had to be quantified and the area used to measure endothelial cell
content adjusted accordingly.
In vivo angiogenesis can also be quantified by measuring the expression of
known angiogenic factors. One such factor is VEGF (also referred to as VEGF-A).
VEGF is a secreted angiogenic mitogen (Leung et al., 1989), specific for endothelial
cell receptors (Plouet and Maukadiri, 1990; Vaisman et al., 1990). VEGF protein has
been located to a subpopulation of granulosa cells in human follicles which sequester
such growth factors in a novel mechanism, and may be released in a new mode of
directed secretion which could serve to support rapid bursts of cellular growth during
folliculogenesis and corpus luteum formation (Antczak et al., 1997). Both VEGF
mRNA and its transcribed protein have been localised to granulosa and theca derived
lutein cells in the human corpus luteum (Kamat et al., 1995; Otani et al., 1999). It
has a paracrine action: expression and secretion from steroidogenic cells and action
at endothelial cells, thus the steroidogenic cells of the corpus luteum drive
angiogenesis to increase vasculature for their own supply of 02, nutrients and steroid
precursors needed for survival and progesterone synthesis.
Termination of active angiogenesis is associated with the stabilisation of the
newly formed vasculature by periendothelial support cells such as pericytes. Fully
differentiated pericytes are contractile cells containing cytoplasmic actin and myosin
filaments, they have large cytoplasmic processes which surround endothelial cells,
converting capillaries to venules and arterioles. Their association with vessels
renders the vessel mature and gives them the ability to survive without the aid of
VEGF (Benjamin et al., 1999). Recruitment of pericytes has been documented soon
after induction of bovine luteal angiogenesis and the percentage of vessels with
associated pericytes increases as the luteal phase progresses (Goede et al., 1998).
Coverage of blood vessels with differentiated pericytes can be regarded as a relative
parameter of the maturity of a developing neovasculature, which can be detected by
immunocytochemistry for the contractile protein, a-smooth muscle actin (Skalli et
al., 1989; Diaz-Flores et al., 1991).
The aim of this chapter was to quantify angiogenesis in the primate corpus
luteum, using the parameters outlined above, taking into consideration not only
components of vessel proliferation, but also their maturation; and how this
quantification was best performed in such dynamic tissue. Since the formation of a
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corpus luteum is associated with prolific angiogenesis, and regression with a
decreased angiogenic rate in the human (Rodger et al., 1997; Gaytan et al., 1998),
rhesus monkey (Christenson and Stouffer, 1996b), bovine (Zheng et al., 1994) and
ovine (Jablonka-Shariff et al., 1993), similar results are expected in the marmoset. A
previous study has demonstrated that the rescue of the human corpus luteum by hCG
in simulated early pregnancy is not associated with increased endothelial cell
proliferation (Rodger et al., 1997). This study aims to test this hypothesis using a
more advanced quantitative method which assesses endothelial cell proliferation as a
percentage of total luteal cells, by obtaining a proliferation index.
3.2 Materials and Methods
3.2.1 Animals, BrdU administration and tissue analysis
Marmoset monkeys were housed as previously described (Chapter 2), and
procedures were carried out in accordance with the Animals (Scientific Procedures)
Act, 1986. Blood samples were collected by femoral venepuncture, three times per
week, without anaesthesia. Ovulatory cycles were monitored by RIA of plasma
progesterone, as previously described (Chapter 2). The stage of the ovulatory cycle
was determined according to plasma progesterone concentration following the
guidelines described in Chapter 2. Ovaries were collected from animals in the early
(luteal days 2-4), mid-(days 8-10), and late (days 16-20) luteal phase of the ovulatory
cycle (n=5 animals per group), and in the follicular phase to examine regressed
corpora lutea (n=4). Twenty milligrams of BrdU (Roche Molecular Biochemicals,
Sussex, UK), dissolved in 500|il physiological saline, was administered i.v., lh
before tissue collection, to label proliferating cells in the S phase of the cell cycle,
via incorporation into DNA. This allowed changes in endothelial cell proliferation
throughout the luteal phase of the ovulatory cycle to be determined. Ovaries from
these animals were also examined for expression of the specific endothelial cell
antigens, von Willebrand factor VHI-related antigen (von Willebrand factor) and
CD31; the pericyte marker, a-SMA; and the potent endothelial cell mitogen, VEGF.
These studies were supplemented with examination of expression of the proliferation
marker, Ki67; the endothelial cell antigen, CD34; and the pericyte marker, a-SMA,
in archived human luteal sections throughout the early, mid- and late luteal phases
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and in hCG rescued tissue (n=4-6 per luteal stage), to examine if luteal rescue is
associated with increased angiogenic activity in the form of endothelial cell
proliferation or with stabilisation of the existing vasculature. Different endothelial
cell markers were immunolocalised in marmoset and human sections because of
interspecies variance in immunoreactivity.
3.2.2 Immunocytochemistry
Immunocytochemistry for BrdU was performed to visualise proliferating cells in
marmoset luteal sections. Sections were dewaxed in histoclear for 5-10 min and
rehydrated by washing in decreasing concentrations (100%, 95% and 70% in H20)
of industrial methylated spirits (20 sec in each), and finally in H20. Antigen retrieval
by heat treatment, either microwaving or pressure cooking, in 0.01M citrate buffer
(pH 6) was necessary to unmask the BrdU antigen covered by tissue fixation and
processing. Methods of antigen retrieval by heat treatment are described in Chapter
2. Slides were cooled in TBS (0.05M Tris/HCl, pH8, + 0.85% w/v NaCl2). The
Sequenza system was set up and non specific background was blocked by incubation
in normal rabbit serum (NRS, SAPU, diluted 1:5 in TBS + 5% w/v bovine serum
albumin; BSA) for 30 min at room temperature. Slides were not washed and primary
antibody, monoclonal mouse anti-BrdU (Boehringer Mannheim), was applied at a
concentration of 3.3p,g/ml in TBS (1:30 dilution) and incubated at 4°C overnight. For
negative control sections primary antibody was replaced with mouse IgG at the same
concentration. TBS was flushed through the Sequenza system 3 times to wash
unbound antibody from sections. Secondary/bridging antibody, rabbit anti-mouse,
was applied at a concentration of 26.6jxg/ml in NRS (1:60 dilution) for 30 min at
room temperature. Unbound antibody was washed from sections, and mouse APAAP
in NRS (lpg/ml, 1:100 dilution) applied for 30 min at room temperature. Slides were
placed in TBS for a thorough wash before NBT detection was performed. Slides
were placed in NBT buffer (0.1M Tris, 0.1M NaCl2, 0.05M MgCl2, pH 9.7) for 5
min. Excess buffer was wiped from each slide and NBT solution (45pl 75mg/ml
NBT in 70% dimethylformamide; 35p,l X-phosphate/5 Bromo-4 chloro-3 inodyl-
phosphate in 100% dimethylformamide; and ImM levamisole; all in 10ml NBT
buffer) applied in a dark humid box for 15-30 min at room temperature. Staining was
evaluated under light microscopy and slides re-incubated in NBT solution if
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necessary. When the desired colour had developed the reaction was stopped in tap
water and sections were counterstained in haematoxylin for 1-5 min, and the colour
developed in Scott's tap water (0.002% w/v potassium hydrogen carbonate, 0.02%
w/v magnesium sulphate in tap H20) for 20-60 sec. Sections were dehydrated in
absolute alcohol for 30 sec and rapidly cleared in xylene before being mounted using
Pertex mounting medium and glass coverslips.
Dual staining for BrdU (Boehringer Mannheim) and either endothelial cell
marker, von Willebrand factor or CD31, was carried out to determine the proportion
of proliferating endothelial cells in the marmoset corpus luteum. Colocalisation of
BrdU with von Willebrand factor was detected using TRITC (tetra rhodamine
TRITC (tetra rhodamine isothyocyanate)/FITC (fluorescein isothyocyanate)
conjugated secondary antibodies. Antigen retrieval was performed by microwaving
as described in Chapter 2. Sections were washed in PBS (0.01M phosphate-buffered
saline, pH 7.4, containing 2.7mM KC1, 0.137M NaCl). and treated for 30 min at
room temperature with normal goat serum, (NGS, diluted 1:5 in PBS + 5% w/v
BSA) followed by dual incubation in rabbit polyclonal anti-von Willebrand factor
(22.8p,g/ml in NGS), and mouse monoclonal anti-BrdU (6.6p,g/ml in NGS) at 4°C,
overnight. Immunolocalisation was undertaken using anti-rabbit FITC conjugate
(diluted 1:50 in NGS, Sigma F-6005) and anti-mouse TRITC conjugate (diluted 1:50
in NGS, Sigma T-5393) dual incubation for 45 min at room temperature. Slides were
mounted from PBS using Permafluor aqueous mounting medium. The U-MWIBA
and U-MWG filters on the Olympus AX70 Provis fluorescent microscope were used
to visualise FITC-stained von Willebrand factor positive cells, and TRITC-stained
BrdU positive cells, respectively.
The occurrence of erythrocyte auto-fluorescence masked BrdU staining in
most sections and this prevented quantification of endothelial cell proliferation in the
majority of corpora lutea. To circumvent this problem a colorimetric approach for
BrdU and CD31 antigens was also used for analysis. Sections were dewaxed and
rehydrated as normal. Both antigens were retrieved by pressure cooking in 0.01M
citrate buffer, pH6. Sections were incubated with anti-CD31 (20.5pg/ml, diluted 1:20
in TBS) alone at 4°C, overnight, and secondary and tertiary antibodies applied as
described for single BrdU immunostaining. Detection was performed using Fast Red
substrate (Sigma). Sections were incubated in Fast Red solution (lmg of Fast Red
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BB salt, per 1ml buffer, containing 20mg naphthol AS-MX Phosphate, 2ml dimethyl
formamide, and 98ml 0.1M Tris pH 8.2, all Sigma), for 15-30 min until a bright red
reaction end product had formed. The reaction was terminated with cold tap water.
For BrdU colocalisation, non-specific binding was blocked using NRS. Sections
were incubated in mouse monoclonal anti-BrdU (3.3pg/ml, in TBS) at 4°C,
overnight, or for 2h at room temperature. BrdU detection was performed as described
for single BrdU immunostaining using NBT. Sections were faintly counterstained
and aqueous mounted in Permaflour mounting medium.
Proliferating cells in human luteal sections were analysed by
immunocytochemistry for Ki67. This was performed by Dr. Christine Wulff.
Sections were dewaxed and rehydrated as previously described. Ki67 antigen was
retrieved by microwaving. Sections were cooled in TBS, and an NRS block was
applied for 30 min at room temperature. Monoclonal anti-human Ki67 antibody
(Novacastra, Peterborough, Cambs, UK) was applied at a dilution of 1:50 in TBS, for
2 h at 37°C. Detection was carried out using biotinylated rabbit anti-mouse (Dako
Ltd: E0464, diluted 1:500 in blocking serum) for 30 min at room temperature,
followed by preconjugated ABC-AP in 0.05M Tris, pH 8, for 30 min at room
temperature. NBT was used for visualisation, and sections were counterstained in
haematoxylin.
Immunocytochemistry for the endothelial cell marker von Willebrand factor,
was performed after dewaxing and rehydrating tissue sections. Proteolytic digestion
was used for antigen retrieval as described in Chapter 2. The sequenza system was
set up and non-specific binding blocked with at 30 min incubation at room
temperature in normal swine serum (NSS, SAPU, diluted 1:5 in TBS + 5% w/v
BSA). Rabbit polyclonal von Willebrand factor antibody was applied at a
concentration of 22.8pg/ml (1:250 dilution in TBS) which bound overnight at 4°C.
Negative controls were incubated in NSS in place of primary antibody. Sections
were washed 3 times with TBS and incubated in swine anti-rabbit at a protein
concentration of lmg/ml (diluted 1:60 in NSS) for 30 min at room temperature. After
washing with TBS, rabbit APAAP (Serotec, 2AB08A; diluted 1:100 in NSS) was
applied for 30 min at room temperature. Sections were washed and NBT used for
detection as described for BrdU immunostaining. Sections were not counterstained
so that image analysis could be performed for quantification purposes.
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Separate immunostainings for CD31 and a-SMA were performed following
the same protocol as for BrdU. Primary antibody, mouse monoclonal CD31, was
used at a working concentration of 20.5|j.g/ml, (diluted 1:20 in TBS), a-SMA was
applied at 4.3|ig/ml (diluted 1:20 in TBS). Negative controls were incubated in
equivalent concentrations of mouse IgG in TBS. NBT detection was used and
sections either counterstained faintly, or not at all, for image analysis quantification.
Immunocytochemistry for the endothelial cell specific antigen, CD34, was
performed on human luteal sections. Sections were dewaxed and rehydrated as
normal and endogenous peroxidase activity was quenched with a 30 min incubation
in 3% hydrogen peroxide in methanol, at room temperature. NGS block was used
and sections were incubated overnight at 4°C in mouse monoclonal CD34 antibody
(Serotec: MCAP547) applied at a 1:25 dilution in TBS. Immunolocaiisation was
undertaken using the mouse EnVision kit (Dako Ltd, Cambridge, UK). One hundred
microlitres of conjugated goat anti-mouse/ABC-HRP was applied for 30 min at room
temperature. Sections were washed in TBS and liquid DAB substrate (EnVision kit)
was used for detection. Sections were not counterstained as image analysis was to be
performed.
Sections for VEGF-A immunocytochemistry were dewaxed and rehydrated.
VEGF antigen was retrieved by pressure cooking slides on full power in 3M glycine,
0.1% EDTA buffer, pH 3.5, for 5 min. The slides remained in hot buffer for a further
20 min and were washed in TBS. Endogenous peroxidase activity and endogenous
biotin were blocked as described in Chapter 2. Rabbit polyclonal VEGF antibody,
specific for VEGF-A (2|ag/ml pre-diluted in NGS; VEGF A-20, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), was added and sections incubated at 4°C,
overnight. Negative controls were incubated in primary antibody pre-absorbed with
VEGF-A peptide in a ratio of 1:5, VEGF-A antibody : blocking peptide (Santa
Cruz). Immunolocaiisation was undertaken using the rabbit EnVision kit in the same
way as the mouse was used for CD34 immunostaining. Sections were counterstained
and mounted.
Human luteal sections were dual stained for von Willebrand factor and a-
SMA to verify that each antibody bound different cell types. Antigens were retrieved
by trypsinisation as described in Chapter 2. An NGS block was performed and both
primary antibodies applied simultaneously at their working concentrations incubating
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overnight at 4°C. Detection and analysis was performed with TRITC/FITC
fluorescent conjugated antibodies as for von Willebrand factor and BrdU dual
staining in marmoset sections.
3.2.3 Haematoxylin and Eosin staining
Sections were dewaxed and rehydrated as described previously. Slides were placed
in haematoxylin for 1-5 min, rinsed in tap water and the nuclear blue colour
developed in Scott's tap water. Staining was checked by light microscopy, if too
intense, staining was cleared by dipping slides in 1% acid alcohol, or back into
haematoxylin if staining was too light. For the cytoplasmic pink stain sections were
dipped for 10 sec in eosin, and rinsed in tap water. Sections were dehydrated in
ascending concentrations of alcohol (70%, 95% and 100% in F[20), cleared in xylene
before being mounted and coverslipped.
3.2.4 Quantification
All marmoset sections were examined for appropriately staged corpora lutea as
defined by the morphology of lutein cells and the presence of an antrum as described
in Chapter 1. Those sections which had not been counterstained were analysed
alongside serial sections stained with H and E to locate suitable corpora lutea for
quantification.
BrdU positive and total cells were counted manually at x400 magnification in
6 fields per corpus luteum. In the early corpus luteum, fields were selected which
formed a cross configuration throughout the corpus luteum, as close as possible
without counting in the antrum if one was present in the section. In the larger mid-
corpus luteum a cross formation was obtainable, this meant a fair representation of
the whole corpus luteum was quantified. A PI was obtained by expressing the
number of BrdU positive cells as a percentage of total cells per 6 fields, and the Pi's
meaned to get a value per animal. Selected sections were quantified by a second
person independently to assess the reproducibility of such quantification. Also, from
selected paraffin wax blocks a second section, cut from a distance into the block, was
quantified to assess how representative quantification of proliferation in one section
was to the whole corpus luteum.
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Manual counting procedures were used to calculate the percentage of
proliferating endothelial cells for each corpus luteum. Quantification was performed
on both fluorescent sections and those stained using the colorimetric approach. Both
left and right ovaries from five animals from the early and mid-luteal phases and
from one animal in the late luteal phase were examined for appropriately staged
corpora lutea and the percentage of proliferating endothelial cells quantified. Six
fields per corpus luteum, arranged in a cross formation, at x400 magnification, were
analysed using a grid overlay. The number of proliferating endothelial cells was
expressed as a percentage of proliferating cells, i.e. (number of dual stained
cells/total number of BrdU positive cells) xlOO.
Quantification of Ki67 immunostaining in human sections was performed by
Dr. Christine Wulff using the Media Pro-Plus 3.0 image analysis system. Sections
were examined using the x20 lens and 6-10 fields of view, randomly chosen,
analysed per corpus luteum. The image analysis system was set to measure the
number of dark stained nuclei only (Ki67 positive), and the number of dark and light
stained nuclei (total cells) per field of view. A PI was obtained by expressing the
number of Ki67 positive nuclei as a percentage of total nuclei per field of view, and
the mean of 6-10 fields taken as representative for that corpus luteum.
The area of each of 10 steroidogenic cells in marmoset corpora lutea and
granulosa lutein cells in human corpora lutea were measured to assess the change in
area over the luteal phase of the cycle. Images of H and E stained sections were
examined under the x40 lens and captured using the Media Pro-Plus 3.0 image
analysis system. Ten cells in ten fields of view, again arranged in a cross formation,
were outlined using the mouse and Outline tool, and a macro was recorded to
measure the area of each outlined shape, and mean the results per field of view. An
average of 10 corpora lutea were analysed per stage in the marmoset, and 4 corpora
lutea in the human.
Immunostaining for von Willebrand factor, CD31, CD34 and a-SMA, in both
the marmoset and human, was quantified by measuring area of staining using the
Media Pro-Plus 3.0 image analysis system. These antigens are all located to cell
cytoplasm or plasma membrane thus it was not possible to visualise cell margins, and
so absolute cell numbers could not be measured. Immunostaining in marmoset
corpora lutea were quantified using the x20 lens, for the larger human corpora lutea
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the xlO lens was used. A macro was recorded to measure the area of dark objects on
a white background in a predetermined area of interest (field of view), and the
threshold for quantification set so that the captured image represented the live image
as closely as possible. At least two thirds of each corpus luteum was quantified by
selecting the next area of interest as close as possible to the previous one. Due to
differences in size of corpora lutea form different stages of the luteal phase varying
numbers of areas of interest were quantified for each luteal stage. To address the
problem of change in luteal volume at different stages of the cycle, as primarily
determined by steroidogenic cell hypertrophy and atrophy, different sized areas of
interest were measured for each corpus luteum at a particular stage of the cycle. The
"area of interest" was a comprehensive coverage of the randomly chosen field of
view. For early luteal phase marmoset corpora lutea the area of interest covered
9.2xl04 pm2, 1.3xl05 pm2 for the mid-luteal phase marmoset corpus luteum, and
5 2
1.1x10 pm for the late luteal phase marmoset corpus luteum. The size of these areas
of interest were calculated by multiplying the largest area of interest by the specific
conversion factor for each stage of the luteal phase (as calculated from the change in
steroidogenic cell area throughout the cycle). If quantification was performed using
the same sized area of interest for corpora lutea from each stage of the cycle, the
mean per group could be multiplied by the specific conversion factor for that stage
which gave results with an identical trend and statistical significance to those gained
from using different sized areas of interest for each luteal phase. Measurements from
human luteal immunostaining were converted in this way using data gained from the
change in area of granulosa lutein cells throughout the human luteal phase.
VEGF-A immunostaining was quantified using Photoshop version 5.0
according to the methods used by Otani et al., (1999) for VEGF quantification as
demonstrated by Lehr et al., (1999). Tissue sections were examined using the x20
lens on an Olympus Provis microscope and images were captured using a digital
camera, either the Kodak DCS420 or Kodak DCS330. Captured images were opened
in Photoshop version 5.0, the default size and resolution was used for each image. To
ensure that only the VEGF-A immunostaining would be quantified and not the
counterstain, the colour contrast of the image was enhanced adjusting the
Hue/Saturation tools in the Image Adjust menu to constant levels. The Magic Wand
tool was used to select one positively stained cell, and using the Similar tool in the
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Select menu all immunopositive tissue was selected. The pixel count of the selected
chromogen was quantified using the Histogram command in the Image menu. The
Histogram also displays the optical density of all pixels within the selected area in
the form of a graph, in which each vertical line represents the number of pixels
which are associated with a brightness level, on the left side the darkest areas and on
the right side the brightest areas. The mean value represents the staining intensity of
selected areas. The lower the optical density, the darker the area, i.e. the more intense
the staining, and hence the greater the expression. For each image the pixel count
(area of staining) and the mean value (intensity of staining) were noted. As many
fields of view were photographed and quantified as the size of the corpus luteum
would allow.
For quantification of all immunostaining the mean of all fields (and all
corpora lutea per marmoset) were taken as representative for each subject, and the
mean of all subjects per group was taken as representative for each stage of the luteal
phase.
3.2.5 Statistical analysis
Data from each method of quantification of immunostaining was statistically
analysed. Separate one way analysis of variance tests were carried out for each set of
data, and a factorial Fisher's protected least significant difference post hoc test
performed. When comparing just 2 groups, i.e. for the comparison of 2 sections per
corpus luteum, or 2 independent quantifications of the same section, two-tailed,
unpaired t tests were used. P<0.05 was taken as the level of significance for each test.
All tests were performed using StatView Version 4.0 for the Macintosh.
3.3 Results
3.3.1 PI and marmoset plasma progesterone throughout the luteal phase
BrdU staining indicating proliferating cells was readily observed in all marmoset
corpora lutea. In the marmoset, differences between theca and granulosa derived
lutein cells are not readily apparent (Webley et al., 1990), both types of hormone
producing cells having a large spherical or polyhedral nucleus and abundant
cytoplasm. It was clear that none of the hormone-producing cells had incorporated
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BrdU. Incorporation was restricted to some cells surrounding the luminal
microvessels and in those whose appearance and was consistent with capillary
endothelial cells (Fig 3.1a). Low power micrographs of sections throughout the
ovulatory cycle demonstrated that BrdU incorporation in the early luteal phase (Fig.
3.1b) appeared to be greater than that in mid- (Fig. 3.1c) and late (Fig. 3.Id) corpora
lutea. Positive nuclei were not present in negative control sections.
Quantification of the PI (Fig. 3.2a) throughout the luteal phase of the
marmoset ovulatory cycle revealed peak cell proliferation in the early corpus luteum,
which declined markedly (PcO.OOl, as compared to early levels) in the mid- and late
corpus luteum. The 2.5 fold decrease in PI from the mid- to late corpus luteum was
significant (P<0.05). Correspondingly, plasma progesterone concentrations (Fig.
3.2b) were maximal (P<0.01) in the mid-luteal phase after proliferation of the
endothelium which signifies growth of the microvascular network. Plasma
progesterone concentration subsequently decreased (PcO.Ol) in the late luteal phase,
coinciding with a fall in endothelial cell proliferation.
To test the reproducibility of calculation of the PI, selected sections (n=15
sections) were independently quantified by Helen Wilson. The two independent
quantifications correlated highly (r=0.978) signifying the method used for
quantification was reproducible (Fig. 3.3).
To examine the representative nature of the quantification of one section to
the whole corpus luteum, the PI of a subsequent second section from selected
corpora lutea were obtained. Figure 3.4a demonstrates that the trend remains the
same over the luteal phase although results from quantification of the first sections
demonstrated a significant difference between mid- and late corpora lutea, whereas
Pi's from the second sections showed no significant change between these stages.
However, there were no significant differences between first and second section Pi's
within one stage of the cycle. This signifies that quantification of one section
represents the whole corpus luteum.
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Figure 3.1 Incorporation of bromodeoxyuridine in marmoset corpora lutea
(a) High power photomicrograph showing the large steroidogenic cells (SC) with abundant
cytoplasm (C), round nucleus (N) and absence of BrdU staining. Note the microvessel
located centrally (BV) composed of endothelial cells with little cytoplasm and elongate
nuclei. Note the presence of dark BrdU proliferating cells associated with the blood vessel
as indicated by arrows, and in endothelial cells (arrow head) of capillaries distributed
between the hormone producing cells, (b-d) low power photomicrographs of early, mid-
and late corpora lutca, respectively. Dark staining indicates nuclear BrdU incorporation.
The insert in (b) demonstrates the absence of staining in a negative control early corpus
lutcum. Scale bar on a = 50pm. Scale bars on b-d = 100pm.

















































Figure 3.2 Proliferation index and plasma progesterone concentrations in marmoset corpora
lutea
(a) Cell proliferation; and (b) plasma progesterone concentrations throughout the luteal phase of the
marmoset ovulatory cycle. Values are means ± SEM. Different letters denote significant differences
between groups, P<0.05. For each stage of the luteal phase n=5 animals.
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Figure 3.3 Correlation of two independent quantifications of the marmoset
corpus luteum proliferation index
The correlation of two quantifications of marmoset luteal cell proliferation. The
correlation coefficient r value from two independent PI quantifications is close to 1,
signifying the method of quantification used is highly reproducible. 15 sections were
quantified by a second individual.
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Figure 3.4 Correlation of proliferation indices from two sections of the same
marmoset corpus luteum
Comparison of the trend in PI from marmoset luteal Section 1 (blue bars) and
Section 2 (turquoise bars) during the luteal phase. There was no significant
difference between sections of the same stage of the luteal phase. Values are means ±
SEM. Different letters denote significant differences between groups, P<0.05. For
each stage of the luteal phase n=5 animals.
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To determine the number proliferating cells in the marmoset corpus luteum
that were endothelial cells, sections (n=10 sections for early and mid-stage corpora
lutea) from selected animals (n=5 for early and mid-stage corpora lutea) were dual
stained with either BrdU and the endothelial cell marker von Willebrand factor, or
BrdU and another endothelial cell marker, CD31 (Fig. 3.5). Colocalisation of the red,
nuclear BrdU stain and the green, cytoplasmic von Willebrand factor stain (Fig.3.5c)
demonstrated dual labelling of most proliferating cells in the early luteal phase.
Similarly, colocalisation of the black, nuclear BrdU stain and red, cell membrane
CD31 stain in the early, mid-, and late luteal phases shows dual staining of most
proliferating cells, as demonstrated by the mid-luteal section under higher power
(Fig. 3.5g). When the proportion of dual staining cells was quantified it was apparent
that over 80% of proliferating cells in the marmoset corpus luteum were endothelial
cells (Fig. 3.6).
Ki67 immunostaining indicating proliferating cells in human luteal sections
was readily observable in all human corpora lutea. A high level of Ki67 positive cells
was observed in sections from the early luteal phase (Fig. 3.7a) which was markedly
reduced in mid- and late luteal sections (Fig. 3.7b-c). A similar pattern of staining as
the early luteal phase was seen in sections after hCG rescue (Fig. 3.7d). When
quantified, the PI for Ki67 staining in the human demonstrated a significant decrease
in the percentage of Ki67 positive cells from early luteal phase levels in the mid-
(P<0.05) and late (P<0.05) corpus luteum, and a marked increase in proliferation
(P<0.05) similar to early luteal phase levels, after hCG rescue (Fig. 3.8).
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Figure 3.5 Colocalisation of BrdU with von Willebrand factor and CD31 in the
marmoset corpus lutcum
(a) Fluorescent immunocytochemical localisation of the endothelial cell marker, von
Willcbrand factor; (b) proliferation marker, BrdU; and (c) colocalisation of the two in an
early corpus luteum. Note that most BrdU positive cells are also von Willebrand factor
positive, (d-f) Colocalisation of BrdU (black nuclei) with CD31 (red staining) in an early
marmoset corpus luteum; mid-luteal section; and late corpus lutcum, respectively, (g) The
mid-lutcal section on higher power to demonstrate that fact that almost all BrdU positive
cells arc also CD31 positive. Scale bars on a-c = 50pm. Scale bars on d-g = 100pm.
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Figure 3.6 The proportion of proliferating endothelial cells in the marmoset
corpus luteum
Quantification of proliferating endothelial cells (dual stained for BrdU and CD31) in
the marmoset corpus luteum. At all stages of the luteal phase proliferating
endothelial cells constituted over 80% of total proliferating cells. No significant
differences between stages of the luteal phase were observed. Values for early and
mid-luteal data are means, the SEM value was not great enough to be seen on this
scale. In the early and mid-luteal stages n=5 animals, in the late luteal phase n=l
corpus luteum.
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Figure 3.7 Ki67 immunostaining in the human corpus lutcum
Low power photomicrographs of (a) Ki67 immunostaining (dark nuclei) in an early corpus
luteum; (b) mid-corpus lutcum; (c) late corpus lutcum; and (d) after hCG rescue of the
corpus lutcum. Scale bar = lOOjim.
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Figure 3.8 Proliferation Index in the human corpus luteum
The proliferation index, or percentage Ki67 positive cells throughout the lifespan of
the human corpus luteum. Values are means ± sem. Different letters denote
significant differences between groups, P<0.05. For each luteal stage n=4-6 corpora
lutea.
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3.3.2 Change in steroidogenic cell area throughout the luteal phase
Haematoxylin and eosin stained sections from different stages of the luteal phase
revealed marked changes in steroidogenic cell morphology and cell content of the
corpus luteum (Fig. 3.9). Low power photomicrographs of early luteal phase sections
demonstrate lutein cell streaming to fill the antrum of the developing corpus luteum
giving the steroidogenic cells an elongated shape (Fig. 3.9a), which is clarified under
higher power (Fig. 3.9b). By the mid-luteal phase the corpus luteum has fully
developed both structurally and functionally (Fig. 3.9c and d). The increased
cytoplasmic volume of steroidogenic cells, coinciding with maximal progesterone
output, gives lutein cells a large round polyhedral morphology typical of this stage of
the cycle. There is an increase in the incidence of luminal blood vessels and densely
staining, probable endothelial cells, associated with each steroidogenic cell. In the
late corpus luteum (Fig. 3.9e) degeneration is associated with lutein cell cytoplasmic
vacuolation and disappearance of these cells which appear more sparsely distributed,
and the infiltration of possible fibroblasts and immune cells, with densely stained
nuclei and little cytoplasm. The intact lutein cells still present have abundant
cytoplasm and obvious nuclei, and are not dissimilar from those in the mid-luteal
phase (Fig. 3.9f).
Measurement of the change in steroidogenic cell area throughout the luteal
phase demonstrated a significant increase (P<0.001) in lutein cell area from early to
mid-luteal phase (Fig. 3.10). Mean steroidogenic cell areas in the late corpus luteum
were greater than early luteal values and lower than mid-luteal results but were not
significantly different from either. Mid-luteal phase steroidogenic cell area was
greatest and so conversion factors for the measurement of immunostaining area in
the early and late luteal phases were calculated from the ratio of change of means
from early to mid- levels and from late to mid- values, respectively. The mean mid-
luteal phase lutein cell area was divided into the early and late luteal phase values
and the resulting figures multiplied by the size of the maximal area of interest
available to measure immunostaining. This gave the size of areas of interest for early
and late luteal sections, the mid-luteal sections were measured using the maximal of
area of interest. These data are summarised in Table 3.1.

































Figure 3.9 Morphology of the marmoset corpus luteum
(a) Low power photomicrograph of an early luteal phase marmoset corpus luteum stained with haematoxylin
and eosin. Note the presence of the antrum (A) in the developing corpus luteum and the small elongated
shape of lutein cells streaming in to fill the antrum, (b) The same section on higher power demonstrates the
elongated lutein cells, some with very little cytoplasm, (c) Low power photomicrograph of a mid-luteal
phase section. Steroidogenic cells are more evenly distributed and luminal blood vessels (BV) are apparent,
(d) In higher power there is an increase in cytoplasmic volume and steroidogenic cells (SC) take on their
characteristic appearance as large polyhedral cells with round nuclei (N) and abundant cytoplasm (C). (e) In
the late corpus luteum low power photo-micrographs demonstrate lutein cell vacuolation (V), the decrease
in steroidogenic cell numbers, and the presence of clusters (arrows) of densely stained cells with little
cytoplasm typical of immune cells, which are characteristic of degenerative change, (f) Under higher power
it is possible to see clearly the vacuolation (V) associated with lutein cell cytoplasm and the general disorg¬
anisation of the corpus luteum. The remaining healthy steroidogenic cells (SC) have obvious nuclei (N) and
abundant cytoplasm (C) similar to mid-luteal cells. Scale bars on a. c and e = l(X)um. Scale bars on b, d and
f = 50pm.






















Figure 3.10 The change in steroidogenic cell area throughout the marmoset
luteal phase
Quantification of marmoset lutein cell area in the early, mid- and late luteal phases.
Values are means ± sem. Different letters denote significant differences between
groups, P<0.05. An average of 10 corpora lutea were analysed per luteal stage.







Area used to measure
immunostaining (pm )
Early 206 0.71 9.2 x 104
Mid- 290 1 1.3 x 105
Late 236 0.81 1.1 x 105
Table 3.1
Conversion of area used to measure immunostaining corresponding to change
in lutein cell area throughout the luteal phase of the cycle
Changes in cell morphology were also evident in H and E stained sections of
human corpora lutea (Fig. 3.11). In the human corpus luteum granulosa and theca
derived lutein cells are distinguishable. Theca lutein cells are smaller with round
nuclei and less cytoplasm and do not undergo noticeable hypertrophy during the
luteal phase. Granulosa lutein cells are larger with central round nuclei and abundant
cytoplasm which undergoes hypertrophy. The change in granulosa cells cytoplasmic
volume over the luteal phase contributes largely to the overall change in luteal
volume. It was the area of these cells which were measured in human luteal sections.
Low power photomicrographs demonstrated the structure of the corpus luteum in
which similar changes as described for the marmoset corpus luteum occurred. The
change in cytoplasmic volume of the granulosa lutein cells was most evident in high
power photomicrographs. After exposure to hCG (Fig. 3.1 lg-h) the degenerative
changes witnessed in the late luteal phase did not take place and the steroidogenic
cells increased in size, coinciding with an increase in progesterone output, as the
corpus luteum was 'rescued' from luteolysis. When compared with mid-luteal
granulosa lutein cell size it was apparent that luteal rescue caused granulosa lutein
cell cytoplasmic volume to increase further.
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Figure 3.11 Morphology of the human corpus luteum
(a) Low power micrograph of an early luteal haematoxylin and eosin stained section. Note the presence of large blood
vessels (BV) in the theca lutein cell compartment (T) and the smaller vessels (SV) in the granulosa lutein cell compart¬
ment (G). (b) The same section on higher power. Note the granulosa derived lutein cells (GLC) have a relatively small
volume of cytoplasm (C) and large central nucleus (N). (c) Low power micrograph of a mid-corpus luteum. Note the
presence of large blood vessels in the granulosa derived compartment (G); and (d) the same section on higher power
revealing an increase in cytoplasmic volume (C) of the granulosa lutein cells (GLC) and the large central nucleus (N),
typical of steroidogenic cells at this stage, (e) Low power micrograph of a late corpus luteum; and (f) a higher power
micrograph of the same section. Note the presence of vacuoles in both the granulosa (G) and theca lutein compartments
(T), and the decrease in cytoplasmic volume (C) of granulosa derived lutein cells (GLC). (g) Low power micrograph of
a corpus luteum rescued from luteolysis with hCG; and (h) a higher power micrograph of the same section demonstrating
the massive increase in cytoplasmic volume (C) of the rescued granulosa lutein cells (GLC). Scale bars on a, c, e and g =
100pm. Scale bars on b, d, f and h = 50pm.
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Figure 3.12 The change in granulosa lutein cell area in the human corpus
luteum
Quantification of area of granulosa lutein cells throughout the luteal phase and after
luteal rescue in the human. Values are means ± sem. Different letters denote
significant differences between groups, P<0.05. An average of 4 corpora lutea were
analysed per luteal stage.
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Measurement of granulosa lutein cell area (Fig. 3.12) demonstrated a marked
increase in granulosa cell area from early to mid- (P<0.001), and decrease from mid-
to late (P<0.01) luteal values. Following luteal rescue these cells were significantly
(P<0.03) larger than at any other stage of the cycle. Again conversion factors were
calculated in the same way as for marmoset cell measurements except that this time
change was calculated against the rescued cell area. Conversion factors are shown in
Table 3.2, and were used to convert immunostaining measurements after
quantification which was performed using the same sized area of interest for all
corpora lutea.






Conversion of immunostaining results corresponding to change in granulosa
lutein cell area throughout the luteal phase of the cycle
3.3.3 Endothelial cell area
Immunostaining for von Willebrand factor was readily observed in all marmoset
corpora lutea (Fig. 3.13). In the early luteal phase (Fig. 3.13a) staining demonstrated
the initiation of development of the microvasculature, associated mainly with
endothelial cells of non luminal smaller capillary vessels. By the mid-luteal phase
(Fig. 3.13b) the microvascular tree was fully established with staining associated to
larger luminal vessels and small capillaries. In the late luteal phase (Fig. 3.13c) von
Willebrand factor positive cells associated to capillaries appeared to have decreased
in number but endothelial cells of larger microvasculature remained present.
Negative control sections were completely devoid of staining (Fig. 3.13d).
Quantification of area of von Willebrand factor immunostaining (Fig. 3.14) showed a
significant increase (P<0.0001) in endothelial cell area from the early to the mid-
luteal phase, and a marked decrease (PcO.OOl) in area from the mid- to the late luteal
phase.
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Figure 3.13 Immunostaining for von Willebrand factor in the marmoset corpus
luteum
(a) Photomicrographs of immunostaining for the endothelial cell specific antigen,
von Willebrand factor (dark staining) in the early marmoset corpus lutcum, note the
presence of endothelial cells which are associated to small non-luminal capillaries as
indicated by the arrows, (b) A mid-lutcal section demonstrating full development of
the microvasculature in the form of luminal vessels (LV) and small capillaries (arrows),
(c) A late corpus lutcum showing the predominance of larger microvessels (LV), and
the reduced appearance of small capillaries, (d) A regressing, follicular phase CL section
demonstrating distinct vWF immunostaining. Scale bar = 100pm.
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Figure 3.14 Measurement of endothelial cell area in the marmoset corpus
luteum
Quantification of the area of endothelial cell staining, following
immunocytochemistry for von Willebrand factor, throughout the marmoset luteal
phase. Values are means ± SEM. Different letters denote significant differences
between groups, P<0.05. For each luteal stage n=5 animals.
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Immunostaining with the endothelial cell marker, CD31, in the same corpora
lutea demonstrated a similar pattern of endothelial cell distribution in the early, mid-,
and late luteal phases (Fig. 3.15a-c, respectively). It was also noticed that in the
regressed follicular phase corpus luteum, CD31 staining was not as defined as in
earlier luteal stages giving rise to areas of diffuse disorganised staining, which were
not apparent in follicular thecal vasculature in the same section (Fig. 3.15d and
insert). As this phenomenon had not been seen previously with von Willebrand
factor immunostaining this suggested a specific breakdown of the CD31 antigen in
luteal endothelium. Comparison of the quantification of CD31 immunostaining in the
early, mid-, and late corpus luteum with von Willebrand factor staining revealed the
same trend in endothelial cell area throughout the luteal phase (Fig. 3.16a). There did
appear to be a significant difference between early and late luteal levels (PcO.Ol)
which was not seen with von Willebrand factor quantification. There was however
no significant differences between CD31 and von Willebrand factor results within
one stage of the luteal phase, as suggested by the high correlation coefficient
(r= 1.000 when rounded to three decimal places) (Fig. 3.16b).
To examine whether measurement of endothelial cell area in one section was
representative of the whole corpus luteum, CD31 immunostaining in second sections
from a selection of corpora lutea (n=3 animals in each luteal stage) was quantified.
The same trend in endothelial cell area was apparent during the luteal phase in both
sections (Fig. 3.17a). There was no significant difference between mid- and late
values from quantification of the second sections, as seen after quantification of the
first sections. However there was no significant differences between endothelial cell
area, in two distal sections, within one stage of the luteal phase, as suggested by the
high correlation coefficient (r=0.979) (Fig. 3.17b).
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Figure 3.15 Immunostaining for CD31 in the marmoset corpus luteum
(a) Early luteal CD31 staining demonstrating the presence of small, non-luminal
capillaries in the developing vasculature throughout the section; and (b) a mid-luteal
phase section showing the incidence of larger luminal vessels (LV) and small capillaries
indicating full development of the microvascular tree, (c) CD31 staining in the late luteal
phase; and (d) in the regressing, follicular phase corpus luteum. Note the presence of
diffuse luteal immunostaining for CD31 (arrows), less distinct than in earlier stages of
development, and (insert in d) the intact staining visible in the ovarian stroma (S) and
thcca layer (TL) of two developing follicles in the same section. Scale bars = 100pm.
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Figure 3.16 Comparison of quantifications of CD31 and von Willebrand factor immunostaining
in the marmoset corpus luteum
(a) Bar graph comparing endothelial cell area measurements from CD31 (purple bars) and von
Willebrand factor (pink bars) immunostaining throughout the lifespan of the marmoset corpus luteum.
(b) The correlation of the trend in CD31 and von Willebrand factor immunostaining area throughout
the luteal phase. Values are means ± SEM. Different letters denote significant differences between
groups, P<0.05. There were no significant differences between quantification of CD31 and von
Willebrand factor staining within a particular group as suggested by the high correlation co-efficient.
For each luteal stage n=5 animals.
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Figure 3.17 Correlation of CD31 immunostaining in two distal sections from the same marmoset
corpus luteum
(a) Comparison of CD31 immunostaining from Section 1 (purple bars) and Section 2 (lilac bars)
throughout the luteal phase in the marmoset corpus luteum. There was no significant difference
between sections of the same stage of the luteal phase, (b) The correlation coefficient of quantification
of the two sections. Values are means ± SEM. Different letters denote significant differences between
groups, P<0.05. For each luteal stage n=5 animals.
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In the human corpus luteum, measurement of CD34 immunostaining was
used to quantify endothelial cell area (Fig. 3.18). In a similar pattern to the
microvasculature in the marmoset corpus luteum endothelial cells associated to small
non-luminal vessels were apparent in the developing corpus luteum (Fig. 3.18a), and
by the mid-luteal phase (Fig. 3.18b) the microvascular tree was fully established with
staining associated to larger luminal vessels and small capillaries (Fig. 3.18c). In the
late luteal phase vessels appeared smaller and more sparsely distributed throughout
the corpus luteum. After luteal rescue vessels remained small but were more tightly
packed signifying an increase in luteal microvasculature (Fig. 3.18d). Quantification,
without converting for the effects of tissue expansion and shrinkage (Fig. 3.19a),
revealed there was no change in endothelail cell area at any stage of the luteal phase.
However, when these values were converted for the effects of tissue expansion and
shrinkage reflecting the true in vivo situation, quantification (Fig. 3.19b) confirmed
the effect seen following immunocytochemistry. An increase (P<0.05) in endothelial
cell area from the early to the mid-luteal phase, and a marked decrease in the late
corpus luteum (P<0.05) was demonstrated. Following luteal rescue, endothelial cell
area significantly increased (P<0.05) from all other luteal levels.
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Figure 3.18 CD34 immunostaining in the human corpus lutcum
Photomicrographs of CD34 immunostaining in (a) an early corpus luteum, note the
presence of small capillaries in the developing vasculature, and the absence of staining
in (inset in a) the negative control section, (b) A mid-corpus luteum, note the incidence
of larger luminal vessels (LV) in addition to the small capillaries (arrows) in the
established microvasculaturc. (c) The late luteal phase, note the presence of small and
large luminal vessels; and (d) the hCG rescued corpus luteum at the same magnification,
in which there is a dramatic increase incidence of small luminal vessels throughout the
corpus luteum. Scale bars = 100pm.
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Figure 3.19 Quantification of endothelial cell area in the human corpus hiteum
(a) Quantification of area of endothelial cell CD34 staining in all luteal phases in the
human corpus luteum. Data not converted for effects of tissue expansion and
shrinkage, (b) Quantification of area of endothelial cell CD34 staining in all luteal
phases in the human corpus luteum. Data converted to consider the effects of tissue
expansion and shrinkage. Values are means ± sem. Different letters denote
significant differences between groups, P<0.05. For each luteal stage n=4-6 corpora
lutea.
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3.3.4 Cyclic VEGF-A expression
In the marmoset antral follicle the avascular granulosa layer and the vascularised
theca layer are separated by a basement membrane. VEGF-A expression was
exclusively located to the vascularised thecal layer (Fig. 3.20a). However, in the
preovulatory follicle, estimated hours before ovulation, degeneration of the
separating basement membrane can be seen and expression of VEGF-A is located to
the granulosa as well as the thecal layer of the follicle (Fig. 3.20b). Early luteal
sections show intense, punctate VEGF-A staining in the cytoplasm of lutein cells
(Fig. 3.20c) becoming more uniform and widespread in the mid-corpus luteum (Fig.
3.20d). Staining was absent from recognisable endothelial cells. In the late corpus
luteum, VEGF-A staining was markedly reduced (Fig. 3.20e). Positive
immunoreactivity was not seen in the negative control section (Fig. 3.20f).
Quantification confirmed a high area of staining in the early and mid-luteal phase
which declined markedly in the late corpus luteum, as compared to early and mid-
luteal levels (P=0.04 and P=0.02, respectively) (Fig. 3.21a). VEGF-A
immunostaining was significantly more intense (P<0.0001) in the early luteal phase
as compared to mid- and late luteal levels (Fig. 3.21b, the optical desity of the early
luteal phase group being significantly lower than other luteal phase values).
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Figure 3.20 VEGF-A immunostaining in marmoset follicles and corpus luteum
(a) Immunostaining for VEGF (brown staining) in an antral follicle. Note that the basement membrane
(BM) separating the theca (T) and granulosa (G) cell layers is intact and that staining is restricted to the
theca layer of the follicle as indicated by the arrow, (b) In a marmoset follicle at the time of ovulation
there is disintegration of the basement membrane and VEGF immunostaining is localised to both granulosa
(G) and theca (T) cell layers as indicated by the arrows, (c) In the early corpus luteum VEGF staining is
found throughout the corpus luteum; and (d) in the larger mid-corpus luteum it is noted that staining is more
widespread and located to the cytoplasm (C) of most steroidogenic cells (SC). (e) In the late corpus luteum
VEGF staining is considerably reduced showing a punctate pattern located to the edges of some steroidogenic
cells. (0 Shows the negative control section in which primary antibody was preabsorbed with the epitope it
was raised to. Scale bars on a, c-f = 100pm. Scale bar on b = 50pm.




























Figure 3.21 Quantification of VEGF-A immunostaining in the marmoset corpus luteum
Quantification of area of VEGF immunostaining throughout the luteal phase of the marmoset corpus
luteum. (b) Quantification of intensity of VEGF immunostaining in the marmoset corpus luteum.
There is an inverse relationship between staining intensity and the units of measurement. A low value
indicates dark staining/high intensity. Values are means ± SEM unless the SEM value was too small for
the scale of the graph. Different letters denote significant differences between groups, P<0.05. For
each luteal stage n=5 animals.
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Immunostaining for VEGF-A in the human corpus luteum was also
measured. In the developing corpus luteum, low power photomicrographs
demonstrate intense VEGF-A staining at the tips of the finger-like processes of
granulosa derived lutein cells invading the antrum (Fig. 3.22a). There is also
expression in other granulosa lutein cell areas and in the theca lutein cell
compartment. High power microscopy reveals that VEGF-A immunostaining is
located to the cytoplasm of these cells (Fig. 3.22b). By the mid-luteal phase,
expression appears to have spread more evenly across the granulosa lutein cell
compartment and decreased in theca lutein cells (Fig. 3.22c-d). As in the marmoset,
VEGF-A immunostaining had markedly declined in the late human corpus luteum,
with only small area of punctate expression remaining localised predominantly to
granulosa lutein cells (Fig. 3.22e-f). After hCG rescue the decrease in VEGF-A
immunostaining seen in the late luteal phase was prevented (Fig. 3.22g-h) and a
tendency for VEGF-A protein content to increase as compared to the mid-luteal
phase. Expression remained located to lutein cell cytoplasm and was uniformly
distributed, similar to the pattern of expression in the mid-luteal phase.
Quantification (Fig.3.23a) confirmed a high area of VEGF-A immunostaining in the
early and mid-luteal phases, and a decreasing trend to late luteal phase levels, which
was not significant. There was however, a significant increase (P<0.05) in the area of
VEGF-A protein detected in the rescued corpus luteum from early and late luteal
levels. The intensity of immunostaining remained unchanged over all luteal stages
(Fig. 3.23b).
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Figure 3.22 VEGF-A immunostaining in the human corpus luteiim
(a) Low power photomicrograph of VEGF imnuinostaining (brown staining) in an early luteal human corpus luteum.
Note the presence of VEGF immunostaining in both the theca (T) and granulosa (G) derived compartments, and the
greater intensity in staining at the leading edge of the granulosa compartment (arrows) invading the antrum (A), (b)
The same section on higher power, note that VEGF staining is located in the cytoplasm (C) of the steroidogenic cells,
(c) Low power micrograph of a mid-corpus luteum, note the widespread appearance of staining throughout the gran¬
ulosa (G) and theca (T) compartments, (d) The same section on higher power, notice that almost every steroidogenic
cell (SC) is expressing VEGF, staining being located to the cytoplasm (C). (e) Low power micrograph of a late corpus
luteum. Note the more punctate palter of VEGF staining in both the granulosa (G) and theca (T) compartments, which
on higher power (0 can be seen located to the cytoplasm (C) of some steroidogenic cells (SC). (g) Low pow er micrograph
of an hCG rescued corpus luteum, note the widespread distribution of VEGF staining throughout the corpus luteum. (h)
The same section on higher power reveals that almost all steroidogenic cells demonstrate staining for VEGF.
Scale bars = lOOum.
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Figure 3.23 Quantification of VEGF-A immunostaining in the human corpus luteum
(a) Quantification of area of VEGF immunostaining throughout the luteal phase of the human corpus
luteum. (b) Quantification of intensity of VEGF immunostaining in the human corpus luteum. There
is an inverse relationship between staining intensity and the units of measurement. A low value
indicates dark staining/high intensity. Values are means ± SEM unless the SEM value was too small for
the scale of the graph. Different letters denote significant differences between groups, P<0.05. For
each luteal stage n=4-6 corpora lutea.
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3.3.5 Luteal pericyte area
Immunostaining for a-SMA was high in the developing marmoset corpus luteum
associated to both non-luminal, capillary vessels and the occasional present luminal
vessel (Fig. 3.24a). In the mid- and late corpus luteum staining was restricted to
pericytes located in rings surrounding luminal vessels (Fig.3.24b-c). This pattern of
staining was particularly evident in the late luteal phase where most luminal vessels
had associated pericytes. Quantification of a-SMA immunostaining area showed a
decreased trend from high levels in the early luteal phase to significantly lower
(P<0.02) levels in the late corpus luteum (Fig. 3.25). A low area of a-SMA staining
in the late corpus luteum corresponds with a decrease in total vasculature at that
stage as seen by von Willebrand factor and CD31 staining.
Colocalisation of staining for a-SMA and von Willebrand factor in the
human revealed the close association of pericytes to endothelial cells at all stages of
the luteal phase, but that staining was in two distinct cell types (Fig. 3.26). Light
field a-SMA staining using NBT detection (Fig. 3.27), demonstrated that pericytes
associated to luminal vessels appeared to be restricted to the theca lutein vasculature,
and the occasional single pericyte was present in the granulosa compartment of the
early corpus luteum. Later in luteal development, pericytes were present associated
only to large luminal vessels in both the theca and granulosa lutein compartments.
Quantification of area of pericyte staining (Fig. 3.28a), not adjusting for changes in
tissue volume during the luteal phase and after rescue, failed to show any significant
differences in pericyte content in the corpus luteum, although there was a tendency
for increased staining during the mid-luteal phase. This trend was amplified when
quantification was converted for the effects of tissue expansion and shrinkage which
represents the in vivo environment more closely (Fig. 3.28b). Quantification of
pericyte area after conversion showed increased staining (PcO.OOOl) from early to
the mid- corpus luteum, and a significant decrease (P<0.0001) in the late corpus
luteum. Pericyte area increased to maximal levels (P=0.02 as compared to mid-luteal
levels) following hCG rescue. In the late luteal phase almost all endothelial cells
were associated to luminal vessels, as seen by CD34 immunostaining, which
appeared to have associated pericytes, as demonstrated by positive a-SMA
immunostaining, suggesting the selective demise of small capillary vasculature. The
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endothelial cell content per unit area also decreased at this time which indicates a
loss of endothelial cells, not their evolution to a mature form.
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Figure 3.24 The incidence of pericytes in the marmoset corpus luteum
(a) Photomicrograph of oc-SMA immunostaining (dark staining) in an early marmoset
corpus lutcum. Note the presence of single positive cells (arrows) which do not appear
to be associated with mature luminal vessels (LV), and staining which is associated with
luminal vessels (LV). (b) a-SMA immunostaining in a mid-corpus luteum. note the
absence of single immunopositive cells and that all staining is associated to large luminal
vessels (LV). (c) A late corpus luteum, again staining is associated to large luminal
vessels only, (d) A negative control section demonstrating the absence of immunostaining.
Scale bar = 100pm.
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Early Mid Late
Figure 3.25 Quantification of pericyte content in the marmoset corpus luteum
Quantification of pericyte area throughout the lifespan of the marmoset corpus
luteum. Values are means ± SEM. Different letters denote significant differences
between groups, P<0.05. For each luteal stage n=5 animals.
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Figure 3.26 Colocalisation of pericytes and endothelial cells in the human corpus
luteum
Dark field photomicrographs showing fluorescent immunostaining of the endothelial cell
marker, von Willcbrand factor (green staining) and the pericyte marker, oc-SMA (red
staining) and colocalisation of the two, in (a-c) an early luteal phase human corpus
lutcum; (d-f) a mid luteal phase human corpus lutcum; (g-h) a late corpus lutcum; and
(j-1) after hCG rescue. Note in the colocaliscd panels that pericytes are closely associated
to, almost intertwined with, endothelial cells of some luminal vessels, but that staining
appears to be in two distinct cell types. Scale bar = lOOfim.
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Figure 3.27 Pericyte distribution in the human corpus luteum
(a) Low power micrograph of a-SMA immunostaining in an early corpus luteum, note that
staining is associated with luminal vessels (LV) in the theca (T) derived compartment and
some small single cells are immunopositive in the granulosa compartment (G). (b) a-SMA
immunostaining in a mid-corpus luteum, note that staining is associated to luminal vessels
(LV) only, present in both the theca (T) and granulosa (G) compartments; similarly in (c)
a late corpus lutcum; and (d) after hCG rescue. Scale bar = 200pm.
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Figure 3.28 Quantification of pericyte area in the human corpus luteum
(a) Quantification of pericyte area throughout the lifespan of the human corpus
luteum. Data not converted for the effects of tissue expansion and shrinkage, (b)
Quantification of pericyte area throughout the lifespan of the human corpus luteum.
Data converted for the effects of tissue expansion and shrinkage. Values are means ±
SEM unless the SEM value was too small for the scale of the graph. Different letters
denote significant differences between groups, P<0.05. For each luteal stage n=4-6
corpora lutea.
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3.4 Discussion
This study has demonstrated that luteal angiogenesis can be measured by assessing
parameters associated with the process in tissue sections collected at specific time
points throughout the lifespan of the corpus luteum. Quantification of endothelial cell
proliferation and resultant changes in luteal endothelial cell area; the expression of
potent angiogenic agents, such as VEGF; and factors associated with vessel
maturation, give detailed information about the rate of angiogenic activity in such
tissue.
It was found that the early luteal phase is associated with intense
angiogenesis, and high VEGF expression, as the initiation of development of luteal
microvasculature and its stabilisation is underway. By the mid-luteal phase,
endothelial cell proliferation continues at a lower rate, although VEGF expression
remains high, and the formation of the microvascular tree is complete, with the
presence of mature, luminal vessels and small capillaries. Late luteal phase
regression is associated with a further decline in endothelial cell proliferation, a
decrease in VEGF production, and the apparent selective degradation of non-luminal,
immature vessels. It also appears that the process of luteal rescue, simulating early
pregnancy, in the human is associated with an increased rate of angiogenesis and
vessel stabilisation as seen by marked increases in cell proliferation, endothelial cell
content, VEGF expression, and pericyte recruitment.
The use of incorporation of BrdU as a marker for cell proliferation for the
first time in the primate demonstrated its specificity as compared with other markers
such as Ki67 and PCNA. These proteins are expressed throughout most of the cell
cycle and so may still be immunoreactive after division has taken place, which could
give rise to false positive staining in some steroidogenic cells. The extent of this is
decreased when using BrdU as a proliferation marker (Young, 1999). This technique
has been used previously to quantify luteal proliferation in the sheep (Jablonka-
Shariff et ai, 1993) and rat (Gaytan et al., 1996) but, to our knowledge, this is the
first description of its use with respect to the primate ovary. It was clear that few (if
any) of the hormone-producing cells had incorporated BrdU; positive staining was
restricted to some cells surrounding the luminal microvessels and others whose
appearance was consistent with that of capillary endothelial cells. From
colocalisation studies using BrdU with both endothelial cell markers, von Willebrand
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factor and CD31, it was shown that over 80% of proliferating cells in the marmoset
corpus luteum are endothelial cells. Observations in rhesus monkeys (Christenson
and Stouffer, 1996b), rodents (Gaede et al., 1985; Tamura and Greenwald, 1987),
domestic animals (Meyer and McGeachie, 1988; Jablonka-Shariff et al., 1993), and
humans (McClure et al., 1994; Rodger et al., 1997) also suggest that that endothelial
cell proliferation comprises the majority of the mitotic activity in the corpus luteum.
Thus it is reasonable to consider cell proliferation in the marmoset corpus luteum,
based on the PI from single BrdU immunostaining as being reflective of endothelial
cell proliferation. There is evidence that there is little or no proliferation of fully
differentiated primate lutein cells (Christenson and Stouffer, 1996b), which implies
that the remaining BrdU positive cells in the corpus luteum are most likely
fibroblasts, infiltrating macrophages or endothelial support cells, such as pericytes.
This study has also demonstrated that the method of quantification of the PI as based
on the percentage of cells which incorporated BrdU in 6 fields of view per corpus
luteum is a robust, reproducible technique. Quantification of one 5pm section per
corpus luteum is sufficient to represent the whole tissue, as based on correlation
studies when two distal sections were analysed.
The demonstration that endothelial cell proliferation was maximal in the early
primate corpus luteum, and significantly decreased in the mid- and late stages of
luteal development is in agreement with previous studies evaluating cell proliferation
in corpora lutea from other species. Proliferation studies in the human (Rodger et al.,
1997; Gaytan et al., 1998), rhesus monkey (Christenson and Stouffer, 1996b), ovine
(Jablonka-Shariff et al., 1993) and bovine (Zheng et al., 1994) show peak levels at
the early stages of luteal development whereas luteal regression is associated with a
decreased proliferative rate. Young et al., (2000), measure cell proliferation in the
marmoset corpus luteum using both Ki67 and BrdU immunocytochemistry, and
demonstrate similar results to those obtained here. It is worth noting that although
levels of proliferation in the mid-luteal phase are considerably lower than early luteal
levels, the rate of angiogenesis remains higher than that of most other normal adult
tissues in which turnover time to replace the endothelium is measured in years
(Hanahan and Folkman, 1996).
Proliferation studies in the non-pregnant human corpus luteum, as seen by
Ki67 immunostaining, show a similar pattern to that seen in the marmoset. Luteal
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development is associated with an intense period of endothelial cell proliferation
which declines in the mature and early regressing corpus luteum. Although co-
localisation studies were not performed in this study, others have previously shown
that the majority of proliferating cells in the human corpus luteum are endothelial
cells (McClure et al., 1994; Rodger et al., 1997). However, it has not been
demonstrated that luteal rescue by exogenous hCG, simulating early pregnancy, is
associated with an increase in endothelial cell proliferation. Luteal rescue in a similar
study in the human (Rodger et al., 1997), in the ewe (Jablonka-Shariff et al., 1993)
and in the rhesus monkey (Christenson and Stouffer, 1996b) detected no increase in
endothelial cell proliferation. Measurements in these studies were performed per unit
area of luteal tissue and so do not address changes in the expansion of granulosa
lutein cells during luteal rescue which would serve to spread proliferating endothelial
cells further apart, and give a result not representative of the true rescued
environment. Proliferating cells in this study were expressed as a percentage of total
cells which portrays a more accurate picture. Because colocalisation with an
endothelial cell marker was not performed it is possible that the proliferating cells we
observed in rescued tissue may reflect another cell type, for example periendothelial
support cells. It is unlikely that there is an influx of proliferating macrophages after
hCG administration as the macrophage content of rescued corpora lutea is
considerably lower than in those not subjected to hCG rescue at the same stage of the
luteal phase (Duncan et al., 1998a).
The observed differences in endothelial cell proliferative rate in the marmoset
corpus luteum are in agreement with the changes witnessed in luteal endothelial cell
content in this study. The intense proliferation in the early luteal phase when the area
of endothelial cells is relatively low, leads to increased vascularisation during
luteinisation and luteal establishment. By the mid-luteal stage in which there was
peak endothelial cell area, it is thought that the majority of steroidogenic cells are in
contact with at least one capillary (Reynolds et al., 1992; Zheng et al., 1994). Peak
plasma progesterone concentration in the mid-luteal phase correlates with the
presence of an extensive capillary network in the corpus luteum, for optimal delivery
of progesterone precursors to, and progesterone from the cell. Decreased endothelial
cell proliferation in the late corpus luteum coincides with the observed fall in
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vascular area and decrease in plasma progesterone concentration and luteal
regression.
The finding of maximal endothelial cell area from von Willebrand factor
immunostaining in the marmoset mid-luteal phase however, is not in agreement with
other similar studies in the marmoset (Young et al., 2000) and bovine corpus luteum
(Augustin et al., 1995). These studies demonstrated maximal vascularisation in the
early luteal phase. However, quantification of von Willebrand factor immunostaining
was performed per area of luteal tissue, this area of measurement was standardised
throughout the cycle and therefore did not consider the effects that tissue expansion
and shrinkage, typical of the corpus luteum, would have on results. In our study we
attempted to address this problem by assuming the major contribution to such change
in gland volume would be from the differences in lutein cell cytoplasmic volume
after lutein cell hypertrophy and atrophy which is known to occur throughout the
lifespan of the corpus luteum (Adams and Hertig, 1969). It is possible that the effects
of tissue fixation and processing may distort the steroidogenic cells, however this
was standardised at each stage of the luteal phase and was not expected to contribute
as greatly as the changes caused by cytoplasmic hypertrophy. In the late luteal phase,
the relative population of other cells, such as fibroblasts and immune cells, may also
play a role in changing luteal volume. Measurements of these cells was however,
beyond the scope of the thesis. Therfore, the contribution of changes in steroidogenic
cell volume only was quantified by measuring steroidogenic cell area in tissue
sections at each of the stages of the luteal phase. Significant differences were found
and so the area used to quantify von Willebrand factor immunostaining was altered
accordingly and not standardised for each luteal stage.
In human luteal tissue, similar changes in luteal volume are seen. Granulosa
derived lutein cells undergo hypertrophy and atrophy as quantified by measuring
their area in luteal sections in all luteal stages and after hCG rescue. The importance
of considering the effects of tissue expansion and shrinkage is reinforced when
quantification of endothelial cell or pericyte areas in the human corpus luteum were
compared before and after conversion for this phenomenon. Prior to conversion,
there were no significant differences in endothelial cell or pericyte content
throughout the luteal phase, as quantification was performed per standard unit area of
tissue. However after conversion for the effect of tissue expansion and shrinkage,
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significant differences were seen, which appeared to more closely reflect the changes
observed in vivo. Gay tan et al., (1998) recognised the problem when measuring
macrophage content of the human corpus luteum, and performed quantification per
number of granulosa derived lutein cells, the area occupied by which was not static
throughout the luteal phase..
The pattern of vascularisation measured using a second endothelial cell
marker, CD31, in the marmoset corpus luteum confirmed results gained with von
Willebrand factor immunostaining, and there were no significant differences within
groups between endothelial cell areas measured from immunostaining with the two
markers. It appears that endothelial cells in the early, mid- and late stages of luteal
development in the marmoset corpus luteum express both von Willebrand factor and
CD31 antigens. Interestingly, it was noted that CD31 immunostaining in the late
regressing, follicular phase corpus luteum was less distinct and more diffuse than in
earlier stages of development. The regressed corpus luteum in the follicular phase is
believed to be associated with a slump in angiogenic activity, although this was not
measured in this study, and so a temporal correlation of decreased angiogenesis and
disturbances in CD31 signifies the association of CD31 in the angiogenic process.
This study does demonstrate that the quantification of one section per corpus luteum
was sufficient to represent the endothelial cell content of the whole corpus luteum, as
no significant differences in area of endothelial cell staining was observed when two
distal sections were compared. In all further experimental work concerning the
marmoset corpus luteum immunostaining for either von Willebrand factor or CD31,
in one luteal section per corpus luteum, were used to measure endothelial cell content
as a parameter of angiogenic activity.
A similar pattern in luteal vasculature to that seen in the marmoset corpus
luteum was observed in the non-pregnant human corpus luteum by quantification of
CD34 immunostaining. After conversion for the effects of tissue expansion and
shrinkage, a significant increase in endothelial cell area was seen from the early to
mid-luteal phase, and a marked reduction in the late luteal regressing corpus luteum.
What was particularly interesting in the human was that hCG-induced luteal rescue,
simulating early pregnancy, demonstrated a significant increase in endothelial cell
content of the corpus luteum. This, taken with the fact that endothelial cell
proliferation, as seen from Ki67 analysis, dramatically increased at this stage,
Chapter 3 Quantification of Luteal Angiogenesis 140
suggests that rescue of the human corpus luteum is associated with an increased
angiogenic activity of the tissue. Rodger et al., (Rodger et al., 1997), following von
Willebrand factor immunocytochemistry, demonstrated an increase in endothelial
cell number per unit area of tissue, from the early to mid-luteal phase which
remained high in the late corpus luteum and after luteal rescue. A concomitant
elevation of cell proliferation after rescue was however, not demonstrated. It is
proposed that this was due to the technique used to quantify proliferation which did
not consider the tissue expansion associated with rescue of the corpus luteum.
The potent endothelial cell growth factor, VEGF, was expressed exclusively
in the theca layer of marmoset antral follicles which correlated with the selective
vascularisation of the theca. Interestingly, in the periovulatory follicle
immunolocalisation of VEGF was detected in the granulosa layer, which correlates
with disintegration of the basement membrane separating the granulosa and theca
layers and the neovascularisation of the granulosa layer during this period for corpus
luteum formation. In both the marmoset and human non-pregnant corpus luteum, the
level of VEGF expression was high not only in the early luteal period of intense
angiogenesis, but also in the less prolific mid-corpus luteum, and was only down
regulated after initiation of luteolysis. These findings agree with VEGF
measurements throughout the lifespan of the corpus luteum in the bovine (Goede et
al., 1998) and the human corpus luteum (Otani et al., 1999). VEGF was localised to
the cytoplasm of lutein cells in the marmoset and granulosa- and theca-derived lutein
cells in the human. There was no visible staining in endothelial or periendothelial
support cells. Similar cellular localisation was also demonstrated in the human ovary
(Kamat et al., 1995; Gordon et al., 1996). Other studies have demonstrated the
expression of VEGF in endothelial cells and pericytes in culture (Yonekura et al.,
1999) and in pericytes in vivo in the ovine (Reynolds et al., 2000). Placental growth
factor, VEGF-B and C were expressed in pericytes and endothelial cells in culture,
however, the VEGF type was not mentioned in the in vivo study, and so it is possible
that these mural cells express predominantly these other forms of VEGF, which
explains why they were not detected with the antibody (specific for VEGF-A) used
in this study.
In this study, intense VEGF expression was observed in lutein cells adjacent
to the antrum of the developing corpus luteum, particularly in the human, giving
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support for the endothelial cell mitogenicity of VEGF, in the antral invasion of blood
vessels forming the mature, mid-corpus luteum. It is possible that a change in
intensity of staining may not reflect an increase in protein concentration as it is likely
that a linear association between staining intensity and amount of protein present
does not exist. This is a particular concern when using immunocytochemistry to
quantify protein content per cell. On the other hand, the area of immunostaining
would consider the number of cells in which the protein is present, and quantitative
immunocytochemistry based on this parameter is fair.
A high area of VEGF immunostaining was demonstrated in the mid-corpus
luteum suggesting a role for VEGF in the ongoing angiogenic process, and in the
survival and maintenance of the extensive mid-luteal phase vasculature. It could also
reflect some of the non-angiogenic functions of VEGF, such as the regulation of
vascular permeability or the mediation of endothelial cell survival as suggested by
Goede et al., (1998). Immunostaining for VEGF was significantly prevented from
down regulation regulated in the rescued human corpus luteum, again signifying that
rescue is associated with an increase in angiogenesis. Although the role of VEGF at
this time may reflect some of the other functions of VEGF as suggested by high
expression in the mid-luteal phase, the finding that endothelial cell proliferation and
content increase dramatically with luteal rescue does suggest a role for VEGF in
active angiogenesis at this time.
Previous studies in the human (Rodger et al., 1997), rhesus monkey
(Christenson and Stouffer, 1996b), and ovine (Jablonka-Shariff et al., 1993) which
do not demonstrate increased angiogenesis associated with luteal rescue suggest that
early pregnancy may be associated with an increase in vessel stability. Vessel
maturation is thought to signify the termination of angiogenic activity and maturation
of the newly formed vasculature, and is a parameter which can be used in the
quantification of angiogenic activity of a tissue. It was for this reason that luteal
tissue from both marmosets and humans were used to study pericyte recruitment,
following immunocytochemistry for a-SMA, throughout the luteal phase and in
simulated early pregnancy in the human. A heterogeneity in the quantification of
expression of a-SMA was found in the marmoset and human corpus luteum. In the
marmoset corpus luteum, the area of a-SMA immunostaining was greatest in the
early luteal phase, which had significantly declined by the late luteal phase
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coinciding with a decrease in vasculature. However the proportion of vessels with
associated pericytes in the regressing corpus luteum, appeared to increase. In the
human corpus luteum, immunostaining for pericytes was associated mostly with
luminal vessels, the area of which was maximal in the mid-luteal phase and hCG
rescued corpus luteum. Similarly, in the late human corpus luteum absolute pericyte
area decreased but the proportion of vessels with associated pericytes appeared to
increase.
In the marmoset early luteal phase there was a high incidence of single
pericytes not associated to the endothelial cells of luminal blood vessels, and to a
lesser extent in the developing human corpus luteum. This was surprising
considering that pericyte recruitment was believed to be a marker for vessel
maturation and termination of angiogenesis, not consistent with the intense
angiogenesis of the early corpus luteum. However, a role for pericytes in capillary
sprouting has been demonstrated in vitro where pericytes were regularly found
between leading edges of opposing sprouts, serving as guiding structures aiding the
outgrowth of endothelial cells (Nehls et al., 1992). Endothelial cells themselves are
thought to be involved in the recruitment of pericytes in vitro where co-culture of
non-contacting endothelial and periendothelial support cells caused migration and
proliferation of pericytes, driven by PDGF-B (Hirschi et al., 1999). Also, VEGF has
been shown to cause pericyte proliferation and migration (Nomura et al., 1995;
Benjamin et al., 1998; Yamagishi et al., 1999) and may drive such recruitment in the
corpus luteum. In culture, contact between endothelial cells and pericytes leads to
pericyte differentiation of endothelial cells and inhibition of growth of both pericytes
and endothelial cells, most likely via the activation of TGF(3 (Hirschi et al., 1999).
This appears to be the situation in the mid-corpus luteum, when pericyte expression
was specifically located in rings surrounding and contacting endothelial cells of
luminal vessels, signifying the maturation and cessation of associated angiogenic
activity of these vessels. In the late luteal phase the area of both endothelial cells and
pericytes decreases, however the remaining vessels almost all appear to have pericyte
contact. The removal of immature vessels, with no associated pericytes, coincides
with a marked decrease in VEGF expression in the regressing corpus luteum.
Benjamin et al., (Benjamin et al., 1999) demonstrate in primary human prostate
tumours that VEGF withdrawal, as a consequence of androgen ablation therapy,
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leads to the selective obliteration of immature vessels, suggesting that the smaller
capillaries without pericyte association require VEGF for survival, whereas vessel
maturation in the form of pericyte contact offers independence from VEGF loss. It
seems likely that VEGF is required in a positive way to maintain endothelial cell-cell
adhesion until periendothelial cells facilitate a more permanent mode of adhesion
(Benjamin et al., 1998).
Rescue of the human corpus luteum by hCG administration is associated with
high pericyte coverage as seen by increased a-SMA immunostaining area, and a
concomitant increase in angiogenic activity, demonstrated by prolific endothelial cell
proliferation and the continued presence of small capillaries with no associated
pericytes, along with high levels of VEGF expression. This indicates that during
luteal rescue both vessel growth and stabilisation are occurring. The increase in
VEGF could lead to: 1) a second angiogenic wave, this time restricted to small
capillaries, the endothelial cells of which are not terminally differentiated by contact
with pericytes recruited in the mid-luteal phase, but remain growth factor responsive;
and 2) the recruitment of pericytes to stabilise the newly formed vasculature and the
continued presence of pericytes from mid-luteal phase mature vessels.
These observations give rise to questions pertaining to the origin and stimuli
for recruitment of luteal periendothelial support cells. The origin of pericytes remains
unclear, suggestions include, in-situ differentiation from fibroblastic precursors at the
time of endothelial sprouting (Nehls et al., 1992), or the formation of pericytes from
the migration and de-differentiation of arterial smooth muscle cells (Nicosia and
Villaschi, 1995). One parameter of pericyte differentiation is a-SMA
immunoreactivity, it seems unlikely therefore that primate luteal pericytes originated
from the differentiation of fibroblastic precursor cells which are negative for a-SMA
when considering the extended a-SMA immunostaining observed in the early corpus
luteum of the marmoset and to some degree in the human, and that the migration and
proliferation of smooth muscle cells along the existing vasculature of the theca
would be a more plausible explanation. A stimulus for pericyte recruitment could be
VEGF. VEGF receptors have been located to pericytes in vitro, and exogenous
application of VEGF to cultured pericytes stimulated their migration in a dose
dependent manner (Yamagishi et al., 1999). In the early marmoset corpus luteum,
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and rescued human corpus luteum there is a correlation with expression of VEGF
and pericyte coverage signifying a role in VEGF in pericyte recruitment in vivo.
This study has demonstrated that in vivo angiogenesis can be effectively
quantified using immunocytochemistry for factors associated with the angiogenic
process. There is a high percentage of BrdU incorporation into proliferating
endothelial cells in the marmoset corpus luteum and reproducible quantification by
formulation of a Proliferation Index can be made. Quantification of endothelial cell
content by area of immunostaining is highly reproducible as seen when more than
one endothelial cell specific antigen was used, and also considers the expansion and
contraction of luteal tissue. This indicates that these techniques are suitable for use in
the analysis of angiogenic activity in the primate luteal phase. Using this approach,
we have demonstrated that the formation of the primate corpus luteum is associated
with intense angiogenesis, which continues as a lower rate in the fully formed gland.
We have also shown that vascularisation of the human corpus luteum shows
significant similarities to the marmoset. The early luteal phase exhibits intense
angiogenesis which declines in the mid- and late corpus luteum. Of particular interest
in the human is that the hCG rescue of the corpus luteum, simulating early
pregnancy, is associated with increased angiogenic activity of the tissue, similar to
the early luteal situation, and with an increase in stabilisation of the newly formed
vasculature, in a dynamic situation of vascular growth and maturation, ultimately to
maintain the high production of progesterone of the mid-luteal phase.
The quantification of in vivo primate luteal angiogenesis and vascularisation
provides a powerful model in the elucidation of the control of such processes by
testing the effects of putative angiogenesis inhibitors in the marmoset. The
knowledge that the early luteal phase is associated with intense angiogenesis which
is ongoing to a lesser degree in the mid-, leads to the development of treatment
regimes which specifically target the early luteal phase to prevent this prolific
angiogenesis, and the mid-luteal phase to intervene once the process has already
been established. It was under this premise that the remaining experimental work
was carried out in the marmoset.
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Chapter 4
Inhibition of Luteal Angiogenesis by GnRH
Antagonist Treatment in the Primate
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4.1 Introduction
The corpus luteum is formed subsequent to follicular development and rupture of the
preovulatory follicle at ovulation (Zeleznik and Benyo, 1994). It is well established
that LH is the major luteotrophic factor regulating the function of the primate corpus
luteum. GnRH antagonist treatment has proved a valuable tool in for the study of the
regulation of the corpus luteum in a number of species. Withdrawal of LH by GnRH
antagonist administration results in luteolysis of the corpus luteum in the Old World
primate (Fraser et al., 1986), New World primate (Webley et al., 1991) and women
(Dubourdieu et al., 1991), as reflected by decreased plasma progesterone levels.
Chapter 3 has demonstrated that luteinisation is accompanied by prolific
angiogenesis. Regulation of angiogenesis is controlled by endothelial growth factors
which regulate cell-cell interactions. Most attention has focused on VEGF. In most
tissues VEGF is stimulated by hypoxia (Shweiki et al., 1992), but in the endocrine
system the tropic hormones appear to play a role. A relationship between
gonadotropin stimulation of cultured luteinised granulosa cells and VEGF production
in vitro has been established (Christenson and Stouffer, 1997; Neulen et al., 1998;
Yan et al., 1998; Hazzard et al., 1999b). In turn, addition of VEGF to isolated
macaque luteal endothelial cells stimulates proliferation (Christenson and Stouffer,
1996a). However, the in vivo connection between gonadotropic stimulation of lutein
cells and angiogenesis has not been established. In this study, the intense early luteal
phase angiogenesis and the mid-luteal continued angiogenesis were targeted for the
effects of gonadotropin withdrawal by treatment with GnRH antagonist in 2 separate
treatment regimes. Assessment of treatment effects was based on examination of
luteal endothelial cell proliferation, establishment of the microvascular tree,
morphology of the lutein cells and mode of cell death, expression of VEGF protein
and mRNA, and plasma progesterone concentration.
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4.2 Materials and Methods
4.2.1 Animals and treatments
Marmoset monkeys (Calithrix jacchus) were housed as described previously
(Chapter 2) and procedures carried out in accordance with the Animals (Scientific
Procedures) Act, 1986. Blood samples were collected by femoral venepuncture three
times per week without anaesthesia. Ovulatory cycles were monitored by
radioimmunoassay of plasma progesterone as described in Chapter 2. The stage of
the luteal phase was determined according to plasma progesterone concentration
following the guidelines described in Chapter 2.
Animals to receive GnRH antagonist treatment and early and mid-luteal
control animals were given lpg prostaglandin F2a analogue i.m. in the mid-late
luteal phase of the pretreatment cycle to induce luteolysis and synchronise
subsequent ovulation (luteal day 0). Blood samples were collected daily from the day
of presumed ovulation and the animals were subsequently treated with either
lmg/kg/s.c. GnRH antagonist, Antarelix™ (Deghenghi et al., 1993) or vehicle on
luteal days 1 and 2, or 8 and 9 (n=4 per group). Ovaries were collected on day 3 or
day 10 as previously described (Chapter 2), lh after administration of BrdU to
animals in both control and treatment groups. The regime of treatment is depicted in
Figure 4.1. Ovaries were fixed immediately in 4% paraformaldehyde for paraffin-
embedding as described previously (Chapter 2). A small piece of corpus luteum was
fixed in 3% glutaraldehyde in 0.1M cacodylate buffer, pH 7.3, for araldite resin-
embedding, which was carried out in the Histology department. These specimens
were fixed for 2h, rinsed in the same buffer, post-fixed in buffered 2% osmium
tetroxide for 2h, and embedded in Araldite after dehydration in ethyl alcohol. Semi-
thin (ljum) sections were stained with toluidine blue for light microscope analysis.
4.2.2 Immunocytochemistry and toluidine blue staining
Paraffin-embedded ovarian sections (5p,m) were mounted onto TESPA coated glass
slides and dried at 50°C overnight. The procedures for BrdU, von Willebrand factor
and VEGF immunostaining are described in Chapter 3. The methodology used for 3'
end labelling of fragmented DNA for in situ detection of apoptotic cell death is
described fully in Chapter 2.




















Day relative to ovulation
Figure 4.1 The regime of GnRH antagonist treatment in the marmoset
Prostaglandin analogue was given in the pretreatment cycle to synchronise the
timing of ovulation and administration of treatment. GnRH antagonist was either
administered on luteal days 1 and 2, or 8 and 9. To investigate the effect of
gonadotropin withdrawal on endothelial cell proliferation, BrdU was administered
I hour before tissue collection on day 3 or day 10.
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To examine the effect of GnRH antagonist treatment on luteal morphology,
treated and control sections were stained with toluidine blue (BDH) by the Histology
department. Araldite resin-embedded, 1pm sections were incubated in toluidine blue
at 70°C for 8 min, dried, and examined under the light microscope.
4.2.3 In situ hybridisation
In situ hybridisation for VEGF-A mRNA was performed using a riboprobe,
synthesised from cDNA, specific for all isoforms of human VEGF-A, gifted from Dr
Charnock-Jones (University of Cambridge). Sequence details are documented in
Appendix A. The procedures involved in riboprobe synthesis and in situ
hybridisation are described in Chapter 2. Due to the absence of cDNA sequences for
marmoset-specific VEGF-A, this tissue was tested for hybridisation with the human
specific probe on a 'trial and error' basis. The methodology for in situ hybridisation
with a probe specific for human VEGF-A mRNA in marmoset ovary is detailed in
Chapter 2. Sections were counterstained with haematoxylin and mounted in Pertex.
4.2.4 Quantification and statistical analysis
Early and mid-luteal phase, left and right ovaries for each animal were examined for
appropriately staged corpora lutea. The PI was calculated by analysis of six
randomly chosen fields per corpus luteum, at x400 magnification, using a grid
overlay. The number of proliferating cells was expressed as a percentage of total
number of cells per graticule field, i.e. (number of BrdU positive cells/total cells)
xlOO.
Immunostaining for von Willebrand factor was quantified as described fully
in Chapter 3. Images were captured using the x20 lens and an area of 9.2xl04p,m2 for
5 2
the early corpus luteum, and the xlO lens and an area of 1.3x10 p,m for the larger
mid-luteal sections, and measured for von Willebrand factor immunostaining.
Between 4 and 8 fields of view were quantified, the number being dictated by the
size of the luteal section and lens magnification used.
Quantification of VEGF protein and mRNA was performed by measuring the
area and intensity of VEGF immunostaining (described fully in Chapter 3) and grain
area and density after in situ hybridisation. VEGF mRNA grain area and density
were measured using the Image Pro-Plus 3.0 image analysis programme. Images
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were captured at x40 lens magnification, as white images on a black background, and
the threshold set so the captured image resembled the live image as closely as
possible. The total area of grain clusters signifying specific VEGF mRNA staining,
not background, and the mean density of grains within clusters were measured using
a pre-recorded macro. Ten fields of view, selected in a stratified random manner
were quantified per corpus luteum.
The effects of GnRH antagonist treatment on PI, endothelial cell area, plasma
progesterone levels, and VEGF expression as compared to controls were determined
using separate two-tailed, unpaired t-tests, with a 95% confidence interval (P<0.05),
using StatView version 4.0.
4.3 Results
4.3.1 Effect of GnRH antagonist treatment in the early luteal phase on PI
An elevation of plasma progesterone was observed prior to treatment in all animals
and confirmed by the identification of recently formed corpora lutea in early luteal
control and GnRH antagonist treated animals. Figure 4.2a-c shows a comparison of
BrdU immunolocalisation and PI in an early luteal control corpus luteum and a
GnRH antagonist treated corpus luteum. BrdU positive staining (dark nuclei) and
haematoxylin stained (pale nuclei) are apparent. A significant decrease (PcO.OOl) in
PI was seen in corpora lutea from the treated group of animals as compared to the
early luteal controls. Clusters of densely stained nuclear fragments, characteristic of
apoptotic cell death, were rarely apparent in the GnRH antagonist treated corpus
luteum (Fig. 4.2b).
4.3.2 Effect of GnRH antagonist treatment in the early luteal phase on
endothelial cell area
Immunostaining for von Willebrand factor in control and treated corpora lutea (Fig.
4.2d and e) demonstrated the beginning of development of the microvascular tree.
Many endothelial cells associated with small capillary, non-luminal vessels were
present in both control and treated sections. Quantification revealed that GnRH
antagonist treatment did not have any apparent effect on formation of the capillary
network (Fig. 4.2f).
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4.3.3 Effect of GnRH antagonist treatment in the early luteal phase on luteal
morphology and plasma progesterone concentration
Figure 4.2g and h shows toluidine blue stained sections of an early control corpus
luteum and a GnRH antagonist treated corpus luteum. There is a marked effect on
lutein cell morphology in the treated corpus luteum as compared to controls. The
lutein cells of the early control corpus luteum appeared normal for this species, with
distinct cell margins and well formed nuclei, containing a single nucleolus within an
abundant cytoplasm, typical of a steroidogenic lutein cell. This contrasted with the
appearance of corpora lutea following GnRH antagonist treatment. After treatment
the corpus luteum showed severe disorganisation, and the lutein cells had much less
clearly defined margins. In addition there was evidence of lipid accumulation and the
occurrence of dense bodies. Typical apoptotic bodies were not observed.
Recognisable lutein cells were smaller than in the control tissue, even those in which
the nucleus remained intact. GnRH antagonist treatment was associated with a
marked reduction (PcO.OOl) in plasma progesterone concentration to follicular phase
levels (Fig. 4.2i).
4.3.4 3vend labelling after GnRH antagonist treatment in the early luteal phase
Control and treated sections were screened for signs of apoptotic cell death. In situ 3s
end labelling revealed an absence of staining in the control tissue (Fig. 4.3a) and a
marked presence of staining after GnRH antagonist treatment (Fig. 4.3b). It is
debatable if this form of cell death was apoptotic because apoptotic bodies were
rarely seen and positive cells were arranged in clusters, whereas apoptosis tends to
occur in single cells. A positively stained atretic follicle is shown in Figure 4.3c, and
as a negative control the same follicle not treated with TdT enzyme is depicted in
Figure 4.3d. In addition, healthy follicles, treated with TdT enzyme displayed no
positive staining (Fig. 4.3e)
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Figure 4.2 The effect of early luteal GnRH antagonist treatment on proliferation index (PI),
establishment of the microvascular tree, cell morphology and progesterone output
Immunocytochemical localisation of BrdU in (a) an early control corpus luteum and (b) the corpus
luteum of a GnRH antagonist treated animal at the same stage of the cycle. Note the marked reduction
in BrdU incorporation and cellular disruption after treatment. Note also the presence of the blood vessel
(BV), and possible apoptotic body indicated by the arrow, (c) The effect ofGnRH antagonist treatment
on PI (% BrdU incorporation), (d-f) von Willebrand factor immunostaining for endothelial cells in (d)
control and (e) treated sections. Note that the preliminary establishment of the microvascular tree, typical
of the early luteal phase, has not been disrupted after GnRH antagonist treatment, (f) Quantification of
endothelial cell area confirms this. Values are means ± SEM. P<0.001. (g-h) Toluidine blue stained sections
of (g) an early control corpus luteum and (h) after GnRH antagonist treatment. Note the healthy appearance
of steroidogenic cells (SC) with abundant cytoplasm (C), clear nuclei with nucleoli (N) and probable endo¬
thelial cells (E) in the control corpus luteum. After treatment the cellular integrity is severely disrupted and
dense bodies, indicated by the arrow heads, lipid droplets (L), and some intact nuclei (N) are present, (i) The
effect ofGnRH antagonist treatment on plasma progesterone concentration. Values are means ± SEM.
PcO.OOl. Scale bars on a and b = 50|im. Scale bars on d and e = 100pm. Scale bars on g and h = 20pm.
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Figure 4.3 In situ 3' end labelling in early luteal control tissue and after GnRH
antagonist treatment
(a) An early control corpus luteum with no staining signifying a lack of DNA fragment¬
ation, and (b) a 3' end labelled (brown staining) section after GnRH antagonist treatment
in the early luteal phase, note the extent of DNA damage throughout the corpus luteum
as a whole, (c) A positively stained atretic follicle and (d) the same follicle in a serial
section incubated without terminal transferase enzyme, as a negative control, (e) A neg¬
ative healthy follicle, which was treated with terminal transferase enzyme.
Scale bars = 100pm.
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4.3.5 Effect of GnRH antagonist treatment in the early luteal phase on VEGF-A
protein and mRNA
Immunocytochemical localisation of VEGF-A protein demonstrated high levels of
expression in both the early luteal control corpus luteum (Fig. 4.4a) and after GnRH
antagonist treatment (Fig. 4.4b). Quantification of VEGF-A immunostaining
revealed there was no decrease in area of VEGF-A protein or intensity of staining
after GnRH antagonist treatment in the early luteal phase (Fig. 4.5a-b). However, a
marked decrease in VEGF-A mRNA expression was seen after GnRH antagonist
treatment as compared to early luteal controls (Fig. 4.4c-f). Figure 4.4g shows
intense staining after in situ hybridisation with the antisense probe, and Figure 4.4h,
demonstrates the absence of staining in a serial section after incubation with the
negative sense probe. This indicates that any VEGF-A mRNA expression would
have been detected after GnRH antagonist treatment when using the antisense probe.
4.3.6 Effect of GnRH antagonist treatment in the mid-luteal phase on PI, luteal
morphology and plasma progesterone concentration
Administration of GnRH antagonist treatment in the mid-luteal phase failed to show
a significant decrease in endothelial cell proliferation (Fig. 4.6a-c). However, similar
effects as with treatment in the early luteal phase were seen on lutein cell
morphology. Toluidine blue staining of the mid- control corpus luteum (Fig. 4.6d)
revealed normal, healthy steroidogenic cells and the presence of many luminal
vessels, typical at this stage of the cycle. After treatment there was a different
picture. Mass accumulation of lipid, severe vacuolation, and the presence of many
densely staining bodies, typical of an unhealthy corpus luteum, were apparent (Fig.
4.6e). Coincidentally a marked decrease in plasma progesterone concentration in
mid-luteal treated animals as compared to controls was observed (Fig. 4.6f).
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Figure 4.4 VEGF-A protein and mRNA in early luteal control tissue and after GnRH antagonist treatment
(a) Localisation of VEGF (brown staining) in an early luteal control section. Note that most lutein cells are positively stained also
that intense staining can be seen in a lutein cell, indicated by the arrow, adjacent to a blood vessel (BV), which demonstrates the
quantitative nature of this immunocytochemical staining, (b) VEGF immunostaining after GnRH antagonist treatment. Note the
extent of disruption of the corpus luteum and that apparent VEGF staining is more granular and not restricted to intact lutein cells.
Note also the presence of luminal blood vessels (BV). (c) Dark field micrograph of VEGF-A mRNA (white grains) in an early
control section. Note that expression is located in clusters corresponding to the steroidogenic cells of the corpus luteum (white arrows),
(d) Expression of VEGF-A mRNA in a GnRH antagonist treated section. Note the great reduction in VEGF-A expression, (e) Light
field micrograph of the same early luteal control section. VEGF A mRNA expression is located in the steroidogenic cells (black
grains), (f) Light field micrograph of the same GnRH antagonist treated section, where a marked reduction in VEGF-A mRNA
expression is seen, (g and h) In situ hybridisation with the anti-sense and sense VEGF-A probes in serial sections, respectively.
Notice the very low level of staining after hybridisation with the sense probe indicating that the high level of staining in (g) reflects
VEGF-A mRNA. Scale bars on a and b = 50pm. Scale bars on c-h = 100pm.








































Early control GnRH antagonist
early luteal
Figure 4.5 Quantification of area and intensity of VEGF-A immunostaining in control and after
GnRH antagonist treatment in the early luteal phase.
(a) Area of VEGF immunostaining (in pixels) in early luteal control sections (closed bar) was not
significantly different from the area measured after treatment (open bar), (b) The intensity of staining
in control section (closed bar) and after treatment (open bar). Differences were not significant. Values
are means ± SEM.
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Figure 4.6 The effect of inid-luteal GnRH antagonist treatment on proliferation
index (PI), cell morphology and progesterone output
(a-c) Immunocytochemical localisation of BrdU in (a) a mid- control corpus luteum and
(b) a GnRH antagonist treated corpus luteum. Note the similar level of incorporation in
control and treated corpora lutea. (c) The effect of GnRH antagonist treatment on PI (%
BrdU incorporation), (d-f) Toluidinc blue stained sections of (d) a mid- control corpus
luteum and (e) after GnRH antagonist treatment. Note the healthy appearance of steroid¬
ogenic cells (SC) with abundant cytoplasm, and central round nuclei, and the presence
of many luminal blood vessels (BV) typical of the mid-control corpus luteum. After
treatment the cellular integrity is severely disrupted, many lipid droplets (L) and large
vacuoles (V) are present, (f) The effect of GnRH antagonist treatment on plasma
progesterone concentration. Values are means ± SEM. P=().()l. Scale bars = 100pm.
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4.3.7 Effect of GnRH antagonist treatment in the mid-luteal phase on VEGF-A
protein and mRNA
VEGF-A immunostaining appeared to be consistently lower after treatment than in
mid-luteal controls (Fig. 4.7a-b). This was demonstrated after quantification of area
of VEGF-A immunostaining (Fig. 4.8a) in control sections and after GnRH
antagonist treatment in the mid-luteal phase. The intensity of staining however,
increased as a result of treatment (Fig. 4.8b; a decrease in optical density indicates an
increase in immunostaining intensity, as described in Chapter 3). However, GnRH
antagonist treatment in the mid-luteal phase, when compared to mid-luteal controls
(Fig. 4.7c) resulted in a marked decrease in VEGF-A mRNA expression (Fig.4.7c).
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Figure 4.7 VEGF-A protein and mRNA in mid-luteal control tissue and after GnRH antagonist
treatment
(a) Localisation of VEGF (brown staining) in mid-luteal control section. Note that many lutein cells are
positively stained at this stage of the cycle and the presence of the blood vessel (BV). (b) VEGF immuno-
staining after GnRH antagonist treatment. Note the extent of disruption of the corpus luteum and that
apparent VEGF staining is more granular and associated to vacuolated cells (V). (c) Dark field micrograph
of VEGF-A mRNA (white grains) in a mid- control section. Note that expression is located in clusters
corresponding to the steroidogenic cells of the corpus luteum (white arrows), (d) Expression of VEGF-A
mRNA in a GnRH antagonist treated section. Note the great reduction in VEGF-A expression, (e) Light field
micrograph of the same mid-luteal control section. VEGF-A mRNA expression is located in the steroidogenic
cells (black grains), (f) Light field micrograph of the same GnRH antagonist treated section, where a marked
reduction in VEGF-A mRNA expression is seen. Scale bars on a and b = 5()jim. Scale bars on c-f = l(X)jim.
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Figure 4.8 Quantification of area and intensity of VEGF-A immunostaining in control and after
GnRH antagonist treatment in the mid-luteal phase
(a) The area of VEGF immunostaining (in pixels) in mid-luteal control sections (closed bar) and after
treatment (open bar). P=0.002 (b) The intensity of staining in control (closed bar) to treated (open bar)
levels. P=0.01. A low value indicates dark staining/high intensity. Values are means ± SEM. Different
letters denote significant differences.
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4.4 Discussion
This study has established for the first time in vivo that the intense angiogenesis in
the primate corpus luteum associated with the early luteal phase is dependent on
gonadotropin support. GnRH antagonist treatment was employed to examine the
gonadotropin dependence of the intense angiogenesis associated with the early luteal
phase, and the ongoing angiogenesis of the mid-luteal phase. The treatment is
presumed to be a consequence of pituitary withdrawal of LH as described previously
in the marmoset (Webley et al., 1991), macaque (Fraser et al., 1986) and human
(Dubourdieu et al., 1991) luteal phase.
In the early luteal phase study, deprivation of gonadotropin support to
steroidogenic cells reduced endothelial cell proliferation by 90%, and plasma
progesterone concentration by 95%, demonstrating the dependence of early luteal
angiogenesis and function on gonadotropin support. Although administration of
GnRH antagonist in the mid-luteal phase failed to effect luteal endothelial cell
proliferation as seen by unchanged levels of BrdU incorporation after treatment,
plasma progesterone concentration was decreased by 95%, signifying the
gonadotropin-dependence of mid-luteal steroidogenic function.
Light microscopy of toluidine blue stained sections revealed a severe
disruption of normal steroidogenic cell morphology in both groups of GnRH
antagonist treated corpora lutea when compared to controls. Accumulation of lipid,
appearance of densely staining bodies and the absence of distinct cell margins were
obvious after treatment. Evidence of fragmented nuclei, characteristic of apoptosis,
was apparent in haematoxylin stained corpora lutea and in situ 3' end labelling
demonstrated positive results after treatment in the early luteal phase. However,
analysis of semi-thin sections indicated widespread cell death by a process other than
apoptosis, as also suggested previously (Fraser et al., 1995; Young et al., 1997), and
ultrastructural studies of GnRH antagonist-induced luteolysis in the marmoset do not
indicate widespread cell degeneration via apoptosis (Fraser et al., 1999b). DNA
fragmentation is characteristic of necrotic as well as apoptotic forms of cell death,
therefore in situ 3' end labelling does not distinguish between necrotic and apoptotic
DNA in tissue sections (Phelouzat et al., 1996). It is only possible to characterise this
form of tissue degradation as apoptotic cell death in the presence of typical DNA
'laddering' following electrophoresis of extracted DNA, and observations of
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apoptotic bodies following ultrastructural analysis of treated corpora lutea. Since the
former was not measured and the latter was not evident, it is difficult to ascertain the
method of luteal cell death seen in this study. It is however, clear that the extent of
luteal cell disruption was such that steroidogenic cell function was significantly
impaired, preventing secretion of progesterone and most likely other factors involved
in normal luteal function.
The proliferation of non-endothelial cells in the distressed corpus luteum after
GnRH antagonist treatment in the mid-luteal phase may explain the unexpected
failure to observe a decrease in proliferation index after treatment at this stage.
During normal luteolysis the proportion of apparent fibroblasts in the corpus luteum
increases. Thus, in a response similar to that seen during natural regression,
proliferating luteal fibroblasts may incorporate BrdU. Similarly, proliferating
immune cells, such as leukocytes or macrophages, which infiltrated the distressed
corpus luteum after initiation of an immune response may also incorporate BrdU.
Another explanation may be a result of the increased incidence of cell death in the
mid-luteal phase treated corpus luteum. It has been reported that during cancer
therapy DNA damage induced by a number of chemical and radiation treatments is
known to activate DNA repair (reviewed by Berges et al., 1993). To detect DNA
repair in androgen-dependent normal prostatic glandular cells after castration in rats,
high dose, long exposure to BrdU was used, maximising the detection of both
scheduled DNA synthesis and unscheduled DNA repair. A 10 fold increase in BrdU
incorporation was seen, which was considered part of a futile G0 DNA repair process
(Berges et al., 1993). It is therefore possible that cells in the corpus luteum after
GnRH antagonist treatment incorporated BrdU in a futile DNA repair mechanism
during a process of cell death which involves DNA fragmentation.
Early luteal phase administration of GnRH antagonist to macaques (Fraser et
al., 1987) and women results in suppression of progesterone secretion and a marked
reduction in response to exogenous hCG administrated in the mid-luteal phase
(Fraser et al., 1987; Dubourdieu et al., 1991). Here we show that administration of
GnRH antagonist in the early luteal phase causes a severe disruption of steroidogenic
cell morphology and angiogenesis, thus providing an explanation, at the cellular
level, for the effects of GnRH antagonist treatment seen previously.
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It is tempting to suggest that the adverse effect of GnRH antagonist treatment
on early luteal angiogenesis is predominantly a consequence of decreased VEGF
production from the dysmorphic steroidogenic cells of the developing corpus luteum.
VEGF is a secreted angiogenic mitogen (Leung et al., 1989), specific for endothelial
cell receptors (Plouet and Maukadiri, 1990; Vaisman et al., 1990). Both VEGF
mRNA and its transcribed protein have been localised to the granulosa and theca
lutein cells of the human corpus luteum (Chapter 3; Kamat et al., 1995; Otani et al.,
1999), and protein in marmoset lutein cells (Chapter 3). Cultured human (Neulen et
al., 1998; Yan et al., 1998) and macaque (Christenson and Stouffer, 1997; Hazzard et
al., 1999b) luteinised granulosa cell-VEGF expression has been shown to be up
regulated by gonadotropins in vitro. In the current investigations using
immunocytochemistry to determine changes in VEGF in the corpus luteum after
GnRH antagonist treatment in the early luteal phase we did not observe the expected
decrease in immunostaining. However, it appears that production of VEGF-A
message was severely compromised by GnRH antagonist treatment, as seen by the
marked reduction in VEGF mRNA expression after treatment in the both the early
and mid-luteal phases. Hypoxia-induced VEGF translation (Stein et al., 1998), the
presence of residual, non-active, or metabolised VEGF, or non-specific staining by
lutein cell debris in the treated corpus luteum may explain the unexpected failure to
demonstrate decreased expression of VEGF protein.
Angiogenesis is a multi-step process involving a number of angiogenic
growth factors, degradation of the extra-cellular matrix by matrix metalloproteinases
and cell-cell interactions. Neutralisation of VEGF in the marmoset over the same
time period reduces endothelial cell proliferation by 80% as compared to control
levels (Chapter 6; Fraser et al., 2000), a significantly lower suppression than the
reduction after GnRH antagonist treatment in this study. This suggests that the
reduction in luteal angiogenesis seen here is most probably a consequence of a
decrease in other angiogenic factors in addition to VEGF, and/or by a break-down in
endothelial-steroidogenic cell interactions following disruption of lutein cell
morphology as caused by treatment. The reduction in local progesterone
concentration may also act to reduce angiogenesis. Progesterone is thought to have a
local action in the peri-ovulatory follicle to regulate expression of factors such as
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matrix metalloproteinase-1 and its tissue inhibitor (Chaffin and Stouffer, 1999),
implying a role in angiogenesis in the early corpus luteum.
The current results establish that the intense angiogenesis associated with the
formation of the corpus luteum is necessary for normal luteal function, and is almost
exclusively dependent upon normal gonadotropin support. The failure of any
apparent effect on endothelial cell area may be a result of the methods used to
quantify endothelial cell staining which do not consider the shrinkage of tissue after
treatment. The ongoing angiogenesis in the mid-luteal phase appears not to be
dependent on gonadotropin support, although this may be explained by the increased
proliferation of non-endothelial cells. However, this study demonstrates that luteal
function in the mid-luteal phase is completely dependent on the luteotropic action of
LH as plasma progesterone levels were reduced by 95%.
Chapter 5 The Effect of TNP-470 on Luteal Angiogenesis 165
Chapter 5
The Effect of the Angiogenesis Inhibitor TNP-
470 on Luteal Establishment and Function in
the Primate
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5.1 Introduction
The corpus luteum is essential for the establishment of pregnancy through the
production of progesterone from the lutein cells. In the primate, intense angiogenesis
occurs during early luteal development (Chapter 3; Christenson and Stouffer, 1996b;
Rodger et al., 1997; Gaytan et al., 1998; Dickson and Fraser, 2000) and it is believed
that this angiogenesis is critical for transport of hormonal precursors of progesterone
to, and progesterone from, the lutein cells (Redmer and Reynolds, 1996). The
angiogenesis inhibitor, TNP-470, is a synthetic analogue of fumagillin which has
been shown to inhibit endothelial cell proliferation, migration and capillary-like tube
formation with a minimal effect on the growth of non-endothelial cells (reviewed by
Fan et al., 1995). Studies have shown that TNP-470 acts directly on endothelial cells
to inhibit growth-factor induced DNA synthesis, and inhibit activation of cyclin-
dependent kinases and phosphorylation of retinoblastoma gene product (Abe et al.,
1994). It has been suggested that the corpus luteum could be a target for fertility
regulation by virtue of its susceptibility to anti-angiogenic agents (Klauber et al.,
1997). The importance of angiogenesis in the establishment of the mouse corpus
luteum has been shown by studies in which TNP-470 inhibited luteal development
and prevented pregnancy by interfering with the process of decidualisation and
placental and yolk sac formation (Klauber et al., 1997). However, the mechanisms
which regulate luteal function in rodents and primates are markedly different, and in
the non-fertile cycle of the rodent, the corpus luteum is active for less than a day,
while that of many primates is functional for 2 weeks prior to its regression
(Behrman et al., 1993). The aim of this study was to investigate the effects of TNP-
470 on the primate corpus luteum. The information gleaned from this primate model
should be useful to the projected clinical use of this compound.
The study was designed to investigate the effects of TNP-470 on
angiogenesis at the time of transformation of the preovulatory follicle into the
functional corpus luteum. We investigated the effects of TNP-470 in the marmoset
monkey in which we have built up considerable information on the cellular and
molecular control of luteal function, and established the temporal relationship
between angiogenesis and establishment of the microvascular tree (e.g. Chapter 3;
Young et al., 1997; Duncan et al., 1998b; Fraser et al., 1998; Fraser et al., 1999a;
Fraser et al., 1999b; Dickson and Fraser, 2000; Fraser et al., 2000). The
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establishment and function of the corpus luteum was determined by measuring
circulating progesterone concentrations. Cellular responses were studied in the
marmoset by determining the number of mitotic cells, following BrdU incorporation,
and by examining the establishment of the microvascular network using von
Willebrand factor staining to identify endothelial cells.
5.2 Materials and Methods
5.2.1 Animals and treatments
Marmoset monkeys (Calithrix jacchus) were housed as described previously
(Chapter 2) and experiments carried out in accordance with the Animals (Scientific
Procedures) Act, 1986. Blood samples were collected 3 times per week by femoral
venepuncture without anaesthesia to confirm normal ovulatory cycles. Criteria for
the occurrence of ovulation and normal luteal phase length (18-22 days) were based
on determination of plasma progesterone concentrations as described previously
(Chapter 2). To synchronise timing of ovulation during the treatment cycle, eight
animals were treated with 1/rg prostaglandin F2a analogue i.m., during the mid- to
late luteal phase of the pre-treatment cycle to induce luteolysis. Four marmosets were
treated with TNP-470 (O-chloroacetylcarbamoyl fumagillol, also known as AGM-
1470) starting 11 days post-prostaglandin, the day of anticipated ovulation, at a dose
of 18 mg/kg/day (equivalent to 120mg/m ), by slow i.v. injection. This treatment was
repeated for a further 9 days. Four controls were treated with vehicle following the
same schedule.
On day 10 after commencement of TNP-470, each marmoset received by
slow i.v. infusion, 20mg BrdU in saline. One hour later, the animals were sedated
and euthanased as described previously (Chapter 2). Ovaries were removed rapidly,
weighed, fixed immediately in 4% paraformaldehyde for 24h and embedded in
paraffin as described in Chapter 2. A small piece of corpus luteum was fixed in 3%
glutaraldehyde in 0.1M cacodylate buffer, pH 7.3, for araldite-resin embedding and
toluidine blue analysis as described previously (Chapter 4).
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5.2.2 Immunocytochemistry and quantification
Proliferating endothelial cells were visualised in ovarian sections using a mouse
monoclonal antibody to BrdU as previously described (Chapter 3). Cell proliferation
was assessed by counting the number of BrdU positive cells in six randomly chosen
fields per corpus luteum and expressed as a mean percentage of the total cells in
these fields. Differences between groups were determined using a two tailed,
unpaired t test, p<0.05 being taken as the level of significance.
Localisation of von Willebrand factor as a marker for endothelial cells was
determined by immunocytochemistry as described in Chapter 2. These sections were
not counterstained, so that quantitative image analysis could be performed, von
Willebrand factor immunostaining was quantified using the Image Pro-Plus 3.0
image analysis programme. Sections were examined at 400x magnification. The
image was converted to grey scale and the area of dark objects on a white
background was counted. For each corpus luteum, six randomly chosen areas, each
of 27860 /tm2 were analysed using the x40 lens, and their mean taken as being
representative for that animal. Differences between groups were determined using a
two tailed, unpaired t test, p<0.05 being taken as the level of significance. Plasma
progesterone results were analysed using a repeated measures ANOVA with Fisher's
PLSD post-hoc test at 5% significance.
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5.3 Results
BrdU staining indicating proliferating cells was readily observed in all corpora lutea
from control and treated marmosets (Fig. 5.1a-b). The Proliferation Index showed
there was no significant difference between the groups (Fig. 5.1c). The development
of the microvasculature of the corpus luteum was confirmed in the control
marmosets by an extensive network of microvessel and capillary staining for von
Willebrand factor and this was also evident in the TNP-470 treated animals (Fig.
5.1d-e). Quantification of von Willebrand factor immunostaining showed no
significant difference associated with treatment (Fig. 5.If).
Examination of toluidine blue stained sections revealed there was no apparent
effect of TNP-470 treatment on lutein cell morphology. In both control (Fig. 5.1g)
and treated (Fig. 5.lh) sections steroidogenic cells had large spherical or polyhedral
nuclei and abundant cytoplasm; endothelial cells, with elongated nuclei, little
cytoplasm and in some cases association with obvious blood vessels, were prevalent;
suggesting these were normal healthy corpora lutea. There was no significant
difference in plasma progesterone concentrations in control and TNP-470 treated
animals (Fig 5.2).
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Figure 5.1 Effect of TNP-470 on endothelial cell proliferation, endothelial cell area
and lutein cell morphology
BrdU incorporation, von Willcbrand factor immunostaining and toluidinc blue staining
in corpora lutea from control and TNP-470 treated marmosets, (a-b) Low power micro¬
graphs showing the general distribution of BrdU staining (dark nuclei) in a control, and
a TNP-470 treated corpus lutcum, respectively, (c) The proliferation index in corpora
lutea from control (closed bar) and TNP-470 treated (open bar) animals, (d-e) von
Willcbrand factor localisation in the corpus luteum of a control and aTNP-470 treated
corpus luteum. (f) Quantification of von Willcbrand factor immunostaining in control
(closed bar) and TNP-470 treated (open bar) marmoset corpora lutea. (g-h) Toluidinc
blue stained sections from a control and a treated corpus lutcum. Note the presence of
large healthy steroidogenic cells (SC) with central round nuclei (N) and abundant cyto¬
plasm (C), and endothelial cells (arrow heads) and luminal blood vessels (arrows) in
both control sections and after treatment. Data arc means ± SEM. Scale bars = 100p.m.
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Figure 5.2 Plasma progesterone concentrations in control and TNP-470 treated
animals
Plasma progesterone concentrations in control marmosets (closed plot symbols) and
in those treated with TNP-470 (open plot symbols) starting on the day of expected
ovulation (n=4 per group). Values are means ± SEM.
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5.4 Discussion
The results show that treatment with TNP-470 had little or no detectable effect on the
development and function of the marmoset corpus luteum. The experiment was
designed to target the intense angiogenesis which occurs in the corpus luteum during
the early stages of development (Chapter 3; Dickson and Fraser, 2000). Accordingly,
treatment was started at the time of predicted ovulation and covered the period of the
early luteal phase to the mid-luteal phase. These studies allowed the examination of
its potential consequences on cell proliferation, the luteal vasculature and luteal
function. As expected, BrdU incorporation demonstrated a moderate level of
proliferation of endothelial cells during the mid-luteal phase and this was unaffected
by treatment with TNP-470. Furthermore, staining for von Willebrand factor
illustrated the establishment of the luteal vascular tree despite treatment with the
putative angiogenesis inhibitor. The morphology of lutein cells remained normal
after treatment and progesterone secretion by these cells was not impaired.
Collectively, these results suggest that TNP-470 does not have negative effects on
the structure and function of the normal corpus luteum of the marmoset, in contrast
to the findings in the mouse (Klauber et al., 1997). At this early stage of experiments
to specifically inhibit angiogenesis in the primate corpus luteum, we were forced to
conclude that the differences between the present results and those in the mouse may
reflect inter-species variance, perhaps because of the presence of compensating
mechanisms in primates and not rodents, and/or differential susceptibility to the anti-
angiogenic effect of TNP-470.
The latter possibility could arise from the dose of TNP-470 employed in the
present study being insufficient to prevent luteal angiogenesis, or the route of
administration being suboptimal. The clinical dose of TNP-470 is 60mg/m
administered by lh i.v. infusion three times per week (Dezube et al., 1998). Studies
in the mouse employed the s.c. route at a dose of 30mg/kg every second day. The
marmosets in the present study were treated with 18mg/kg daily, so approaching the
murine dose. It should be noted that TNP-470 is metabolised very rapidly and that its
pharmacodynamic properties are incompletely understood (Cretton-Scott et al.,
1996). Thus, differences in the pattern of exposure to the drug may result from the
different routes of administration. However, at present, a preparation of TNP-470
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that can be administered by the s.c. route to larger animals and humans is not
available.
This was the first report of an attempt to block angiogenesis in the primate
corpus luteum with a specific angiogenic inhibitor. Although inhibitory effects were
not observed, the approach used to study angiogenesis was of value to future
experiments on the effects of angiogenesis inhibitors, such as anti-VEGF treatment
(Chapter 6), on luteal function in the marmoset.
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Chapter 6
Suppression of Luteal Angiogenesis in the
Primate after Neutralisation of Vascular
Endothelial Growth Factor
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6.1 Introduction
In Chapter 5, it was demonstrated that TNP-470 failed to affect luteal function in the
marmoset which emphasises the need for caution when extrapolating results from the
rodent in which this angiogenesis inhibitor prevented pregnancy (Klauber et al.,
1997). Thus it is of major importance to investigate the regulation of angiogenesis
specifically in the primate corpus luteum. Chapter 4 demonstrated that luteal function
and angiogenesis was driven by pituitary gonadotropins. However, this treatment
resulted in lutein cell death and prevented the action of all locally produced growth
factors. To identify the factors involved in the regulation of luteal angiogenesis
potential factors should be specifically targeted and the consequential effects on
luteal angiogenesis investigated. The angiogenic process is regulated by a number of
growth factors, degradation of the extracellular matrix and cell-cell interactions.
VEGF is highly expressed in the early and mid-luteal phases of the primate corpus
luteum (Chapter 3). It is evident therefore, that the role of VEGF in the primate
corpus luteum should be addressed.
This study examined the potential role of VEGF in regulating luteal
angiogenesis by specific neutralisation of this potent endothelial cell mitogen, using
a monoclonal antibody in three separate treatment regimes (Figure 2.1). We
investigated whether it was possible to prevent luteal angiogenesis by administration
of anti-VEGF treatment on the day of ovulation for 3 days (regime 1), or after
chronic treatment for 10 days after ovulation (regime 2). We also analysed if it was
possible to intervene in the already established angiogenic process by administering
anti-VEGF treatment for 3 days in the mid-luteal phase (regime 3). The effects of
VEGF withdrawal on luteal angiogenesis were examined by quantifying endothelial
cell proliferation and establishment of the microvascular tree. It was also of
relevance to examine the effect of such VEGF inhibition on VEGF expression itself.
Previous studies on the effects of withdrawal of VEGF in other angiogenic
dependent systems report the requirement on VEGF for the survival of immature
endothelial cells. For example in human prostate cancer the acute loss of VEGF, as a
result of androgen ablation therapy, leads to selective apoptosis of endothelial cells
in vessels devoid of periendothelial support cells (Benjamin et al., 1999). To
investigate whether the recently formed endothelial cells of the primate corpus
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luteum may be susceptible to withdrawal of VEGF we determined the incidence of
apoptosis after acute anti-VEGF treatment in the mid-luteal phase (regime 3).
There is evidence to suggest that the recruitment of periendothelial support
cells for vessel stabilisation is dependent on VEGF (Nomura et al., 1995; Yamagishi
et al., 1999). To assess the relationship between pericyte coverage and VEGF
bioactivity in the early and mid- corpus luteum, the area of pericyte coverage in
control corpora lutea and after anti-VEGF treatment was quantified. Finally, to
examine the effect of VEGF inhibition on endometrial angiogenesis, endothelial cell
proliferation in the vascularised endometrial stroma was measured.
6.2 Materials and Methods
6.2.1 VEGF antibody
Mouse monoclonal anti-VEGF, VG76e, was obtained from Dr Roy Bicknell (ICRF,
Cambridge). It was raised by immunisation with recombinant human VEGF-189.
Using recombinant proteins on western blots, it was demonstrated that VG76e
recognises the 121, 165 and 189 isoforms of VEGF-A. VG76e was shown to be a
blocking antibody in vitro by its inhibition of the growth stimulatory activity of
VEGF on human umbilical vein endothelial cells (HUVEC) (Fraser et al., 2000).
6.2.2 Animals
Common marmoset monkeys (Callithrix jacchus) were housed in cages as described
previously (Chapter 2). Adult females with a body weight of approximately 350g,
with regular ovulatory cycles, were housed together with a younger sister or
prepubertal female. Blood samples were collected three times per week by femoral
venipuncture without anaesthesia and plasma was stored at -20°C until required for
progesterone assay (Chapter 2) to confirm normal ovulatory cycles. Criteria for the
occurrence of ovulation and normal luteal phase length (18-22 days) were based on
determination of plasma progesterone concentrations as described previously
(Chapter 2).
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6.2.3 Treatment
The experiments were carried out in accordance with the Animals (Scientific
Procedures) Act, 1986. The timing of ovulation was synchronised during the pre-
treatment cycle as described previously (Chapter 2). Four marmosets were treated
with VEGF antibody at a concentration of 2.7 mg/ml starting on the day of
anticipated ovulation (luteal phase day 0), at a dose of 2 mg followed by 1 mg on
days 1 and 2 (regime 1). Four controls were treated with the same dose of mouse
gamma globulin (Sigma) following the same schedule. Treatment was extended to
the mid-luteal phase in a further 6 marmosets; additional injections of lmg anti-
VEGF were administered on days 3, 5, 7 and 9, with six animals receiving mouse
gamma globulin as controls (regime 2). Another four animals were treated with 2mg
VEGF monoclonal antibody on luteal day 7 and lmg on luteal days 8 and 9 (regime
3), and four control animals were given equivalent doses of mouse gamma globulin.
All treatments were by slow i.v. injection. The regimes of administration of
treatment are depicted in Figure 2.1.
Ovaries were obtained the day after final treatment, luteal day 3 or 10, after
the animals had received 20mg BrdU in saline by slow i.v. injection. One hour later,
the animals were sedated and ovaries and uteri were removed immediately and fixed
in 4% paraformaldehyde as previously described (Chapter 2). It was presumed that
an effect on lutein cell morphology would most likely be seen after treatment with
anti-VEGF for 10 days (regime 2), so a small portion of a representative corpus
luteum was placed in 3% glutaraldehyde in 0.1M cacodylate buffer, pH 7.3, for
araldite-resin embedding and toluidine blue analysis as described in Chapter 4. When
the mid-luteal group were examined, it was apparent that the density of the lutein
cells had increased following treatment. In order to quantify this change, paraffin
sections were stained with haematoxylin and eosin (Chapter 3) and lutein cell density
in 12 corpora lutea per group, determined by Dr. Christine Wulff.
The establishment and function of the corpus luteum were determined by
measuring plasma progesterone concentrations in daily blood plasma samples as
described previously (Chapter 2). Only marmosets in which treatment was started at
the time of presumptive ovulation (plasma progesterone having reached >30nmol/L
and found retrospectively to be sustained at luteal phase values) were included in the
study. Analysis of differences in plasma progesterone concentrations was performed
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by repeated measures analysis of variance followed by a post-hoc Fisher's Protected
Least Significant Difference test, P<0.05 taken as the level of significance.
6.2.4 Immunocytochemistry, in situ hybridisation, in situ 3' end labelling and
quantification
Cellular responses were studied: 1) by determining the number of mitotic cells,
following BrdU administration as a marker; 2) by examining the establishment of the
microvascular network using von Willebrand factor and/or CD31 staining to identify
endothelial cells; 3) by quantifying pericyte coverage using a-SMA as a marker; and
4) by analysing the expression of VEGF mRNA and protein in lutein cells by
immunocytochemistry. Uterine sections were dual-stained for CD31 and BrdU to
assess endometrial angiogenic activity.
Methods for all immunocytochemical procedures and analyses not outlined
here were described in detail in Chapter 3. For von Willebrand factor, CD31 and
a-SMA immunostaining, a minimum of four randomly chosen areas per corpus
luteum were quantified using the Image Pro-Plus 3.0 image analysis programme, as
described previously (Chapter 2). For early luteal treated and control sections areas
of 1.3xl05 jam2 (using x20 lens), and for the larger mid-luteal treated and control
5 2
sections areas of 1.3x10 jam (using xlO lens) were studied; in total these areas
covered approximately two thirds of each corpus luteum. Uterine sections stained
with BrdU and CD31 were analysed at x400 magnification and a minimum of 10
fields of view quantified per section. Uterine endometrium was located under the
light microscope, the vasculature of which was restricted to the stroma, and the
number of cells co-localising BrdU and CD31 per field, manually counted. The mean
of all fields of view for one section was taken as representative for that animal.
In situ hybridisation for VEGF-A was performed using a riboprobe
synthesised from plasmid inserted VEGF-A cDNA from Dr Charnock Jones
(sequence details are documented in Appendix A), and following the same
methodology as described in Chapter 2. Quantification was carried out using the
Image Pro-Plus 3.0 image analysis as described in Chapter 4. In situ 3' end labelling
was performed using the protocol described in detail in Chapter 2. An index of cell
death in the corpus luteum was obtained by manually counting the number of
positively stained cells per luteal section, and the mean per animal calculated. A
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statistical comparison of the size of each sectioned corpus luteum in treated and
control groups was made using a standard two-tailed, unpaired t-test. The size of
each corpus luteum from treated and control groups was not significantly different.
Following quantification of all parameters, differences between treated and
control groups were determined using separate two-tailed unpaired t tests, P<0.05
being taken as the level of significance. Plasma progesterone results were analysed
using a repeated measures ANOVA with Fisher's PLSD post-hoc test at 5%
significance.
6.3 Results
6.3.1 Regime 1: Cell proliferation, endothelial cell area and periendothelial
support cell coverage
Treatment with anti-VEGF during the early luteal phase did not prevent the
formation of clearly identifiable corpora lutea, and ovarian sections revealed the
presence of recently formed corpora lutea in all control and treated marmosets.
Proliferation was high within corpora lutea from control marmosets (Fig. 6.1a) and
was markedly reduced by anti-VEGF treatment (Fig. 6.1b), as confirmed by the
decreased proliferation index (Fig. 6.1c). von Willebrand factor immunostaining
demonstrated the initiation of development of the microvasculature in control
corpora lutea (Fig. 6.Id) but although there was an indication of reduced capillary
number associated with anti-VEGF treatment (Fig. 6.1e), quantification of von
Willebrand factor immunostaining showed no significant difference at this time (Fig.
6.If). Sections stained with a second endothelial cell marker, CD31, also revealed
similar staining in control (Fig. 6.1g) and treated (Fig. 6.1h) corpora lutea.
Quantification of CD31 staining also showed that there was no significant difference
in endothelial cell area after treatment in the early luteal phase (Fig. 6.1i).
The incidence of periendothelial support cells was high in corpora lutea from
early luteal control animals, associated with mainly small capillary endothelial cells,
(Fig. 6.1j) and was markedly reduced by anti-VEGF treatment (Fig. 6.1k), as
confirmed by a decrease in pericyte area (Fig. 6.11).
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Figure 6.1 Effects of anti-VEGF treatment in the early luteal phase (regime 1) on BrdlJ incorporation, endothelial
cell area, and pericyte recruitment
Low power photomicrographs of early luteal phase marmoset corpora lutea showing the general distribution of BrdU
incorporation (dark-staining nuclei) into endothelial cells of microvessels and capillaries in (a) a control corpus luteum
showing high incorporation and (b) reduced incorporation following anti-VEGF treatment, (c) The proliferation index
in corpora lutea from early luteal phase control (closed bar) and anti-VEGF treated (open bar) marmoset corpora lutea.
Values from treated animals were significantly lower (P<().()l) than in controls, (d) and (e) von Willebrand factor
localisation (dark staining) in the endothelial cells of microvessels and capillaries of corpora lutea from control and anti-
VEGF treated marmosets, respectively, (f) Quantification of von Willebrand factor immunostaining in control (closed bar)
and anti-VEGF treated (open bar) marmoset corpora lutca. There was no significant difference between the groups, (g)
and (h), CD31 (dark staining) in vascular endothelial cells in control and anti-VEGF treated corpora lutea, respectively,
and (i) quantification of control (closed bar) and treated (open bar) CD31 immunostaining reveals no significant change
in endothelial cell area between groups, (j) High oc-SMA immunostaining (dark staining) is present throughout control
corpora lutca and (k) is greatly reduced in treated sections. (1) Quantification of (x-SMA area shows a significant decrease
(P=0.01) in staining. Data are means ± SEM. Scale bars = l(K)//m.
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6.3.2 Regime 1: VEGF-A expression
VEGF protein was localised to the cytoplasm of the majority of steroidogenic cells in
the early control corpus luteum (Fig. 6.2a). Staining appeared most intense in leading
lutein cells, adjacent to the antrum, streaming inwards to form the full corpus luteum,
suggesting angiogenic activity in this direction. The pattern and intensity of VEGF
immunostaining was similar in treated animals treatment (Fig. 6.2b) to that in
controls.
In situ hybridisation with a probe to VEGF-A demonstrated, in dark field
micrographs, that VEGF mRNA was arranged in clusters in control (Fig. 6.2c) and
anti-VEGF treated (Fig. 6.2d) sections. From bright field microscopy, VEGF mRNA
was localised to both nuclei and cytoplasm of lutein cells in control sections (Fig.
6.2e). After treatment, however, clusters appeared more densely located to the nuclei
of lutein cells (Fig. 6.2f).
Quantification of VEGF protein expression demonstrated there was no effect
of treatment on area of VEGF immunostaining (Fig. 6.3a) or intensity of
immunostaining (Fig. 6.3b). Similarly, measurement of grain area (Fig. 6.4a) and
density (Fig. 6.4b) after in situ hybridisation revealed there were no effects of anti-
VEGF treatment in the early luteal phase on expression of VEGF mRNA, although
some dark field micrographs suggested otherwise (Fig. 6.2d).
Chapter 6 Neutralisation of VEGF 182
Figure 6.2 VEGF-A expression in control sections and after anti-VEGF treatment
in the early luteal phase (regime 1)
lmmunolocalisation of VEGF protein (brown staining) in (a) early luteal control sections
and (b) after anti-VEGF treatment. VEGF is localised to the cytoplasm (C) of steroidogenic
cells (SC), most intense staining is found in those lutein cells adjacent to the antrum (A)
which is still visible in the early corpus lutcum. (c) Dark field micrograph showing location
of VEGF mRNA (white grains) in control sections and (d) in anti-VEGF treated sections.
VEGF mRNA is located in clusters (white arrows), (e) Light field micrographs of the same
control section reveal expression is associated with nuclei and cytoplasm of lutein cells as
indicated by the black arrows, (f) After treatment VEGF mRNA appears to be more densely
expressed, exclusively in the nuclei of lutein cells (black arrow heads). Scale bars = 50pm.








































Figure 6.3 Quantification of VEGF-A immunostaining in controls and after anti-VEGF
treatment in the early luteal phase (regime 1)
(a) The area of luteal VEGF immunostaining in controls and anti-VEGF treated animals. There was
no significant difference after treatment, (b) Quantification of intensity of VEGF immunostaining,
indicating no significant difference in the level of expression by any one cell in treated sections as
compared to controls. Values are means ± SEM.
















































Figure 6.4 Quantification of mRNA for VEGF-A in controls and after anti-VEGF treatment in
the early luteal phase
(a) The area of clusters of VEGF mRNA expression in control and treated sections. There was no
significant increase in overall expression of VEGF mRNA after anti-VEGF treatment, (b)
Quantification of grain density per unit area of luteal tissue in control and treated sections. There was
no significant difference of VEGF mRNA expression by any one cell between groups. Values are
means ± SEM.
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6.3.3 Regime 2: Cell proliferation, endothelial cell area and periendothelial
support cell coverage
In the mid-luteal phase group, treatment with anti-VEGF for 10 days from the day of
ovulation did not prevent formation of fresh corpora lutea. In corpora lutea from
control animals, the numbers of proliferating cells had declined, as expected by this
stage of the luteal phase (Fig. 6.5a). Some moderate proliferation was also evident in
all corpora lutea from the anti-VEGF treated marmosets (Fig. 6.5b), and the
proliferation index showed no significant treatment differences (Fig. 6.5c). However,
while in control corpora lutea staining for von Willebrand factor revealed that a fully
developed microvasculature had been established (Fig. 6.5d), treatment with anti-
VEGF resulted in corpora lutea with a much lower degree of vascularisation and
absence of an extensive capillary bed, similar to that observed in the early luteal
phase (Fig. 6.5e). Quantification of von Willebrand factor immunostaining showed a
marked suppression (PcO.OOl) of endothelial cell area associated with treatment (Fig.
6.5f). Figure 6.5g and h depicts CD31 immunostaining with the second endothelial
cell marker, CD31, in control and treated corpora lutea, respectively. Quantification
revealed the same effect as seen with staining for von Willebrand factor,
demonstrating a significant reduction (P<0.01) in endothelial cell area with treatment
(Fig. 6.5i).
In control sections, pericytes were mostly found aggregated in rings
surrounding luminal vessels (Fig. 6.5j), whereas after anti-VEGF treatment single
immunopositive cells were also found distributed through the corpus luteum (Fig.
6.5k). This was confirmed by quantification of pericyte area (Fig. 6.51) which had
increased significantly (P<0.01).
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Figure 6.5 Effects of anti-VEGF treatment, for 10 days from the early to the mid luteal phase (regime 2), on
BrdU incorporation, endothelial cell area, and pericyte recruitment
Low power photomicrographs of mid-1 uteal phase marmoset corpora lutea showing the general distribution of BrdU
incorporation (dark-staining nuclei) into endothelial cells of microvessels and capillaries in (a) control and (b) similar
incorporation after anli-VEGF treatment. (c)The proliferation index in corpora lutea from mid-luteal phase control
(closed bar) and anti-VEGF treated (open bar) marmoset corpora lutea. There was no significant difference between
the groups, (d) von Willebrand factor localisation (dark staining) in the endothelial cells of microvessels and capillaries
of corpora lutea in a control corpus luteum and (e) reduced staining, especially for incidence of capillary endothelial
cells after anti-VEGF treatment, (f) Quantification of von Willcbrand factor immunostaining in control (closed bar)
and anti-VEGF treated (open bar) marmoset corpora lutea. Values from treated animals were significantly lower
(P<().()01) than in controls, (g) and (h), CD31 (dark staining) in vascular endothelial cells in control and anti-VEGF
treated corpora lutea, respectively, and (i) quantification of control (closed bar) and treated (open bar) CD31 immuno¬
staining which reveals a significant decrease (P<0.0001) in endothelial cell area after treatment, (j) Low cc-SMA
immunostaining (dark staining) aggregated in rings surrounding luminal vessels, is present in control corpora lutea.
(k) In treated sections staining is greatly increased, being associated with non-luminal smaller vessels. (1) Quantification
of area shows a significant increase (P=0.04) in staining. Data are means ± SEM. Scale bars = 100 //m.
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6.3.4 Regime 2: VEGF-A expression
VEGF protein was localised to the cytoplasm of lutein cells in both mid-luteal
control (Fig. 6.6a) and treated (Fig. 6.6b) corpora lutea. Coverage in both control and
treated corpora lutea was quite uniform and appeared not to be altered by treatment.
VEGF mRNA was again arranged in clusters in both control (Fig. 6.6c) and
treated (Fig. 6.6d) corpora lutea and localised to both the cytoplasm and nuclei of
control corpora lutea (Fig. 6.6e) and after treatment (Fig. 6.6f).
Quantification of VEGF immunostaining area (Fig. 6.7a) and intensity (Fig.
6.7b), and mRNA grain area (Fig. 6.8a) and density (Fig. 6.8a) showed there was no
effect of treatment on cither VEGF protein or VEGF mRNA expression.
6.3.5 Regime 3: Cell proliferation and endothelial cell area
Moderate BrdU incorporation into endothelial cells was observed in control corpora
lutea (Fig. 6.9a) but was significantly lowered by anti-VEGF treatment (Fig. 6.9b).
This was confirmed by comparing the PI from control and treated groups (PcO.Ol)
(Fig. 6.9c). In the control corpus luteum, CD31 immunostaining revealed the
establishment of the microvascular tree demonstrated by numerous blood vessels and
capillary endothelial cells which were observed in association with each lutein cell
(Fig. 6.9d). In the treated animals, the number of capillaries appeared reduced (Fig.
6.9e) and quantitative analysis revealed a significant (P=0.02) decrease in endothelial
cell area after treatment (Fig. 6.9f).
Again in mid-luteal control sections, pericytes were mostly found aggregated
in rings surrounding luminal vessels (Fig. 6.9g), and after anti-VEGF treatment
immunopositive cells were also found distributed through the corpus luteum (Fig.
6.9h), as confirmed by quantification of periendothelial support cell area (Fig. 6.91)
where a significant increase with treatment was seen (PcO.Ol).
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Figure 6.6 VEGF-A expression in control sections and after anti-VEGF treatment
from the early luteal to the mid-luteai phase (regime 2)
(a) Immunolocalisation of VEGF protein (brown staining) in early luteal control sections
and (b) after anti-VEGF treatment. VEGF is localised to the cytoplasm (C) of most
steroidogenic cells (SC) of the mid-luteal phase, (c) Dark field micrograph showing
location of VEGF mRNA (white grains) in control sections, and (d) in anti-VEGF treated
sections. VEGF mRNA is located in clusters (white arrows), (e) Light field micrographs
of the same control and (f) treated sections reveal expression is associated with nuclei
and cytoplasm of lutein cells as indicated by the black arrows. Scale bars = 50pm.


























Figure 6.7 Quantification of VEGF-A immunostaining in controls and after anti-VEGF
treatment from the early to the mid-luteal phase (regime 2)
(a) Shows the area of luteal VEGF immunostaining in controls and anti-VEGF treated animals. There
was no significant difference after treatment, (b) Quantification of intensity of immunostaining,
indicating no significant difference in the level of expression by any one cell in treated sections as
compared to controls. Values are means ± SEM.



































Figure 6.8 Quantification of mRNA for VEGF-A in controls and after anti-VEGF treatment
from the early to the mid-luteal phase
(a) The area of clusters of VEGF mRNA expression in control and treated sections. There was no
significant increase in overall expression of VEGF mRNA after anti-VEGF treatment, (b)
Quantification of grain density per unit area of luteal tissue in control and treated sections. There was
no significant difference of VEGF mRNA expression by any one cell between groups. Values are
means ± SEM.
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Figure 6.9 Effects of anti-VEGF treatment in the mid-luteal phase (regime 3) on BrdlI incorporation, endothelial
cell area, and pericyte recruitment
Low power photomicrographs of mid-luteal phase marmoset corpora lutca showing (a) the general distribution of Brdll
incorporation (dark-staining nuclei) into endothelial cells of microvessels and capillaries in control and (b) decreased
incorporation after anti-VEGF treatment, (c) The proliferation index in corpora lutea from mid-luteal phase control
(closed bar) and anti-VEGF treated (open bar) marmoset corpora lutca. There was a significant reduction after treatment
(P<O.OI). (d) von Willebrand factor localisation (dark staining) in the endothelial cells of microvcssels and capillaries of
corpora lutea in a control corpus luteum and (c) reduced staining, especially for incidence of capillary endothelial cells after
anti-VEGF treatment, (f) Quantification of CD31 immunostaining in control (closed bar) and anti-VEGF treated (open bar)
marmoset corpora lutea. Values from treated animals were significantly lower (P=0.02) than in controls, (g) Low a-SMA
immunostaining (dark staining) aggregated in rings surrounding luminal vessels, is present in control corpora lutea. (h) In
treated sections staining is greatly increased, also being associated with non-luminal capillary vessels, (i) Quantification of
area shows a significant increase (P<().(X)1) in staining. Data arc means ± SEM. Scale bars = 100/im.
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6.3.6 Regime 3: VEGF-A expression
After anti-VEGF treatment according to regime 3 no apparent difference in VEGF
immunostaining was seen in either mid-luteal control (Fig. 6.10a) or anti-VEGF
treated (Fig. 6.10b) corpora lutea.
VEGF mRNA expression appeared, from dark field microscopy, to be greater
than control levels (Fig. 6.10c) after anti-VEGF treatment (Fig. 6.10d). The apparent
location of expression appeared not to differ with treatment (Fig. 6.10e-f).
Measurement of VEGF immunostaining area (Fig. 6.11a) demonstrated a
lack of effect of treatment on area of VEGF expression. However, quantification of
the intensity of VEGF staining demonstrated a significant increase (P=0.001) in
intensity of VEGF expression in any one cell after treatment (Fig. 6.11b, a decrease
in optical density indicates an increased intensity of VEGF staining). Following
quantification of VEGF mRNA grain area (Fig. 6.12a) and density (Fig. 6.12b) no
effect of treatment on VEGF mRNA expression was demonstrated, although dark
field microscopy suggested otherwise.
6.3.7 In situ 3vend labelling
Figure 6.13 demonstrates 3s end labelling in mid-luteal control sections and sections
after acute withdrawal of VEGF in the mid-luteal phase. One positive apoptotic
endothelial cell associated with a blood vessel can be seen in Figure 6.13a. Incidence
of apoptotic nuclei increased with anti-VEGF treatment (Fig. 6.13b) which shows
two positive nuclei probably of endothelial cell origin. Positive apoptotic nuclei
remained sparsely distributed, even though anti-VEGF treatment significantly
(P=0.03) increased the occurrence of apparent endothelial cell apoptosis (Fig. 6.13c).
The incidence of apoptotic cells was measured per sectioned corpus luteum as the
size of the control and treated corpora lutea did not significantly differ. Atretic
follicles in sections treated with the terminal transferase enzyme and digoxygenin
label were positively 3" end labelled (Fig. 6.13d). Atretic follicles in serial sections
not treated with terminal transferase were negative (Fig. 6.13e). In addition, healthy
follicles in sections treated with the enzyme were negative (Fig. 6.13f).
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Figure 6.10 VEGF-A expression in control sections and after anti-VEGF treatment
specifically in the mid-lutcal phase (regime 3)
(a) Immunolocalisation of VEGF protein (brown staining) in mid-luteal control sections
and (b) after anti-VEGF treatment. VEGF is localised to the cytoplasm (C) of most
steroidogenic cells (SC) in the mid-lutcal phase, (c) Dark field micrograph showing
location ofVEGF mRNA (white grains) in control sections, and (d) in anti-VEGF treated
sections. VEGF mRNA is located in clusters (white arrows). Light field micrographs of
(e) the same control and (f) treated sections reveal expression is associated with nuclei
and cytoplasm of lutein cells as indicated by the black arrows. Scale bars = 50pm.






























Figure 6.11 Quantification of VEGF-A immunostaining in controls and after anti-VEGF
treatment specifically in the mid-luteal phase (regime 3)
(a) The area of luteal VEGF immunostaining in controls and anti-VEGF treated animals. There was
no significant difference after treatment, (b) Quantification of intensity of immunostaining, indicating
a significant increase (P=0.001) in the level of expression by any one cell in treated sections as
compared to controls. Values are means ± SEM.































Figure 6.12 Quantification of mRNA for VEGF-A in controls and after anti-VEGF treatment
specifically in the mid-luteal phase (regime 3)
(a) The area of clusters of VEGF mRNA expression in control and treated sections. There was no
significant increase in overall expression of VEGF mRNA after anti-VEGF treatment, (b)
Quantification of grain density per unit area of luteal tissue in control and treated sections. There was
no significant difference of VEGF mRNA expression by any one cell between groups. Values are
means ± SEM.
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Figure 6.13 Effect of acute removal of VEGF in the mid-luteal phase (regime 3) on
endothelial cell death
High power photomicrographs of 3V end labelled apoptotic cells (brown staining) in (a) a
mid-control marmoset corpus luteum and (b) after anti-VEGF treatment. Note the presence
of endothelial cells (EC) surrounding a blood vessel (BV) in the control section, and
smaller dark hacmatoxylin-stained nuclei representing endothelial cells and pericndothclial
support cells in both control and treated corpora lutea. Arrows point to positive apoptotic
nuclei assumed to be endothelial cells by their small, elongated form, (c) Quantification of
positive cells in control (closed bar) and treated sections (open bar) shows increased
presence of positive nuclei in anti-VEGF treated sections. Note that values arc per corpus
luteum section so the incidence of apoptosis even after treatment is very low. (d) An atretic
follicle positively stained for DNA fragmentation, and (e) the same atretic follicle in serial
section not treated with terminal transferase enzyme as a negative control for the in situ 3'
end labelling method, (f) A negative healthy follicle, in a section which has been treated
with terminal transferase. Data are mean ± SEM. Scale bars on a and b = 20pm. Scale
bars on d and e = 100pm. Scale bar on f = 50pm.
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6.3.8 Morphology
Semi-thin sections stained with toluidine blue showed that the most prominent
features in the control corpora lutea collected during the mid-luteal phase were the
large polyhedral lutein cells, characterised by circular nuclei in cross-section with a
nucleolus and large cytoplasmic volume (Fig. 6.14). Within the cytoplasm were
mitochondria and lysosomes together with occasional, less basophilic inclusions
typical of lipid droplets. The lutein cells were supported by connective tissue
including fibroblasts and there was an extensive blood supply characterised by the
occurrence of endothelial cell nuclei and numerous lumina, often containing
erythrocytes. In the corpora lutea from the mid-luteal anti-VEGF-treated marmosets,
lutein cells appeared more densely packed (Fig. 6.14b), with a closer contact with
neighbouring lutein cells. Quantification of lutein cell number showed that numbers
of lutein cells per area were significantly greater (p<0.001) in the treated group
(79.2±3 for controls, versus 103.8± 5.5 after anti-VEGF). In addition, numerous
clusters of basophilic cells, presumably lutein, were present principally in the central
area of the corpus luteum. Higher magnification revealed that although the majority
of the lutein cells had retained their integrity, they exhibited an increased occurrence
of lipid droplets in the peripheral zone of the cytoplasm identified by their grey
coloration and homogeneous appearance (Fig. 6.14d).
6.3.9 Plasma progesterone concentrations
Plasma progesterone concentrations were reduced (p<0.001) by anti-VEGF treatment
to at least 50% of the normal values in the early luteal (data not shown), mid-luteal
chronic treatment (Fig. 6.15a) and mid-luteal acute treatment (Fig. 6.15b).
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Figure 6.14 Examination of cell morphology after anti-VEGF treatment
Photomicrographs of toluidinc blue-stained corpora lutea to show the appearance of
hormone-producing lutein cells in the mid-lutcal corpus luteum of (a) control, and (b)
anti-VEGF treated marmosets. Note how the lutein cells of the treated animal arc more
closely packed and the cluster of densely stained cells (arrows), presumably of luteal
origin. Higher magnification of a control corpus luteum shows (c) the appearance of
the lutein cell nucleus (N) and cytoplasm (C), with each cell being in contact with an
endothelial cell (E). (d) In the anti-VEGF corpus luteum, the lutein cells have main¬
tained their integrity, but contain numerous lipid droplets (grey staining, arrowhead)
in the peripheral zone. Scale bars on a and b = 50//m. Scale bars c and d = 20//m.
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Figure 6.15 Plasma progesterone concentrations in control and anti-VEGF treated marmosets
(a) Marmoset plasma progesterone concentrations in controls (closed plot symbols) and after anti-
VEGF treatment for 10 days from the early luteal phase to the mid-luteal phase (open plot symbols)
(n=6 per group). Treatment started on the day of expected ovulation and is associated with a
significant suppression (P<0.001). (b) Marmoset plasma progesterone concentrations in controls
(closed plot symbols) and after anti-VEGF specifically in the mid-luteal phase (open plot symbols)
(n=4 per group). A sustained elevation of plasma progesterone was observed prior to treatment in all
animals. After administration of anti-VEGF treatment starting on luteal day 7 there was a marked
reduction in plasma progesterone concentrations which had fallen by over 50% by day 10 (P=0.01).
Values are means ± SEM.
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6.3.10 Proliferation of endometrial endothelial cells
Endothelial cell proliferation in the stroma of uterine endometrium was measured to
examine the effect of anti-VEGF treatment on angiogenesis in utero. Dual staining of
uterine sections with CD31 and BrdU revealed a relatively low level of stromal
endothelial cell proliferation overall (Fig. 6.16), which appeared not to be affected by
anti-VEGF treatment at any stage of the cycle. Quantification of proliferating
endothelial cells revealed there was no effect of treatment on stromal angiogenesis in
the uterine endometrium (Fig. 6.17). It is worth noting that stromal endothelial cell
proliferation had almost decreased by a factor of 10 from levels in early control
endometrium to those in mid- controls.
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Figure 6.16 Effect of anti-VEGF treatment on endometrial angiogenesis
Dual immunocytochemistry for BrdU (black nuclear staining) and CD31 (red cytoplasmic
staining) in (a) an early luteal control uterine section, and (b) after anti-VEGF treatment
in the early luteal phase (regime 1). Note that only the stroma (S) not the epithelial glands
(G), is vascularised. (c) and (d) Dual staining for BrdU and CD31 in mid-luteal control
and after anti-VEGF treatment from the early luteal to the mid-luteal phase (regime 2),
respectively, (e) Similar staining in mid-lutcal control and (f) after anti-VEGF treatment
specifically in the mid-luteal phase (regime 3). Note the decrease in endothelial cell
proliferation (dual stained cells) from the early control endometrium (a) to the mid control
sections (c) and (e). Arrows point to proliferating endothelial cells which stain for both
BrdU and CD31. Scale bars = 50pm.
























Figure 6.17 Quantification of endometrial angiogenesis after anti-VEGF treatment
The number of cells colocalising BrdU and CD31 immunostaining in endometrial stroma in (a)
control sections and after early luteal phase treatment, (b) in mid-luteal controls and those treated with
anti-VEGF from the early to the mid-luteal phase, and (c) in controls and after specific mid-luteal
phase inhibition of VEGF. Note that endothelial cell proliferation in the early control has decreased by
a factor of 10 in the mid-controls. There was no significant effect of any regime of treatment
employed. Values are means ± SEM.
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6.4 Discussion
This study has shown not only that the intense angiogenesis in the early luteal phase,
but also the ongoing angiogenesis of the mid-luteal phase are susceptible to
inhibition by VEGF neutralisation. Inhibition of the intense early luteal phase
angiogenesis was demonstrated by the marked decrease in BrdU incorporation in the
marmosets treated with antibody during the early luteal phase. An effect on
endothelial cell area was not initially apparent after this short term treatment, but by
the mid-luteal phase, this parameter was markedly inhibited in anti-VEGF-treated
corpora lutea, as a consequence of the inhibition of endothelial cell proliferation
during the intense period of angiogenesis. Although larger blood vessels were
established by the mid-luteal phase in treated animals, there was a marked overall
reduction in the number of endothelial cells, suggesting the establishment of early
luteal vasculature (possibly from pre-existing vessels) and its survival through the
mid-luteal phase, but indicating blockade of development of the normally extensive
capillary bed. The absence of an effect on cell proliferation in the mid-luteal animals
treated with anti-VEGF was surprising. However, by this stage, proliferation in
controls was much reduced over that seen during the early luteal phase and this mid-
luteal proliferation suggests that the rate is maintained either by low levels of VEGF
that remain as a result of incomplete neutralisation, or has resulted from the action of
other angiogenic factors in the corpus luteum.
Whilst it is recognised that VEGF has an angiogenic function during the
prolific early luteal phase it has been suggested that the presence of VEGF in the less
prolific mid-luteal phase signifies other functions of VEGF at this time. This study
demonstrates that VEGF in the mid-luteal phase is essential for mid-luteal
angiogenesis and function as shown by the suppression of endothelial cell
proliferation and endothelial cell area, and the decline in plasma progesterone
concentrations. By the mid-luteal phase, the vasculature is becoming highly
developed and progesterone is being maximally secreted. If the effect of anti-VEGF
was solely to suppress angiogenesis it might be anticipated that progesterone would
be maintained at pretreatment levels, at least during the first 1-2 days of treatment.
The rapid decline in plasma progesterone concentration seen on the first day of this
acute mid-luteal phase anti-VEGF treatment, indicates that in addition to the
regulation of ongoing mid-luteal angiogenesis, VEGF also modulates vascular
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permeability in the corpus luteum. An effect on corpus luteum vascular permeability
could deprive the lutein cells of both the necessary precursors for progesterone
production and the efficient release of their products into the bloodstream, which
would result in marked reductions in plasma progesterone values.
It was observed that acute removal of VEGF in the mid-luteal phase resulted
in endothelial cell death as seen by positive in situ 3^ end labelling. Benjamin et al.,
(1999) demonstrated that in both xenografted tumour and primary human tumours
VEGF withdrawal resulted in specific obliteration of immature vessels; and in
human prostate cancer loss of VEGF led to selective apoptosis of endothelial cells
devoid of periendothelial cells. Mature vessels with associated pericytes are believed
to be VEGF independent (Benjamin et al., 1998). Thus, in the current study, it
appears that the increase in death of endothelial cells after anti-VEGF treatment is a
consequence of lack of VEGF support to susceptible, immature vessels with no
associated pericytes. It could follow therefore, that endothelial cells of more mature
vessels with associated pericytes would be VEGF independent and not susceptible to
anti-VEGF treatment. Our finding that mid-luteal VEGF withdrawal led to an
increase in endothelial cell death in the presence of extended pericyte coverage
suggests that it is the endothelial cells associated with the few remaining immature
capillaries, which were susceptible to loss of VEGF support. This in turn indicates
that the reduction in endothelial cell area after anti-VEGF treatment may not only be
a consequence of a decreased angiogenic rate, but also of increased endothelial cell
death.
VEGF inhibition in the early luteal phase and from the early through to the
mid-luteal phase also had an effect on luteal pericyte recruitment. Pericytes are
believed to be involved in the remodelling process which occurs during blood vessel
maturation (reviewed by Darland and D'Amore, 1999) a process thought also to take
place in the corpus luteum (Tsukada et al., 1996; Goede et al., 1998). High levels of
periendothelial support cells in the early luteal phase is consistent with the
infiltration of the preformed thecal vasculature from the mature follicle to the newly
formed corpus luteum. VEGF is thought to have a role in recruitment of these
periendothelial support cells. Yamagishi et al., (1999) demonstrated the proliferation
and migration of pericytes in a dose dependent manner upon addition of VEGF. This
action of VEGF was blocked with polyclonal antibodies to VEGF. In addition, they
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found pericytes express the gene for Fit-1 the predominant form of VEGF receptor.
Thus the decline in pericytes after VEGF withdrawal in the early luteal phase in this
study can be explained. However, it is surprising that VEGF inhibition from the early
to the mid-luteal phase, and in the mid-luteal phase alone served to significantly
increase luteal pericyte coverage.
It appears therefore that a stage specific regulation of pericyte recruitment is
occurring in the marmoset corpus luteum. In the early luteal phase, pericyte
differentiation and/or proliferation appears to be regulated by VEGF. However, in
the mid-luteal phase the absence of VEGF results in increased pericyte recruitment,
perhaps through activation of other factors. For example, a stage specific increase in
other members of the VEGF family, not neutralised by the monoclonal antibody
which is specific for VEGF-A, such as P1GF, VEGF-B or C, which are believed to
stimulate pericyte proliferation in vitro (Nomura et al., 1995; Yamagishi et al.,
1999), some of which are shown to be regulated by hypoxia (Yonekura et al., 1999).
Other factors involved in the recruitment of pericytes include platelet-derived growth
factor-B (reviewed by Darland and D'Amore, 1999) and angiopoietin-1 (Davis et al.,
1996; Maisonpierre et al., 1997; Koblizek et al., 1998), while TGF(3 is thought to
regulate pericyte differentiation (Hirschi et al., 1999). It thus remains to be
determined whether factors such as angiopoietin-1 may be activated specifically in
the mid-luteal phase after VEGF inhibition, to act as a survival mechanism to
"rescue" existing vessels from the absence of the immature endothelial cell survival
factor, VEGF.
VEGF inhibition specifically in the mid-luteal phase exhibited an increase in
the intensity of VEGF immunostaining without an increase in area of staining or
mRNA production, which suggests this was not an effect of treatment per se. The
other treatment regimes employed had no effect on lutein cell VEGF expression as
seen by unaltered VEGF immunostaining and in situ hybridisation signal for VEGF
mRNA in treated as compared to control corpora lutea. Considering the probable
hypoxic conditions enforced as a consequence of decreased vascularisation a more
conclusive increase in VEGF production was expected after VEGF
immunoneutralisation. It may be that oxygen tension did not reach critical levels, or
that a local VEGF feedback mechanism did not detect the decline in VEGF, VEGF
having a paracrine action on endothelial cells not an autocrine action on lutein cells.
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One other possibility is that with the reduction in luteal vasculature, lutein cells were
starved of nutrients essential for growth factor biosynthesis.
There was also no effect of VEGF inhibition on endometrial angiogenesis.
Growth of the endometrial vasculature begins during the proliferative phase and
continues at a lower level in the secretory phase (Meschia, 1983). although there is
some discrepancy concerning this matter (Rogers et al., 1998). Nevertheless, this
chapter demonstrates a low level of stromal endothelial cell proliferation in the
secretory phase, and that from the early to the mid-secretory phase such proliferation
declines, suggesting maximal vascular proliferation in the proliferative endometrium.
It is therefore possible that VEGF could be a major driving force of angiogenesis in
the proliferative endometrium, and its expression/action in the secretory
endometrium is probably decreased, thus its inhibition would not effect the low level
of angiogenesis occurring at this stage. It is however likely that the decrease in
plasma progesterone concentration following anti-VEGF treatment would have a
detrimental effect on endometrial differentiation.
The absence of marked morphological change in the lutein cells after anti-
VEGF treatment contrasts with observations on the characteristic effects of
withdrawal of the tropic factor, LH, described in Chapter 4 and by Fraser et al.,
(1999b), and Dickson and Fraser, (2000). Such treatment also results in inhibition of
early luteal angiogenesis, but this is secondary to the destruction of the lutein cells in
which it is assumed most of the principal angiogenic factors are produced (Chapter
4; Dickson and Fraser, 2000). The observed changes in the structure of the corpus
luteum after neutralisation of VEGF are likely to result from the specific inhibition
of angiogenesis. The increased density of the lutein cells resulted primarily from the
dearth of capillaries, whereas the occurrence of aggregates of subsets of lutein cells
with more densely stained nuclei and cytoplasm, found principally in the central area
of the corpus luteum, suggests a premature onset of cell death. This observation
would be compatible with a failure of blood vessel development to deliver essential
survival factors. The increased presence of lipid droplets is more difficult to explain,
but suggests either a lack of tropic hormone stimulus for steroid hormone release or a
failure of the normal secretory process. The accumulation of lipid is often associated
with the onset of degenerative change in steroid-producing cells including the early
stages of luteolysis in the marmoset (Fraser et al., 1999b). Despite the absence of
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major structural effects within lutein cells, secretion of the principal steroidal
hormonal product of these cells is reduced by over 50%. The most likely explanation
for these findings is that the reduction in development of the microvasculature
deprives the lutein cells of both the low density lipoprotein precursors necessary for
progesterone production and the transport system for efficient release of their
products into the bloodstream.
This study demonstrates almost conclusively that VEGF-A is the primary
factor driving luteal angiogenesis in the early and mid-luteal phases in the marmoset
corpus luteum. The rapid reduction in plasma progesterone concentrations also
suggest a role for VEGF in regulating vascular permeability in this tissue. We have
provided compelling evidence that VEGF is required for luteal angiogenesis in the
primate, and in turn, that luteal angiogenesis is essential for normal luteal function in
the primate.
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Chapter 7
Molecular Control of Human Luteal
Angiogenesis: Changes in Angiopoietin, Tie-2,
VEGF, Flt-1 and KDR mRNA.
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7.1 Introduction
Angiogenesis is thought to depend on a balance between endogenous positive and
negative regulatory molecules (Hanahan and Folkman, 1996). This is particularly
prominent during the spontaneous cyclic angiogenesis which occurs in the corpus
luteum, where vessel proliferation is followed by regression unless luteal rescue
occurs as a result of conception. It follows that such a potentially divergent series of
events must be tightly controlled. Perhaps the best characterised of the pro-
angiogenic factors is VEGF. The VEGF family of growth factors totals at least 5
members and VEGF-A (or VEGF) provides the first example of a growth factor
specific for the vascular endothelium. The specific actions of VEGF on the
endothelium are a result of the restriction of its two VEGF receptors (Fit-1 and Flk-
1/KDR) to these cells (Plouet and Maukadiri, 1990; Vaisman et al., 1990). The
effects of VEGF on vascular growth have largely been elucidated from studies
examining embryonic vascular development in transgenic mice which lack VEGF or
either receptor. VEGF is shown to be involved in the proliferation, migration and
sprouting of endothelial cells, promoting the formation of tube-like vascular
structures. This function of VEGF in early vasculogenesis is mediated largely
through the Flk-l/KDR receptor (Shalaby et al., 1995; Carmeliet et al., 1996; Ferrara
et al., 1996). Murine Fit-1 knock-outs demonstrate a later role for Fit-1 in
vasculogenesis. Vessels do form in mutant embryos but are organised abnormally,
with seemingly excess levels of endothelial cells being generated and entering the
lumens of the abnormal vascular channels (Fong et al., 1995). Thus, Fit-1 may
actually be involved in down regulating VEGF-A activity to ensure that the right
number of endothelial cells are generated (Gale and Yancopoulos, 1999).
A second family of growth factors, termed the angiopoietins, specific for the
vascular endothelium has been identified (Suri et al., 1996; Davis et al., 1996;
Maisonpierre et al., 1997). These growth factors are specific for the endothelial cell
tyrosine kinase, Tie receptors, Tie-1 and Tie-2. All known angiopoietins bind to Tie-
2, but it is still unclear whether they utilise Tie-1 (Holash et al., 1999). The
angiopoietins seem to act in a complementary and co-ordinated fashion with VEGF,
playing a later role in vascular development (Holash et al., 1999). Ang-1 appears to
play a key role in mediating interactions between endothelial cells and surrounding
support cells such as pericytes and smooth muscle cells (Folkman and D'Amore,
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1996; Suri et al., 1996). This was demonstrated by the severe retardation of
remodelling and stabilisation of primitive vasculature in mice lacking Ang-1 or Tie-
2. Ang-1 is also shown to have a direct action on endothelial cell survival
(Papapetropoulos et al., 1999). In the adult, Ang-1 appears to be constitutively
expressed serving to maintain the integrity of the already established vasculature
(Maisonpierre et al., 1997; Witzenbilcher etal., 1998).
Ang-2 is believed to act as a naturally occurring antagonist to Ang-1, binding
the Tie-2 receptor but inhibiting its phosphorylation (Maisonpierre et al., 1997).
Transgenic over-expression of Ang-2 leads to a phenotype reminiscent of that seen in
embryos lacking either Ang-1 or Tie-2 (Maisonpierre et al., 1997). Whereas Ang-1 is
widely expressed in normal adult tissues, correlating with increased vessel maturity,
Ang-2 is typically expressed at sites of vascular remodelling, notably the female
reproductive tract (Maisonpierre et al., 1997). Detailed localisation of Ang-2 mRNA
in the rat ovary revealed that Ang-2 was either expressed at regions of active
angiogenesis together with VEGF at sites of vessel sprouting and ingrowth, in the
early corpus luteum, or at sites of vascular regression in the absence of VEGF, in
atretic follicles. This led to the proposal of a model in which Ang-2, by blocking a
constitutive stabilising action of Ang-1, either plays a role in active angiogenesis by
destabilising vessels in the presence of VEGF allowing growth factor access and
angiogenic action; or in the absence of VEGF, destabilisation of vessel leads to
regression as in the atretic follicle (Maisonpierre et al., 1997).
Most evidence of the co-ordinated actions of the angiopoietins and VEGF
was accumulated during examinations of mouse embryonic vascular development in
specific gene knock-out studies. Expression in the rat ovary suggests that the
angiopoietins may also play a critical role in adult ovarian angiogenesis. The corpus
luteum is associated with robust angiogenesis, vessel maturation and regression, and
so this chapter examines the temporal expression of mRNA for these factors in
association with development, maturation, regression and hCG rescue of the human
corpus luteum. So far this thesis has emphasised the quantification of luteal
angiogenesis by immunocytochemical methods in histological sections, which was
shown to be adequate to measure specific angiogenic parameters. Now, because of
the availability of archived frozen human luteal tissue, it is possible to quantify the
expression of mRNA for these angiogenic factors in the four stages of the human
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luteal phase. A 'state of the art' technique has recently become available for the
quantification of specific mRNA species using quantitative reverse transcription-
polymerase chain reaction (RT-PCR) amplification. This technique, known as Real
Time Quantification of RT-PCR, allows measurement of the cDNA produced from
each cycle of PCR amplification from the detection of the fluorescence emitted as
each strand is synthesised with an associated cleavage of fluorescent quencher.
Quantification is based on the cycle number at which the level of emitted
fluorescence i.e. proportion of cDNA synthesised, rises above a specified threshold
in relation to an 18S internal control and a predetermined standard sample, which is
known to express the mRNA species of interest. The principles of this technique are
further outlined in Chapter 2. Human term placenta was chosen as it is a readily
available source of RNA for the angiopoietins, and their Tie-2 receptor
(Maisonpierre et al., 1997) as well as VEGF and its Fit-1 and Flk-l/KDR receptors
(Clark et al., 1996; Torry and Torry, 1997).
If the postulated roles for the angiopoietins and their co-ordinated action with
VEGF in vasculogenesis in the mouse holds true, expression of mRNA species in the
corpus luteum should reflect the neovascularisation, stabilisation and regression
which has been shown to occur in this tissue (Chapter 3). It is likely that the intense
angiogenesis of the developing corpus luteum will be associated with high
expression of Ang-2, VEGF and VEGF receptor mRNAs, and that the maturation of
the less angiogenic mid-stage corpus luteum will have an associated increase in Ang-
1 expression. According to postulated actions of Ang-2, luteal regression is thought
to be associated with an increase in Ang-2 and a decline in VEGF mRNA. Human
CG rescue of the corpus luteum should demonstrate increases in mRNA for Ang-2,
Ang-1, VEGF and VEGF receptors in accordance with the increased angiogenic
activity and vessel stabilisation associated with luteal rescue, which was established
earlier in the thesis (Chapter 3).
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7.2 Materials and Methods
7.2.1 Subjects and tissue collection
Details of patient recruitment and dating of luteal tissue were described in Chapter 2.
Corpora lutea were collected by enucleation of the whole gland from the ovary at the
time of hysterectomy. The tissue was immediately divided into 4 radial segments.
Two segments were snap frozen in liquid nitrogen and stored at -70°C for RNA
extraction. Between 4 and 6 corpora lutea were analysed per group.
7.2.2 RNA extraction and DNase treatment of RNA
Total RNA was extracted from small slices of frozen corpora lutea, using Tri-
Reagent (Sigma). Details of the extraction procedure can be found in Chapter 2. One
microgram of total RNA was DNase-treated in a 10ja,l reaction containing 1 x
reaction buffer (Gibco BRL; 200nM Tris-HCl (pH8.4), 20mM MgCl2, 500mM KC1)
1U of DNase I, and RNase-free H20 up to lOpl. Samples were incubated for 15 min
at room temperature, the DNase was inactivated by the addition of lpl 25mM EDTA
and heating at 65°C for 10 min, then chilled on ice. Samples were then ready for the
reverse transcription step of RT-PCR.
7.2.3 Reverse transcription
Complementary DNA synthesis was carried out by reverse transcription of total
RNA using the TaqMan reverse transcription reagents (Perkin Elmer) which uses
Murine Leukemia Virus Reverse Transcriptase (MuLV-RT). Two hundred
nanograms of DNase-treated RNA was reverse transcribed in a lOpl reaction,
containing 1 x reaction buffer, 5mM MgCl2, ImM each dNTPs (dGTP, dATP, dTTP
and dCTP), 2.5p.M random hexamer primers, 0.2U RNase inhibitor, 0.625U MuLV-
RT, and RNase-free H20 up to 10pL Enough mixture was made for all samples and
all positive and negative controls (outlined below). Reverse transcription was carried
out in a PCR Thermal Cycler (Hybaid Ltd., Ashford, Middlesex, UK), during one
cycle of 25°C for 1 hour, 48°C for 45 min and 95°C for 5 min. cDNA was then ready
for PCR.
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7.2.4 Real Time quantitative polymerase chain reaction
Probes and primers for Real Time quantitative PCR were designed from published
human sequences to Ang-1, Ang-2, Tie-2, VEGF-A, Flt-1 and KDR using the Primer
Express software following the guidelines outlined in Chapter 2. The sequence of
each probe and primer set are documented in Appendix B. All primer Tm values were
in the range of 58-60°C, and the probe Tm values at 68-70°C. The probe and primers
for 18S were designed by Perkin Elmer Applied Biosystems the sequences of which
were not made public.
For one 25pl reaction, a PCR cocktail of 12.5pl TaqMan Universal PCR
Master Mix (Perkin Elmer; containing AmpliTaq Gold DNA polymerase, AmpErase
uracil-N-glycosylase, A, T, C, G dNTPs, MgCl2 and the passive reference ROX (6-
carboxy X rhodamine) fluorofore), 300mM forward and reverse primers, 5pmols
specific FAM (6-carboxyfluorescein) fluorescent probe, 0.05pM each of 18S
forward and reverse primers, 0.2p,M 18S VIC fluorescent probe, and 9.525p,l RNase-
free H20 was made. Enough cocktail for duplicates of each sample, the reference
placental cDNA, the two reverse transcription negatives and a third PCR negative,
containing H20 in place of cDNA template, was prepared. Forty eight microlitres of
PCR cocktail was aliquotted into 0.2ml RNase/DNase-free tubes (ABgene, Epsom,
Surrey, UK) and 2pl (initially 20ng RNA) of cDNA template added. The tubes were
briefly vortexed and centrifuged to collect all components. In an ABI Prism 96-well
optical reaction plate (Perkin Elmer) 2 x 24pl of each PCR sample were aliquotted in
adjacent wells on the plate. A note of the contents of each well was made. The plate
was capped with MicroAmp optical caps (Perkin Elmer) and PCR carried out using
ABI Prism 7700 Sequence Detector cycling and detection. PCR conditions consisted
of 40 cycles of 50°C for 2 min, 95°C for 10 min 15 sec, and 60°C 1 min.
7.2.5 Positive and negative controls for Real Time RT-PCR
Total RNA from human term placenta was used as a positive control and as the
standard, which was used to calculate the relative expression of specific mRNA in all
luteal samples. Two reverse transcription negative controls were used for the
placental RNA and for a nominated luteal sample. Control 1 contained RNAse-free
H20 in place of MuLV-RT to ensure PCR amplification was not from genomic DNA
contamination. Control 2 included RNAse-free H20 in place of RNA template, to
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detect H20 contamination. A third PCR negative for placental and one luteal RNA
was used. This contained RNAse-free H20 in place of cDNA template. A control
without DNA polymerase was not possible as the ready-made Universal Maser Mix
contained AmpliTaq DNA polymerase.
7.2.6 Quantification
Quantification is based on the emission of the fluorescent probe for the specific
cDNA of interest in relation to an internal 18S control and the nominated standard, in
this case placenta. It involves a number of calculations which utilise the CT values
provided by the TaqMan software following PCR, and culminating in the production
of a 2"ddCT value for each sample, which is used for statistical analysis. The CT value
is the PCR cycle number (between 1 and 40) at which a statistically significant
increase in emission intensity of the reporter from the passive reference is reached,
set by a predetermined threshold. The CT values for the specific mRNA probe (FAM
reporter emission) and 18S signal (VIC reporter emission) for each sample was
obtained from Sequence Detector Version 1.6.3 software after the 40 PCR cycles.
Delta CT considers the change in CT of the specific FAM reporter from the 18S VIC
signal, this was calculated from subtracting the 18S CT value from the corresponding
sample FAM CT. The delta CT for each of the two duplicates for each sample were
meaned. The placental standard CT was subtracted from all delta CT values to obtain
the delta delta CT value. Messenger RNA expression, relative to the placental
standard was calculated from 2"ddCT, which considers the exponential increase in
PCR amplification and enhances the differences between samples. The relative
mRNA expression was meaned for each group of samples corresponding to the
different stages of the luteal phase, and the sem calculated.
Each of the negative controls had a FAM CT value > 37 (40 was optimal and
in most cases achieved), which was also a minimum of 10 cycles above the highest
luteal or placental sample CT value. An 18S CT value >35 and also 10 cycles above
the highest luteal or placental sample 18S CT value was acceptable.
2"ddCT values from each stage of the luteal phase and after hCG rescue were
analysed for significant variation using a one way analysis of variance with Fisher's
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post hoc test, the level of significance being taken as P<0.05. The tests were
performed using StatView Version 4.0.
7.3 Results
The results reflect quantification from one PCR run. Ideally the average of 3
independent PCR runs should be used for statistical analysis, however, due to the
cost of reagents this was not possible. It is worth noting that results from preliminary
trials over the luteal stages exhibited comparable trends in expression as the
definitive run, which is documented here.
7.3.1 Angiopoietin and Tie-2 mRNA expression
Figure 7.1 suggests a trend from high Ang-1 expression in the early luteal phase to
minimal levels in the rescued corpus luteum. However, due to the low number of
corpora luteal per stage (n=4-6) and hence the large SEM, particularly in the early
luteal group the only significant value was a decrease (P<0.05) in Ang-1 mRNA
expression from early luteal levels, in the rescued corpus luteum. Similarly for Ang-2
mRNA expression (Fig. 7.2), highest levels were found in the early luteal phase
which significantly declined in the rescued corpus luteum. In these results however,
there is a trend for expression to increase in the late corpus luteum, although the high
SEM values do not make these differences significant. Expression of the common
angiopoietin receptor, Tie-2 mRNA (Fig. 7.3) appears greatest in the early luteal
phase declining throughout the remainder of the luteal phase and following luteal
rescue, although there are no significant differences in level of expression, probably
due again to the large SEM values.
7.3.2 VEGF, Flt-1 and KDR mRNA expression
Figure 7.4 demonstrates that VEGF expression is maximal in the early luteal phase
and is significantly reduced in the mid- and late corpus luteum. There is a tendency
for expression to increase following hCG rescue however this increase is not
statistically significant. Similarly, the expression of Flt-1 receptor (Fig. 7.5) and
KDR receptor mRNAs (Fig. 7.6) were significantly higher in the early luteal phase
than any other stage of the cycle. The same tendency, as for VEGF, for increased
VEGF receptor expression in the rescued corpus luteum however, was not apparent.
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Early Mid Late Rescued
Figure 7.1 Expression of Angiopoietin-1 mRNA in the human corpus luteum
Quantification of Ang-1 mRNA expression during the luteal phase and in hCG
rescued human corpora lutea, following Real Time Quantitative RT-PCR. Values are
means ± sem. Different letters denote significant differences between groups,
P<0.05.































Figure 7.2 Expression of Angiopoietin-2 mRNA in the human corpus luteum
Quantification of Ang-2 mRNA expression during the luteal phase and in hCG
rescued human corpora lutea, following Real Time Quantitative RT-PCR. Values are
means ± sem. Different letters denote significant differences between groups,
P<0.05.
















Early Mid Late Rescued
Figure 7.3 Expression of the Angiopoietin receptor, Tie-2 mRNA in the human
corpus iuteum
Quantification of Tie-2 mRNA expression during the luteal phase and in hCG
rescued human corpora lutea, following Real Time Quantitative RT-PCR. Values are
means ± SEM. Significant differences between groups were not observed.




































Early Mid Late Rescued
Figure 7.4 Expression of VEGF-A mRNA in the human corpus luteum
Quantification of VEGF mRNA expression during the luteal phase and in hCG
rescued human corpora lutea, following Real Time Quantitative RT-PCR. Values are
means ± SEM. Different letters denote significant differences between groups,
P<0.05.




































Figure 7.5 Expression of the VEGF receptor, Flt-1 mRNA in the human corpus
Iuteum
Quantification of Flt-1 mRNA expression during the luteal phase and in hCG rescued
human corpora lutea, following Real Time Quantitative RT-PCR. Values are means
± sem. Different letters denote significant differences between groups, P<0.05.



























Early Mid Late Rescued
Figure 7.6 Expression of the VEGF receptor, KDR mRNA in the human corpus
luteum
Quantification of KDR mRNA expression during the luteal phase and in hCG
rescued human corpora lutea, following Real Time Quantitative RT-PCR. Values are
means ± sem. Different letters denote significant differences between groups,
P<0.05.
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7.4 Discussion
This study indicated that the early luteal phase is associated with high levels of
mRNA for the Ang-1, Ang-2, their Tie-2 receptor, VEGF and its Fit-1 and KDR
receptors, and that there was no significant up regulation of any factor in the corpus
luteum at any stage of the luteal phase or in simulated early pregnancy following
hCG rescue. The results imply that the angiopoietins and VEGF may modulate the
intense angiogenesis associated with the early luteal phase.
High levels of Ang-1 mRNA in the early luteal phase is consistent with the
postulated role of this molecule in the recruitment of pericytes and stabilisation of
blood vessels. Presumably, translation of this mRNA and protein expression of Ang-
1 protein would occur later in the development of the corpus luteum coinciding with
the increased pericyte coverage demonstrated in the mid-luteal phase (Chapter 3).
Without measuring Ang-1 protein levels this cannot be clarified. In the developing
corpus luteum there is an invasion of mature vessels from the thecal layer of the
ovulatory follicle, and so high expression of Ang-1 in the early luteal phase could be
attributed to continued expression in the theca derived lutein compartment which
would be necessary for the maintenance of stability in a proportion of vessels in
which intense angiogenesis was not taking place. Nevertheless, postulated roles for
Ang-1 in associated angiogenic activities, directly regulating the endothelial cell
phenotype have recently been demonstrated. Koblizek et al., (1998), demonstrated
that Ang-1 stimulates endothelial cell sprouting in vitro, and Ang-1 is chemotactic
for cultured endothelial cells (Witzenbilcher et al., 1998), both effects occurring in
the absence of accessory cells. This suggests a new role for Ang-1 early in the
angiogenic process.
High levels of Ang-1 expression in the early corpus luteum were coincidental
with increased Ang-2 expression. Goede et al., (1998) demonstrated that levels of
Ang-1 mRNA expression equalled Ang-2 expression in the early bovine corpus
luteum. It is believed that Ang-1 is constitutively expressed in the normal vasculature
of the adult being present in non-angiogenic tissues (Maisonpierre et al., 1997) and
that it is the relative proportions of Ang-2 which dictate the Tie-2 mediated effects.
Thus, in the human corpus luteum, the high level of Ang-2 expression in the
angiogenic early luteal phase could reflect the postulated role for Ang-2
competitively inhibiting Ang-1 at the level of the Tie-2 receptor causing vessel
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destabilisation and allowing access of angiogenic growth factors to susceptible
endothelial cells. The associated high level of Tie-2 expression in the early corpus
luteum however, provides extra binding sites for both ligands, supporting roles for
both Ang-1 and Ang-2 in the intense angiogenesis associated with the developing
corpus luteum.
Ang-2 mRNA expression increased in the late luteal phase. Although this was
not a significant elevation, it does reflect a role for Ang-2 in the vessel
destabilisation and regression associated with this stage. In the absence of VEGF, as
demonstrated by low mRNA and protein levels (Chapter 3), the Ang-2 inhibition of
Tie-2 phosphorylation and subsequent facilitation of vessel destabilisation is likely to
promote the regression of luteal vasculature which has been shown to occur in the
late human corpus luteum (Chapter 3). However, there is no evidence from this
Chapter to support this hypothesis and so it is not possible to contribute to the debate.
As previously demonstrated (Chapter 3) VEGF protein is highly expressed in
the early human corpus luteum correlating with the current findings of high VEGF
mRNA expression. Elevated VEGF and Ang-2 levels are consistent with the high
angiogenic activity of the early luteal phase, in which VEGF access and subsequent
endothelial cell proliferative and migratory actions are likely to be facilitated by the
effects of Ang-2 on vessel destabilisation. Simultaneous high expression of both
VEGF receptors (Flt-1 and KDR) supports the potent angiogenic action of VEGF at
this stage in luteal development, confirming the role of KDR in endothelial cell
proliferation and migration, and suggests a previously undefined role for Flt-1 early
in the angiogenic process. In the mid-luteal phase, VEGF mRNA expression
decreased significantly. This is not consistent with the high levels of VEGF protein
as demonstrated by quantitative immunocytochemistry in the human mid-corpus
luteum (Chapter 3), however does suggest that VEGF activity could be subject to
post-transcriptional regulation. Hazzard et al., (1999b) demonstrated in the rhesus
monkey that after the administration of an ovulatory stimulus of hCG, periovulatory
follicular fluid VEGF protein concentrations increased dramatically, however VEGF
mRNA expression was not altered, signifying translational regulation of VEGF.
There was no significant up-regulation of any factor in the hCG rescued
corpus luteum, although there was a tendency for VEGF message to increase as a
result of luteal rescue. It has been demonstrated that hCG rescue leads to an increase
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VEGF protein expression above mid-luteal values signifying the increased
angiogenic activity of this tissue (Chapter 3). The failure to demonstrate a concurrent
rise in VEGF mRNA gives further evidence for the translational regulation of VEGF
in the primate corpus luteum. Surprisingly, this study demonstrates that the
angiopoietins are not involved in the increased angiogenic activity or vessel
stabilisation previously demonstrated to occur during luteal rescue (Chapter 3),
although translational regulation of these factors cannot be disregarded.
Conversely, a role for Ang-2 during hCG rescue has been indicated by others
in our group using quantitative in situ hybridisation (Wulff et al., 2000). This study
demonstrates that hCG rescue of the human corpus luteum is associated with an up-
regulation of Ang-2 and VEGF mRNAs, which correlates with the postulated role of
Ang-2 in prolific angiogenesis in the presence of VEGF. This finding supports the
results in Chapter 3 which indicate that hCG rescue is associated with increased
endothelial cell proliferation, endothelial cell area and VEGF protein expression. The
demonstration that expression of VEGF mRNA increased during luteal rescue in vivo
correlates with the previous finding in vitro that expression of VEGF mRNA was up-
regulated in cultured human luteinised granulosa cells following CG administration
(Neulen et al., 1998). In this study, maximal Tie-2 expression in the early luteal
phase is concurrent with elevated Ang-1 and Ang-2 mRNA expression, suggesting
that Tie-2 expression is regulated by the availability of its ligands. This was also
proposed by Wulff et al., (2000) where rescue of the corpus luteum led to
corresponding increases in Ang-2 and Tie-2 mRNA.
It appears that the failure to find elevations in Ang-2, Tie-2 and VEGF
mRNA expression during luteal rescue by quantitative RT-PCR, is in contrast to
previous studies. The reasons for these discrepancies are possibly due to limitations
in the RNA extraction method. Wulff et al., (2000) describe a complex pattern of
expression of Ang-2 mRNA in the human corpus luteum. Ang-2 mRNA was
strongly expressed in a minority of individual luteal and endothelial cells, found
either singly or in clusters, presumably associated to areas of intense angiogenic
activity as suggested for the rat corpus luteum (Maisonpierre et al., 1997). Therefore,
the extraction of RNA from a small piece of luteal tissue cannot represent the whole
structure, in which differential patterns of growth factor expression are present. This
notion is supported by the fact that there is a homogeneous expression of VEGF
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mRNA throughout the corpus luteum (Wulff et al., 2000) and RT-PCR-quantified
expression of VEGF mRNA from total RNA extracted from these small pieces of
luteal tissue reflects the in situ quantified levels of expression of VEGF mRNA more
closely, with an increase, although not significant, during luteal rescue. The large
sem values seen for each group, signify a large variety in levels of expression
between samples in one group, and subsequent failure to demonstrate statistically
significant differences in expression between groups, which also signifies the
heterogeneous nature of the tissue analysed. Results in this study correlated with the
trends seen in preliminary data collected from other Real Time quantitative RT-PCR
runs, and so discrepancies between these data and previous studies using other
techniques appears not to reflect any pitfalls in the RT-PCR quantitative method
used, such as inter-run variance. Due to the small differences in expression of the
angiopoietins, their Tie -2 receptor, VEGF-A and its fit-1 and KDR receptors,
observed between stages of the luteal phase we're uncertain whether the whole luteal
mRNA population was represented in the RNA investigated. Therefore, we can
conclude that this study demonstrates the importance of mRNA quantification from a
large pool of RNA which represents the tissue as a whole.
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This thesis has presented the results of a series of investigations into the control of
luteal angiogenesis in the primate and its in vivo manipulation in the marmoset
monkey. A discussion of the results obtained have been presented in the relevant
experimental chapters, and so this section provides an opportunity to summarise the
main findings of the thesis, discuss the relative merits of the model used for
inhibition of luteal angiogenesis and its clinical implications. In an attempt to clarify
unexplained results and to expand the clinical applications of the model, areas for
further investigation will be documented throughout the General Discussion.
8.1 The findings of the thesis
At the beginning of this research information concerning primate luteal angiogenesis
was limited. A description of the timing of luteal angiogenesis in the primate had
recently been described (Christenson and Stouffer, 1996b) demonstrating that luteal
development was associated with intense angiogenesis, however, no working model
for the analysis of anti-angiogeneic agents had been established. This thesis was
designed to investigate the control of angiogenesis in the primate corpus luteum and
examine the dependence of luteal function on such angiogenesis by in vivo
manipulation in the marmoset monkey. A number of important findings have been
described. 1) We have demonstrated that luteal angiogenesis can be quantified by
measuring specific parameters associated with neovascularisation, such as
endothelial cell proliferation, endothelial cell content, growth factor expression, and
recruitment of periendothelial support cells for maturation of the newly formed
vasculature; and that this can be quantified effectively by immunocytochemical
methods. 2) The early luteal phase displays an intense period of angiogenesis which
results in the formation of an extensive microvascular network in the mid-luteal
phase. Angiogenesis is ongoing in the mid-luteal phase but at a lower level. Luteal
regression is associated with a marked decrease in angiogenesis; and hCG rescue, in
the human, with a significant increase in angiogenic activity and vessel stabilisation.
3) We have developed a robust model to test anti-angiogenic factors using
approaches which target both the intense early luteal angiogenesis and ongoing
angiogenesis in the mid-luteal phase. In doing so, we have demonstrated that the
intense period of angiogenesis during the early luteal phase in the marmoset is
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controlled by gonadotrophin stimulation of luteal steroidogenic cells, growth factors
from which are believed to act in a paracrine fashion stimulating endothelial cell
migration and proliferation. 4) The angiogenesis inhibitor TNP-470, which prevented
normal luteal development and function in the rodent, had no effect on luteal
angiogenesis in the marmoset, indicating that caution is needed when extrapolating
results from infraprimate species. 5) Finally, and of paramount importance, this
thesis reports that luteal angiogenesis is essential for normal luteal function in the
marmoset. This research established the fact that luteal angiogenesis is driven
primarily by VEGF, the biological activity of which is critical for normal luteal
function throughout the active lifespan of the primate corpus luteum.
The use of quantitative immunocytochemistry was demonstrated to be
effective in measuring the angiogenic activity of each corpus luteum, and for
assessing morphological changes associated with luteal development and effects of
treatment. The incorporation of BrdU by proliferating cells in the S phase of the cell
cycle was shown to be a robust, reproducible technique, which could serve as the
basis for measuring vessel proliferation in subsequent studies. Whilst investigating
the possibility of quantifying luteal angiogenesis by immunocytochemical methods it
was important to address whether one luteal section would reflect the whole corpus
luteum, especially when considering the fact that neovascularisation of this tissue
results in a complex web of branching blood vessels, which are not necessarily
distributed evenly throughout the gland. It was demonstrated that for measurements
of both endothelial cell proliferation and endothelial cell area, one section was
representative of the whole gland, and that quantification of angiogenesis in one
luteal section in future studies was sufficient to assess the effects of putative
inhibitors of angiogenesis.
The techniques developed for quantitative analysis of endothelial cell
proliferation and measurements of endothelial cell area in luteal sections, were
extended to quantify angiogenic growth factors, such as VEGF, and the degree of
vessel maturation as determined by periendothelial support cell contact. In doing so,
it was established that pericytes were recruited in the early, intensely angiogenic
phase of luteal development, suggesting that they play a dual role, contributing to
both the angiogenic activity of the corpus luteum and to vessel maturation and
cessation of vessel growth. The roles were determined by the spatial relationship of
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pericytes with respect to endothelial cells. This in vivo data supports previously
reported in vitro studies in which the contact of co-cultures of endothelial cells and
pericytes determined the stimulatory or inhibitory action of pericytes on endothelial
cell growth and migration (Hirschi et al., 1999).
Using the novel information concerning the level of angiogenic activity and
expression of VEGF during luteal development in the marmoset, gained in Chapter
3, it was possible to develop a robust model to test the effects of putative angiogenic
inhibitors on luteal angiogenesis and function. The first approach was to determine
the gonadotrophin support of early luteal intense angiogenesis and mid-luteal
ongoing angiogenesis by inhibiting release of the principal luteal gonadotropin, LH,
using a GnRH antagonist. This treatment had a profound inhibitory effect on early
luteal endothelial cell proliferation and a marked disruptive effect on lutein cell
morphology, surprisingly however, a concurrent decrease in establishment of the
microvascular tree was not seen. The method of quantification of endothelial cell
content per area of luteal tissue may be one explanation for the failure to find a
decrease in endothelial cell area following GnRH antagonist treatment. The severe
disruption of lutein cell morphology induced by LH withdrawal led to shrinkage of
the corpus luteum. To address this problem, a similar approach as used for
quantification of endothelial cell content throughout the luteal phase, compensating
for a difference in luteal volume, would be necessary. However, because of the loss
of lutein cell integrity, the major factor contributing to luteal volume, it was not
possible to measure lutein cell area and obtain a conversion factor to measure a
correspondingly smaller area of GnRH antagonist-treated tissue. An alternative
approach to measure endothelial cell content or luteal volume should therefore be
considered, perhaps measuring endothelial cell area per constant number of cell
nuclei.
Another surprising effect of GnRH antagonist treatment was the failure to
suppress endothelial cell proliferation in the mid-luteal phase although lutein cell
morphology was severely compromised. It is possible that other cell types, such as
fibroblasts, are proliferating and incorporate BrdU after such damaging treatment, in
a similar response as that seen during normal luteolysis when the proportion of
fibroblast-like cells is shown to increase. Dual labelling studies with BrdU and a
specific fibroblast marker would determine if fibroblast proliferation was induced
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after GnRH antagonist treatment in the mid-luteal phase. Another explanation for the
failure to demonstrate decreased endothelial cell proliferation after treatment in the
mid-luteal phase could be that the control of ongoing angiogenesis at this stage is not
dependent on gonadotropin support. The fact that the intense angiogenesis in the
early luteal phase is clearly gonadotropin-dependent could suggest a differential
stage-dependent regulation of luteal angiogenesis in the marmoset.
The use of GnRH antagonist treatment is limited in the fact that it results in
withdrawal of the major driving force of luteal function, and therefore suppresses all
aspects of the angiogenic process, which makes it difficult to elucidate individual
mechanisms of angiogenic regulation. A more scientific approach was to specifically
target the angiogenic process. This led to the use of a synthetic angiogenesis
inhibitor, TNP-470, based on a previous study (Klauber et al., 1997) in which TNP-
470 , administered subcutaneously, was demonstrated to inhibit luteal development
in mice. This compound was also being used in clinical trials as an inhibitor of
tumour angiogenesis (Figg et al., 1997; Kudelka et al., 1997; Dezube et al., 1998)
and so it was pertinent to investigate possible side effects on female reproduction.
The failure of TNP-470 to effect luteal angiogenesis in the marmoset following i.v.
injection (Chapter 5; Fraser et al., 1999a), may be due to the different route of
administration and/or short half-life of the compound. Clinical trials have shown that
all active metabolites of this compound are cleared from the circulation in
approximately 2.5 hours (Figg et al., 1997; Bhargava et al., 1999). Variable effects
of TNP-470 to reduce tumour growth have been demonstrated in clinical trials
(Kudelka et al., 1997; Twardowski and Gradishar, 1997; Dezube et al., 1998), doses
were however low, as neurotoxic side effects were apparent. These side effects were
completely reversible due to the short half life of the compound and so it was
recommended that exploration of prolonged i.v. infusion was warranted (Bhargava et
al., 1999). In the marmoset, doses of TNP-470 similar to those used in the Klauber
study, on a body weight basis, were administered on the day of ovulation and for 10
days thereafter, with a lack of effect on luteal development. This may be explained
by interspecies variability of TNP-470 metabolism (Placidi et al., 1997) or the route
of administration. Constant infusion of the drug to marmosets over the 10 day period
was not possible as animals would need constant anaesthesia and restraint to prevent
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removal of the infusion device and self-harm, although an alternative approach using
a subcutaneous or intrauterine releasing system cannot be ruled out.
The concept of targeting luteal angiogenesis was developed further with the
specific inhibition of VEGF, which was believed to be a prime regulator of
angiogenesis. Targeting specific endogenous angiogenic factors in vivo in this way
gives an insight into the roles that they play and elucidates the dependence of the
system on such factors. Thus, the neutralisation of VEGF proved a powerful tool in
the assessment of its role in the regulation of luteal angiogenesis in the marmoset.
Inhibition of VEGF activity in both the early and mid-luteal stages demonstrated that
VEGF plays a pivotal role in the control of endothelial cell proliferation and
establishment of the luteal vasculature. Suppression of neovascularisation in the
corpus luteum as a result of VEGF withdrawal demonstrates that luteal angiogenesis
is essential for normal luteal function in the primate, as determined by substantial
decreases in plasma progesterone concentration in the absence of steroidogenic cell
defects.
The decline in plasma progesterone concentrations was initially considered to
be solely the result of decreased angiogenic activity and compromised formation of
luteal vasculature. However, studies of VEGF inhibition specifically in the mid-
luteal phase, resulted in a rapid decrease of plasma progesterone concentration. Since
the microvasculature is fully established at this time an effect of angiogenesis
inhibition would not be expected to cause such a rapid decline in plasma
progesterone concentrations, more likely result in the maintenance of pretreatment
levels. This signifies a major role for VEGF in controlling vascular permeability and
thus the diffusion of cholesterol precursors to steroidogenic cells and/or progesterone
into the circulation. In vitro studies suggest that VEGF increases vascular
permeability through the Flt-1 receptor and the production of nitric oxide (Murohara
et al., 1998), which leads to dilation of endothelial cell tight junctions (Clancy et al.,
1997) permitting extravasation. Therefore, further investigation, for example into the
effects of VEGF withdrawal on 1) expression of nitric oxide synthase, 2) expression
of endothelial gap junction proteins, and 3) endothelial cell-cell connections by
ultrastructural analysis, is warranted to determine the role of vascular permeability in
relation to the rapid fall in plasma progesterone concentration. It is also conceivable
that the treatment could have an inhibitory effect on pituitary LH secretion. A
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decrease in permeability of the hypophysial portal vessels at the hypathalomic-
pituitary level, may result in suppression of GnRH access to its pituitary receptor and
consequential declines in LH pulsatility. However, it has been demonstrated that
suppression of LH during the luteal phase results in characteristic and marked
changes in the morphology of the lutein cells (Chapter 4; Fraser et al., 1999b;
Dickson and Fraser, 2000) that were not observed after VEGF inhibition, indicating
that any change in LH secretion would be minor. Decreased as opposed to complete
suppression of LH release may not have such a severe effect on lutein cell
morphology whilst still compromise the ability of the cell to synthesis and secrete
progesterone. LH pulsatility in the luteal phase is low and detection of any small
change in plasma LH concentration is unlikely using existing assays and with the
sampling frequency employed, although further analysis could be undertaken.
A comparison of the effects of GnRH antagonist treatment and VEGF
immunoneutralisation in the early luteal phase demonstrates a greater suppression of
endothelial cell proliferation after GnRH antagonist treatment (Figure 8.1) than after
VEGF immunoneutralisation. This suggested that growth factors other than VEGF
control primate luteal angiogenesis, such as FGF and the angiopoietins. However,
subsequent studies undertaken in our laboratory during the last few months, using a
truncated soluble Fit-1 receptor demonstrate similar levels of suppression of
endothelial cell proliferation as those obtained after GnRH antagonist treatment
(Figure 8.1; Wulff et al., 2001). This signifies that the soluble Flt-1 receptor is a
more potent inhibitor of VEGF action, perhaps suppressing other members of the
VEGF family, and that full VEGF withdrawal was possibly not obtained using the
monoclonal antibody. More importantly, it indicates that luteal angiogenesis in the
primate is driven almost solely by VEGF and that contributions of other growth
factors are likely to be minimal.























Figure 8.1 The inhibition of Proliferation Index in the marmoset corpus luteum
following administration of anti-angiogenic agents
The effect of administration of three anti-angiogenic treatments on luteal endothelial
cell proliferation in the marmoset monkey. Note the difference in suppression of PI
after GnRH antagonist and anti-VEGF treatment, and the further reduction of PI with
truncated soluble Flt-1 receptor as compared to anti-VEGF treatment.
Source: Chapter 4, Chapter 6 and Wulff et al., 2001).
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Other studies have demonstrated that VEGF is synthesised by endothelial
cells and pericytes in culture (Nomura et al., 1995) and in vivo in the bovine corpus
luteum (Reynolds and Redmer, 1998). This was not demonstrated in this thesis using
an antibody specific to VEGF-A for immunocytochemistry. Yonekura et al., (1999)
have demonstrated the expression of VEGF-B, VEGF-C and P1GF mRNA in these
vascular cells, and suggest that VEGF related factors produced by endothelial cells
and pericytes may have an indirect effect on vessel growth, migration and tube
formation in an autocrine or paracrine manner, via the modulation of VEGF-A
action. Microvascular cells express plural types of VEGF receptors, such as Fit-1,
KDR and Flt-4. Vascular endothelial growth factor-A binds to both Fit-1 and KDR.
Platelet derived growth factor and VEGF-B bind to Fit-1. Therefore the presence of
high P1GF or VEGF-B may result in masking of Fit-1 in endothelial cells, thereby
inhibiting VEGF-A high affinity binding to this receptor. This may in turn allow
access of VEGF-A to the low affinity KDR that is abundantly expressed on
endothelial cells, in turn stimulating endothelial cell proliferation. Vascular
endothelial growth factor-C binds to KDR and Flt-4, thus over production of VEGF-
C could decrease the binding of VEGF-A to KDR by competing with VEGF-A and
promote Flt-1 binding, and contribution to vascular permeability. The expression of
the VEGF-related family of growth factors has not been elucidated in the primate
corpus luteum, and their contributions to luteal angiogenesis are unknown. We have
demonstrated that VEGF-A can stimulate pericyte recruitment in the early luteal
phase however, such recruitment in the mid-luteal phase appears not to be driven by
VEGF-A. The stage-specific differences in the control of pericyte recruitment may
be a result of differences in the relative expression and actions of other members of
the VEGF family. The inter-relationships between VEGF-A and other related factors
appear complex, therefore, to increase the understanding of action of VEGF-A in the
corpus luteum such studies investigating other VEGF family members are warranted.
Suppression of luteal progesterone production is likely to have adverse effect
on endometrial receptivity to an implanting blastocyst. Investigation of expression of
progesterone-dependent proteins in the uterus after VEGF withdrawal would address
this issue. In the marmoset, endometrial prolactin expression is regulated by
progesterone, and prolactin is believed to be essential for endometrial differentiation
and ultimately implantation (Dalrymple et al., 2000). A decrease in prolactin levels
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in these uterine sections would suggest an indirect effect of VEGF neutralisation, via
the suppression of progesterone, on the endometrium. Endometrial quantification of
prolactin was however, beyond the scope of this thesis.
This thesis also demonstrated the use of a novel technique, Real Time
quantitative RT-PCR, in an investigation to evaluate the expression of angiopoietin
and their Tie-2 receptor mRNA in the human corpus luteum. Results using this
technique were inconclusive and did not correlate with previous studies from our
laboratory (Wulff et al., 2000), due to the fact that extracted RNA did not represent
the total luteal population. This research therefore emphasises the need for, and value
of multiple techniques which measure both expression of mRNA and protein, using
both molecular and histological analysis, to resolve the role of these potential
angiogenic factors in the primate corpus luteum.
8.2 The marmoset model for inhibition of luteal angiogenesis
The studies in this thesis utilised the marmoset monkey to examine the dependence
of luteal function on angiogenesis, and elucidate the primary factor(s) involved in
this process. As a model for the human, the marmoset is not ideal. It is not a mono-
ovulatory species, it has a luteal phase length of approximately 20 days as opposed to
14 days in the human, the structure of its corpus luteum differs to that of humans,
and the marmoset does not menstruate. However, such invasive investigations of
luteal angiogenesis could not be carried out in higher primates. The marmoset has an
ovulatory cycle more analogous than any rodent species to that of the human, and so
is the most appropriate animal model.
The model of manipulating luteal angiogenesis by targeting specific
angiogenic phases of luteal development was designed as a result of extensive
research into the angiogenic activity of the corpus luteum (Chapter 3). During the
course of this research Ferrara et al., (1998), used truncated soluble Flt-1 receptor to
inhibit VEGF activity in a rodent model of hormonally induced ovulation. Despite
this being a rodent model which is limited in its relevance to the control of
angiogenesis in primates and humans, the timing of treatment casts serious doubt as
to whether luteal angiogenesis was specifically targeted. Rats were treated with
pregnant mares serum gonadotropin (PMSG), rich in FSH, to initiate follicular
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development, then given a bolus of hCG to stimulate ovulation and corpus luteum
formation. Truncated soluble Fit-1 receptor was administered twice daily
commencing 4-6 hours before PMSG. Treatment of marmosets with truncated
soluble receptor, in our laboratory, inhibits follicular development (Wulff et al.,
unpublished observations). This indicates that, in the study by Ferrara et al., (1998),
it was unlikely that luteal angiogenesis was specifically targeted because the timing
of treatment probably inhibited normal follicular development which would lead to
subnormal corpus luteum formation and function.
The approach taken in this thesis was to inhibit luteal development by
specifically timing the administration of treatment to the early luteal phase, that is
after ovulation, so any effect on luteal function would be a consequence of inhibition
of luteal angiogenesis, not an effect on follicular development. This approach has
been successful in elucidating that angiogenesis is essential for normal luteal
function, and the role of potential growth factors in luteal angiogenesis by their
specific inhibition in the primate. Therefore, this model could be used to examine the
effects of other putative endogenous regulators. The recent discovery of differences
in expression of the angiopoietins in the human corpus luteum (Wulff et al., 2000)
correlating with the known angiogenic activity of the gland indicates a role for these
factors in the control or modulation of luteal angiogenesis. There is increasing
interest in the scientific world to elucidate the functions of the angiopoietins, and
monoclonal antibodies and truncated soluble Tie-2 receptors are being developed at
this time. The use of such potential angiopoietin inhibitors in the model created here
would be decisive in establishing their contribution to luteal angiogenesis in the
primate. The angiopoietins are believed to exert their actions in conjunction with
VEGF. Although expression in comparison to VEGF expression has been examined
(Chapter 7; Wulff et al., 2000), the dependence of actions of angiopoietins on this
primary angiogenic factor has not been established in the primate corpus luteum. It
would therefore be justified to evaluate their expression in relationship to VEGF
withdrawal after VEGF immunoneutralisation and soluble truncated Fit-1 receptor
treatment during the angiogenic stages of the luteal phase.
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8.3 Clinical implications of the findings of this thesis
The major function of the corpus luteum is the production of progesterone which
results in endometrial receptivity and myometrial quiescence for blastocyst
implantation after conception. We have demonstrated that luteal angiogenesis is
essential for progesterone production in the primate. Therefore, the strategy to inhibit
luteal angiogenesis provides a novel approach to post-ovulatory fertility control.
However, a number of scientific questions arise when considering this. 1) Are the
effects in ovarian angiogenesis reversible? 2) Is progesterone concentration
sufficiently suppressed to prevent the establishment of pregnancy? 3) If not, what
would the effects on foetal vasculogenesis be?
Ongoing studies in our laboratory are beginning to answer these questions.
Plasma progesterone profiles of animals in which VEGF action was inhibited,
demonstrated that after an initial period of plasma progesterone decrease coinciding
with treatment, progesterone levels rose to normal values with termination of
treatment. This suggests that normal luteal angiogenesis and function was restored,
indicating that any effect on follicular development occuring at this time would also
be reversible and followed by normal preovulatory development, ovulation and
corpus luteum formation. In order to prevent the establishment of pregnancy, further
research is needed to investigate the required level of progesterone suppression and
the degree of variation between animals. It is possible that the corpus luteum
produces an excess of progesterone, and that complete progesterone suppression
would be needed to prevent pregnancy in all animals. If this was not achieved it is
presumed that the effects of VEGF inhibition on foetal vascularisation would be as
detrimental as those seen in murine transgenic models. Therefore the use of
angiogenesis inhibition for fertility control demands much more research to ascertain
the minimal level of progesterone required to establish pregnancy.
The demonstration that luteal function is dependent on normal luteal
angiogenesis not only has implications for new approaches to fertility control but
could also lead to treatment of luteal inadequacy which is caused by deficient
follicular or luteal angiogenesis.
Tumour growth is dependent on stimulation of new blood vessel growth from
the pre-existing vasculature (Folkman and Klagsbrun, 1987) and this dependence on
angiogenesis has long been proposed as an attractive therapeutic target. Therefore,
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angiogenesis inhibitors are currently being developed primarily for treatment of
vascular solid tumours. Anti-angiogenic agents do not kill tumour cells directly, they
operate indirectly by inhibiting vascularisation of the tumour and tumour cells die by
hypoxia, or from deprivation of endothelial cell-derived survival factors. Inhibition
of VEGF has been shown to reduce tumour growth in murine models (Kim et al.,
1993) and is currently being tested in clinical trials along with other anti-angiogenic
agents which target the pathway at different stages, some of which are shown in
Table 8.1. These factors are also likely to have a role in the control of rheumatoid
arthritis, retinal neovascularisation and psoriasis in which uncontrollable
angiogenesis occurs. The model developed in this thesis could test new generation
anti-angiogenic compounds and examine their suitability for further development.
Since these inhibitors are being used clinically it is essential that their potential
effects on the reproductive system be determined, and the model established here
would be highly suitable for such assessment.
Physiological angiogenesis in the corpus luteum is tightly regulated and
angiogenic activity decreases with age of the corpus luteum. This could be exploited
in a similar model to elucidate endogenous anti-angiogenic factors. In addition,
inhibition of these factors or prolonged expression of VEGF could result in
continued angiogenic activity. This would serve to assess the relationship between
angiogenesis and luteolysis, investigating whether inhibition of vascular regression
would prolong the lifespan of the corpus luteum.
The elucidation of pro-angiogenic agents in the primate corpus luteum could
have clinical applications in the treatment of conditions which are characterised by
decreased vascularisation, such as limb and heart ischaemia. Recent research
demonstrates progress in the treatment of such conditions by vascular gene therapy
employing recombinant human VEGF DNA (Baumgartner et al., 1998) and local
delivery of aFGF, bFGF and VEGF (Thompson et al., 1999).
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AGENT MECHANISM OF ACTION
AG-3340 Metalloproteinase inhibitor
Anti-VEGF monoclonal antibody Inhibition of VEGF action
Batimastat Metalloproteinase inhibitor
Bay 12-9526 Metalloproteinase inhibitor
Flavopuridol Protein kinase C inhibitor




Octreotide Growth factor antagonist
Paclitaxel (Taxol, Docetaxel, Paxane) Cytotoxic and antiproliferative
Pentosan polysulphate Growth factor antagonist
PI-88 Growth factor antagonist
Psorvastat Metalloproteinase inhibitor
Razoxane Cytotoxic and antiproliferative
SU101 PDGF antagonist
SU5416 VEGF antagonist
Suramin Growth factor antagonist
Tamoxifen Cytotoxic and antiproliferative
Tecogalan sodium Growth factor antagonist
Thalidomide Unknown
TNP-470 (AGM-1470) Numerous
Vitaxin Anti-integrin monoclonal antibody
Table 8.1 Anti-angiogenic agents that have entered clinical trials
Source: Clinical Trials Registry, The Angiogenesis Foundation, (Thompson et al.,
1999)
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Additional research into the potential side effects of inhibition or promotion
of angiogenesis is required. Clinical trials have demonstrated unexpected effects of
anti-angiogenic agents on the central nervous system (reviewed by Thompson et al.,
1999). The discovery that VEGF is a ligand for neuropilin (Soker et al., 1998), a
receptor that guides axonal growth, points to links between the control of growth of
the microvasculature and the central nervous system. It is therefore appropriate that
such effects be explored, and this will depend on the further development of suitable
animal models.
8.4 Conclusions
A unique and powerful model has been established to investigate the regulation of
luteal angiogenesis in the primate. Using this model, studies reported in this thesis
provide compelling evidence that the specific inhibition of luteal angiogenesis
severely compromises luteal function. The specific targeting of VEGF has
demonstrated that this factor is the major driving force of luteal angiogenesis in the
primate. The potential to inhibit angiogenesis in the female reproductive tract should
have important implications for clinical practice, but the development of safe and
effective strategies will require detailed investigation of suitable animal models, as
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Appendix A: VEGF-A Riboprobe Sequence for Situ Hybridisation
Atie 1131
:qu (jitaT<
gcc ^ fiaaRV EcdRi
•'2 ' .
«U 4? Mt
«T ♦ ' P'
3e CTA&STGATCAAGATCTCOC 5' 3* CSGGATATCA£7
5K Primer r? Pr»
Sequence of the plasmid insert which was specific for all isoforms of VEGF-A
ATGAACTTTC TGCTGTCTTG GGTGCATTGG AGCCTTGCCT TGCTGCTCTA
CCTCCACCAT GCCAAGTGGT CCCAGGCTGC ACCCATGGCA GAAGGAGGAG
GGCAGAATCA TCACGAAGTG GTGAAGTTCA TGGATGTCTA TCAGCGCAGC
TACTGCCATC CAATCGAGAC CCTGGTGGAC ATCTTCCAGG AGTACCCTGA
TGAGATCGAG TACATCTTCA AGCCATCCTG TGTGCCCCTG ATGCGATGCG
GGGGCTGCTG CAATGACGAG GGCCTGGAGT GTGTGCCCAC TGAGGAGTCC
AACATCACCA TGCAGATTAT GCGGATCAAA CCTCACCAAG GCCAGCACAT
AGGAGAGATG AGCTTCCTAC AGCACAACAA ATGTGAATGC AGACCAAAGA
AAGATAGAGC AAGACAAGAA AAATGTGACA AGCCGAGGCG GTGAGCCGGG
CAGGAGGAAG GAGCCTCCCT CAGGGTTTCG GGAACCAGAT CTCTCACCAG
GAAAGACTGA TACAGAACGA TCGATACAGA AACCACGCTG CCGCCACCAC
ACCATCACCA TCGACAGAAC AGTCCTTA
The insert was ligated into the plasmid at the Xba l site. The anti-sense riboprobe was
synthesised using Xho l digestion for plasmid linearisation and T7 RNA polymerase.
The sense probe was synthesised using Not l and T3.
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Angl-Probe on reverse strand
TGGTTTTGTC CCGCAGTATA GAACATTCCA T
Designed from sequence according to the PubMed entrez nucleotide Accession No.:
NM_001146






Ang2- FAM labelled probe on reverse strand
TTCTCCAGCACTTGCAGCCTCTGCA
Designed from sequence according to the PubMed entrez nucleotide Accession No.:
NM_001147
Length of amplicon: 77bp
Tie 2
Tie 2- Forward primer
CTTATTTCTGTGAAGGGCGAGTTC
Tie 2- Reverse primer
ATAGTTAAAGTAGCTGGTAGGAAGGAAGCT
Tie 2- FAM labelled probe on reverse strand
TCATGGTTCGTATCCTGATTGCCTCTCCT
Designed from sequence according to the PubMed entrez nucleotide Accession No.:
NM_000459







VEGF- FAM labelled probe on reverse strand
ACTTCGTGATGATTCTGCCCTCCTCCTT
Designed from sequence according to the PubMed entrez nucleotide Accession No.:
E15157
Length of amplicon: 103bp






Fit- FAM labelled probe on reverse strand
CTCTCCTTCCGTCGGCATTTTTTCCAA
Designed from sequence according to the PubMed entrez nucleotide Accession No.:
NM_002019






KDR- FAM labelled probe on forward strand
CTTGGCA TCGCGAAAGT GTATCCACA
Designed from sequence according to the PubMed entrez nucleotide Accession No.:
AF063658
Length of amplicon: 1 lObp
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The effect of the angiogenesis inhibitor TNP-470 on
luteal establishment and function in the primate
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Angiogenesis during luteal development is probably
essential for normal lutein cell function. Since the
angiogenesis inhibitor TNP-470 inhibits pregnancy in
mice, the current study investigated its effects on the
establishment and function of the primate corpus luteum.
Regularly ovulating macaques were treated with TNP-
470 (6 mg/kg), i.v. in three doses, 48 h apart. Serum
progesterone concentrations, as indicators of treatment
effect, were normal in four macaques where treatment
commenced at the onset of the ovulatory progesterone
rise, and in five of eight in which treatment commenced
a few days before ovulation. In the other three the
normal progesterone rise was absent. To investigate the
direct effect on luteal angiogenesis of a daily dose over
a longer period, four marmosets received 18 mg/kg/day
of TNP-470 i.v. for 9 days starting at ovulation. On day
10, luteal cell proliferation was determined by nuclear
bromodeoxyuridine incorporation. Luteal microvasculat-
ure was examined using immunocytochemical factor VIII
staining, and endothelial cell and luteal function assessed
by in-situ hybridization of insulin-like growth factor
binding protein-3 mRNA and plasma progesterone concen¬
trations respectively. None of these parameters were
affected by the TNP-470 treatment The results show
that, with the treatment regimens employed, TNP-470
had no significant effect on the expression of the
differentiated state of the primate corpus luteum.
Key words: endothelial cells/factor VIII/lGFBP-3/monkey/
proliferation
Introduction
The corpus luteum is essential for the establishment of
pregnancy through the production of progesterone from the
lutein cells. Intense angiogenesis occurs during early luteal
development (Rodger et al., 1997) and it is believed that
the angiogenesis is critical for the transport of hormonal
precursors of progesterone to, and progesterone from, the
lutein cells (Redmer and Reynolds, 1996). Recently, the
importance of angiogenesis in the establishment of the rat
corpus luteum has been shown by studies in which the
process has been inhibited by blocking the action of vascular
endothelial growth factor (Ferrara et al., 1998). Further
studies in mice have shown that the angiogenesis inhibitor,
TNP-470, which acts on endothelial cells at a number of
sites in the angiogenic pathway (Abe et al., 1994), inhibits
luteal development and prevents pregnancy by interfering
with the process of decidualization and placental and yolk
sac formation (Klauber et al., 1997). It has been suggested
that the corpus luteum could be a target for fertility
regulation by virtue of its susceptibility to anti-angiogenic
agents (Klauber et al., 1997; Ferrara et al., 1998). The
mechanisms which regulate luteal function in rodents and
primates are markedly different and in the non-fertile cycle
of the rodent the corpus luteum is active for less than a
day, while that of many primates is functional for 2 weeks
prior to its regression (Behrman et al., 1993). The aim of
this study was to investigate the effects of TNP-470 on the
primate corpus luteum. The information gleaned from this
primate model should be useful to the projected clinical use
of this compound.
The study was designed to investigate the effects of TNP-
470 on angiogenesis at the time of transformation of the
pre-ovulatory follicle into the functional corpus luteum. Two
species of non-human primate were employed. First, stump-
tailed macaques were investigated to allow detailed analysis
of the endocrinology in response to TNP-470 treatment. We
chose this species because we have previously established
its clinical relevance with respect to manipulation of the
menstrual cycle in studies using gonadotropin releasing
hormone analogues (Fraser et al., 1997) and on the
physiology of inhibin (Fraser et al., 1999). In addition, we
investigated the effects of TNP-470 in the marmoset monkey
in which we have built up considerable information on the
cellular and molecular control of luteal function (e.g. Young
et al., 1997; Duncan et al., 1998; Fraser et al., 1998). The
establishment and function of the corpus luteum was
determined by measuring circulating progesterone concentra¬
tions in both species. Cellular responses were studied in the
marmoset by determining the number of mitotic cells,
following bromodeoxyuridine (BrdU) administration as a
marker, by examining the establishment of the microvascular
network using factor VIII staining to identify endothelial
cells, and by studying the capacity of the endothelial
cells to express insulin-like growth factor-binding protein-3
(IGFBP-3) messenger ribonucleic acid (mRNA) which we
have shown previously to be a marker for healthy endothelial
cells in the marmoset corpus luteum (Fraser et at., 1998).
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Luteal function after TNP-470
Materials and methods
Animals
Adult female stump-tailed macaques weighing 10-13 kg were captive
bred and housed as described previously (Fraser et al., 1999) in a
unit opened in 1996. Daily vaginal swabs were taken to detect the
pattern of menstrual bleeding and the first day of menstruation was
designated day 1 of the cycle. Blood samples were collected by
femoral venepuncture without anaesthesia. All the animals in the
study had regular ovulatory cycles as determined from menstrual
pattern monitored for 6 months prior to the study and serum
concentrations of oestradiol-17(3 and progesterone in blood samples
obtained three times per week during the cycle prior to treatment.
Common marmoset monkeys were housed in cages in rooms at a
temperature of 22.5°C, exposed to the same lighting conditions as
described above. The animals were fed daily with a selection of fruit,
SDS Mazuri (E) primate diet pellets, and high protein porridge with
multivitamin supplements three times per week. Adult females having
a body weight of approximately 350 g, with regular ovulatory cycles,
were housed together with a younger sister or prepubertal female in
cages measuring 1.15 m in height, 1.1 m in depth and 0.6 m wide.
Each contained larch branches and a nest box with the floor of the
cage filled with wood chippings to allow foraging. Blood samples
were collected three times per week by femoral venepuncture without
anaesthesia to confirm normal ovulatory cycles. Plasma was stored
at -20°C until required for assay. Criteria for the occurrence of
ovulation and normal luteal phase length (18-22 days) were based
on determination of plasma progesterone concentrations as described
previously (Smith et al., 1990).
Treatments
The experiments were carried out in accordance with the Animals
(Scientific Procedures) Act, 1986. TNP-470 (O-chloroacetylcarbamoyl
fumagillol, also known as AGM-1470), has been administered to
patients with Kaposi's sarcoma at doses ranging from 10-70 mg/m2
given by i.v. infusion over a period of 1 h once per week (Dezube
et al., 1998). The current clinical schedule is of 60 mg/m2 TNP-470
administered by i.v. infusion over a period of 1 h three times per
week (Dezube etal., 1998). In an attempt to ensure effective treatment,
it was decided to administer 120 mg/m2 to the primates, calculated
according to a published formula (Du Bois and Du Bois, 1916). On
a dose/kg basis, for a woman weighing 56 kg, the total daily dose
would be 96 mg, i.e. 1.7 mg/kg. For the macaques, a dose of between
60 and 84 mg was used, equivalent to 6 mg/kg. Seven stump-tailed
macaques, with regular ovulatory menstrual cycles, were treated with
TNP-470 dissolved in 5% dextrose at a concentration of 4 mg/ml
immediately before use. On three occasions 2 days apart, starting
around the time of predicted ovulation, the macaques received a
total volume of between 15-21 ml, depending upon body weight,
administered by slow i.v. injection in two separate doses 1 h apart.
A second experiment was undertaken in which five macaques were
given the same treatment, commencing 4 days prior to expected
ovulation, a period covering final pre ovulatory development.
Since the final results in macaques indicated an absence of effect
of treatment on luteal function, it was decided to investigate the
susceptibility of the primate corpus luteum to an increased (daily)
dose of TNP-470 over a longer time period (10 days) and, to
investigate the possibility that angiogenesis could be inhibited in the
absence of an effect on progesterone secretion, a further experiment
was undertaken using the marmoset. To synchronize timing of
ovulation during the treatment cycle, eight animals were treated with
1 pg prostaglandin F2a analogue (Planate®; Coopers Animal Health
Ltd, Crewe, Cheshire, UK) i.m., during the mid- to late luteal phase
of the pre-treatment cycle to induce luteolysis. This treatment is
normally followed by ovulation 10-12 days later (Summers et al.,
1985). Four marmosets were treated with TNP-470 starting 11 days
post-prostaglandin, the day of anticipated ovulation, at a dose of 18
mg/kg/day (equivalent to 120 mg/m2), by slow i.v. injection. This
treatment was repeated for a further 9 days: the remaining four
controls were treated with vehicle following the same schedule.
On day 10 after commencement of TNP-470, each marmoset
received by slow i.v. infusion, 20 mg BrdU (Boehringer Mannheim,
Essex, UK) in saline. One hour later, the animals were sedated using
100 pi ketamine hydrochloride (Parke-Davis Veterinary, Pontypool,
Gwent, UK) i.m. and euthanased with an i.v. injection of 400 pi
sodium pentobarbitone (Euthetal®; Rhone Merieux, Ireland). Ovaries
were removed rapidly, weighed, and fixed immediately in 4% parafor¬
maldehyde for 24 h. After fixation, the corpora lutea of the cycle
were identified macroscopically, the ovaries were bisected as closely
as possible through the centre of the corpora lutea, and the tissues
dehydrated and embedded in paraffin.
Hormone assays
Circulating progesterone and oestradiol concentrations were measured
as described previously for the stump-tailed macaque (Fraser and
Sandow, 1985; Fraser etal., 1997) and marmoset (Smith etal., 1990).
Immunocytochemistry
Tissue sections (5 pm) were cut onto Tespa-coated (Sigma, Poole,
Dorset, UK) slides for immunocytochemistry and morphological
examination. Sections were stained with haematoxylin and eosin
and examined for morphological features of apoptosis as described
previously (Young et al., 1997). Localization of factor VIII as a
marker for endothelial cells was determined by immunocytochemistry
as described for the human corpus luteum (Rodger et al., 1997)
except that visualization was with nitro blue tetrazolium (NBT) in
buffer (100 mol/1 Tris pH 9.5, 100 mol/1 NaCl and 50 mol/1 MgCl2).
These sections were not counterstained, so that quantitative image
analysis could be performed, the corpora lutea being identified from
the haematoxylin and eosin-stained sections. Factor VIII immuno-
staining was quantified using the Image Pro-Plus 3.0® (Media
Cybernetics, Silver Spring, MD, USA) image analysis program.
Sections were examined at X400 magnification. The image was
converted to grey scale and the area of dark objects on a white
background was counted at a threshold of 70. For each corpus luteum,
six randomly chosen areas, each of 27 860 pm2, were analysed and
their mean taken as being representative for that animal. Differences
between groups were determined using a two tailed unpaired /-test,
P < 0.05 being taken as the level of significance.
Proliferating cells were visualized in ovarian sections using a mouse
monoclonal antibody to BrdU (Boehringer Mannheim). Sections were
dewaxed in histoclear and rehydrated in decreasing concentrations of
industrial methylated spirits. Antigen retrieval was accomplished by
microwaving sections for 4X5 min in 0.01 M citrate buffer. Using
Sequenza racks (Life Sciences International, Hampshire, UK), sections
were treated for 30 min with normal rabbit serum block (NRS; Dako,
High Wycombe, Bucks, UK), then incubated in mouse monoclonal
anti-BrdU (3 pg/ml in TBS) at 4°C, overnight. Control sections were
treated with mouse IgG (Vector Laboratories, Peterborough, UK)
(3 pg/ml in TBS) in place of primary antibody. Secondary antibody,
rabbit anti-mouse (26 pg/ml in blocking serum), was applied for 30
min at room temperature. BrdU binding was visualized using mouse
APAAP (1 pg/ml in blocking serum) incubation for 30 min, and the
NBT detection system (Boehringer Mannheim). Sections were briefly
counterstained with haematoxylin and mounted for analysis. Cell
proliferation was assessed by counting the number of BrdU positive
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Figure 1. Serum progesterone concentrations in macaques treated with TNP-470 (vertical arrows, 6 mg/kg body weight) starting (a) during
the follicular phase of the menstrual cycle in which luteal function was not detected (n = 3), (b) during the follicular phase of the menstrual
cycle in which luteal function appeared normal (n = 5) and (c) during the ovulatory period/early luteal phase of the menstrual cycle in
which luteal function appeared normal (n = 4). The shaded area represents the mean ± SD for 18 control cycles (taken from Fraser et al.,
1997).
Day relative to start of treatment
0
Day relative to start of treatment
■8
Day relative to ovulation
TNP 470 (18 mg/kg)
Figure 2. Plasma progesterone concentrations in control marmosets
and in those treated daily with TNP-470 (arrows) starting on the
day of expected ovulation (n = 4 per group). Values are means ±
SEM.
cells in six randomly chosen fields per corpus luteum and expressed
as a mean percentage of the total cells in these fields. Differences
between groups were determined using a two tailed unpaired /-test,
P < 0.05 being taken as the level of significance.
In-situ hybridization
Paraffin sections (5 pm) were mounted onto poly-L-lysine coated
glass slides for IGFBP-3 mRNA localization undertaken by in-situ
hybridization as described previously (Fraser et al., 1998). In addition
to the ovaries from control and treated animals, ovaries from follicular
phase marmosets known to contain spontaneously regressing corpora
lutea were included in the same run. Following hybridization with
antisense (two slides per ovary) and sense probes, and washing, dry
slides were dipped in Kodak NTB-2® liquid emulsion (Eastman
Kodak, Rochester, NY, USA) and exposed for 3.5 weeks at 4°C in
light-tight slide boxes. Slides were developed with D-19 developer
(Eastman Kodak) for 3.5 min at 4°C, fixed, and the sense and one
antisense stained with haematoxylin (Richard-Allan, Richland, MI,
USA), while the remaining antisense slide was stained with both
haematoxylin and eosin to allow a more reliable identification of cell
type. Identified endothelial cells that were not associated with a
Figure 3. Factor VIII localization in the corpus luteum of (a) a
control and (b) a TNP-470 treated marmoset. In both examples
staining of endothelial cells forming the microvessels and a
proportion of endothelial cells forming capillaries can be observed
(bar = 200 pm).
perceptible vascular lumen were classified as capillary endothelial
cells: when a lumen was evident, they were classified as microvessels
and included venules and arterioles. The localization of expression
to microvessels, capillaries and lutein cells of the corpora lutea was
scored as follows: no expression above tissue background -, low
expression +, moderate expression + + , high expression + + + .
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Figure 4. Quantification of factor VIII immunostaining in control
and TNP-470 treated marmoset corpora lutea. Data are means ±
SEM.
Results
In the first experiment, retrospective analysis indicated that
TNP-470 treatment had begun at, or immediately after, ovula¬
tion in four of the seven macaques and no effects on serum
progesterone were recorded. In these animals, the treatment
had commenced when serum oestradiol concentrations had
reached pre-ovulatory values (>400 pmol/1) or shortly after¬
wards. In the other three macaques treatment had commenced
prior to ovulation when oestradiol concentrations were <400
pmol/1. In one of these animals, ovulation occurred at the
expected time (as demonstrated by normal luteal phase proges¬
terone concentrations), while in the other two animals such a
progesterone rise did not occur. This suggested an absence of
effect of TNP-470 on luteal function, but indicated that follicle
development may be susceptible to such treatment. To study
this possibility, a second experiment was performed in which
treatment was initiated during the mid-follicular phase: how¬
ever, ovulation occurred in four of the five macaques as
determined by serum oestradiol and progesterone levels. For
the purpose of analysis, the results from both experiments
were combined according to whether treatment had begun
during the follicular phase and was associated with absence
of ovulation (Figure la, n = 3), normal serum progesterone
(Figure lb, n = 5), or had commenced at the time of ovulation
(Figure lc, n = 4).
In the marmoset, plasma progesterone concentrations (Figure
2) and numbers of corpora lutea were similar in control and
treated animals. The presence of corpora lutea was evident in
both control and treated animals by gross observation. Study
of ovarian sections revealed the presence of similar numbers
of recently formed corpora lutea (control: 2,2,3,3; treated:
2,2,3,4). The development of the microvasculature of the
corpus luteum was confirmed in the control marmosets by an
extensive network of microvessel and capillary staining for
factor VIII and this was also evident in the TNP-470 treated
animals (Figure 3). Quantification of factor VIII immuno¬
staining showed no significant difference associated with
treatment (Figure 4).
BrdU staining indicating proliferating cells was readily
observed in all corpora lutea. In the marmoset differences
between theca and granuolosa derived lutein cells were not
readily apparent (Webley et al., 1990), both types of hormone
producing cells having a large spherical or polyhedral nucleus
and abundant cytoplasm (Figure 5a). Although dual staining
Figure 5. Bromodeoxyuridine (BrdU) incorporation (dark staining
nuclei) into endothelial cells of microvessels and capillaries of
corpora lutea from control and TNP-470 treated marmosets.
(a) High power photomicrograph showing the large hormone
producing cells with abundant cytoplasm, round nucleus and
absence of BrdU staining. Note the microvessel located centrally
composed of endothelial cells with little cytoplasm and elongate
nuclei. Note the presence of dark BrdU proliferating cells
associated with the blood vessel and in endothelial cells of
capillaries distributed between the hormone producing cells (bar =
25 gm). (b, c) Low power micrographs showing the general
distribution of BrdU staining in (a) a control, and (c) a TNP-470
treated marmoset (bar = 100 gm).
experiments were not performed, it was clear that none of the
hormone-producing cells had incorporated BrdU. Incorporation
was restricted to some cells surrounding the luminal micro-
vessels and in those whose appearance was consistent with
capillary endothelial cells. BrdU staining in these cells was
evident in all corpora lutea from control and treated marmosets
(Figure 5). Proliferation index showed there was no significant
difference between the groups (Figure 6). Examination of





Figure 6. The proliferation index in corpora lutea from control and
TNP-470 treated marmoset corpora lutea. Data are means ± SEM.
with expertise in identification of apoptotic cells as described
previously (Young et al., 1997) revealed a virtual absence of
apoptosis in both groups.
In mid-luteal control ovaries, IGFBP-3 mRNA was strongly
expressed in the endothelial cells lining microvessels and in a
small number of capillaries within the corpora lutea (Figure
7). In the TNP-470 treated animals, a similar pattern of
IGFBP-3 mRNA expression was observed in all corpora lutea.
As expected, the regressing corpora lutea in normal follicular
phase ovaries exhibited only a low level of expression in a
few microvessels (not shown). Hybridization with the IGFBP-3
cRNA sense probe showed no signal above background,
underlining the specificity of hybridization using the mRNA
antisense probe (not shown).
Discussion
The results show that short-term treatment with TNP-470 had
little or no detectable effect on the development and function
of the primate corpus luteum of either the stump-tailed macaque
or the marmoset monkey. When TNP-470 was administered
at the time of expected ovulation, the function of the corpus
luteum and duration of the luteal phase, as assessed by
circulating progesterone concentrations, was normal. From the
oestradiol data in the first experiment in macaques, there was
an indication that initiation of treatment at a time when
follicular development was less advanced than expected led
to suppression of ovulation, but when this was investigated in
a second experiment in which treatment was initiated during
the late follicular phase, four out of five animals had normal
progesterone profiles. Thus, of the 12 cycles studied with
TNP-470, nine resulted in normal luteal function while the
expected rise in progesterone failed to occur in three animals.
Perhaps the simplest explanation of this result is that these
three animals were destined to have anovular cycles irrespective
of treatment. Alternatively, it is possible that TNP-470 had a
marginal effect upon angiogenesis and/or follicular develop¬
ment at this dose. With respect to the former, one could
speculate that angiogenesis was being inhibited to some degree,
but that luteal function was not uniformly affected.
With respect to timing and duration of treatment, the
experiment was designed to target the intense angiogenesis
which occurs in the corpus luteum during the early stages of
development (Christenson and Stouffer, 1996; Rodger et al.,
1997). Accordingly, treatment was started at the time of
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Figure 7. Insulin-like growth factor binding protein (IGFBP)-3
mRNA expression in the corpus luteum from (a) control, (b) and
(c) TNP-470-treated animals. Each depicts expression in the
microvessels while isolated grain clusters indicate expression in
capillary endothelial cells. Note the absence of detectable
differences in the level and pattern of IGFBP-3 mRNA expression
after treatment (bar = 100 |xm).
predicted ovulation and covered the period of the early luteal
phase in the macaque and was extended to the mid-luteal
phase in the marmoset. The studies in the marmoset allowed
the investigation of the effects of a more frequent and prolonged
dose schedule of TNP-470 and the examination of its potential
consequences on cell proliferation and the luteal vasculature.
Progesterone secretion was not impaired and the number of
corpora lutea formed was normal. Furthermore, staining for
factor VIII illustrated the establishment of the luteal vascular
tree despite treatment with the putative angiogenesis inhibitor.
As expected, BrdU incorporation demonstrated a high level of
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proliferation of endothelial cells during the mid-luteal phase
and this too was unaffected by treatment with TNP-470.
Finally, expression of IGFBP-3 mRNA, which we have previ¬
ously shown to be a marker for endothelial cells in the
functioning corpus luteum of the marmoset and human (Fraser
et al., 1998), was also unchanged. Collectively, these results
suggest that TNP-470 does not have negative effects on the
structure and function of the normal corpus luteum of the
marmoset, in contrast to the findings in the mouse (Klauber
et al., 1997). At this early stage of experiments to inhibit
angiogenesis in the primate corpus luteum, we are forced to
conclude that the differences between the present results and
those in the mouse may reflect inter-species variance, and/
or differential susceptibility to the anti-angiogenic effect of
TNP-470.
The latter possibility could arise from the dose of TNP-470
employed in the present study being insufficient to prevent
luteal angiogenesis, or the route of administration being
suboptimal. The clinical dose of TNP-470 is 60 mg/m2
administered by 1 h i.v. infusion three times per week (Dezube
et al., 1998). The dose chosen for the macaques was twice
that with respect to surface area and 3.5 times that of the
human dose when expressed on a drug weight to body weight
ratio. Also, a dose of 6 mg/kg by I h infusion in macaques
was anti-angiogenic with respect to suppression of ocular
angiogenesis (J. Folkman and M. O'Reilly, personal commun¬
ication). The stump-tailed macaques used in the present study
were treated using two i.v. injections 1 h apart, rather than by
infusion over 1 h, because this enabled the treatment to be
administered without surgical intervention or sedation. Studies
in the mouse employed the s.c. route at a dose of 30 mg/kg
every second day. The marmosets in the present study were
treated with 18 mg/kg daily, so approaching the murine dose.
It should be noted that TNP-470 is metabolized very rapidly
and that its pharmacodynamic properties are incompletely
understood (Cretton-Scott et al., 1996). Thus, differences in
the pattern of exposure to the drug may result from the
different routes of administration. However, at present, a
preparation of TNP-470 that can be administered by the s.c.
route to larger animals and humans is not available.
This is the first report of an attempt to block angiogenesis
in the primate corpus luteum. Although inhibitory effects were
not observed, we believe that the approach used to study
angiogenesis in the marmoset will be of value to future
experiments on the effects of angiogenesis inhibitors on luteal
function in the primate. BrdU incorporation proved an accurate
method of identifying proliferating cells in the corpus luteum.
This technique has been used previously to quantify luteal
proliferation in the sheep (Jablonka-Shariff et al., 1993) and
rat (Gaytan et al., 1996) but, to our knowledge, this is the first
report of its use with respect to the primate ovary. The high
level of proliferation during the mid-luteal phase in the
marmoset agrees with results using the proliferation marker
Ki67 in the rhesus monkey and human (Christenson and
Stouffer, 1996; Rodger et al., 1997). The localization of
IGFBP-3 mRNA in the marmoset ovary confirms and extends
our recent observation that production of this mRNA is
associated with the functioning corpus luteum in the primate
(Fraser el al., 1998), and contrasts with the situation in the
rodent where its expression is temporally associated with
luteolysis (Erickson et al., 1993). This binding protein is likely
to be of importance in the modulation of IGF activity within
the corpus luteum. The observation that the expression of the
IGFBP-3 mRNA is associated with the endothelial cells of the
functioning corpus luteum only, also indicates a role yet to be
defined in endothelial cell proliferation and survival.
The potential of using angiogenesis inhibitors as anti-fertility
agents is currently generating considerable interest (Klauber
et al., 1997; Ferrara et al., 1998). Furthermore, while they are
being developed primarily for treatment of vascular solid
tumours, they are also likely to find a role in control of
rheumatoid arthritis, retinal neovascularization and psoriasis
(Folkman, 1995). It is essential, therefore, that their potential
effects upon the reproductive system and its function in such
patients be determined. However, the current results show that
with the treatment regimens employed, TNP-470 has no
significant effect on the expression of the differentiated state
of the primate corpus luteum.
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ABSTRACT
Manipulation ofangiogenesismay have a profound effect on female
reproductive function, but this has not yet been demonstrated by
direct experiment in species with ovulatory cycles similar to those in
women. To investigate whether angiogenesis could be inhibited in the
primate corpus luteum, and the consequences of such inhibition on
luteal function, marmosets were treated with an antibody to vascular
endothelial growth factor (VEGF). Treatment commenced at the time
of ovulation and was continued for 3 days (early luteal group) or 10
days (midluteal group). Bromodeoxyuridine was used to label prolif¬
erating cells, being administered 1 h before collecting ovaries from
control and treated animals in the early or midluteal phase. Ovarian
sections were stained using an antibody to bromodeoxyuridine, and
a proliferation index was obtained; endothelial cell quantification was
performed using factor VIII as an endothelial cell marker. Intense
proliferation in the early luteal phase was suppressed by anti-VEGF
treatment. This resulted in blockade of development of the normally
extensive capillary bed, as in the animals treated until the mid-luteal
phase the numbers of endothelial cells were reduced. The hormone-
producing cells remained largely unaltered in the posttreatment cor¬
pus luteum, although the presence of lipid accumulation, and small
pockets of cells showing basophilia and nuclear condensation were
observed. Significantly, luteal function, as judged by secretion of
progesterone, was markedly compromised by the treatment, being
reduced by 60% in comparison with controls. It is concluded that
VEGF-mediated angiogenesis is an essential component of luteal
function in primates and therefore has the potential to be regulated.
(Endocrinology 141: 995—1000, 2000)
IT IS ESTABLISHED that inhibition of angiogenesis bybroad spectrum or systematic targeting (1-4) of the an¬
giogenic pathway can have suppressive effects on tumor
growth. However, comparatively little is known about the
effect of inhibition of the highly active physiological angio¬
genesis that occurs in the reproductive tissues: the ovary,
uterus, and placenta. The corpus luteum is essential for the
establishment of pregnancy through the production of pro¬
gesterone from lutein cells. Active angiogenesis occurs dur¬
ing early luteal development. It is believed that this angio¬
genesis is critical for establishment of the vasculature
essential for transport of hormonal precursors of progester¬
one to and progesterone from the lutein cells (5). The role of
angiogenesis in the rodent ovary has been addressed (6, 7),
but the mechanisms that regulate luteal function in rodents
and primates are markedly different (8). Our finding of the
failure of TNP-470 to affect luteal function in Old World or
New World primates (9) emphasizes the need for caution in
extrapolating results from the rodent, in which this angio¬
genesis inhibitor prevented pregnancy (7). Thus, an effect of
inhibition of angiogenesis on female reproductive function
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has not yet been demonstrated by direct experiment in spe¬
cies with ovulatory cycles similar to those in women.
The aim of this study was to investigate the effects of
immunoneutralization of vascular endothelial growth factor
(VEGF) on the marmoset corpus luteum of the normal cycle
as a means of exploring the role of angiogenesis in luteal
function of the primate. VEGF has been shown to be ex¬
pressed in the corpus luteum of the human and nonhuman




Mouse monoclonal anti-VEGF, VG76e, was raised by immunization
with recombinant human VEGF-189. The pET146 expression plasmid
was used to enable affinity purification of Escherichia coli-expressed
recombinant protein. The antibody was produced from hybridomas
grown in culture, and a highly purified preparation was obtained using
protein A-Sepharose columns. Hybridomas were screened by Western
blotting of VEGF-189. Using recombinant proteins, it was demonstrated
that VG76e recognizes the 121, 165, and 189 isoforms of VEGF.
VG76e was shown to be a blocking antibody by its inhibition of the
growth stimulatory activity of VEGF on human umbilical vein endo¬
thelial cells (HUVEC), a gift from Prof. B. R. Binder, Vienna University
(Vienna, Austria). The cells were cultured inmedium 199 (Sigma, Poole,
UK) with 20% heat-inactivated FBS (Sigma), 100 IU/ml penicillin/100
/xg/ml streptomycin (Life Technologies, Inc., Paisley, UK), 250 ng/mL
fungizone (Life Technologies, Inc.), 2 mM glutamine (Life Technologies,
Inc.), 5 IU/ml heparin (Sigma), and 50 p.g/ml endothelial cell growth
supplement (ECGS) (Technoclone, Inc., Vienna, Austria). HUVEC (3 X
10 ) at passage 5 were plated in complete medium in 96-well plates and
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allowed to attach overnight. Growthwas arrested by incubationwith 100
p.1 reduced growth medium (medium 199 containing the supplements
described above without HCGS and 2% FBS) for 24 h. Human VEGF (10
ng/ml; R&D Systems, Abingdon, UK) was added to wells with various
concentrations of the anti-VEGF antibody (VG76e), a positive control
anti-VEGF blocking antibody 2C3 (a gift from Prof. P. Thorpe, ME
Medical Center, Portland, ME), or a negative control (mouse IgG, Sig¬
ma). Control wells received medium with orwithout VEGF. After 3 days
of incubation, cell number was quantified colorometrically by the ad¬
dition of 20 pi Cell Titer 96 Aqueous One Solution Cell Proliferation
Assay (Promega Corp., Southampton, UK) at 492 and 620 nm reference
filter. Background absorbance was determined with substrate alone and
subtracted from all wells. Cell growth was calculated by subtracting
absorbance in wells with cells grown without VEGF.
Animals
Commonmarmosetmonkeys (Callithrix jacchus) were housed in cages
in rooms at a temperature of 22.5 C as described previously (9). Adult
females with a body weight of approximately 350 g, with regular ovu¬
latory cycles, were housed together with a younger sister or prepubertal
female. Blood samples were collected three times per week by femoral
venipuncture without anesthesia, and plasma was stored at -20 C until
required for progesterone assay to confirm normal ovulatory cycles.
Criteria for the occurrence of ovulation and normal luteal phase length
(18-22 days) were based on determination of plasma progesterone con¬
centrations as described previously (13).
Treatment
The experiments were carried out in accordance with the Animals
(Scientific Procedures) Act, 1986. To synchronize timing of ovulation
during the treatment cycle, animals were treated with 1 p.g PGF2a analog
(Planate, Coopers Animal Health Ltd., Crewe, UK), im, during the mid-
to late luteal phase of the pretreatment cycle to induce luteolysis. This
treatment is normally followed by ovulation 10 days later (14). Four
marmosets were treated with VEGF antibody at a concentration of 2.7
mg/ml starting 10 days after PG, i.e. the day of anticipated ovulation
(luteal phase day 0), at a dose of 2 mg followed by 1 mg on days 1 and
2 (early luteal group). Four controls were treated with the same dose of
mouse y-globulin (Sigma) following the same schedule.
Treatment was extended to the midluteal phase in an additional six
marmosets; additional injections of 1 mg anti-VEGF were administered
on days 3, 5, 7, and 9, with six animals receiving mouse "/-globulin as
controls (midluteal group). All treatments were given by slow iv
injection.
Ovaries were obtained the day after final treatment, luteal day 3 or
10, after the animals had received 20 mg bromodeoxyuridine (BrdU:
Roche Molecular Biochemicals, Essex, UK) in saline by slow iv injection.
One hour later, the animals were sedated using 100 pi ketamine hy¬
drochloride (Parke-Davis Veterinary, Pontypool, UK), im, and killed
with an iv injection of 400 pi Euthetal (sodium pentobarbitone, Rhone
Merieux, Harlow, Essex, UK). Ovaries were removed immediately,
weighed, fixed in 4% paraformaldehyde for 24 h, dehydrated, and em¬
bedded in paraffin. In addition, a small portion of a representative
corpus luteum was placed in 3% glutaraldehyde in 0.1 m cacodylate
buffer, pH 7.3. These specimens were fixed for 2 h, rinsed in the same
buffer, postfixed in buffered 2% osmium tetroxide for 2 h, and embedded
in Araldite after dehydration in ethyl alcohol. Semithin (1 /urn) sections
were stained with toluidine blue for light microscope analysis. When the
midluteal group was examined, it was apparent that the density of the
lutein cells was increased after treatment. To quantify this change, par¬
affin sections were stained with hematoxylin and eosin, and lutein cell
density was determined in 12 corpora lutea/group.
The establishment and function of the corpus luteum were determined
by measuring plasma progesterone concentrations in daily blood plasma
samples as described previously (13). Only marmosets in which treatment
was started at the time of presumptive ovulation (13) (plasma progesterone
having reached >30 nmol/liter and found retrospectively to be sustained
at luteal phase values) were included in the study. Analysis of differences
in plasma progesterone concentrations was performed by repeated mea¬
sures ANOVA followed by post-hoc Fisher's protected least significant dif¬
ference test (when a significant interaction was found).
Immunocytochemistry
Cellular responses were studied by determining the number of mi¬
totic cells, after BrdU administration as a marker, and by examining the
establishment of the microvascular network using factor VIII staining to
identify endothelial cells. Tissue sections (5 pm) were cut onto Tespa-
coated (Sigma) slides for immunocytochemistry and morphological ex¬
amination. Sections were stained with hematoxylin and eosin and ex¬
amined for morphological features of apoptosis as described previously
(15). Localization of factor VIII was determined by immunocytochem¬
istry as described previously (16); visualization was performed with
nitro blue tetrazolium. These sections were not counterstained, so that
quantitative image analysis could be performed; the corpora lutea were
identified from the hematoxylin- and eosin-stained sections. Immuno-
staining for factor VIII to compare control and treated animals was
carried out in separate runs for the early and midluteal groups. Factor
VIII immunostaining was quantified using the Image Pro-Plus 3.0 (Me¬
dia Cybernetics, Silver Spring, MD) image analysis program. Four to six
randomly chosen areas of 13.3 X 104 pm2 for the early luteal sections,
and 5.3 X 104 pm2 for the largermidluteal sections were studied; in total,
these areas covered approximately two thirds of each corpus luteum.
The captured gray scale image was thresholded and converted to a
binary image, and the factor VHI-positive area was quantified. The mean
of these areas per corpus luteum was taken as representative for that
animal.
Proliferating cells were visualized in ovarian sections using a mouse
monoclonal antibody to BrdU (Roche Molecular Biochemicals) as de¬
scribed previously (9). Cell proliferation was assessed by counting the
number of BrdU-positive cells in six randomly chosen fields of 62,500
pm2/corpus luteum and expressed as a mean percentage of the total
cells in these fields. For factor VIII quantification, proliferation index,
ovarian weight, and luteal cell numbers, differences between groups
were determined using a two-tailed unpaired t test; P < 0.05 was taken
as the level of significance.
Results
Neutralizing antibody
The endothelial cell growth assay demonstrated that the
monoclonal antibody to human VEGF (VG76e) inhibited
Antibody (pg/ml)
Fig. 1. Effect ofVEGF antibody, VG76e, on VEGF-mediated HUVEC
growth. Results are given as a percentage of the control value, where
cells were grown in the presence of VEGF alone. Results show the
mean ± sd of three independent experiments for VG76e and two
experiments for positive control VEGF antibody, 2C3, and control
IgG. Both VEGF antibodies exhibited a marked inhibitory effect on
VEGF-stimulated proliferation ofHUVECs. A negative control anti¬
body of irrelevant specificity had no effect on endothelial cell growth.
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Fig. 2. Low power photomicrographs of early luteal phase marmoset corpora lutea showing the general distribution of BrdU incorporation
(dark-staining nuclei) into endothelial cells ofmicrovessels and capillaries in controls, showing high incorporation (a) and reduced incorporation
(b) after anti-VEGF treatment, c, The proliferation index in corpora lutea from early luteal phase control (open bar) and anti-VEGF-treated
(closed bar) marmoset corpora lutea. Values from treated animals were significantly lower CP < 0.01) than those in controls, d and e, Factor
VIII localization (dark staining) in the endothelial cells of microvessels and capillaries of corpora lutea from control and anti-VEGF-treated
marmosets, respectively. Scale bar, 100 pm. f, Quantification of factor VIII immunostaining in control (open bar) and anti-VEGF-treated (closed
bar) marmoset corpora lutea. There was no significant difference between the groups. Data are the mean ± sem.
VEGF-stimulated HUVEC growth in a dose-dependent man¬
ner (Fig. 1). These results indicate that VG76e is a blocking
antibody that inhibits the growth stimulatory activity of
VEGF.
Cell proliferation and endothelial cell area
Treatment with anti-VEGF during the early luteal phase
did not prevent the formation of clearly identifiable corpora
lutea, and ovarian sections revealed the presence of recently
formed corpora lutea in all control and treated marmosets.
BrdU staining of proliferating cells was readily observed in
all corpora lutea (Fig. 2a). It was clear that few (if any) of the
hormone-producing cells had incorporated BrdU; positive
staining was restricted to some cells surrounding the luminal
microvessels and others whose appearance was consistent
with that of capillary endothelial cells. We have shown pre¬
viously that cells incorporating BrdU have the location and
morphological appearance of endothelial cells (9). In addi¬
tion, colocalization studies have demonstrated that more
than 80% proliferating cells stain with endothelial cell mark¬
ers (17). Proliferation was high within the corpora lutea from
controlmarmosets and wasmarkedly reduced by anti-VEGF
treatment (Fig. 2b), as confirmed by the decreased prolifer¬
ation index (Fig. 2c). Factor VIII immunostaining demon¬
strated the initiation of the development of the microvascu-
lature in control corpora lutea (Fig. 2d), but although there
was an indication of reduced capillary number associated
with anti-VEGF treatment (Fig. 2e), quantification of factor
VIII immunostaining showed no significant difference at this
time (Fig. 2f).
In the midluteal phase group, treatment with anti-VEGF
from day of ovulation again did not prevent formation of the
fresh corpora lutea. In corpora lutea from control animals, the
numbers of proliferating cells had declined, as expected by
this stage of the luteal phase (Fig. 3a). Some proliferation was
also evident in all the corpora lutea from the anti-VEGF-
treated marmosets (Fig. 3b), and the proliferation index
showed no significant treatment differences (Fig. 3c). How¬
ever, whereas in control corpora lutea staining for factor VIII
revealed that a fully developed microvasculature had been
established (Fig. 3d), treatment with anti-VEGF resulted in
corpora lutea with a much lower degree of vascularization
and the absence of an extensive capillary bed, similar to that
observed in the early luteal phase (Fig. 3e). Quantification of
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Fig. 3. Low power photomicrographs of midluteal phase marmoset corpora lutea showing the general distribution of BrdU incorporation
(dark-staining nuclei) into endothelial cells of microvessels and capillaries in controls (a) and similar incorporation after anti-VEGF treatment
(b). c, The proliferation index in corpora lutea from midluteal phase control (open bar) and anti-VEGF-treated (closed bar) marmoset corpora
lutea. There was no significant difference between the groups, d, Factor VIII localization (dark staining) in the endothelial cells ofmicrovessels
and capillaries of corpora lutea in a control corpus luteum. e, Reduced staining, especially for incidence of capillary endothelial cells, after
anti-VEGF treatment. Scale bar, 100 p.m. f, Quantification of factor VIII immunostaining in control (open bar) and anti-VEGF-treated (closed
bar) marmoset corpora lutea. Data are the mean ± sem. Values from treated animals were significantly lower (P < 0.001) than those in controls.
factorVIII immunostaining showed a marked suppression of
endothelial cell area associated with treatment (Fig. 3f).
Morphology
The weights of the ovaries of the early and midluteal
control animals were similar, as were those of both treated
groups. However, comparison of the combined weights of
the controls (215 ±11 mg) with those of the treated animals
(158 ± 14 mg) revealed a significant reduction (P < 0.005)
after anti-VEGF. Examination of sections stained with he¬
matoxylin and eosin by two observerswith expertise in iden¬
tification of apoptotic cells, as described previously (15),
revealed a virtual absence of apoptosis in both groups. Semi-
thin sections stained with toluidine blue showed that the
most prominent features in the control corpora lutea col¬
lected during the midluteal phase were the large polyhedral
lutein cells, characterized by circular nuclei in cross-section
with a nucleolus and large cytoplasmic volume (Fig. 4).
Within the cytoplasm were mitochondria and lysosomes to¬
gether with occasional, less basophilic inclusions typical of
lipid droplets. In some tissue sections a few lutein cells
showed varying degrees of basophilia, although it was not
possible to determine whether cytoplasmic density was cor¬
related with distinct differences in organelle or inclusion
content. The lutein cellswere supported by connective tissue,
including fibroblasts, and there was an extensive blood sup¬
ply characterized by the occurrence of endothelial cell nuclei
and numerous lumina, often containing erythrocytes. In the
corpora lutea from the midluteal anti-VEGF-treated marmo¬
sets, lutein cells appeared more densely packed (Fig. 4b),
with a closer contact with neighboring lutein cells. Quanti¬
fication of lutein cell number showed that numbers of lutein
cells per area were significantly greater (P < 0.001) in the
treated group (103.8± 5.5, for controls vs. 79.2 ± 3 after
anti-VEGF). In addition, numerous clusters of basophilic
cells, presumably lutein, were present principally in the cen¬
tral area of the corpus luteum. Highermagnification revealed
that although the majority of the lutein cells had retained
their integrity, they exhibited an increased occurrence of
lipid droplets in the peripheral zone of the cytoplasm iden¬
tified by their gray coloration and homogeneous appearance
(Fig. 4d).
Progesterone
Plasma progesterone concentrations were reduced (P <
0.001) by anti-VEGF treatment to approximately 40% of the
normal values in both the early luteal (data not shown) and
midluteal treatments (Fig. 5).
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Fig. 4. Photomicrographs of toluidine blue-stained corpora lutea to show the appearance of hormone-producing lutein cells in the midluteal
corpus luteum of control (a) and anti-VEGF-treated (b) marmosets. Note how the lutein cells of the treated animal are more closely packed,
and the cluster ofdensely stained cells (arrows) presumably of luteal origin. Scale bars, 50 pm. Higher magnification ofa control corpus luteum
(c) shows the appearance of the lutein cell nucleus (N) and cytoplasm (C), with each cell being in contact with an endothelial cell (E). In the
anti-VEGF corpus luteum (d) the lutein cells have maintained their integrity, but contain numerous lipid droplets (gray staining, arrowhead)
in the peripheral zone. Scale bars, 20 pm.
the midluteal phase, agrees with studies using the prolifer¬
ationmarker Ki67 in the rhesusmonkey (18) and human (16).
We have shown that it is this intense angiogenesis in the early
luteal phase that is susceptible to VEGF inhibition, as evi¬
denced by the marked decrease in BrdU incorporation in the
marmosets treated with antibody during the early luteal
phase. An effect on endothelial cell area was not initially
apparent after this short term treatment, but by themidluteal
phase, this parameter was markedly inhibited in anti-VEGF-
treated corpora lutea as a consequence of the inhibition of
endothelial cell proliferation during the intense period of
angiogenesis. Although larger blood vessels were estab¬
lished by the midluteal phase in treated animals, there was
a marked overall reduction in the number of endothelial
cells, suggesting the establishment of early luteal vasculature
(possibly from preexisting vessels) and its survival through
themidluteal phase, but indicating blockade of development
of the normally extensive capillary bed. The absence of an
effect on cell proliferation in the midluteal animals treated
with anti-VEGF was surprising. However, by this stage, pro¬
liferation in controls has been much reduced over that seen
during the early luteal phase, and this midluteal proliferation
suggests that the rate is maintained either by low levels of
VEGF that remain as a result of incomplete neutralization or
has resulted from the action of other angiogenic factors in the
corpus luteum.
The absence of marked morphological change in the lutein
cells after treatment contrasts with observations on the char¬
acteristic effects of withdrawal of the tropic factor, LH,which
Anti-VEGF
Day relative to start of treatment
Fig. 5. Plasma progesterone concentrations in control (O) and anti-
VEGF-treated marmosets (•). Treatment started on the day of ex¬
pected ovulation and is associated with a significant suppression (P <
0.001). Values are the mean ± sem (n = 6/group).
Discussion
This is the first report of the successful inhibition of an¬
giogenesis in the primate corpus luteum. To our knowledge,
this is the first time physiological angiogenesis has been
successfully targeted in a primate species. The high level of
endothelial cell proliferation during the early luteal phase in
the marmoset, with decreased levels of proliferation during
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we have described recently (17, 19). Such treatment also
results in inhibition of early luteal angiogenesis, but this is
secondary to the destruction of the lutein cells, in which it is
assumed most of the principal angiogenic factors are pro¬
duced (10-12,17). The observed changes in the structure of
the corpus luteum after neutralization of VEGF are likely to
result from the specific inhibition of angiogenesis. The in¬
creased density of the lutein cells results primarily from the
dearth of capillaries, whereas the occurrence of aggregates of
subsets of lutein cells with more densely stained nuclei and
cytoplasm, found principally in the central area of the corpus
luteum, suggests a premature onset of cell death, an obser¬
vation that would be compatible with a failure of blood
vessel development to deliver essential survival factors. The
increased presence of lipid droplets is more difficult to ex¬
plain, but suggests either a lack of tropic hormone stimulus
for steroid hormone release or a failure of the normal secre¬
tory process. The accumulation of lipid is often associated
with the onset of degenerative change in steroid-producing
cells, including the early stages of luteolysis in the marmoset
(19). Despite the absence of major structural effects within
lutein cells, secretion of the principal steroidal hormonal
product of these cells is reduced by 60%. The most likely
explanation for these findings is that the reduction in de¬
velopment of the microvasculature deprives the lutein cells
of both the low density lipoprotein precursors necessary for
progesterone production and the transport system for effi¬
cient release of their products into the bloodstream. Some
effects of the treatment could also be related to an inhibition
of the vascular permeability properties of VEGF, although
this was not studied specifically. It is also conceivable that the
treatment could have an inhibitory effect on pituitary LH
secretion. However, we have recently shown that suppres¬
sion of LH during the luteal phase results in characteristic
and marked changes in the morphology of the lutein cells
(19) that were not observed in this study, indicating that any
change in LH secretion would be minor, making detection of
any change unlikely using existing assays and with the sam¬
pling frequency employed.
The present results are in agreement with a recent report
in the immature rat in which VEGF was inhibited while
follicle development and multiple ovulations were induced
by PMSG and hCG, respectively (6). However, in the rat
model, as VEGF antagonist treatmentwas initiated before the
onset of follicular hyperstimulation, it was not possible to
dissociate the luteal inhibition from the consequences of in¬
hibition of angiogenesis in the developing follicle.
Because angiogenesis inhibitors are currently being de¬
veloped primarily for treatment of vascular solid tumors and
are also likely to have a role in the control of rheumatoid
arthritis, retinal neovascularization, and psoriasis it is essen¬
tial that their potential effects on the reproductive system and
its function be determined. In addition, the potential of using
such inhibitors as antifertility agents is currently generating
considerable interest. However, it is unlikely that all angio¬
genesis inhibitors identified in studies using nonprimate spe¬
cies will influence fertility, as shown by our findings in the
marmoset, in which TNP-470 was administered in a protocol
similar to that used in the present study but had no inhibitory
effect on luteal angiogenesis (9).
As we have shown that luteal inadequacy is associated
with inhibition of angiogenesis, this suggests that the clinical
incidence of these conditions may in part be the result of
defects in the angiogenic process. They may therefore prove
to be amenable to treatment with angiogenic growth factors
such as VEGF. The potential to inhibit angiogenesis in the
female reproductive tract should have important implica¬
tions for clinical practice, but the development of safe and
effective strategieswill require detailed investigation of suit¬
able animal models, as described in this study. Finally, ma¬
nipulation of VEGF in this fashion should provide a novel
approach to investigate the precise physiological role of
VEGF in ovarian angiogenesis.
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Inhibition ofEarly Luteal Angiogenesis by
Gonadotropin-Releasing Hormone Antagonist
Treatment in the Primate
SARAH E. DICKSON and HAMISH M. FRASER
Medical Research Council Human Reproductive Sciences Unit, Centre for Reproductive Biology,
Edinburgh, EH3 9ET, United Kingdom
ABSTRACT
Angiogenesis during luteal development is essential for normal
lutein cell function, but the control of this process and the relation¬
ships between the steroidogenic and endothelial cells have still to be
elucidated. The aim of this study was to: 1) quantify endothelial cell
proliferation throughout the luteal phase of the marmoset ovulatory
cycle; 2) determine the effect ofgonadotropinwithdrawal usingGnRH
antagonist treatment on the early luteal phase angiogenesis peak;
and 3) describe the resultant morphological changes in the corpus
luteum (CL). Ovaries were collected during the early, mid-, and late
luteal phase, and changes in angiogenic activity were determined by
quantification of bromodeoxyuridine incorporation. Animals were
treated with a GnRH antagonist, on luteal days 1 and 2, and ovaries
were collected on day 3. A proliferation index was obtained by count¬
ing the number of bromodeoxyuridine immunopositive cells in luteal
sections. Cell proliferation wasmaximal in the early luteal phase and
fell significantly in the mid- and late CL. GnRH antagonist treatment
reduced the early luteal phase proliferation peak by 90%, suppressed
plasma progesterone, and severely disrupted lutein cell morphology.
These results demonstrate that the intense angiogenesis in the early
primate CL is dependent on gonadotropin stimulation of lutein cells.
(J Clin Endocrinol Metab 85: 2339-2344, 2000)
THE CORPUS luteum (CL) is formed subsequent to fol¬licular development and rupture of the preovulatory
follicle at ovulation (1). It is well established that LH is the
major luteotrophic factor regulating the function of the pri¬
mate CL. Withdrawal of LH by GnRH antagonist adminis¬
tration results in luteolysis of the CL in the Old World pri¬
mate (2),NewWorld primate (3), and women (4), as reflected
by decreased plasma progesterone levels.
Luteinization is accompanied by prolific angiogenesis,
which is essential for normal CL function. During the estab¬
lishment of the CL, vascularization of the granulosa cell layer
takes place as the basement membrane, which in the follicle
separated the avascular granulosa from the highly vascu¬
larized theca, undergoes loss of integrity. The increased
blood supply provides luteal steroidogenic (lutein) cells with
oxygen, nutrients, and substrates for progesterone and
growth factor biosynthesis, and it facilitates removal of end
products of metabolism. The growth of new blood vessels
can bemonitored bymeasuring endothelial cell proliferation.
Proliferation studies in the human (5,6), nonhuman primate
(7), ovine (8), and bovine (9) show peak levels at the early
stages of luteal development, whereas CL regression is as¬
sociated with a decreased proliferative rate.
Regulation of angiogenesis is controlled by endothelial
growth factors, which regulate cell-cell interactions. Most
attention has focused on vascular endothelial growth factor
(VEGF). It has been shown that neutralization ofVEGF in the
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rat (10) and marmoset monkey (11) blocks both luteal an¬
giogenesis and progesterone production. In most tissues,
VEGF is stimulated by hypoxia; but in the endocrine system,
the tropic hormones are likely to play a role. A relationship
between gonadotropin stimulation of cultured luteinized
granulosa cells and VEGF production in vitro has been es¬
tablished (12-15). In turn, addition of VEGF to isolated ma¬
caque luteal endothelial cells stimulates proliferation (16).
However, the in vivo connection between gonadotropic stim¬
ulation of lutein cells and angiogenesis has not been dem¬
onstrated. In this study, endothelial cell proliferation in the
CL throughout the luteal phase of the ovulatory cycle of the
marmoset was evaluated. The most intense phase of angio¬
genesis was subsequently targeted for the effects of gonad¬
otropin withdrawal by treatment with GnRH antagonist.
Assessment of treatment effects was based on examination of




Marmoset monkeys (Calithrix jacchus) were housed as described pre¬
viously (17), and procedures were carried out in accordance with the
Animals (Scientific Procedures) Act, 1986. Blood samples were collected by
femoral venepuncture, three times per week, without anesthesia. Ovu¬
latory cycles were monitored by R1A of plasma progesterone, as pre¬
viously described (18). The day of ovulation (day 0 of the luteal phase)
was taken as the day on which progesterone concentration rose above
30 nmol/L when followed by a sustained increase, characteristic of the
luteal phase.
Ovaries were collected from animals in the early (luteal days 2-4),
mid-(days 8-10), and late (days 16-20) luteal phase of the ovulatory
cycle (n = 5 animals per group). Twenty milligrams of bromodeoxyuri¬
dine (BrdU; Roche Molecular Biochemicals, Sussex, UK), dissolved in
500 p.1 physiological saline, was administered iv, 1 h before tissue col¬
lection, to label proliferating cells in the S phase of the cell cycle, via
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incorporation into DNA. This allowed changes in endothelial cell pro¬
liferation throughout the luteal phase of the ovulatory cycle to be de¬
termined; and, because the early luteal phase exhibited most intense
angiogenesis, this period was selected for targeting with GnRH antag¬
onist to investigate the gonadotropin dependence of early luteal primate
angiogenesis.
The animals to receive GnRH antagonist treatment and early luteal
control animals were given 1 /xg PG F2o analog (Planate;Coopers Animal
Health Ltd., Crewe, Cheshire, UK) im, in the mid- to late luteal phase
of the pretreatment cycle, to induce luteolysis and synchronize subse¬
quent ovulation, which was presumed to occur 10 days after PG treat¬
ment (luteal day 0) (19). Blood samples were collected three times per
week, then daily from the day of presumed ovulation, and the animals
were subsequently treated with either 1 mg/kg sc. GnRH antagonist,
Antarelix (20) or vehicle on luteal days 1 and 2 (n = 4). Ovaries were
collected on day 3, as previously described (21), 1 h after administration
of BrdU to animals in both control and treatment groups. Ovaries were
fixed immediately in 4% paraformaldehyde for paraffin-embedding,
and a small piece of CL was fixed in 3% glutaraldehyde in 0.1 mol/L
cacodylate buffer, pH 7.3, for araldite resin embedding.
Immunocytochemistry
Paraffin-embedded ovarian sections (5 pm) were mounted onto
TESPA (Sigma, Dorset, UK) coated glass slides and dried at 50 C over¬
night. Fluorescent and colorimetric colocalization of BrdU (Roche Mo¬
lecular Biochemicals) and the endothelial cell marker, von Willebrand
Factor VHI-associated antigen (Factor VIII; DAKO Corp., Cambridge,
UK) was carried out on early and mid-luteal ovarian tissue. Sections
were dewaxed in Histoclear (National Diagnostics, Hull, UK), rehy-
drated in descending concentrations of industrial methylated spirits,
and washed in distilled water. Antigen retrieval was performed by
microwaving (750W) slides on full power in 0.01 mol/L citrate buffer,
pH6, for 4 sessions of 5 min. A constant volume of buffer was kept by
addition of warm distilled H20 after each 5 min of microwaving. The
slides remained in hot buffer for a further 20 min and were washed in
PBS (0.01 mol/L PBS, pH 7.4, containing 2.7 mmol/L KCI, 0.137 mol/L
NaCl). The following procedures, with the exception of immunostaining
development, were carried out in Sequenza racks (Life Sciences Inter¬
national, Hampshire, UK). Sections were treated for 30 min, at room
temperature, with normal goat serum, diluted 1:5 in PBS + 0.25 g BSA
[normal goat serum (NGS) diluted 1:5 in PBS + 0.25 g BSA], followed
by dual incubation in rabbit polyclonal anti-Factor VIII (22.8 pg/mL in
NGS), and mouse monoclonal anti-BrdU (6.6 pg/mL in NGS) at 4 C,
overnight. Immunolocalization was undertaken using anti-rabbit FITC
conjugate (diluted 1:50 in NGS, Sigma F-6005) and anti-mouse TRITC
conjugate (diluted 1:50 inNGS, Sigma T-5393) dual incubation for 45 min
at room temperature. The U-MWIBA and U-MWG filters on the Olym¬
pus Corp. AX70 Provis fluorescent microscope were used to visualize
FITC-stained Factor VHI positive cells, and TRITC-stained BrdU positive
cells, respectively.
The occurrence of erythrocyte autofluorescence masked BrdU stain¬
ing inmost sections, and this prevented quantification of endothelial cell
proliferation in the majority of CL. To circumvent this problem, a col¬
orimetric approach was also used for analysis. Endogenous peroxidase
activity was quenched with a 30-min incubation in 3% hydrogen per¬
oxide inmethanol, at room temperature.Microwaving and NGS [diluted
in Tris-buffered saline (TBS) (pH 7.4), containing 50 mmol/L Tris-HCl,
150 mmol/L NaCl] blocking was performed as before. Sections were
incubated with anti-Factor VIII (28.8 pg/mL in TBS) alone at 4 C, over¬
night. Immunolocalization was detected with the mouse EnVision sys¬
tem (DAKO Corp.), according to the guidelines of the manufacturer. For
BrdU colocalization, nonspecific binding was blocked with normal rab¬
bit serum in TBS (NRS). Sections were incubated in mouse monoclonal
anti-BrdU (3.3 pg/mL, in TBS) at 4 C, overnight, or for 2 h at room
temperature. Rabbit anti-mouse (DAKO Corp., 26.6 pg/mL in NRS),
was applied for 30 min at room temperature. BrdU binding was visu¬
alized usingmouse APAAP (DAKOCorp., 1 pg/mL in NRS) incubation
for 30 min, and the Fast Blue detection system (1 mg Fast Blue BB salt,
per 1 mL Fast Blue buffer, containing 20mg naphthol AS-MX Phosphate,
2 mL dimethylformamide, and 98 mL 0.1 mol/L Tris (pH 8.2), all from
Sigma). The reaction was stopped with distilled water, and the slides
were very lightly counterstained with hematoxylin and mounted with
Permafluor aqueous mounting medium (Coulter Electronics, Bedford¬
shire, UK).
The procedure for BrdU immunostaining alone to determine changes
in cell proliferation throughout the cycle and after treatment was carried
out as described previously (17). In this case the NBT (nitro-blue tetra-
zolium, Roche Molecular Biochemicals) detectionmethod was used, and
intense counterstaining was needed.
To examine the effect of GnRH antagonist treatment on CL mor¬
phology, treated and control sections were stained with toluidine blue
(BDH, Poole, Dorset, UK). Araldite, resin-embedded, 1-pm sections
were incubated in toluidine blue at 70 C for 8 min, dried, and examined
under the light microscope.
Labeling index and statistical analysis
Manual counting procedures were used to calculate the percentage
of proliferating endothelial cells for each CL. Quantification was per¬
formed blind on both fluorescent sections and those stained using the
colorimetric approach. Both early and mid-luteal phase, left and right
ovaries for each animal were examined for appropriately aged CL. Data
from all CL fulfilling these criteria were collected for subsequent anal¬
ysis. Six randomly chosen fields per CL, at X400 magnification, were
analyzed using a grid overlay. The number of proliferating endothelial
cells was expressed as a percentage of proliferating cells, i.e. (number of
dual stained cells/total number of BrdU positive cells) x 100.
The proliferation index (PI) was calculated in a similar manner. Ova¬
ries throughout the luteal phase of the cycle were stained with anti-BrdU
only. The number of positive BrdU cells was expressed as a percentage
of total number of cells per graticule field, i.e. (number of BrdU positive
cells/total cells) x 100. Representative sections were also quantified by
a second individual. The Pis obtained correlated highly (r = 0.97, P <
0.001).
PI and plasma progesterone data throughout the luteal phase of the
cycle were analyzed using Fisher's protected least-significant difference
ANOVA test, at 5% significance. The effects of GnRH antagonist treat¬
ment on PI and plasma progesterone levels, as compared with controls,
were determined using a two-tailed, unpaired t test, with a 95% con¬
fidence interval. Both tests were performed using Statview version 4.0.
Results
PI and plasma progesterone throughout the cycle
Figure 1 depicts the CL PI and plasma progesterone con¬
centration throughout the luteal phase of the marmoset ovu¬
latory cycle. Peak cell proliferation was observed in the early
luteal phase CL and declined markedly (P < 0.001, as com¬
pared with early levels) in the mid- and late CL. The 2.5-fold
decrease in PI from the mid- to late CL was also significant
(P < 0.05). Plasma progesterone concentration increased (P <
0.01) from early luteal levels, to peak in the mid-luteal phase,
subsequently decreasing (P < 0.01) from mid- to late luteal
phase.
Immunolocalization ofBrdU and Factor VIII antibodies
Figure 2 shows fluorescent colocalization of Factor VIII
and BrdU. Fig. 2a demonstrates the green cytoplasmic im¬
munostaining for Factor VIII, and Fig. 2b shows red nuclear
fluorescent staining for BrdU in the same section. Fig. 2c
illustrates colocalization of Factor VIII and BrdU by over¬
laying 2a and 2b. From quantification of this and the color¬
imetric method of dual staining, the mean percentage Factor
VIII and BrdU colocalization in the early CL was 84.6 ± 0.9
(mean ± sem); and in the mid-CL, 84.4 ± 1.3 (n = 4 per
group).



















Fig. 1. A, Cell proliferation in the marmoset CL; B, plasma proges¬
terone concentration throughout the luteal phase of the ovulatory
cycle. Values are means ± sem. Different letters denote significant
differences between categories, P < 0.05.
GnRH antagonist treatment
An elevation of plasma progesterone was observed before
treatment in all animals and confirmed by the identification
of recently formed CL in control and GnRH antagonist-
treated animals. Fig. 2, d-f, shows a comparison of BrdU
immunolocalization and PI in an early luteal control CL and
an Antarelix-treated CL. BrdU positive staining (dark nuclei)
and hematoxylin staining (pale nuclei) are pbvious. A signif¬
icant decrease (P < 0.001) in PI is seen in CL from the
Antarelix-treated group of animals, as compared with the
early luteal controls. Clusters of densely stained nucleic frag¬
ments, characteristic of apoptotic cell death, were apparent
in the Antarelix-treated CL (Fig. 2e).
Figure 2, g and h, shows toluidine blue-stained sections of
an early control CL and an Antarelix-treated CL. There is a
significant effect on lutein cellmorphology in the treated CL,
as compared with controls. The lutein cells of the early con¬
trol CL appear normal for this species, with distinct cell
margins, and well formed nuclei containing a single nucle¬
olus contained in an abundant cytoplasm, typical of a ste¬
roidogenic lutein cell. This contrasts with the appearance of
the CL after GnRH antagonist treatment. Here, the CL shows
disorganization, and the lutein cells show much-less-clearly
defined margins. In addition, there is evidence of lipid ac¬
cumulation and the occurrence of dense bodies. Typical
apoptotic bodies were not observed. Recognizable lutein
cells are smaller than in the control tissue, even those in
which the nucleus remains intact. Finally, GnRH antagonist
treatment was associated with a marked reduction (P <
0.001) in plasma progesterone concentration, to follicular
phase levels (Fig. 2i).
Discussion
This study has established, for the first time in vivo, that the
intense angiogenesis in the primate CL associated with the
early luteal phase is dependent on gonadotropin support.
Over 80% of proliferating cells in the marmoset CL are en¬
dothelial cells; and thus, it is reasonable to consider cell
proliferation in the CL, based on the PI from single BrdU
immunostaining, as being reflective of endothelial cell pro¬
liferation. There is evidence that there is little or no prolif¬
eration of fully differentiated primate lutein cells (7), which
implies that the remaining BrdU positive cells in the CL are
most likely fibroblasts, infiltrating macrophages, or endo¬
thelial support cells, such as pericytes.
The quantification of endothelial cell proliferation
throughout the luteal phase, using the so-called gold stan¬
dard BrdU technique, shows peak endothelial cell prolifer¬
ation in the early CL, which had significantly decreased by
the mid- and late stages of luteal development. The results
agree with studies evaluating cell proliferation in corpora
lutea from other species (6-9, 22). The intense proliferation
in the early luteal phase leads to increased vascularization
during luteinization and CL establishment. By themid-luteal
stage, it is thought that themajority of steroidogenic cells are
in contact with at least one capillary (9, 22). Peak plasma
progesterone concentrations in the mid-luteal phase corre¬
late with the presence of an extensive capillary network in the
CL, for optimal delivery of progesterone precursors to, and
progesterone from, the cell. Decreased endothelial cell pro¬
liferation in the late luteal phase CL coincides with the ob¬
served fall in plasma progesterone concentration and luteal
regression (22).
GnRH antagonist treatment was employed to examine the
role of gonadotropin dependence of the intense angiogenesis
associated with the early luteal phase. In the marmoset, di¬
rect effects of GnRH antagonist treatment on the CL are
unlikely (23), so the treatment is presumed to be a conse¬
quence of pituitary withdrawal of LH, as described previ¬
ously in the marmoset (3), macaque (2), and human (4) luteal
phase. Deprivation of gonadotropin support to steroidogenic
cells reduced endothelial cell proliferation by 90%, and
plasma progesterone concentration by 95%, demonstrating
the dependence of early luteal angiogenesis and function on
gonadotropin support.
Light microscopy of toluidine blue-stained sections re¬
vealed a severe disruption of normal steroidogenic cell mor¬
phology in the GnRH antagonist-treated CL, when com¬
pared with early luteal controls. Accumulation of lipid,
appearance of densely staining bodies, and the absence of
distinct cellmargins were obvious after treatment. There was
evidence of fragmented nuclei, characteristic of apoptosis, in
hematoxylin-stained CL from treated marmosets. Flowever,
FIG. 2 Fluorescent colocalization of Factor VIII and bromodeoxyuridine (BrdU), and effect of GnRH antagonist treatment on prolif
eration index (PI), cell morphology and progesterone output.(a-c) Fluorescent immunocytochemical localization of (a) endothelial
cell marker, Factor VIII; (b) proliferation marker, BrdU; and (c) colocalization of the two, in an early CL. Note that most BrdU pos¬
itive cells are also Factor VIII positive, (d-f) Immunocytochemical localization of BrdU in (d) an early control CLand (e) the CLof
a GnRH antagonist treated marmoset at the same stage of the cycle. Note the marked reduction in BrdU incorporation and cellular
disruption afer treatment. Note also, the presence of the blood vessel (BV), and possible apoptotic body indicated by the arrow. (0
The effect of GnRH antagonist treatment on PI (% BrdU incorporation). Values are means ± sem, p<0.001 .(g-i) Toluidine blue
stained sections of early control CL and (h) a CL after GnRH antagonist treatment. Note the healthy appearence of steroidogenic
cells with abundant cytoplasm (C), clear nuclei with nucleoli (N) and probable endothelial cells (E) in the control CL. After treat¬
ment the cellular integrity is severely disrupted and dense bodies indicated by the arrow heads, lipid droplets (L), and some intact
nuclei (N) are present, (i) The effect of GnRH antagonist treatment on plasma progesterone concentration. Values are means ± sem,
pcO.OOl. Scale bars = 50pm.
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analysis of semi-thin sections indicated widespread cell
death by a process other than apoptosis, as also suggested
previously (24, 25); and because ultrastructural studies of
GnRH antagonist-induced luteolysis in the marmoset do not
indicate widespread cell degeneration via apoptosis (26), it
is difficult to ascertain the method of luteal cell death seen in
this study. It is clear, however, that the extent of luteal cell
disruption was such that steroidogenic cell function was
significantly impaired, preventing secretion of progesterone
and, most likely, other factors involved in normal CL
function.
Early luteal phase administration of GnRH antagonist to
macaques (27) and women results in suppression of proges¬
terone secretion and a marked reduction, in response to
exogenous hCG administered in the mid-luteal phase (4,27).
Here,we show that administration ofGnRH antagonist in the
early luteal phase causes a severe disruption of steroidogenic
cell morphology and angiogenesis, thus providing an expla¬
nation, at the cellular level, for the effects ofGnRH antagonist
treatment seen previously.
It is tempting to suggest that the adverse effect of GnRH
antagonist treatment on early luteal angiogenesis is predom¬
inantly a consequence of decreased VEGF production from
the dysmorphic steroidogenic cells of the developing CL.
VEGF is a secreted angiogenic mitogen (28), specific for en¬
dothelial cell receptors (29,30). Both VEGF messenger RNA
(mRNA) and its transcribed protein have been localized to
the granulosa and theca lutein cells of the human CL (31,32).
Cultured human (12, 13) and macaque (14, 15) luteinized
granulosa cell VEGF expression has been shown to be up-
regulated by gonadotropins in vitro. In preliminary investi¬
gations, using immunocytochemistry to determine changes
in VEGF in the CL after GnRH antagonist treatment, we did
not observe a decrease in immunostaining (unpublished ob¬
servation). Hypoxia-induced VEGF production; the presence
of residual, nonactive, or metabolized VEGF; or nonspecific
staining by lutein cell debris in the treated CL may explain
the unexpected failure to demonstrate decreased VEGF. An¬
giogenesis is a multistep process involving a number of an¬
giogenic growth factors, degradation of the extracellular ma¬
trix by matrix metalloproteinases, and cell-cell interactions.
Neutralization of VEGF in the marmoset, over the same time
period, reduces endothelial cell proliferation by 80%, as com¬
pared with control levels (11), a significantly greater sup¬
pression is demonstrated afterGnRH antagonist treatment in
this study. This suggests that the reduction in luteal angio¬
genesis seen here is most probably a consequence of a de¬
crease in other angiogenic factors in addition to VEGF,
and/or by a breakdown in endothelial-steroidogenic cell
interactions after disruption of lutein cell morphology as
caused by treatment. The reduction in local progesterone
concentration may also act to reduce angiogenesis. Proges¬
terone is thought to have a local action in the periovulatory
follicle, to regulate expression of modulators of the angio¬
genic process, such as matrix metalloproteinase-1 and its
tissue inhibitor (33), implying a role in angiogenesis in the
early CL.
The potential of manipulation of angiogenesis in the hu¬
man reproductive tract is currently generating considerable
interest (10,11,17), and itwill be important to elucidate fully
the mechanisms regulating the physiological process in suit¬
able primate models. The current results establish that the
intense angiogenesis associated with the formation of the CL,
and necessary for normal luteal function, is almost exclu¬
sively dependent on normal gonadotropin support.
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Abstract
Vascular endothelial growth factor (VEGF) is essential for
the angiogenesis required for the formation of the corpus
luteum; however, its role in ongoing luteal angiogenesis
and in the maintenance of the established vascular network
is unknown. The aim of this study was to determine
whether VEGF inhibition could intervene in ongoing
luteal angiogenesis using immunoneutralisation of VEGF
starting in the mid-luteal phase. In addition, the effects on
endothelial cell survival and the recruitment of peri-
endothelial support cells were examined. Treatment with
a monoclonal antibody to VEGF, or mouse gamma globu¬
lin for control animals, commenced on day 7 after ovu¬
lation and continued for 3 days. Bromodeoxyuridine
(BrdU), used to label proliferating cells to obtain a
proliferation index, was administered one hour before
collecting ovaries from control and treated animals. Ovar¬
ian sections were stained using antibodies to BrdU, the
endothelial cell marker, CD31, the pericyte marker,
alpha-smooth muscle actin, and 3' end DNA fragments as
a marker for apoptosis. VEGF immunoneutralisation sig¬
nificantly suppressed endothelial cell proliferation and the
area occupied by endothelial cells while increasing peri¬
cyte coverage and the incidence of endothelial cell apop¬
tosis. Luteal function was markedly compromised by
anti-VEGF treatment as judged by a 50% reduction in
plasma progesterone concentration. It is concluded that
ongoing angiogenesis in the mid-luteal phase is primarily
driven by VEGF, and that a proportion of endothelial cells
of the mid-luteal phase vasculature are dependent on
VEGF support.
Journal of Endocrinology (2001) 168, 409-416
Introduction
Formation of the primate corpus luteum (CL) is ac¬
companied by prolific angiogenesis in the early luteal
phase, and throughout the life span of the CL angiogenesis
continues at a lower rate until the late luteal phase when
endothelial cell proliferation decreases further (Jablonka-
Shariff et al. 1993, Rodger et al. 1997, Dickson & Fraser
2000). The angiogenic process is regulated by a number of
growth factors, degradation of the extracellular matrix
and cell—cell interactions. One growth factor primarily
involved is vascular endothelial growth factor (VEGF).
The importance of VEGF in the onset of luteal angio¬
genesis has been demonstrated by specific VEGF neutral¬
isation in the rat (Ferrara et al. 1998) and the marmoset
monkey (Fraser et al. 2000) which resulted in suppression
of endothelial cell proliferation, restricted development of
the microvascular tree and decreased progesterone produc¬
tion. These studies have solely addressed prevention of
angiogenesis by targeting the early luteal phase just before
the onset of angiogenesis (see Fig. 1) (Dickson & Fraser
2000, Fraser et al. 2000). Surprisingly, while immunone-
utralisation of VEGF for the first 3 days of the luteal
phase markedly suppressed angiogenesis, extending treat¬
ment to 10 days post ovulation failed to affect mid-luteal
cell proliferation (Fraser et al. 2000). It is possible that
endothelial cell proliferation was unaffected at this stage
as a result of (1) induction of a compensatory effect
from other growth factors after chronic inhibition of
VEGF, (2) an immune response against the mouse mono¬
clonal antibody or (3) the possibility that VEGF was
not involved in stimulating endothelial cell prolifer¬
ation during this period. In the light of this observation
the current study investigated the role of VEGF specifi¬
cally during the mid-luteal phase to determine whether
VEGF inhibition would intervene in ongoing luteal angio¬
genesis.
First, using quantitative immunocytochemistry we es¬
tablished that VEGF was present in high amounts during
the mid-luteal phase. We then investigated whether it was
possible to intervene in the already established angiogenic
process by administering anti-VEGF treatment for 3 days
in the mid-luteal phase and examining the effects on
angiogenesis and luteal function.
Online version via http://www.endocrinology.orgjournal of Endocrinology (2001) 168, 409-416
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Previous studies on the effects of withdrawal of VEGF
in other angiogenic-dependent systems report the require¬
ment of VEGF for the survival of immature endothelial
cells. For example, in human prostate cancer the loss of
VEGF as a result of androgen ablation therapy leads to
selective apoptosis of endothelial cells in vessels devoid of
periendothelial support cells (Benjamin et al. 1999). To
investigate whether endothelial cells of the primate CL
may be susceptible to withdrawal of VEGF, we deter¬
mined the incidence of apoptosis after anti-VEGF treat¬
ment. Finally, to assess the relationship of periendothelial
support cells to endothelial cell survival, the area of




Marmoset monkeys (Calithrix jacchus) were housed as
described previously (Fraser et al. 1999a) and procedures
were carried out in accordance with the Animals (Scien¬
tific Procedures) Act 1986. Blood samples were collected
by femoral venepuncture three times per week without
anaesthesia. Ovulatory cycles were monitored by radio¬
immunoassay of plasma progesterone as previously de¬
scribed (Smith et al. 1990). The day of ovulation (day 0 of
the luteal phase) was taken as the day on which proges¬
terone concentration rose above 30 nmol/1 when followed
by a sustained increase, characteristic of the luteal phase.
Ovaries collected from animals in the early (luteal days
2-4), mid- (days 8—10) and late (days 16-20) luteal phase
of the ovulatory cycle (n = 4-5 animals per group) for
previous studies (Fraser et al. 1999a, fc, Dickson & Fraser
2000) were used for immunocytochemical localisation and
quantification of VEGF protein.
The mid-luteal phase was targeted for anti-VEGF
treatment to determine whether luteal angiogenesis could
be prevented at the stage when high levels of VEGF are
present, as seen by VEGF immunolocalisation throughout
the luteal phase of the marmoset ovulatory cycle.
Animals were given 1 pg prostaglandin F2(1 analogue
(Planate; Coopers Animal Health Ltd, Crewe, Cheshire,
UK) i.m. in the mid- to late luteal phase of the pre-
treatment cycle to induce luteolysis and to synchronise
subsequent ovulation which was presumed to occur 10
days after prostaglandin treatment (luteal day 0) (Fig. 1)
(Summers et al. 1985). Blood samples were collected every
second day, then daily from the first day of treatment. The
properties of the VEGF monoclonal antibody have been
described previously (Fraser et al. 2000). Four animals
were subsequently treated with 2 mg VEGF monoclonal
antibody on luteal day 7 and 1 mg on luteal days 8 and 9,
and four control animals were given equivalent doses of
mouse gamma globulin (Fig. 1). Ovaries were collected on
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Figure 1 Schematic diagram showing the different treatment
regimes (1, 2 and 3) with VECF monoclonal antibody designed to
determine whether inhibition of angiogenic factors can prevent
angiogenesis (regimes 1 and 2) or intervene once the process is
underway (regime 3). The approach used in the current study was
to intervene in the already established angiogenic process by
administering a 3-day treatment with VEGF monoclonal antibody
in the mid-luteal phase according to regime 3. PG, prostaglandin
F2(I analogue.
after administration of 20 mg bromodeoxyuridine (BrdU;
Boehringer Mannheim, Lewes, East Sussex, UK) dissolved
in 500 pi physiological saline, to label proliferating cells
in the S phase of the cell cycle. Ovaries were fixed
immediately in 4% paraformaldehyde in 0-01 M PBS
(phosphate-buffered saline, pH 7-4, containing 2-7 mM
KC1, 0-137 M NaCl) for paraffin-embedding.
Immunocytocliemistry
Paraffin-embedded ovarian sections (5 pm) were mounted
onto TESPA- (Sigma, Poole, Dorset, UK) coated glass
slides and dried at 50 °C overnight. To carry out immu-
nocytochemistry for VEGF, sections were dewaxed in
Histoclear (National Diagnostics, Aylesbury, Bucks, UK),
rehydrated in descending concentrations of industrial
methylated spirits and washed in distilled water. VEGF
antigen was retrieved by pressure cooking slides on full
power in 3 M glycine, 0-1% EDTA buffer, pH 3-5, for
5 min. The slides remained in hot buffer for a further
20 min and were washed in TBS (0-05 M Tris-buffered
saline, pH 7-4, containing 50 mM Tris-HCl, 150 mM
NaCl). Endogenous peroxidase activity was quenched
with a 30-min incubation in 3% hydrogen peroxide in
methanol at room temperature. The following procedures,
with the exception of immunostaining development, were
carried out in Sequenza racks (Shandon Scientific Ltd,
Runcorn, Cheshire, UK). To block endogenous biotin,
sections were incubated in avidin (Vector Laboratories,
Burlingame, CA, USA) at a concentration of 8 drops/ml
normal swine serum (NSS, 1:5 dilution in TBS + 0-25 g
bovine serum albumin), followed by a 20-min incubation
Journal of Endocrinology (2001) 168, 409-416 www.endocrinology.org
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in biotin (Vector Laboratories) in TBS (8 drops/ml).
Rabbit polyclonal VEGF antibody (2 pg/ml pre-diluted in
NSS, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
was added and sections were incubated at 4 °C overnight.
Negative controls were incubated in primary antibody
pre-absorbed with VEGF peptide in 1:5 ratio of VEGF
antibody:blocking peptide (Santa Cruz). Immunolocalisa-
tion was undertaken using the rabbit EnVision kit (Dako
Ltd, Cambridge, Cambs, UK) according to the guidelines
of the manufacturer.
BrdU immunocytochemistry was carried out using a
monoclonal antibody (Boehringer Mannheim) as pre¬
viously described (Fraser et al. 2000). Immunocytochemis¬
try for the endothelial cell marker, CD31 (Dako Ltd), and
the pericyte marker, alpha-smooth muscle actin (SMA;
Dako Ltd), were performed using monoclonal antibodies
(20-5 pg/ml in TBS and 4*3 pg/ml in TBS respectively)
and the same method as for BrdU immunostaining.
Apoptosis was detected by 3' end labelling as previously
described in the marmoset CL (Young et al. 1997), with
modifications according to Sharpe et al. (1998). An ad¬
ditional proteinase K digestion step was performed after
dewaxing and rehydrating the sections. Slides were incu¬
bated for 6 min at room temperature in 20 pg/ml proteinase
K in buffer containing 0-05 M Tris, pH 8, 0-05 M EDTA,
pH 8, in distilled H20. After blocking of endogenous
peroxidase activity, it was necessary to block endogenous
biotin using the avidin-biotin block in PBS as above.
Analysis
A BrdU proliferation index (PI) was obtained as previously
described (Dickson & Fraser 2000). Endothelial cell and
pericyte areas were quantified in at least 6 randomly
chosen areas of 5*3 x 104 pm2 (approximately two thirds
of each CL) as described by Fraser et al. (2000) for the
endothelial cell marker, Factor VIII. The area of VEGF
immunostaining was measured using Photoshop version
5 0 according to the method of Otani et al. (1999).
Statistical analysis of VEGF immunostaining throughout
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Figure 2 Photomicrographs of marmoset corpora lutea showing VEGF localisation (brown staining cytoplasm) in (A) an early luteal phase
corpus iuteum, (B) a mid-luteal phase corpus luteum and (C) a late luteal phase corpus luteum. Bar represents 50 gm. (D) Quantification
of the area of VEGF immunostaining in the marmoset corpus luteum throughout the luteal phase of the ovulatory cycle. Early and
mid-luteal values are significantly higher (P=0-04 and P=0 02 respectively) than the late luteal value. Data are means ± s.e.m.
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the ovulatory cycle was carried out using a factorial
one-way analysis of variance (ANOVA) with Fisher's
PLSD (protected least significant difference) post-hoc test
at 5% significance. The effects ofanti-VEGF treatment on
PI, endothelial cell and pericyte areas, apoptotic index and
VEGF immunostaining, as compared with controls, were
determined using separate two-tailed, unpaired t-tests,
with 95% confidence intervals. Serum progesterone con¬
centrations were analysed using a repeated measures
ANOVA with Fisher's PLSD post-hoc test at 5% signifi¬
cance. All tests were performed using Statview version 4-0.
Results
VEGF immunocytochemistry throughout the cycle
Figure 2 illustrates the localisation and quantification of
VEGF immunostaining in the CL during the early, mid-
and late luteal phase. Early luteal sections show intense,
punctate VEGF staining in the cytoplasm of lutein cells
(Fig. 2A) which becomes more uniform and widespread in
the mid-luteal phase CL (Fig. 2B). Staining was absent
from recognisable endothelial cells. In the late luteal phase
CL, VEGF staining was markedly reduced (Fig. 2C).
Quantification confirmed a high area of staining in the
early and mid-luteal phase which declined markedly in the
late luteal phase CL, as compared with early and mid-
luteal levels (P=0-04 and P= 0-02 respectively) (Fig. 2D).
BrdU, CD3 / and SMA immunocytochemistry
Figure 3 shows comparisons ofBrdU incorporation, CD31
and SMA immunostaining, and their quantification in
mid-luteal control and anti-VEGF-treated CL. Moderate
BrdU incorporation into endothelial cells was observed in
control CL (Fig. 3A) but this was significantly lowered by
anti-VEGF treatment (Fig. 3B). This was confirmed
by comparing the PI from control and treated groups
(PcOOl) (Fig. 3C). In the control CL, CD31 immuno¬
staining confirmed the establishment of the microvascular
tree demonstrated by numerous blood vessels and capillary
endothelial cells being observed in association with each
lutein cell (Fig. 3D). In the treated animals, the number of
capillaries appeared reduced (Fig. 3E) and quantitative
analysis revealed a significant (P= 0-02) decrease in endo¬
thelial cell area after treatment (Fig. 3F). The converse was
apparent for SMA immunostaining. In control sections,
pericytes were mostly found aggregated in rings surround¬
ing luminal vessels (Fig. 3G), whereas after anti-VEGF
treatment single immunopositive cells were also found
distributed through the CL (Fig. 3H). Quantification of
pericyte area in control sections and after anti-VEGF
treatment is shown in Fig. 31 (P<0 ()1).
Apoptotic cell death
Figure 4 demonstrates 3' end labelling in mid-luteal
control and treated sections. One positive apoptotic endo¬
thelial cell associated with a blood vessel can be seen in Fig.
4A. The incidence of apoptotic nuclei increased with
anti-VEGF treatment as seen in Fig. 4B which shows two
positive nuclei probably of endothelial cell origin. Positive
apoptotic nuclei remained sparsely distributed, even
though anti-VEGF treatment significantly (P= 0-03) in¬
creased the occurrence of apoptosis (Fig. 4C). The inci¬
dence of apoptotic cells was measured per CL section as
the size of the control and treated CL did not differ
significantly. The regular shape of the steroidogenic lutein
cells in control CL was retained in the treated CL.
Plasma progesterone concentration
A sustained elevation of plasma progesterone was observed
prior to treatment in all animals. After administration of
anti-VEGF treatment starting on luteal day 7 there was a
marked reduction in plasma progesterone concentrations
which had fallen by over 50% by day 10 (Fig. 5) (P=0-01).
Discussion
This study has demonstrated for the first time that VEGF
is essential for luteal angiogenesis even when the process is
already established. Furthermore, inhibition of VEGF at
this time suppresses the function of the CL. We have also
demonstrated that VEGF appears to have a role in
maintenance of the vascular network in the mid-luteal CL
as shown by an increase in 3' end labelling after VEGF
withdrawal.
Our findings also show that the expression of VEGF is
high not only in the early luteal period of intense angio¬
genesis, but also in the less prolific mid-luteal phase CL,
and is only down regulated after initiation of luteolysis.
This agrees with VEGF measurements throughout the life
span of the CL in the bovine (Goede et al. 1998) and the
human CL (Otani et al. 1999). In the present study, the
deleterious effect of acute removal ofVEGF on mid-luteal
angiogenesis shows that ongoing mid-luteal angiogenesis is
driven primarily by this growth factor. This indicates that
the failure to observe an effect on mid-luteal endothelial
cell proliferation after chronic withdrawal ofVEGF treat¬
ment from the time of ovulation (Fraser et al. 2000) is a
consequence of induction of other growth factors to
compensate for the inhibition of VEGF or inactivation of
the neutralising antibody by an immune response.
The high mid-luteal expression of VEGF could also
reflect some of the non-angiogenic functions of VEGF,
such as the regulation of vascular permeability or the
mediation of endothelial cell survival as suggested by
Goede et al. (1998). By the mid-luteal phase, the vascu¬
lature is becoming highly developed and progesterone is
being maximally secreted. If the effect of anti-VEGF was
solely to suppress angiogenesis it might be anticipated that
progesterone would be maintained at pretreatment levels,
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Figure 3 Low power photomicrographs of marmoset corpora lutea showing the general distribution of endothelial cell BrdU
incorporation (dark-staining nuclei) in a control section (A) and its reduced incorporation after anti-VEGF treatment (B). (C) The
proliferation index in corpora lutea from mid-luteal phase controls (solid bar) and anti-VEGF-treated (open bar) marmoset corpora
lutea. Values from treated animals were significantly lower (P<001) than those from controls. (D) CD31 localisation (dark staining) in
the endothelial cells of the vascular network in a mid-luteal phase control corpus luteum. (E) Reduced CD31 staining after anti-VEGF
treatment. (F) Quantification of CD31 immunostaining in control (solid bar) and anti-VEGF-treated (open bar) marmoset corpora lutea.
Values from treated animals were significantly lower (P=0-02) than those from controls. (G) Smooth muscle actin localisation in
pericytes in a control section, and (H) increased smooth muscle actin immunostaining after anti-VEGF treatment. Note that the dark
stained cells in control and treated sections are characteristic of perivascular cells, based on the small size and elongated shape; none
appears to be of lutein cell origin. (I) Quantification of alpha-smooth muscle staining in control (solid bar) and anti-VEGF-treated (open
bar); values from treated animals were significantly (P=<0 01) higher than those from controls. Data are means ± S.e.m. Bar represents
100 |am.
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Figure 4 High power photomicrographs of 3' end labelled apoptotic cells (brown staining) in (A) a mid-luteal phase control
marmoset corpus luteum and (B) after anti-VEGF treatment. Note the presence of endothelial cells (EC) surrounding a blood vessel
(BV) in the control section, and smaller dark haematoxylin-stained nuclei representing endothelial cells and periendothelial support cells
in both control and treated CL. Arrows point to positive apoptotic nuclei assumed to be endothelial cells by their small, elongated
form. The morphology of steroidogenic cells (SC) appears unaffected by treatment. (C) Quantification of positive cells in control (solid
bar) and treated sections (open bar) shows increased presence of positive nuclei in anti-VEGF-treated sections. Note that values are

























Figure 5 Plasma progesterone concentrations in control (O) and
anti-VEGF-treated (•) marmosets. Treatment started on day 7 after
ovulation and is associated with a significant suppression
(P=0-01). Data are means ± s.e.m.
at least during the first 1—2 days of treatment. The rapid
decline in plasma progesterone concentration seen on the
first day of this acute mid-luteal phase anti-VEGF treat¬
ment, indicates that in addition to the regulation of
ongoing mid-luteal angiogenesis, VEGF also modulates
vascular permeability in the CL. An effect on CL vascular
permeability could deprive the lutein cells of both the
necessary precursors for progesterone production and the
efficient release of their products into the bloodstream,
which would result in marked reductions in plasma
progesterone values.
After anti-VEGF treatment, morphological changes in
lutein steroidogenic cells were not apparent. This contrasts
with observations on the characteristic effects of with¬
drawal of the trophic factor, luteinising hormone (LH),
which have been described recently (Fraser et al. 1999b,
Dickson & Fraser 2000), suggesting that anti-VEGF treat¬
ment does not markedly interfere with pituitary LH
secretion.
In this study, we have also observed an increase in
pericyte coverage as a result of VEGF withdrawal. Peri¬
cytes are believed to be involved in the remodelling
process which occurs during blood vessel maturation
(reviewed by Darland & D'Amore 1999), a process also
thought to take place in the CL (Tsukada et al. 1996,
Goede et al. 1998). Benjamin et al. (1999) demonstrated
that in both xenografted tumour and primary human
tumours, VEGF withdrawal resulted in specific obliter¬
ation of immature vessels and that in human prostate
cancer loss of VEGF led to selective apoptosis of endo¬
thelial cells devoid of periendothelial cells. Mature vessels
with associated pericytes are believed to be VEGF
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independent (Benjamin et al. 1998). It is possible that, in
the current study, the increase in apparent apoptosis in
endothelial cells after anti-VEGF treatment is a conse¬
quence of a lack of VEGF support to susceptible, imma¬
ture vessels with no associated pericytes. It could follow,
therefore, that endothelial cells of more mature vessels
with associated pericytes would be VEGF independent
and not susceptible to anti-VEGF treatment. Our finding
that mid-luteal VEGF withdrawal led to an increase in
endothelial cell apoptosis, the occurrence of which was
rare, in the presence of extended pericyte coverage sug¬
gests that it is the endothelial cells associated with the few
remaining immature capillaries which were susceptible to
loss of VEGF support. This, in turn, indicates that the
reduction in endothelial cell area after anti-VEGF treat¬
ment may be a consequence not only of a decreased
angiogenic rate, but also of increased endothelial cell
death.
Factors involved in the recruitment of pericytes
include platelet-derived growth factor-B (reviewed in
Darland & D'Amore 1999) and angiopoietin-1 (Davis
et al. 1996, Maisonpierre et al. 1997, Koblizek et al. 1998),
while transforming growth factor P is thought to regulate
pericyte differentiation (Hirschi et al. 1999). It remains
to be determined whether factors such as angiopoietin-1
may be activated after VEGF inhibition to act as a sur¬
vival mechanism to 'rescue' existing vessels from the
absence of the immature endothelial cell survival factor,
VEGF.
In conclusion, this study demonstrates that VEGF is a
primary factor controlling angiogenesis and luteal function
in the mid-luteal phase. The rapid decline in plasma
progesterone after VEGF inhibition suggests that another
function ofVEGF at this stage may be in the maintenance
of vascular permeability. In addition, the increase in
endothelial cell apoptosis indicates a role for VEGF in the
survival of a proportion of endothelial cells, perhaps those
without associated periendothelial support cells. However,
further investigation into the role of VEGF in pericyte
recruitment is required to further elucidate the processes
of blood vessel maturation in the CL. Since the mid-luteal
phase is a crucial period in the establishment of early
pregnancy and a time at which survival of the luteal
vasculature may be important in the 'rescue' of the CL,
manipulation of VEGF may have clinical importance
with respect to, on the one hand, treatment of early
pregnancy loss, and, on the other hand, interruption
of pregnancy.
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